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ABSTRACT 
The research described in this thesis was aimed at synthesizing novel 
lipophilic nucleotide and CpG dinucleotide conjugates with the purpose of 
improving their immunostimulatory activity. 
The first part of the discussion describes the successful synthesis of novel 
acetal, carbonate, carbamate and ester linkers of tocopherol and cholesterol 
for attaching lipophilic molecules to the nucleotide constructs. This was done 
in order to improve transport of the molecules across cell membranes as the 
lipophilic tail can assist the likelihood of oligonucleotide uptake into the cells 
by reducing their polarity. 
Furthermore, a linker was synthesized which was used to link tumour 
targeting GRE1, GRE4 and G34 rabbit antibodies provided by the labs in 
Queens Medical Center and Aphton Corporation to different DNA constructs 
containing antisense insert. The resulting solutions of bound antibodies were 
purified to give the biologically active antibody constructs. The antibodies 
retained at the binding sites were eluted and showed biological activity, which 
unfortunately could not be maintained. 
The second part reports the development of new improved methods for the 
global and partial protection of nucleosides employing tert-butyldimethylsilyl 
chloride (TBDMSCI) as a suitable and versatile protecting group for the 
hydroxyl functions of the nucleosides without the need for base protection. 
The conditions employed averted any silylation of the amino bases, increased 
the rate of reactions and afforded high yields of the protected nucleosides. 
Selective 5'-desilylation was also achieved and the silylated derivatives of the 
nucleosides were utilized in the formation of lipophilic nucleoside conjugates 
and subsequent synthesis of CpG dinucleotides. 
The third part entails the synthesis of nucleosides covalently linked to 
lipophilic molecules through the exocyclic amino base or the 3'-hydroxyl 
group, forming novel carbonyl-type links. 
II 
This was done with the aim of improving their transport and hybridization 
properties and increasing their nuclease resistance. Lipophilic N-carbamate 
and N-acetamide conjugates of globally protected guanosine and adenosine 
were synthesized in very good yields. Modifications at the 3'-terminus of the 
nucleosides, which can potentiate their immunostimulatory activity, afforded 
their lipophilic 0-carbonate analogues in good yields. 
An alternative method for the synthesis of these conjugates was also 
investigated by employing the acid chloride of cholesterol, which led to low 
yields. Furthermore thioctic acid, which is also considered a lipophilic 
compound, was utilized and formation of its N-carbamate analogue of 
adenosine was achieved though employment of coupling reagents. 
The fourth part describes the successful formation of CpG dinucleotides with 
or without the attachment of lipophilic molecules using both solution and solid 
phase synthesis. Also, the 5'-dicetyl, dicholesterol and ditocopherol 
phosphates of the CpG dinucleotides were synthesized in order to examine if 
modifications at the 5'-terminus can enhance cellular uptake and increase 
immunostimulatory activity. Hence, the N,N-diisopropyl-phosphoramidites of 
cetyl alcohol, cholesterol and tocopherol were prepared which were 
subsequently coupled to CpG through their 5'-end, in order to form the 
lipophilic phosphodiester CpG dinucleotides. 
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INTRODUCTION 
Synthetic oligonucleotides have proved to be invaluable tools of modern 
molecular biology 1• The facile and efficient production of synthetic 
oligonucleotides has spurred interest in the application of these biomolecules 
to a variety of diagnostic and therapeutic indications. Oligonucleotides 
fuctionalized with intercalators, cross linkers, affinity ligands and DNA/RNA 
cleaving agents are examples of such applications2·They can also been used 
for the enzymatic construction of genes3 , physical studies of the stability and 
conformational behaviour of nucleic acids4 and investigation of drug-nucleic 
acid and protein nucleic acid interactions5 . 
Recent advances in chemical synthesis especially polymer supported 
methods6 have markedly reduced the enormous amount of time formerly 
required for oligonucleotide synthesis. Compounds which stimulate the 
immune response have great potential7 in the treatment of diseases such as 
cancer where conventional therapies using cytotoxic agents cause serious 
side effects due to the low discrimination between cancer cells and the cells of 
normal healthy tissue. 
Inhibition of the gene expression, where the oligonucleotides found 
application, has become an attractive method for the treatment of viral 
disease and cancer8. 
Oligonucleotides can be used to block deleterious genes by binding to a run 
of complimentary bases if the gene sequence is known, thus preventing 
expression of the gene and production of harmful proteins (antisense 
oligonucleotide). Complementary oligonucleotides can be utilized either to 
block sequences of DNA before transcription, or to block mRNA before 
translation occurs. Being normal products of cell biosynthesis they are rapidly 
processed and degraded and have low or no toxicity, thus avoiding the side 
effects common with many therapeutic agents. 
Antisense oligonucleotides (ODN's) have been proposed as a major class of 
new pharmaceuticals. In general, antisense refers to the use of small 
synthetic oligonucleotides; resembling single stranded DNA, to inhibit gene 
expression. 9' 11 • 
Antisense binding was first described as a naturally occurring phenomenon in 
which cells transcribe an antisense RNA complementary to a cellular 
mRNA.9•10·12 This antisense RNA was found to be a repressor of gene 
expression, hybridizing to a target mRNA, inhibiting its translation and 
decreasing the cellular levels of the protein 12. 
Antisense RNA is produced from the corresponding antisense genes by 
transcription. In the simplest case this can take place by transcription of the 
complementary (antisense) DNA strand. The antisense RNA then binds to the 
complementary (sense) target nucleic acid via Watson-Crick base pairing 13 in 
which adenosine and thymidine or guanosine and cytidine interact through 
hydrogen bonding (Figure 1) 
G-C Base Pair A-T Base pair 
Figure 1. Base pairing interactions for Adenosine with Thymidine (A-T) 
and Guanosine with Cytidine (G-C) where dR is the 2-deoxyribose sugar 
The process of binding of the oligonucleotide to a complementary nucleic acid 
is called hybridization. These simple base pairing rules govern the interaction 
between the antisense ODN's and the cellular RNA, allowing the design of 
ODN's to target any gene of a known sequence. 
2 
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A major advantage of this strategy is in the potential specificity of action. In 
principle, an ODN can be designed to target any single gene within the entire 
human genome, potentially creating specific therapeutics for any disease in 
which the causative gene is known. As a result there have been numerous 
studies of antisense ODN activity for potential antiviral 14~ 16 and anticancer17•18 
applications. Although the field has progressed over the past decade, recent 
papers indicate that the observed activity of ODN's in tissue culture can be 
predominantly through non-antisense mechanisms.15·16·19 
Oligonucleotide reagents have found wide application in biotechnology and 
more recently in medicinal chemistry to the extent that "antisense" 
oligonucleotides have been shown to block the translation and transcription of 
genes. Inhibition of gene expression through the use of an exogenously 
added oligonucleotide was first reported in 1978. 
Zamecnik and Stepherson20•21 were able with a 13-mer oligonucleotide that 
was complementary to the RNA of Rous sarcoma virus, to inhibit the 
replication of this virus in cell culture. Various cellular processes can be 
inhibited depending on where the oligonucleotide hybridizes on single 
stranded regions of the DNA or mRNA. A simple model describes the 
inhibition of protein biosynthesis by an antisense oligonucleotide being bound 
to the m RNA (Figure 2). 
Although this illustrative model does not always reflect the actual 
mechanisms, nevertheless it reveals the essential steps in the new principal 
and the problems associated with it: for the antisense oligonucleotide to be 
able to inhibit translation it must reach the interior of the cell unaltered. The 
requirements for this are stability of the oligonucleotide toward extra- and 
intracellular enzymes and also ability to penetrate through the cell membrane. 
Once the antisense oligonucleotide has reached the cytoplasm it must bind 
specifically and with sufficient affinity to the target mRNA to inhibit its 
translation into the corresponding protein. In order to meet all these 
requirements it is necessary for the normal oligonucleotides to be chemically 
modified in a suitable manner. 
3 
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Inhibition 
Cytoplasma 
Normal 
""' Protein ".._ mRNA 0 m RNA • DNA • 
No Protein I • <= <= J 10 <= • • • 
! Cellular Membrane 
Nucleus 
Antisense Oligonucleotide 
Figure 2. Principle of action of the antisense oligonucleotides 
A variety of possible oligonucleotide modifications are shown in the Figure 3 
below. 
it is also known22 that the presence of certain base sequences such as GC 
pairs in an oligonucleotide can lead to stimulation of the immune system and 
in the case of therapeutic agents helps the body's own defences to fight the 
disease. 
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5'-conjugates 
0 e 1 
o-~0 
ASE 
CD G 
Figure 3 
Ribose: 
2'-0-methylribose 
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1. METHODS FOR THE SYNTHESIS OF 
OLIGONUCLEOTIDES AND THEIR ANALOGUES 
The preparation of unmodified oligodeoxynucleotides has been the center of 
interest of many research groups. One of the most important aspects of the 
synthesis is the chain-extension process in the conventional methods used up 
to date. 
Three principal methods: the phosphoramidite (known as amidite method), 
phosphotriester and H-phosphonate, have been widely used for the 
synthesis of oligonucleotides. The phosphotriester approach has been used 
widely for solution phase synthesis, whereas the phosphoramidite and H-
phosphonate methods have found application mainly in solid-phase synthesis. 
(A) Phosphoramidite method 
The synthesis via phosphoramidites, originally introduced by Letsinger23 
(REF), is currently the most efficient method24 for preparing oligonucleotides 
and can be used to construct oligomers having up to 175 nucleosides using 
automatic DNA synthesizers. The basic steps in the phosphoramidite method 
are shown in Scheme 1 below. 
6 
Basic steps in a cycle of nucleotide addition 
by the phosporamidite method 
DMTrO~o__JASEPG _...:_"-'---~-
')---/ _ CCJ3C02H 
()-L,, 
Capping off step 
Ac201 DMAP 
Repeat 
cycle 
DMTr0~0~sl8 
)---/ Tetrazole 
0 NC~O-f?/ 
~(i-Pr)2 
Oxidation DMTrOL.--o---JASEPG 
12, Pyridine/ H20 'Y 
Scheme 1 
0 NC~O, / 
'f 
O~ASEPG 
o--[:""0 
This method includes use of a highly efficient coupling reaction between a 5'-
hydroxyl group of a support-bound deoxynucleoside and an alkyl 5'-
Dimethoxytrityl-protected-(N-protected}-deoxynucleoside-3'-0-(N,N-
diisopropyl)phosphoramidite, the alkyl group being methyl or 2-cyanoethyl. 
Protonation at the nitrogen converts the phosphoramidite into a highly reactive 
phosphitylating agent, where the tetrazole is just sufficiently acidic in order to 
activate the phosphitylation without causing loss of the protecting groups. 
The product of the coupling is a dinucleotide phosphite, which must be 
oxidized with iodine and water in the presence of pyridine to the 
phosphotriester before proceeding with chain extension. The efficiency of the 
coupling is extremely high and the only side reaction is the phosphitylation of 
the 0-6 position of guanine. Treatment though with acetic anhydride and N-
methylimidazole (introduced before hand to cap off any unreacted hydroxyl 
groups) completely reverses this side reaction25 
7 
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(B) H-phosphonate method 
In the past two years the H-phosphonate method, which was first described 
by Todd26 in 1957 has become reestablished and has in some cases replaced 
the amidite method, particularly because the synthons are easier to handle, 
and no phosphate protective group is employed.27-29 This method entails the 
5'-0H group of the growing DNA chain to react with a nucleoside 3'-H-
phosphonate (Scheme 2) 
Basic steps of the H-phosphonate method 
DMTr~oo--J ASEPG __ __.::.__:'-----CCI3C02H 
Q-L"o 
Repeat 
cycle 
Condensation 
p R-e, Pivaloyl chloride. adamantoyl chloride 
Cl 
Scheme 2 
The condensing agents used are sterically hindered carbonyl chlorides such 
as adamantoyl or pivaloyl chloride. 
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The resulting phosphite diester is oxidized with terl-butyl hydroperoxide or 
iodine to the phosphotriester only after construction of the chain is complete, 
in contrast with the amidite method. The H-phosphonate method can also be 
used to prepare oligomers of considerable chain length. 
(C) Phosphotriester method 
The phosphotriester method30•31 , which dominated oligodeoxynucleotide 
preparation for a long time, is still regarded as the method of choice for large-
scale synthesis31 , although the H-phosphonate approach has gained ground 
too.32 In this method the required phosphotriester is obtained in one step from 
the 5'-0H group of the growing chain and the nucleoside 3'-phosphodiester 
units as shown in Scheme 3. 
Phosphotriester method 
DMTrO\YASEPG 
DMTr\---oo._j ASEPG+ HO~o-._JASEPG -----~ ? ~ ')---./ Condensation 
0 0 Ar-502-NT RO-I?i ==a e 1 Q-t: 
o-r=o 01--o__JASEPG 
OR ')---./ 
CH3 
Ar-502-NT H3C*S02-Nj_ 
CH3 N N02 
MSNT 
?8 
-Hzy(i) I , 
k 
OCH3 
Scheme 3 
Q-t'o 
-""N 0 2S-N. ~ ~ N N02 
~ 
QSNT 
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The condensation is brought about with 3-nitro-1 ,2,4-triazolides of an 
arenesulfonic acid preferably 2,4,6-triisopropylbenzene-sulfonic acid33·34 
(TIPS) or 8-quinolinesulfonic acid35·36 (QNS). 
A further improvement was achieved by using nucleophilic catalysts, e.g. 4-
substited pyridine N-oxides, which intramolecularly attached to the phosphate 
protecting group, improve the coupling yield to 98% and reduce the time taken 
for a synthesis cycle to 7-8 min. 37 
The synthetic oligodeoxynucleotides can be purified by polyacrylamide gel 
electrophoresis followed by removal of the salts or, by HPLC.38·39 Capillary gel 
electrophoresis40.41 is proving to be extremely useful for the analysis and 
fractionation of small amounts of oligodeoxynucleotides and may be regarded 
in the future as the method of choice. 
Sequence analysis of purified oligonucleotides is possible by two methods: 
The first method is by Maxam and Gilbert,42 which is based on chemical 
cleavage and subsequent gel electrophoresis. The second one is the 
wandering-spot method,43 in which the oligodeoxynucleotide is subjected to 
partial enzymatic degradation and fractionated by two-dimensional 
electrophoresis. Sequences of shorter oligodeoxynucleotides can also be 
analyzed by FAB or by plasma desorption mass spectrometry.44.45 Since 
these rapid and accurate analytical methods can also be applied to modified 
oligonucleotides,46 they could well achieve greater importance. 
When normal oligonucleotides have been used as antisense oligonucleotides, 
problems such as instability to nucleases and insufficient membrane 
penetration have been encountered. That gave rise to a variety of 
modifications of the oligonucleotide structure in order to try to overcome those 
problems. 
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2. SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES 
AND THEIR CONJUGATES 
Modifications to the oligonucleotide have been employed most often for use in 
antisense inhibition where it is necessary for oligonucleotides to survive in cell 
cultures, or other biological environments, and also to cross the cell 
membrane. Modifications can be adopted to improve performance in both 
areas. 
Nucleases are widespread and the lipophilic cell membrane is an effective 
barrier against passive diffusion of polyelectrolytes. Changes can be made at 
the bases, the sugars, the end of the chain, or at the phosphate groups of the 
backbone. Those at the bases and sugars are generally the most difficult 
chemically and require the most synthetic work. In addition they must not 
disrupt the ability of bases to form hydrogen bonds. 
Modifications to the ends and backbone of the molecule are easier 
synthetically. The 5'-terminus is the most common site for conjugation as they 
are the site of action of nucleases and also carry the charges that inhibit 
cellular uptake. This represents the most direct approach for further 
derivatization. 
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A. OLIGONUCLEOTIDES WITH A MODIFIED PHOSPHATE 
RESIDUE 
Currently there is a great interest in the chemical synthesis of oligonucleotides 
bearing modifications of the phosphodiester internucleotide linkages. These 
changes in the backbone of DNA fragments often lead to an increased 
stability towards enzymatic hydrolysis by nucleases and a greater overall 
lipophilicity without influencing too much the hybridization conditions to a 
complimentary single-stranded DNA or RNA sequence. 
Therefore such backbone-modified DNA fragments seem to be the ideal tools 
for being applied in the control of gene expression on the mRNA level known 
as the anti-sense approach. This could finally lead to agents capable of 
stopping the growth of viruses of malignant cells.47 
The most extensively studied analogues have been those containing modified 
phosphate linkages. Since the early experiments, researchers have observed 
that oligonucleotides containing methylphosphonate 1, phosphotriester 2, 
phosphorothioate 3 or phosphoramidate 4 linkages (shown below) have 
inhibitory activity against viral replication or expression of cellular genes in a 
number of different tissue culture systems 
0 0 0 0 
11 11 11 11 
~o-P-o~ ~o-P-O'VVVV' ~o-P-O""""" ~o-P-o""""" 
I I ~0 I CH3 OR NR2 
1 2 3 4 
12 
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(I) Methylphosphonates (1) 
The methylphosphonate linkage is uncharged and gives rise to nucleotides, 
which are less water-soluble than their phosphate counterpart. In order to 
improve uptake by the cells and extend the biological half-life, Miller and 
Ts'048.49, have concentrated on eliminating the negative charge on the 
internucleotide phosphate bridge. 
Methylphosphonate oligodeoxynucleotides, which are called MATAGENES 
(masking tape for gene expression)50, are very stable with respect to cellular 
nucleases51 and can enter cells although through a passive mechanism which 
is not related to that which appears to drive the uptake the of charged 
oligonucleotides.52 A methyl group, which is neutral and sterically 
undemanding, replaces the negatively charged phosphate oxygen. 
Initially the triester method found application in the synthesis of 
methylphosphonates which involved the condensation of 3'-
methylphosphonates with 5'-unprotected nucleosides using various coupling 
reagents such as 1-(2-mesitylsulfonyl)-3-nitro-1 ,2,4-triazole (MSNT). 53• 54 Miller 
and Ts'055 eventually optimized this strategy, by using 5'-protected 
nucleoside 3'-methylphosphonic acid imidazolides as shown in Scheme 4. 
DMTr~ASEP+G 
I 
H3C-t 0 
[ ,) 
N 
HO~c-o__JASEPG y 1H-Tetrazole 
Q-t:p 
DMTrO.~ASEPG 
? 
H3c-rr=o 
O~ASEPG 
Q-Lp 
Scheme 4 Preparation of oligonucleotide methylphosphonates by the 
phosphotriester method. 
The yields in each coupling step are 88-92%, which allows 15-mers to be 
synthesized in an isolated yield of 4%. 
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However the method of choice utilizes methylphosphonoamidites on a solid 
support56·57 that proceeds in high yields (97%) in each coupling step (Scheme 
5). The use of these synthons also allows unmodified oligodeoxynucleotides 
with one or several methylphosphonates bridges to be introduced at any 
desired point in the molecule, using the usual synthesis cycle.56 
DMTr~o_JASEPG 
HO~ASEPG )----"" 0 
1) 1H-Tetrazole ? H,c-f?
1
=o 
o-L"O 2) l2 I H20 O~ASEPG 
o-t:o 
Scheme 5 Preparation of oligonucleotide methylphosphonates by the amidite 
method. 
Since the intemucleotide methylphosphonate bridge is more base labile than 
the natural intemucleotide linkage,57•58 milder conditions are necessary for 
cleavage from the support and deprotection. Whereas the latter is normally 
carried out with concentrated NH40H at 60 °C for 8h, in the case of 
methylphosphonate it is carried out again with concentrated NH40H at room 
temperature for only 2h and then with ethylenediamine /ethanol (1 :1) for 7h, 
likewise at room temperature.55·56 
Modifications to phosphates though pose a problem as they make the 
methylphosphonate bridge chiral, with an Rp or Sp configuration. Attempts 
were made early on to separate diastereomeric dinucleotides by 
chromatographic methods.53 Stec et aP9·60 introduced the first promising 
approach to stereoselective synthesis. 
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This entails the Rp or Sp diastereomers of T MeT being obtained by 
stereospecific reaction of the P-chiral nucleotide components 5'-0-
(monomethoxytrityl )thymidine, 3' -0-(0-(4-nitrophenylmethanephosphonate) 
and 3'-0-acetylthymidine as shown in Scheme 6. 
The 5'-0H group is activated by tert-butylmagnesium chloride, and the 
reaction takes place with inversion of the stereochemistry of phosphorus. The 
stereochemistry is >95% but the chemical yield of ea. 70%, resulting in a little 
hope of successful use in solid-phase synthesis. 
MMTr? +HO~ __ t-_Bu_M_gc_l_. P-y-rid-in_•_ O O 
l~o + H3Co····· .. R\~ 
OAc 0~ 
OAc 
"Sp" > 95% 
Scheme 6 
MMTr? 
0 
H3c-_l-c/o ~ 
OAc 
Only tetramers with all Rp and Sp configuration are obtained by stepwise 
reaction. Predominantly Sp-configured benzylphosphonates have been 
reported recently61 via the reaction of organozinc halides with PCI3• 
15 
(11) Phosphotriesters (2) 
Oligodeoxynucleotide phosphate triesters lack the usual negative charge 
present on the oxygen in the oligodeoxynucleotides and are accessible via 
several routes. They are produced as intermediates in the amidite as well as 
in the phosphate triester method, as well as the amidite method. In these 
cases, the triester serves to protect the phosphate and must accordingly, be 
easily cleaved. DNA phosphate esters have been of interest for a long time as 
products of alkylating agents, but they acquired additional significance as 
potential antisense oligonucleotides.48•62 
The amidite method is widely used to synthesize phosphate triesters from 
nucleoside dimers and oligomers. Mainly employed for this are the 5'-
protected nucleoside 3'-(0-isopropyi-N ,N-diisopropyl-phosphoramidites) and 
their 0-ethyl analogues63.65 (Scheme 7) 
DMTr?ASEPG 
? 
--~~~,~ 
H~o__JASEPG ~ 1) 1H-Te1razole 
Q-t'0 2) lz I H20 
Q-Lp 
Scheme 7 Preparation of oligonucleotide phosphotriesters by the amidite 
method 
The synthesis is efficient and moreover provides the opportunity to replace 
the lz /HzO oxidation by a reaction with Ss /pyridine, thus obtaining 
phosphorothioate triesters. lt is possible to incorporate both groups at any 
desired point in normal oligodeoxynucleotides64•65• The cleavage of the 
support and the deprotection of the bases is carried out with 25% NH40H at 
room temperature for 48 h. 
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The ethyl and isopropyl phosphate triesters are stable under these conditions, 
whereas methyl and cyanoethyl esters are completely removed.65 
Stec et a/.,66 developed in 1987 a method that combines some advantages of 
the classical amidite method with some of the H-phosphonate method. This 
employs 5'-protected nucleoside 3'-0-phosphorodimorpholidites as synthons, 
with hydrolysis to the H-phosphonate at each synthesis cycle (yields between 
90 and 99%), and then oxidation is necessary only once at the end of the 
synthesis. 
Alternatively alcohols can be used for alcoholysis, and the resulting phosphite 
triesters are oxidized at the end of the synthesis. This method shown below in 
Scheme 8 is attractive due to its versatility. 
DMTrO~ASEPG 
0 
~I 
q,____~rrf 
O?ASEPG 
Q-L,P 
Scheme 8 Preparation of oligonucleotide phosphotriesters by synthesis with 
phosphodimorpholino amidites, alcoholysis, and oxidation 
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The problem of chirality that has already been mentioned also occurs with the 
phosphate triesters. Considerable efforts have been made to separate the 
diastereomers arising due to this chirality center and to characterize them. 63·67 
A method was employed to allow for configurational assignment at the 
phosphorus irrespective of the nature of triester. 
Such a method is based on the stereoselective reaction of a P-chiral 
phosphothionotriester with H202 in acetonitrile /water to give an 0-triester on 
one hand and with thiophenol /triethylamine in dioxane to give a 
phosphorothioate on the other hand.68 This kind of reaction is shown in 
Scheme 9 below. 
Ph-SH I Et3N 
dioxane 
Scheme 9 
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(Ill) Phosphorothioates (3) 
In phosphorothioate oligodeoxynucleotides one of the phosphate oxygen 
atoms not involved in the bridge, is replaced by a sulfur atom, with the 
negative charge being distributed asymmetrically and located mainly on 
sulfur. This substitution results in properties such as stability to nucleases, 
retention of solubility in water, and stability to base-catalyzed hydrolysis, 
which makes it exceptionally interesting for use in antisense technology. 
The incorporation of internucleotidic phosphorothioate linkages into 
oligonucleotides has considerably enchanced their resistance to hydrolysis 
consequently increasing the stability of DNA to enzymatic hydrolysis. 
lt has been demonstrated that antisense phosphorothioates complementary to 
the messenger RNA (the sense sequence) of the HIV-1 gene inhibited the 
cytopathic effect of the virus in chronically infected H9 cells69• Just like the 
unmodified oligodeoxynucleotides, the phosphorothioates analogues can be 
prepared by the 3 main methods of synthesis, amidite, phosphotriester and H-
phosphonate methods. 
Synthesis of all-phosphorothioate oligodeoxynucleotides is more easily 
carried out as single-step sulfurization in a modification of the H-phosphonate 
method.7° Fujii et a/}1 was the first to describe the oxidation of the H-
phosphonate with S8 in pyridine/triethylamine, which was subsequently 
applied to solid-phase synthesis,72•73 as shown in Scheme 10. 
The advantage of this approach is that oxidation with sulfur (0.1 M S in 9:1 
CS2 I triethylamine, 2h), is necessary only once after the completion of the 
synthesis. 
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'0 ASEPG ~ S8 /CS2/Et3N 
? H-r= a 
O~ASEPG 
Q-L"o 
Scheme 10 Synthesis of oligonucleotide all-phosphorothioates by a 
modification of the H-phosphonate method 
The usual amidite method is also used for the synthesis of phosphorothioates, 
the only change being oxidation with 0.4 M Sa in 2,6-lutidine or 5% Sa in 
pyridine at room temperature in place of the usual 12/H20,74 as shown in 
Scheme 11 below. 
Scheme 11 Synthesis of oligonucleotide phosphorothioates by a modification 
of the amidite method 
The yield in the subsequent coupling step remains at the same high level. 75 
This method is particularly attractive because it can be carried out without 
extensive alteration of the normal synthesis cycle and is therefore still 
regarded as the method of choice. 76 Another advantage derives from the fact 
that phosphorothioate bridges can be introduced in this way at any desired 
point in the oligonucleotide synthesis. 74-76 
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This is of interest particularly for studies of enzyme mechanisms77 but also for 
antisense technology. 76 Subsequent oxidation with l2 I H20 does not seem to 
cause loss of sulfur. The de protection of the thiophosphate group from the 0-
methyl ester is carried out at the end of the synthesis with thiophenol. 
The phosphotriester method, without any modification in terms of strategy for 
the removal of the protective groups or the cleavage of the support, has also 
found applicability in the synthesis of phosphorothioate analogues. 
The groups of Reese78 and van Boom79, have synthesized the 
phosphorothioate by the above method employing 2,5 dichlorophenyl 
phosphorodichloridothioate, as phosphorylating and coupling component. The 
preferred activator for the reaction is 1-hydroxy-6-benzotriazole (Scheme 12). 
DMTr?ASEPG 
S ~/oj)CI 
I Cl 
O~ASEPG 
Q-t.,P 
Scheme 12 Synthesis of oligonucleotide phosphorothioates by the 
phosphotriester method 
Standard methods were used for cleavage of the support and removal of the 
protective groups/9 while yields of >90% were reported for a 10 m in 
synthesis. 
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The dinucleotide phosphorothioates have, as do the methylphosphonates and 
phosphotriesters, a chirality center at the phosphorus. There is a great 
interest in chromatographic separation of the diastereomeric dimers,80·81 
spectroscopic characterization82 and the possibility of stereospecific 
synthesis. 
Fujii et a/.71 published in 1986 a method (shown in Scheme 13) for the 
stereoselective preparation of the Rp diastereomeric dimmers TsT and dA5T. 
This entailed the corresponding aroylphosphonates being reacted with tert-
butylamine in the presence of DBU and sulfur directly and exclusively to the 
Rp isomer with a yield of ea. 60%. 
DMTr~ 
0 0 Q-~-f=o 
n-BuNH2, DBU 
Sa 0\Y 
OAc 
Scheme 13 
DMTr~ 
Q 
es-t=o 0\Y 
OAc 
"Rp" configuration (> 99%) 
yield 60% 
The chirality problem can be avoided if the second phosphate oxygen, which 
is not involved in the bridge, is also replaced by sulfur. Caruthers et a/.83·84 
have described the synthesis of such phosphorodithioates. In this, a 
phosphorothioamidite is condensed with a second nucleoside with tetrazole 
catalysis and the resulting intermediate is oxidized with 5% sulfur to the 
phosphorodithioate. The synthesis can also be carried out on a solid support. 
To ensure high coupling yields the phosphorothioamidite must be supplied 
twice to the solid support in the coupling step. 
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(IV) Phosphoramidates (4) 
The phosphoramidates are an easily obtainable group of nucleotide 
analogues, which can be prepared in various ways from three- and five-valent 
phosphorus intermediates. 
The method of phosphorylaf1ng amines by condensation with phosphate 
diesters in the presence of triphenylphosphine and CCI4 has often been used 
to prepare dinucleotide phosphoramidites. 85.87 However the yields were 
moderate85·87 (between 53-65%) while yields of 70% were reached only on 
solid supports.87 
By contrast, oxidation of dinucleotide H-phosphonates in the presence of 
amines gives the corresponding dinucleotide phosphoramidates88·89 in high 
yields. 90 The reaction can easily be extended to polymer-bound di- and 
oligonucleotide H-phosphonates. The oxidizing agent used for the coupling, 
which can be carried out with primary and secondary a mines, is l2 employing 
CCI4 as the solvent89·91 as shown in Scheme 14 below 
HND HN~, 
' \_/ 
,r\, 
HN N-Me 
\_/ 
Scheme 14 Synthesis of phosphoroamidates by oxidation of H-phosphonates 
Besides the described oxidation of H-phosphonates, which results in all 
phosphoramidate oligodeoxynucleotides, phosphite triesters are also oxidized 
with iodine in the presence of alkylamines. 
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This oxidation, which was first described by Nemer and Ogilvie88 is particularly 
attractive87 because it can be carried out without expensive alteration to the 
amidite synthesis cycle. 87 This entails oxidation with 0.1 M l2 in 2:1 THF I 
alkylamine, resulting in selective elimination of the methyl protective group 
(Scheme 15). 
12 / R.NH2 , THF 
Scheme 15 Synthesis of phosphoramidates by oxidation of dinucleotide 
phosphite triesters 
This high yield method utilizes methanolic tert-butylamine for deprotection and 
cleavage of the support. An additional feature of the method is that 
phosphoramidite bridges can be incorporated at any desired point in the 
oligonucleotide. The process also allows for the generation of oligonucleotide 
conjugates, 87•92 e.g., with intercalating agents via alkylamine linkers that can 
be introduced during the oxidation step. 
None of the methods used above result in the preferential formation of a 
diastereomer, but the mixtures in the case of the dimers can be separated by 
chromatography and characterized by spectroscopy.87 N-
Aikylphosphoramidates are suitable as functionalizing groups, via the alkyl 
radical and can be used to produce oligonucleotide conjugates (REF). 
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B. OLIGONUCLEOTIDES WITH A MODIFICATION AT THE 5' 
OR 3'-END AND THE AMINO BASE 
Oligodeoxynucleotides can be covalently linked to a wide variety of molecules 
and the coupling can be done through sites present naturally in nucleic acids. 
The naturally occurring groups that can be used are amino groups on the 
bases, hydroxyl groups on the sugars and phosphate groups, both terminal 
and internal. 
In the context of antisense technology, this is usually done to improve 
transport and hybridization properties of the oligonucleotides. Conjugates are 
differentiated according to the position of their linkage to oligonucleotides and 
according to their function. This linkage can be introduced at one of the three 
stages during oligonucleotide synthesis. 
• The linker can be attached to a nucleotide before incorporation into the 
growing chain. 
• Molecules other than nucleotides can be introduced during the synthesis of 
the oligonucleotide. 
• A linker group can be attached to a natural nucleic acid or to a synthetic 
oligonucleotide after deblocking. 
The conjugates formed are designed to improve some of the existing features 
of the oligonucleotide, which will be endowed with some completely new 
property, either physical or chemical, while retaining its ability to base pair. 
Linker groups combined with oligonucleotides fall into two major categories: 
1. Chemically Reactive Groups. Groups that cleave or cross-link with other 
nucleic acids or proteins are used to study interactions between these 
molecules and oligonucleotides, and to create possible therapeutic agents. 
2. Groups Promoting Intermolecular Interactions. The best example of this 
category is the intercalating agents or lipophilic compounds used to 
strengthen the hybridization of the oligonucleotide with its complement and 
enhance cellular uptake. 
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(I) Conjugation via the 5' End 
Covalent linkage from the 5' end of oligonucleotides is particularly attractive 
because it can be carried out in the solid phase synthesis in a similar manner 
to the 5'-phosphorylation of oligonucleotides The group that is to be linked can 
be derivatized as a phosphoramidite, H-phosphonate, or phosphate and 
withstands the coupling and deprotec!ion. 
(a) Intercalating Agents 
The idea of linking an intercalating compound to an oligonucleotide was first 
described by Letsinger.93 There has been a number of papers in which 
phosphotriester, or amidite chemistry was used for covalent attachment of 
intercalating agents, usually acridine derivatives to the 5' end of modified and 
unmodified oligodeoxynucleotides.94"96 
Thus, 2-methoxy-6-chloro-9-((5-hydroxypentyl)amino)acridine (shown in 
Scheme 16) has been linked via its phosphoramidite to oligodeoxynucleotide 
methylphosphonates and a-anomeric oligodeoxynucleotides.97•98 The same 
intercalating agent has previously been incorporated using phosphotriester 
chemistry99"1 00 . 
a) acridine-conjugate 
~ ~"~ N3 N NI H H(l} 
(CH2l3 o I 11 
S-l-O~ASEPG e o 
c) azidoproflavlne-conjugate 
0 
0" 
0 0 
-o- 11 11 N3 C-CH,-S-1?1 -o~ASEPG e o 
b) p-azldophenacyl·conjug:e 0" 
Scheme 16 
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(b ) Cross-Linkers 
Cross-linkers can be linked to the 5' -position by a variety of methods. 94-96 
Thus psoralen derivatives (shown above in Scheme 16) have been 
incorporated in oligonucleotides and oligonucleotide methylphosphonates via 
the amidite chemistry101 and phosphotriester chemistry. 102 
Helene et al., introduced azidophenacyl,103 azidoproflavine 105 (shown above in 
Scheme 16) and proflavine104 and to the 5'-position by first converting the 
oligonucleotide into the 5'-thioshosphate, which could then be alkylated via a 
bridge with the particular cross-linker (3-azido-6-((3-bromo-
propyl)amino )acridine.105 
(c) Lipophilic Carrier 
The transport of oligodeoxynucleotides into the cells has been facilitated, by 
linking them to lipophilic carriers. Goodchild et al.1061•l described the 
incorporation of long chain alcohols as phosphate esters in the 5'-position of 
oligonucleotides. This can take place at the end of solid phase synthesis by 
use of an appropriate phosphoramidite. Letsinger106ibl has reported only one 
example of a cholesterol conjugate of oligonucleotides in the literature. 
Universal methods for fuctionalizing oligodeoxynucleotides with amino or 
mercapto groups have been described Sinha and Connolly, 107 who used H-
phosphonate and amidite chemistry to attach amino-alkyl and mercaptoalkyl 
linkers to the 5'end (Scheme 17). A large number of derivatives, such as dyes 
or other nonradioactive markers, can be introduced via these linkers. Simple 
linkage with polylysine, which is intended as a carrier for oligonucleotides 108, 
via a maleimide has also been described. 
DMTr-Y N(iPr), I / 
n(H2C)-O-P"'. CN 
0~ 
DMTr-Y 0 
I 11 
n1H2C)-O-J?I-H 
oG 
Y=S, NH 
Synthons for the amino- and thiofunctionalization of oligonucleotides 
Scheme 17 
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!Ill Conjugation via the 3' End 
Modifications at the 3'-end are less common due to the inaccessibility of this 
site in solid support synthesis. This problem was though solved using a 
support with a modification build in. 
Polyamide or polypeptide chains were synthesized on a support to give 
conjugates with a 3'-polypeptide tail. The spacer between the nucleoside and 
the support was designed so that on cleavage, a reactive nucleophile is 
generated at the end of the oligonucleotide. 
Reactions at the 3'-end can be performed more readily using solution phase 
synthesis. Examples are the condensation between a 3'-phosphate and the 
hydroxyl group of an acridine or phenanthroline derivative using triester 
chemistry.109,110 
(a) Intercalating Agents 
The synthesis of conjugates of intercalating agents with oligonucleotides via 
the 3' position has been extensively investigated; the agent mostly used was 
2-methoxy-6-chloroacridine. Whereas 5'-derivatization is primarily carried out 
in solid-phase synthesis using amidite chemistry, the one in the 3'-position 
mainly employs triester chemistry11 H 14, as shown below in Scheme 18. 
3'-Conjugation of modified oligonucleotides containing methyl esters has also 
been described. 115 
'0 BASEPG 
\---O;I /CH,),.OH I H-N 
0 ~~~/OCH, MsNT 
Cl-o-0-~=0 )ll"~ 
- be Cl N Pyridine 
Scheme 18 
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(b) Alkvlating Oligonucleotides 
Grineva et al. 116 put into practice the idea of specific and irreversible 
modification of DNA by cross-linking. They used for this a dinucleotide that 
was fuctionalized at the 3' end via an acetal linkage with an anomeric (2-
chloroethyl) amino group (Scheme 19). Alkylating groups have also been 
attached in the 5'-position via phosphoramidate linkages, as shown in 
Scheme 16 in page 26. 
a) 3'- conjugate b) 5'- conjugate 
Scheme 19 
The neighbouring group participation of the nitrogen means that the 
(chloroethyl) amino groups are particularly susceptible to alkylation and thus 
cross-linking. This mode of substitution was subsequently extended to 
oligonucleotides with a 3'-nucleoside residue and has been widely used in 
antisense technology. 117-119 The alkylation reaction appears to be 
"hybridization triggered" because no self-alkylation takes place. 
(c) Oligonucleotide-Peptide Conjugates 
Haralambidis et al. 120 described the successive solid-phase synthesis of 
oligodeoxynucleotides with a 3' -peptide unit. After the peptide chain has been 
synthesized on the support of the Fmoc method, a 4-hydroxy-butyryl linker 
was attached and then the oligonucleotide synthesis was carried out. The 
conjugate was deprotected at the end of the solid-phase synthesis Also 
Lebleu et al, 121 •122 synthesized oligonucleotide-polylysine conjugates, in order 
to improve the transport properties of oligonucleotides. 
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C. INCORPORATION OF LINKER GROUPS DURING 
CHEMICAL SYNTHESIS OF OLIGONUCLEOTIDES 
From a synthetic point of view, incorporation of the linkers during the 
assembly of an oligonucleotide rather than afterwards is the most rigorous 
approach. lt gives greater control over the number and location of the 
modifications, the protective groups of the nucleotides minimize side reactions 
and advantage is taken of the benefits of solid-support synthesis for work-up 
and purification. 
The incorporation of modified nucleotides is appealing for chemical synthesis 
as the nucleotide building block carrying the desired modifier can be 
introduced precisely at any internal or terminal position in the oligonucleotide 
with . assurance that modification at that position is complete. The 
modifications though must be able to withstand the coupling reaction and the 
rigours of acid and basic deblocking. 
Substituents may be attached to nucleotides at the base and sugar, but 
ideally, changes should not interfere with hybridization. Emphasis will be 
given on the nature of the bond-making reactions and the coupling reactions 
used for different linker groups. 
Substituents used for the formation of conjugates could be either electrophilic 
linkers or phosphoramidites. They are used most commonly for coupling at 
the 5' -end of an oligonucleotide while it is still fixed to a solid support or the 
amino base of nucleotides. The linkers must be soluble in an organic solvent 
suitable for the coupling reaction and, again, must withstand the deblocking 
procedure. 
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(I) Electrophilic linkers 
Most examples of conjugate formation use a nucleophile to react with 
electrophilic linkers. Oligonucleotides contain a number of reactive sites that 
can be used for conjugation. For the most part these are nucleophiles and 
include the nitrogen function on the bases, primary and secondary hydroxyl 
groups and phosphomono- and diesters. 
Unwanted reactions may occur at other sites of the nucleotide, which are 
predominantly nucleophilic in nature, particularly the bases. Reactions at 
these sites are likely to lead to complex mixtures unless they can be 
controlled in some way. 
An electrophilic linker can be used providing that it does not undergo 
intramolecular coupling with other sites. Steric hinderance around the reacting 
amino group can be a troublesome. Electrophiles can be used in the form of 
carbonyl compounds or activated carboxylic acids and are directly coupled to 
the amino group of nucleosides. 
Related species that have been used in literature include nitrophenyl92•123; 
and pentachlorophenyl esters 124 , acid anhydride 125•126 and the ester of N-
hydroxysuccinimide that give an amide. 127"130 The reactions have also been 
extended to reactive sites other than amines and been studied in some detail 
to minimize base modification. The N-hydroxysuccinimide ester gave less 
reaction at the bases but was also less efficient overall. 
Also electrophilic linkers were used to label RNA with a number of fluorescent 
dyes and other agents. 131 •132 For the labeling of RNA with biotin, periodate 
was used to oxidize the 3'-terminal nucleoside to a dialdehyde that was then 
reacted with a primary amine and reduced with borohydride. 
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(11) Phosphoramidites 
A site amenable to ready modification is the internucleoside phosphate, 
during the oxidation of intermediate phosphites. The covalent linkage is 
usually brought about at the 5' -end with phosphorylating agents, such as 
phosphoramidites that have the general structure below. 
They can be employed to phosphorylate the 5'-hydroxyl group using triester 
chemistry and introduce one or more lipophilic groups into the backbone. The 
phosphate can be used for modification at a later stage or it can be selectively 
deblocked before cleaving from the solid support. 
Letsinger and his eo-workers 124 have done much of the work on conjugation 
here. They reported a method for linking through phosphoramidates to 
prepare conjugates of phenathridine and cholesterol. 
Phosphoramidite derivatives of biotin 133 and anthraquinone 134 have been used 
similarly. Other workers have introduced derivatives of tetramethylrhodamine, 
and acridine using triester synthesis both by solid support and solution-phase 
synthesis.109•135 
Modifications at the 3'-end are less common due to the inaccessibility of this 
site in solid-support synthesis. Reactions at the 3'-end may be performed 
more readily during solution phase synthesis. 
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D. INCORPORATION OF LINKER GROUPS AFTER THE 
SYNTHESIS OF OLIGONUCLEOTIDES 
Conjugate groups can be introduced after the synthesis and de blocking of the 
oligonucleotide. This normally requires less effort than incorporation during 
synthesis but introduces other problems. Post synthetic reactions on 
oligonucleotides can be used to modify linkers or introduce a conjugate group. 
As oligonucleotides are polyionic, post synthetic reactions are usually 
performed in water or aqueous solvent in which the reagents will be 
sufficiently soluble and stable. This in itself is restricting, as many synthetic 
reactions are not intended to be performed under these conditions. 
Since linkers are usually electrophiles, unwanted reactions may occur at 
many internal sites in oligonucleotides. The separation of oligonucleotides 
with different numbers of conjugated groups is difficult, as is their purification, 
which is usually not attempted. 
The structure of the product is frequently assumed from the nature of the 
starting materials, particularly with conjugates of large molecules, where it is 
generally not possible to apply the more rigorous standards of organic 
chemistry. For example analysis by NMR spectroscopy is not possible, and 
identification may only be achievable by mass spectrometry for very large 
conjugates. 
However, the reasons for making these compounds are usually for practical 
reasons and provided that they function as intended, then the precise number 
and location of the conjugate group may not be crucial. 
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3. PROPERTIES OF MODIFIED OLIGONUCLEOTIDES 
AND THEIR CONJUGATES 
Oligonucleotide derivatives are considered as potential biologically active 
compounds capable of interfering with the functions of target nucleic acids 
possessing complimentary oligonucleotide sequences. The efficiency of these 
derivatives as reagents targeted to cellular nucleic acids can be in increased 
by improving their ability to penetrate into cells and by stabilizing their 
complexes with the target nucleic acids. 
The factors that are usually assumed to limit the activity of the modified 
oligonucleotides are cellular uptake, resistance to nucleases and the 
stability of the hybrid formed. 
Modifications are usually chosen to improve one or more of these properties 
and the conjugate itself may prove beneficial in these regards if it is lipophilic 
or otherwise inhibits the action of nucleases 
Overall activity results from the interplay of these and other factors whose 
relative importance is not known. However, a steady improvement in activity 
has been achieved by using this rational approach that is encouraging for the 
designing of conjugates to meet specific requirements. 
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A. The effect of modification on oligonucleotide hybridization 
Modifications to the internucleoside phosphates can affect hybridization in a 
number of different ways, but it is important that they should not prevent base 
pairing. Reduction in charge density lessens electrostatic repulsion between 
the strands and should facilitate their association. 
lt has been suggested that steric interactions of substituents will normally 
destabilize the helix, as will their electronic and other properties. 136 These 
might include disruption of hydration of the helix. However the grooves of the 
hybrid might also provide a more lipophilic environment, thereby promoting 
hybridization. Cases where stronger hybridization resulted on increasing the 
lipophilicity of the substituent can be examples of such an effect.137·138 
The relative contributions of all these factors are governed by intrinsic factors 
such as the length of the oligonucleotide, the degree of modification, the 
localization of a given modification relative to the ends or middle of the helix, 
and the sequence of the bases around it. 136 Thus, the consequences of a 
particular modification will vary from case to case. 
In their early studies of uncharged methylphosphonates and triesters, Miller 
and Ts'0139·140 found that racemic di- to tetramers hybridized to unmodified 
strands with greater affinity than the parent phosphodiesters. While 
diastereoisomers of dimers differed from each other, both formed more stable 
hybrids than the natural charged compounds. This was attributed to the lack 
of charge-charge repulsion between the strands of the complex. 141 ·142 
An adverse effect on hybridization as the size of the substituent increased 
from PCH3 to POCH3 to POCH2CH3 seemed to be due to steric interactions. 
Similar improvements to hybridization were reported for other low molecular 
weight triesters and phosphoramidates. 138·143 With substituted amidites, these 
included a positively charged backbone. 
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Extensive substitution of longer oligonucleotides with various 
phosphoramidate linkages gave somewhat less stable hybrids than the 
phosphonates. Those derived from primary amines were superior to those 
from secondary amines.144 
Also improvements in hybridization were reported when bulkier substituents 
were used in the modification of the internucleoside phosphates. In an attempt 
to stabilize hybridization with short oligonucleotides, Letsinger and Scott124 
attached an intercalating agent to the phosphate groups of TpT. This proved 
successful and permitted the use of shorter oligonucleotides that would 
otherwise be possible for antisense studies. 
The physical chemistry of these interactions has been investigated145•146 and it 
has been shown that an intercalating agent at the end of an oligonucleotide 
especially the 3' -end is more beneficial than on an internucleotide 
phosphate.109•146 lt was also shown that a second intercalating group offers no 
further advantage. 
Modifications other than an internucleoside phosphate may also effect 
hybridization. a-oligonucleotides, for example, hybridize with ,8-RNA and DNA 
by forming the usual Watson-Crick base pairs. These hybrids are 
considerably more stable than when both strands are j3. 147 
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B. The effect of modification on nuclease resistance 
A number of studies have demonstrated degradation of unmodified 
oligonucleotides at greatly varying rates in different cells. Survival times vary 
from minutes to day.148-151 Consequently it has been a goal to develop 
derivatives that will be resistant to the enzymes that degrade nucleic acids 
(nucleases), on the assumption that they will be more potent. 
Modifications to internucleoside phosphates that have been investigated 
inhibit the action of nucleases. Most reports suggest complete resistance of 
phosphoramidate, 137•138•152•153 phosphonate, 154•155 or phosphotriester137•142•156 
linkages towards the nucleases that have been tested. All substituted 
phosphoramidates were resistant. While the modified linkages themselves 
may be resistant, in oligonucleotides containing mixtures of modified and 
natural linkages, exonucleases that work progressively from one end of the 
chain can sometimes skip over an isolated phosphonate or triester linkage to 
cleave the adjacent phosphodiester at a reduced rate. 155•157 
Modifications at groups other than phosphate may also induce resistance to 
nucleases. a-oligonucleotides, for example, proved to be far more stable than 
p.oligonucleotides in a number of different biological environments.158·159 
Increasing lipophilicity is likely to decrease the rate of degradation by 
nucleases that are designed to degrade polyanions. A presence of a bulky 
group such a lipophilic compound at an appropriate end of an oligonucleotide 
(either the 3' or 5' end) can increase its resistance to nucleases, thus 
preempting exonuclease attack.158·160 RNA was found to be more stable than 
DNA in nuclear cell extracts.161 Methylation of the 2' -hydroxyl group increases 
its resistance to nucleases. 162 
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C. The effect of modification in the penetration of 
oligonucleotides through membranes (cellular uptake} 
The activity of the oligonucleotides is crucially affected by how well they reach 
their site of action unmetabolised. The protein biosynthesis apparatus of the 
cell is located in the cytoplasm and comprises 55% of the cell volume. 
Thousands of enzymes bring about there the biosynthesis of sugars, fatty 
acids, nucleotides, amino acids and proteins. 
The m RNA produced in the nucleus by transcription of the DNA is translated 
into the corresponding protein on the ribosomes in the cytoplasm. In order for 
the oligonucleotides to act to stop translation by hybridization, they must pass 
through the plasma membrane into the interior of the cell. The plasma 
membrane is a natural barrier and can therefore be considered as a 
bottleneck in the antisense oligonucleotide concept. (Figure 2 in page 4 
shows the principal of the oligonucleotide action). 
A problem common to uptake studies is the difficulty in distinguishing material 
inside the cell from that bound to the outer membrane. Surprisingly though, 
despite their high charge density, oligonucleotides are taken up reasonably 
well by mammalian cells. This appears to be energy-requiring process and 
may involve receptor proteins on the cell surface. Intermolecular 
concentrations may rise to about 10% of those outside the cell within 15 m in 
to 2 h.14B.151.163.164 
Shorter oligonucleotides are taken up more rapidly and phosphorothioates are 
taken up more slowly than unmodified oligonucleotides.160 Uptake of 
uncharged methylphosphonates appears to be quite different. Intracellular 
levels of dimers to nonamers reached extracellular concentrations within 1.5 
h. 138 This would appear to be passive diffusion across the cell membrane. 
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Various ways have been employed to improve the penetration of the 
antisense oligonucleotides through the membranes with the most important 
being the lipophilic modification of the oligonucleotides. Lipophilic substituents 
such as intercalating agents and lipophilic alcohols facilitate uptake. 165•166 
Increasing lipophilicity to improve the cellular uptake is likely to decrease the 
rate of degradation by nucleases that are designed to degrade polyanions. 
The conjugate group itself can be proved beneficial in these regards if it is 
lipophilic to inhibit the action of nucleases. Among those conjugates are 
derivatives with acridine linked at the 3'end, which has a beneficial effect on 
both the ability to penetrate and the stability to nuclease. 167•168 
Conjugates of poly-L-Iysine were reported169•170 to stimulate the uptake of 
homooligoribonucleosides in tumor cells. Poly-L-Iysine can form complexes 
with the polynucleotides themselves, and these complexes have high affinity 
for the cellular membrane. 169 it is also able by interacting with the cellular 
receptor of HSV-1, to block the binding of the virus to the receptor. 171 In this 
connection, poly-L-Iysine, of molecular weight of 50,000 proved to be toxic in 
the micromolar range. 
Another group that like poly-L-Iysine, is intended to increase uptake, is 
cholesterol. Its conjugates can penetrate through the membrane in a specific 
manner in order to improve the passage of oligonucleotides through 
membranes. This can have beneficial effects for both unmodified and 
modified backbones as well as for alkylating agents. 172 
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4. IMPORTANCE OF LIPOPHILIC COMPOUNDS 
TOWARDS OLIGONUCLEOTIDE SYNTHESIS 
Major obstacles that prevent wider application of the antisense 
oligonucleotides are their limited oral bioavailability and permeability through 
cell membranes. Modification of oligonucleotides using lipophilic compounds 
is a possible method to improve their pharmacokinetics as they assist the 
likelihood of oligonucleotide uptake into the cells by reducing their polarity. 
These lipophilic groups fall into two groups: 
(a) Those known to interact specifically with cell membranes. e.g. 
Cholesterol173-175 and certain lipids 176 
(b) Those who impact general lipophilicity to the oligonucleotide e.g. Alkyl 
chains 177•178 
Molecules such as cholesterol 1 and tocopherol 2 (shown in Scheme 20 
below) are known to have an immune stimulating effect and can enhance the 
adjuvant effect of the oligonucleotide. lt is unclear by what mechanism these 
compounds exert their ability due to their lack of sequence specificity, but the 
lipophilic tail has been shown to improve cellular uptake.175•177 
0 
CHOLESTEROL 
2 OH 
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Scheme 20 
Vitamin E (tocopherol) and cholesterol are attractive candidates as lipophilic 
carriers for the following reasons: 
• They are inexpensive and essentially non-toxic 
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• They are found mainly in association with membranes of subcellular 
organelles 179 such as the endoplasmic reticilum and mitochondria, rather 
than in the plasma membrane. This maximizes the possibility of 
intracellular transport 
(A) TOCOPHEROL 
The protection of organic materials, including living organisms, against 
oxidative degradation is provided by fairly small quantities of certain specific 
compounds called antioxidants. 180 Tocopherol (known as vitamin E) is a major 
lipid-soluble chain-breaking antioxidant in mammalian cells and there is 
evidence that it may be involved in the division of normal and cancerous cells. 
181 lt has already182•183 been connected to DNA through ester linkages but little 
is known about the behaviour of these DNA constructs in cells. 
The term vitamin E6 refers to one or more of four structurally phenolic 
compounds called tocopherols. The tocopherols differ from one another only 
in the number and position of the methyl groups in the aromatic ring. 
a-Tocopherol, which is fully methylated, is the most plentiful and the most 
biologically active of these four compounds. lt has only one functional group 
for derivatization; the rest of the molecule is chemically inert. 
Biological membranes, which are composed largely of phospholipid 
molecules, cholesterol and the membrane-bound proteins,184 must be 
protected against peroxidation. Vitamin E appears to play a vital role in this 
protection and the chemistry that can occur depends on the average position 
of the various reactants and their mobilities. lt has been proved181 ·185 that in 
lipid bilayers, tocopherol is oriented with the phenolic hydroxyl group "head" 
towards the surface while the hydrophobic phytyl "tail" is embedded in the 
membrane, Thus attachment of the oligonucleotide to the phenolic hydroxyl 
group should have a minimal effect on the interactions of the vitamin E with 
membranes. 
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(B) CHOLESTEROL 
Cholesterol has a high affinity for lipid bilayers and a strengthening effect 
upon the vesicles (also called "liposomes"), which have delivered a 
widespread attention for drug delivery in cancer therapy.186 The lipophilicity of 
cholesterol transiently anchors the oligonucleotide to the cell membrane and 
may enhance the facility of cellular uptake and stabilize complexes formed 
with cellular nucleic acids. 187·188 
lt has been shown that molecules attached to unsaturated fatty acid esters of 
cholesterol are incorporated most readily into the LDL core (low-density 
lipoprotein).189 This protein is a selective and rapid vehicle for the delivery of 
lipophilic compounds to mammalian cells in tissue culture.190 Also addition of 
cholesterol to the 3' or 5'-terminus of phosphorothioate oligonucleotides has 
been shown to improve therapeutic affect in an HIV assay.191 
Both endogenous cholesterol, synthesized in the liver endoplasmic 
reticilum 192•193 and exogenous cholesterol are rapidly transported throughout 
the liver cell and are found in all the intracellular membranes and in small 
amounts in the cytosol.194 Reports have shown 195 that exogenous cholesterol 
appears rapidly in a number of subcellular fractions, including the chromatin 
fraction of rat liver, indicating that there must be a mechanism for rapid 
transport of cholesterol from the liver plasma membrane to other sites of the 
cell. 
In one cell line, cholesterol-modified oligonucleotides are localized in the 
nucleus, probably delivered by a cholesterol binding protein. 196 Such a protein 
can function as an intracellular cholesterol transport or receptor protein. lt can 
bind to both free and esterified cholesterol in roughly equal amounts and 
possesses the properties expected of an intracellular cholesterol transport or 
receptor protein.196 
42 
(C) THIOCTIC ACID 
Thioctic acid 3, which is also known as lipoic acid can also be considered as a 
0 
OH 
s-s 3 
THIOCTIC ACID (LIPOIC ACID) 
lipophilic compound. lt is widely distributed in plant and animal tissues 197 and 
as a lipoamide it functions as a co-factor for the multi-enzyme complex that 
catalyses the oxidative decarboxylation of a-keto acids and also as a growth 
factor in many bacteria and protozoa. 198 
Thioctic acid exhibits antioxidant functions: it scavenges hydroxyl radicals; 
singlet oxygen and also chelates transition metals. Thioctic acid and its 
reduced form (dihydrolipoic acid) appeared to be able to regenerate other 
antioxidants such as ascorbate and vitamin E. 199 
Due to these antioxidant properties and its high level of biological activity, it is 
useful for the treatment of various diseases.200 lt has beneficial effects in 
prevention and treatment of both type-1 and type-11 diabetes, and in preventing 
damage in myocardial and cerebral ischemia-reperfusion injury in rat. I! can 
also act as a radioprotective agent against damages to DNA and its 
components produced by radiation exposure. 
lt has also be shown to be potentially useful for the treatment of heavy-metal 
poisoning, degenarative diseases of the central nervous system, and AIDS 
which makes lipoic acid a biologically important molecule. 
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5. AIMS OF THE PROJECT 
The objectives of this project were: 
(a) Synthesis of novel linker groups for attaching lipophilic 
molecules to the oligonucleotide constructs 
This is done in order to improve transport of the molecules across cell 
membranes, which can be easily cleaved off once the DNA construct has 
entered the cell. 
(b) Development of methods for the global and partial protection-
deprotection of the nucleosides. 
The aim is to employ suitable and versatile protecting groups for the 
hydroxyl functions of the nucleosides without the need for base protection. 
(c) Synthesis of conjugates of different nucleotides, where the 
lipophilic groups are connected, to the exocyclic amino base or 
the 5' primary hydroxyl group, through novel type links. 
The scope of this is to improve the transport and hybridization properties 
of the nucleotides and explore their stability whilst containing these novel 
linkages. 
{d) Formation of dinucleotides containing the desirable 
immunostimulating sequences, such as CpG dinucleotides. 
The aim of this is to study the chemistry of such compounds with or 
without the attachment of lipophilic molecules, and to investigate the 
stability of the linkers, towards the deprotection conditions required to 
complete the oligonucleotide synthesis. 
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A. SYNTHESIS OF LINKERS 
Oligonucleotides attached to lipophilic groups may become adhered to cell 
membranes and could therefore become unavailable for binding to mRNA.201 
This problem can be addressed by attachment of lipophilic compounds via 
potentially cleavable linkers, a strategy that is well known as a prodrug 
strategy for the delivery of therapeutic molecules.202 
Previously, several groups have been used to tether a lipophilic group to a 
synthetic oligonucleotide. A tetrathymidylate sequence with unmodified 
phosphodiester bonds may in principle be cleaved by intracellular 
endonucleases considerably faster than the phosphorothioate backbone of 
first generation antisense oligonucleotides. 203·204 
More recently, a triglycyl spacer, the target for intracellular peptidases, has 
been used to conjugate cholesterol to the 3'-terminus of triple helix forming 
oligonucleotides.205 A biodegradable disulfide bridge has also been employed 
to attach an alkyl chain to the base moiety of an oligonucleotide206 and a 
phospholipid group to the 5' -terminus of an oligonucleotide.207 
In our approach a number of reagents has been used for the synthesis of 
linkers of lipophilic compounds. They and are generally much simpler 
synthetic targets that mainly aid the incorporation of linkers during 
oligonucleotide synthesis. The groups introduced are achiral, thus avoiding 
the difficult separation of diastereisomers during the linker synthesis. 
They were chosen to be stable enough to stand up to the conditions of DNA 
synthesis, but can also be easily hydrolyzed in the cell. They also form 
electrophilic linkers and act as good leaving groups for the subsequent 
coupling reactions. This reduces the potential for side reactions and simplifies 
purification. The reagents were soluble in organic solvent suitable for the 
coupling procedure and could withstand the deblocking procedure 
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(I) Acetal Linkers 
The benzotriazole methyl ethers of tocopherol cholesterol and thioctic acid 7, 
and 8 and 9, respectively (shown in Scheme 23), will be synthesized, by 
treatment of the corresponding lipophilic compounds with 1-chroromethyl 
benzotriazole 5, and bis-benzotriazole methane 6. Scheme 21 shows the 
synthesis of 1-chloromethyl benzotriazole 5 as the acetal-forming reagent. 
oc:N 
4 lOH 
SOCJ2 
1-hydroxymethyl-benzotriazole 1-chloromethyl-benzotriazole 
Scheme 21 
Bis-benzotriazol-1-yl methane 6, was also synthesized in two steps208 
(starting from 1-hydroxymethyl-benzotriazole 4), as shown in Scheme 22 
below. 
(X\ SOCJ2 (X\ I I N N 
4 lOH reflux, 60-80° c 5 le, 
+ 
Q Q DMF (X\ heat N 
N0- /N'-...../N'- ..;,N 60-80°C 0 
Na0 6 N N 
Bis-benzotriazol-1-yl methane 
Scheme 22 
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Scheme 23 
1-chloromethyl-benzotriazole 
Bis-benzotriazole methane 
These linkers will then be used in acetal and amide forming reactions with the 
5'-terminal hydroxyl group and the NH2 amino group of the nucleosides, 
respectively. 
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(11) Linkers containing carbonyl groups 
Carbamate209•210 and carbonate211 linkages have been shown to have 
biochemical properties such as template activity and resistance to enzymatic 
degradation. They possess linkages, which are achiral, thus avoiding the 
difficult separation of diastereoisomers during their synthesis and purification. 
The phenolic groups act as good leaving groups for the subsequent coupling 
reactions. 
(a) Carbonate linkers 
Using 4-Nitrophenyl Chloroformate 
The p-nitrophenoxy group exhibits a high propensity to act as a leaving group 
in nucleophilic displacement reactions. This ability has been widely used in 
biochemistry.212 The 4-nitrophenyl carbonate linkers 10 and 11 of the 
corresponding lipophilic alcohols (1 and 2) will be designed by reaction with 
the 4-nitrophenyl chloroformate 12 as shown in the Scheme 24 below. 
4·nitrophenyl carbonate linker of cholesterol 
4-nitrophenyl chloroformate 
4-nitrophenyl carbonate linker of tocopherol 
0 JP N02 12 
11 
Scheme 24 
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(b) Carbamate linkers 
The carbamate linkage is attractive due to its stability over a wide pH range 
and its stability under physiological conditions. Its resistant to nuclease 
hydrolysis and it is also stable to hydrolysis by base, a property that favours 
their use in a biological context. 
Using N,N'-Carbonyi-Diimidazole (COil 
The use of COl as a carbonyl synthon has found to afford clean, high yield 
reactions in the synthesis of oligonucleotide analogues.213 
Carbonylimidazolide derivatives 13 and 14 of the corresponding lipophilic 
alcohols (1 and 2), will be designed by reaction with N,N'-carbonyl-diimidazole 
15 (Scheme 25). 
carbonylimidazolide derivative of cholesterol 
N,N'-Carbonyi-Diimidazole 
13 
carbonylimidazolide derivative of tocopherol 
0 15 
14 
Scheme 25 
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(c) Ester tinkers 
An ester bond may be hydrolyzed by intracellular esterases. 214 Attachment of 
a lipophilic linker through an ester bond is hence an attractive approach to 
obtaining prodrug forms of oligonucleotides. The reactivity of ester function 
towards nucleophiles can be used for the synthesis of the desired 
oligonucleotide conjugates. 
Using 2,3,4,5,6-Pentafluorophenol 
Esters linkers will also be formed with an extra CH2 group, which makes them 
more stable for further coupling reactions. Scheme 26 below shows the 
pentafluorophenyl ester linkers of cholesterol 16 and tocopherol 17 formed by 
reaction of the corresponding lipophilic alcohols (1 and 2), firstly with ethyl 
bromoacetate and then conversion of the ethyl ester to the carboxylic acid. 
Subsequent reaction of the carboxylic acid with 2,3,4,5,6-pentafluorophenol 
18 gave the desired ester linkers 16 and 17. 
pentafluorophenyl ester linker of cholesterol 
F 
;~~·~~~~~~~~ 2,3,4,5,6-Pentaflurorophenol 
F 
16 
pentaflurophenyl ester linker of tocopherol 
18 
17 
Scheme 26 
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(Ill) Linkers for linking antibody to DNA 
Linkers were also proposed for linking tumour targeting GRE1, GRE4 Rabbit 
lmmunoglobin G antibodies (NRbt lgG), provided by the labs in Queen's 
Medical Center and Aphton Corporation to different DNA constructs 
containing antisense insert. These antibodies will be linked through a 
degradable linker to four different types of DNA Anticancer Agents (for 
detailed explanation see Discussion Part 1-E). 
(a) Linearised Antisense DNA 
(b) Circular Plasmid DNA 
(c) Apoptotic Synthetic Peptides AK79 (sequence of 9 amino acids long) 
(d) Bisindolylmaleimide Ill HCI (selective inhibitor of protein Kinase C) 
The N-S bond can form an acetal or aminal link with DNA where the 
disulphide bond can form a disulphide link with antibody. Scheme 27 shows 
how the proposed linker 19 can connect the antibodies to DNA. 
Linker for connecting gastrin antisense DNA to GRE1 and GRE4 antibodies 
CCN, Antibody selective group 'N N' I n . l~s..__A.) 
form acetal or more likely \S S N 
aminal link to DNA . 19 ""' form disulfide link 
. ""to antibody 
NH2 
t£y 
~N 
5'-hydroxyl group or an amino group in DNA cysteine residue in antibody 
couple first 
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8 GLOBAL AND PARTIAL PROTECTION OF NUCLEOSIDES 
There are three main points that should be accounted for in dinucleotide 
synthesis 
(a) the selection of suitable protecting groups for the hydroxyl, amino and 
phosphate groups 
(b) the actual synthesis of nucleosides protected on the 2'-hydroxyl and/or 
the 2' and 5' -hydroxyls 
(c) the condensation of the protected nucleosides to dinucleotides 
Progress in the chemical synthesis of oligodeoxynucleotides has climaxed 
with the development of automated procedures for the synthesis of gene 
fragments.215 The success in the deoxy- area is due primarily to the 
establishment of adequate and versatile protecting groups for the amino, 
hydroxyl and phosphate functions.216 Oligoribonucleotides though have posed 
a more difficult challenge in terms of protecting groups. The presence of the 
2'-hydroxyl group not only requires protection but also places serious 
limitations on the nature of protecting groups used. 
Methods have been explored for protection-deprotection of ribonucleosides 
and condensation. Alkyl silyl protecting groups have been exploited for the 2'-
and 3'-position of ribonucleosides217, monomethoxytrityl and dimethoxytrityl 
groups for the protection of 5' -hydroxyl groups218 and trichloroethyl and 
cyanoethyl groups for the protection of phosphates. 219 Amino groups have 
normally been protected with benzoyl groups. 
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(I) Problems associated with protection of the exocyclic amino 
function of the nucleosides 
The need to protect the amino groups of nucleoside bases has been 
recognized early in the development of chemical methods for synthesizing 
oligonucleotides. 220 The introduction and removal and the reagents required 
in these steps, though, limit the range of functional groups that can be 
tolerated in the synthesis. Also the presence of the 2'-hydroxyl group in the 
ribose ring requires selective protection and may sterically hinder the 3'-
position during the formation of the internucleotide linkage. 
In the current synthesis of DNA and RNA as well as their analogs, base-labile 
protecting groups generally block the nucleobases during chain elongation221 . 
In the phosphoramidite method used, the NH2 moieties of the nucleoside 
bases have universally been protected to prevent the N-phosphitylation in the 
conventionally employed synthetic methods.222 
However highly sensitive DNA analogs could not be synthesized with such 
protection modes cause they readily decompose under the standard basic 
condition described for the removal of the protecting groups. 
The 5'0-DMTr group is currently the preferred protecting group for the 5'-0H 
function of nucleosides, during solid phase synthesis. The introduction of this 
protective group, however, required the prior protection of the exocyclic amino 
function of nucleoside bases to prevent these from tritylating as well. Also the 
acid-catalyzed depurination of 6-N-benzoyldeoxyadenosine during acidic 
removal of the dimethoxytrityl protecting group (DMTr) can reduce the overall 
yield of the synthesis.223 
Furthermore as a result of adenine depurination, a heterogeneous mixture of 
5'-dimethoxytrityl deoxynucleosides is present at the conclusion of the 
synthesis. Thus purification, especially with chromatographic methods based 
on the presence of the hydrophobic DMTr group becomes more difficult due 
to the heterogeneity of the DMTr-containing species. 
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One approach to solving the problem has involved modification of the acidic 
detritylation conditions. Lewis acids such as ZnBr2, the use of trichloroacetic 
acid {TCA) and trifluoroacetic acid (TFA) with variable acidity has been 
observed in each case to decrease depurination.224 Several examples have 
been reported that use amino-protecting groups, which can be removed under 
neutral or basic conditions for the synthesis of phosphoramidate analogs of 
oligonucleotides.225 
(11) Advantages for employing nucleosides with the exocyclic 
amino function unprotected (the N-un protected method) 
Because the DMTr group is ideally suited for protecting the nucleoside 5'-
hydroxyl and can removed by using relatively mild acids, a more 
straightforward approach for synthesizing labile DNA analogs is a method 
utilising nucleotide building blocks having unprotected nucleobases. 
As Letsinger has stated226 ideally it would be best to avoid the N-protecting 
groups because they entail at least two additional steps, introduction and 
removal, and the reagents required for these steps limit the range of 
functional groups that can be tolerated in the synthesis. Furthermore, the 
approach without the nucleoside base protection (the N-unprotected method) 
may considerably diminishes the risk of depurination of deoxyadenosine, 
which is a serious problem in the N-protected method particularly using acyl 
protectors such as benzoyl.227 
5' -0-(Dimethoxytrityl)-2-deoxyribonucleosides without the protection of the 
amino functions are important substances for the synthesis of various kinds of 
nucleic acid derivatives. These compounds are useful as building blocks for of 
synthesis via the hydroxyl activation method.228 They have also served as key 
intermediates of N-free nucleoside-3-phosphoramidites229, which are 
monomer units for the synthesis of DNA oligomers via the N-unprotected 
approach 
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. Preparation of the nucleoside derivatives without the amino protecting group 
can be complicated though, by the fact that each of the amino groups but 
most specifically the guanine amino group, is subject to reaction with 
dimethoxytrityl chloride. For that reason a different protecting group must be 
utilized that does not react with the unprotected amino groups of the 
nucleosides but still carries all the advantages of a protecting group 
compatible with the conditions of the oligonucleotide synthesis 
(Ill) Requirements for selection 
The chemical synthesis of oligonucleotides requires the availability of versatile 
reagents protecting the hydroxyl groups of nucleosides. A suitable protective 
group must be stable under the conditions of: 
1. coupling, deprotection of the 5-'protecting group 
2. oxidation 
3. deprotection of the phosphate protecting groups and in the case of 
polymer-supported syntheses, cleavage from the solid support. 
lt must also be removed under mild conditions to prevent the attack of the 
released 2'-hydroxy function on the adjacent phosphodiester linkage. 
Tert-butyldimethylsilyl ether (TBDMS), which was first promoted by Corey and 
Venkateswarlu in the prostaglandin area, 230 has proven to be an exceedingly 
useful group for protecting the hydroxyl moieties of the nucleosides. lt is 
sufficiently stable, provides a rapid and sufficient synthesis of 
monosubstituted nucleosides. lt provides a range of selectivity towards the 5'-
hydroxyl group and can be stable towards acid hydrolysis. 
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Methods are developed for the global and partial TBDMS protection and 
deprotection of the OH groups of the different nucleosides, without nucleoside 
base protection. Scheme 28 represents the proposed synthesis followed. 
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Scheme 28 
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C. SYNTHESIS OF LIPOPHILIC-NUCLEOTIDE CONJUGATES 
A variety of nucleic acid analogues containing substantially uncharged 
backbones have been shown to enter the living animal cells and be resistant 
to nucleolytic degradation therein.231 •232 Paul Mille~33 has shown that one 
class of nucleic acids analogues significantly inhibits the intracellular activity 
of genetic sequences to which the analogues are complementary. These 
results suggest that uncharged nucleic acid analogues can be of value for the 
study of genetic mechanisms for the treatment of viral diseases, and possibly 
as anticancer agents. 
Various nucleotide analogues containing linkages such as phosphonate, 234 
thiophosphonate,235 carboxymethyl,236 and carbonate237 have been reported 
in the literature and several of these have been found to have ·rnterest"mg 
biochemical activity. Especially analogues containing carbonyl-type bond-
linkages are of interest due to their potential as anti-viral agents and 
repressors of gene expression at the transcriptional and translation levels. 
They can also be used as models for the study of nucleic acid structure and 
function. 
Major obstacles that prevent wider application of the antisense 
oligonucleotides as potential therapeutics are their limited oral bioavailability 
and permeability through cell membranes. The permeability across the cell 
membrane and into the nucleus plays a critical role in determining the cellular 
efficacy of these oligonucleotides. 
Oligonucleotides conjugated to lipophilic compounds can be taken up into the 
cell more efficientry, 172 exhibit better antiviral activity178•188 and enhanced 
nuclease resistance.158•160 Lipophilic-nucleotide conjugates will be synthesized 
as models in order to investigate the stability of modified nucleotides 
containing such linkages. Nucleotides can be covalently linked to the lipophilic 
molecules through sites present naturally in nucleic acids. 
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The naturally occurring sites that will be used for the coupling are amino 
groups on the bases, hydroxyl groups on the sugars and phosphate groups, 
both terminal and internal. This coupling will result in the formation of new 
acetal; carbamate and carbonate type links. Attachment of lipophilic groups to 
the amino base or the 5' -terminus of the nucleotides can improve their 
diagnostic utility as DNA probes and their potential therapeutic applications as 
antisense oligonucleotides.238 
Initially the coupling will be conducted on a simpler system such as the single 
nucleoside derivatives, 22 and 23, which are useful building blocks for 
investigation of the coupling chemistry of the existing linkers. The guanosine 
conjugate 24, will be formed by coupling the novel linkers synthesized above, 
to the 5'-primary position of the 2',3'-0-TBDMS protected parent nucleoside 
23 (shown in Scheme 29)., Adenosine conjugate 25 will also be formed by 
coupling to the NH2 amino group of the 2',3',5'-0-TBDMS protected parent 
nucleoside 22, as shown in Scheme 29. 
The strategy is shown below for guanosine and adenosine nucleotides. 
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Protected Guanosine linked to lipophilic molecules at the 5-terimus, 
through different linker groups 
RO-X 
RO = or 
0 
Protected Adenosine linked to lipophilic molecules at the NH2 amino group 
through different linker groups 
NH2 (f:J 
TBDMSO\:o-J N 
TBDMS~OTBDMS 
22 
RO-Y 
RO-Y, 
NH ~N:CJ 
TBDMSO\:o-J N 
TBDMSrOTBDMS 
25 
Scheme 29 
Scheme 29 shows conjugates of the guanosine and adenosine nucleotides, 
containing novel carbonate and carbamate lipophilic linkages, respectively. 
This allowed for intermediates and products to be synthesized on a 
preparative scale. The other DNA nucleosides conjugates (using different 
linker groups) will be similarly investigated. 
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D. SYNTHESIS OF CpG DINUCLEOTIDES 
Synthetic oligodeoxynucleotides containing CpG-dinucleotides (CpG-DNA) in 
specific sequence contexts activate the vertebrate immune system.239 lt has 
been reported240·241 that bacterial DNA and phosphodiester oligonucleotides 
containing CpG motifs, stimulate cells of the innate immune system, induce 
secretion of interferons (INF's) and show antitumor activity. The mechanism of 
activation of immune stimulation by CpG it is believed to occur upon CpG 
uptake that triggers the immune cascade by binding to an intracellular 
receptor identified as TLR9.242 
Growing evidence suggest that this recognition receptor exhibits considerable 
specificity for CpG dinucleotides and initiates immune signaling pathways. 
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·
244 That ultimately leads to the activation of NF-KB245 and the subsequent 
up-regulation of various cytokines including IFN-y, IL-6, IL-12 and TNF-a.246-
248 Alternately, CpG-DNA triggers DNA protein kinase activation which 
phosphorylates kinaseB leading to the activation of NF-KB, which further 
leads to the production of cytokines.249 lt is not clear if the pathways are 
activated sequentially or in parallel leading to a common function of activating 
the NF-KB pathway. 
The observation that oligodeoxynucleotides containing CpG dinucleotides 
(CpG-DNA) exhibit several immunological effects has led to their use as 
therapeutic agents and adjuvants for various diseases.250 Several CpG-DNA 
drug candidates are currently being evaluated, either as monotherapies or as 
adjuvants (with vaccines, antibodies, antigens and allergens), in preclinical 
and clinical trials against cancers, viral and bacterial infections, allergies and 
asthma.251 ·252 Knowledge gained from studies of the medicinal chemistry of 
CpG DNA has provided a basis for designing a second generation of CpG 
DNA agents with desirable cytokine-inducing and potent immunostimulatory 
activity. 253-257 
In the approach to the synthesis of macromolecular DNA, chemical synthesis 
of short deoxyribonucleotide segments continues to determine the progress in 
the synthesis of DNA molecules. 
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Intensive efforts have been made to date in order to enhance the rapidity and 
efficiency of these chemical procedures and subsequently facilitate the large-
scale preparation of dinucleotide blocks.258 
One of the main aims of this project is to develop a short, convenient, high 
yielding dinucleotide synthesis of phosphodiester (PO) CpG, using the 
phosphoramidite approach. Due to the ability of phosphodiester CpG to 
enhance cytotoxic T lymphocyte activity they elicit efficient antitumor activity in 
vivo.259"261 Unlike the phosphorothioate analogs, PO-CpG's induce higher 
levels of IFN-y in human cultures and in vivo. As a result they act as superior 
adjuvants by promoting immune responses when used in combination with 
vaccines and allergens. 262"264 
CpG dinucleotides will be synthesized manually, using solid support or 
solution phase synthesis. These syntheses will be performed with or without 
attached lipophilic groups to improve the transport properties required for the 
oligonucleotide uptake into the cell. 
1. SOLUTION PHASE SYNTHESIS 
With the recent success of various antisense oligonucleotides undergoing 
human clinical trials and the possibility of their commercial launch, soon very 
large quantities of therapeutically useful oligonucleotides may be required. 265 
Thus development of methods for their large-scale synthesis has become a 
matter of urgency. Particularly when bigger quantities of oligonucleotides are 
required, solution-phase synthesis seems to be an alternative method of 
choice instead of the traditional solid-phase synthesis.266 •267 
Solution-phase synthesis can be applied for the formation of modified 
dinucleotides containing the nucleotide conjugates formed previously. In 
contrast with the solid phase synthesis where harsh conditions are used for 
the simultaneous deblocking of the N-protection and detachment from the 
solid support, the advantage of this method is the usage of mild deprotection 
conditions in order to avoid cleavage of the internucleoside linkages. 
Described below is the formation of CpG dinucleotides using solution phase 
synthesis. 
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(I) CpG synthesis without the attachment of lipophilic groups 
This synthesis will be performed by joining the 5'-position of the N-free-2',3'-
protected guanosine nucleoside 23 to the 3'-end of the N-free-5'-protected-3'-
cyanoethyl-phosphoramidite of cytidine 27 (Scheme 30). N-free-5'-0-
dimethoxytritylated derivative of cytidine 26, will be prepared from the parent 
nucleoside by reacting it with dimethoxytrityl chloride (DMTr). The reaction of 
26 with (CNCH2CH20)[i-C3H7hNJPCI in THF by the assistance of 
ethyldiisopropylamine, in pyridine, afforded the phosphoramidite of cytidine 
(27). 
(CNCH2CH20)[i-C3H7 )z)NPCI ti t.i 
OMTrOyHo O') N -Ol-------HOy-Ho O--:) N 0 
OiPEA 
J:2 
tl, DMTrO~ O 
? p" ~if N(i-Pr)z 
NC 27 
+ 
Hr _ DMTr-CI Hr 
26 
<t{rH 
HO~ N NH2 
TBDMSO OTBDMS 
23 
De protection 
(removal of protective 
groups) 
Scheme 30 
Oxidation, 
0.1M l2 in 80:40:20 
THF: Pyridine: H20 
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The dinucleotide 28 formed from the condensation of 27 and 23 will be 
subject to oxidation and subsequent deprotection to furnish the CpG 
dinucleotide 29, as shown in Scheme 30. 
(11) CpG synthesis with the attachment of lipophilic groups 
The effects of structural changes in CpG-DNA have been studied that might 
potentiate or neutralize immunostimulatory activities in an attempt to 
understand the molecular recognition events between TLR9 receptor and 
CpG-DNA.268 Studies have shown a number of structural and functional group 
requirements in the pentose sugar269 phosphate backbone270 and 
nucleobases271 for immunostimulatory activity. These studies suggested that 
the receptor recognized base modifications that mimic natural C and G, while 
modifications at the 3'-position of the sugar are well tolerated and can have an 
effect on immunostimulatory activity.272 I! was also. shown that an unbridged 
oxygen on the phosphate group between C and G of a CpG motif suppresses 
immunostimulatory activity suggesting that negative charge on the phosphate 
group is essential for protein recognition and interaction.273 
Based on these studies it was proposed to investigate the synthesis of 3'-5'-
linked CpG dinucleotides using the phosphoramidite approach but modifying 
the approach to allow the introduction of lipophilic groups. The previously 
synthesized lipophilic N-carbamate and 0-carbonate conjugates of the 
nucleosides will be used as useful building blocks for the formation of CpG 
dinucleotides. Solution phase synthesis will be employed to investigate the 
coupling chemistry of the linkers and the stability towards the deprotection 
conditions. 
When a guanosine nucleoside with the conjugation at the 3' -position is 
utilized, dinucleotide synthesis will be performed by joining the 5'-position of 
the N-free-2'-protected-3'-0-lipophilic conjugate of guanosine 30 to the 3'-end 
of the N-free-5'-protected-3'-cyanoethyl-phosphoramidite of cytidine 27. The 
product furnished, will then be subject to oxidation to give the 3'-conjugated 
CpG dinucleotide 31 as shown in Scheme 31 below. 
63 
c:~ ,,~An 
0 
I 
/p" 
~0 N(i-Pr), 
NC 27 
RO = 
or 
0 
0 11 
t£;H X=H2C-O, O=C-O,H2C-C-O 
+ 
HO'R N" NH2 
RO-X OTBDMS 
30 
Oxidation, 
0.1 M 12 in 80:40:20 
THF: Pyridine: H20 
0 
0 
N_)l_NH < Jl~ /Y-OR 
HO\c--0--J N NH 
TBDMSnTBDMS 
32 
Oxidation, 
31 
0 
11 
Y=H2C, O=C, H2C-C 
0.1 M 12 in 80:40:20 
THF: Pyridine: H20 
c:~ ,.,~An 0 
? NJCNH R"'o < I 1 Y-OR /' p...... / 
0 O~N N NH NC~ 
TBDMS OTBDMS 
33 
Scheme 31 
When the conjugation is performed on the amino base of guanosine, CpG will 
be formed, by joining the 5'-position of the N-lipophilic analogue of 2',3'-
protected guanosine 32 to the 3'-end of the N-free-5'-protected-3'-cyanoethyl-
phosphoramidite cytidine 27. The product furnished, will be subject to 
oxidation to give the N-conjugated CpG dinucleotide 33, as shown in Scheme 
31 above. 
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2. SOLID PHASE SYNTHESIS 
Merrifield274 first described the solid phase synthesis of peptides in 1962. 
Since then considerable efforts have been invested toward the development 
of a suitable solid-phase strategy for the synthesis of oligonucleotides. 
Letsinger and Mahadevan,275 who described the preparation of a popcorn 
copolymer from styrene (88%) p-vinylbenzoic acid (12%) and p-
divinylbenzene (0.2% ), reported the first successful approach. This support 
was insoluble in water, alkaline solutions and organic solvents commonly 
used in oligonucleotide synthesis. The reaction of the acid chloride form of the 
polymer with the exocyclic amino function, 3'-0H, or the 5'-0H of properly 
protected nucleosides afforded the polymer bound nucleosides 34-36 
respectively. 275-277 (Shown in Scheme 32 below). 
cv---Jy: 
C1 DMTr~ O 
OH 
34 
Chain extensions from those polymer bound nucleosides, was achieved 
according to the phosphotriester approach and the resulting oligomer was 
subsequently cleaved from the support under basic conditions. This technique 
enabled the separation of the products from the solvents, excess reagents 
and soluble by-products by simple filtration, thereby avoiding numerous time-
consuming steps. 
Through the years, various polystyrene-derived supports, 278-280 in addition to 
polyamides,278•280(a) and cellulose279(a).281 were tested in the solid-phase 
synthesis of oligonucleotides. The swelling of polystyrene supports with 
organic solvents is an advantage as it allows rapid diffusion of the reagents 
and solvents through the matrix. 
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Because of these findings, silica supports including controlled pore glass 
(CPG), were mainly used. During the last decade the solid phase synthesis of 
oligonucleotides according to the phosphoramidite approach has been mainly 
performed on silica-derived supports. 282 This synthesis proceeds with an 
average coupling of 96%, when a standard controlled pore glass support was 
used. 
The relative importance of the type of linkage between the 3'-0H of the leader 
nucleoside and the spacer arm; along with the length of the spacer arm and 
the pore size of the solid support; with respect to the efficiency of 
oligonucleotide synthesis, has been investigated by Katzhendle~83 and van 
Aerschot.284 
lt was indeed found that the length and the distance of the spacer arm 
between the matrix and the leader molecule were important for optimum 
synthetic efficiency and product purity. A spacer length of more that 25 atoms 
were recommended and it was also important to avoid the possibility of folded 
conformations within the structure of the spacer. These may arise from 
internal hydrogen bonding, dipole-dipole or n interactions and could decrease 
the yield and purity of the final product. 
The pore size of the silica supports is also of importance during the synthesis 
of relatively large oligonucleotides. An abrupt termination of chain propagation 
occurred when the synthesis of oligomers larger than 100 bases was 
attempted on CPG with a pore size of 500 A. 285 This phenomenon was 
attributed to the increasing steric crowding around the pores and channels of 
the support caused by growing oligomers chains, which, presumably, reduced 
the diffusion of the reagents through the matrix. 
Silica supports with pore size of at least 1000 A were, satisfactory for the 
synthesis of large oligonucleotides.285 For example, 98-mers were prepared 
with an average coupling yield of 99.3% from deoxyribonucleotide 
phosphoramidite monomers. 283 
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(I) Synthesis of 5'-lipophilic phosphates of CpG dinucleotides, on 
solid support 
Oligonucleotides possessing 5' -phosphate group are required as valuable 
tools for gene construction, 286 mutagenesis/87 and other biological 
applications.288 Often, they are prepared by T 4-kinase catalysed 
phosphorylation employing nucleoside 5'-triphosphate as the phosphate 
source.289 A number of methods have been reported290 that allow chemical 5'-
phosphorylation of pre-assembled oligonucleotide precursor. Some of them 
include preparation of modified nucleotide-based building blocks to be 
attached at the last step of the oligonucleotide synthesis.291 Another strategy 
based on no-nucleosidic building blocks, seems to be more universal since a 
single reagent can be employed. 
Terminal modifications that can enhance exonuclease resistance have been 
studied,260·264•292 and the modified compounds were compared with the parent 
(natural) deoxynucleosides. The resistance toward exonucleases was 
assessed, in vitro and in vivo and it was shown that stability of all the modified 
oligonucleotides was at least 12 times that of the parent compound.259.261 
CpG-containing phosphodiester linkages demonstrated that 
immunostimulatory activity is significantly reduced when the 5'-end of the 
oligonucleotide is not accessible, rather than the 3'-end, suggesting that the 
5'-end plays a critical role in immunostimulatory activity.253 
We were interested in the chemical solid-phase synthesis of oligonucleotides, 
which bear a lipophilic-phosphoramidite link at a distinct position within the 
CpG fragment. In this case the backbone modification is situated on the 5-
phosphate group. Such modification lead to dinucleotides with a number of 
interesting properties. They do not form diastereoisomers and they still 
hybridize very specifically to a target strand. 
Furthermore, they can function as templates and primers in enzymatic 
reactions. Restriction endonuclease recognition sites containing 
phosphoramidate linkages at the cleavage point also show interesting 
properties. 
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These phosphoramidate linkages should be sufficiently stable to allow the 
handling of such modified dinucleotides without precaution, and also be 
susceptible to a chemical cleavage under mild acidic conditions, resulting to 
the desired phosphate 
Phosphoramidites coupled to lipophilic groups will be formed that can lead to 
preferential phosphitylation of the 5'-hydroxyl group. The N, N diisopropyl-
phosphoramidites of cetyl alcohol 37 (cetyl = straight chain C16 group), 
cholesterol 38 and tocopherol 39, will be synthesized by one-flask procedure 
(shown in Scheme 33 below) 
---l /0--..L--- ------f--£i:::-Z::::S: 
N-R A \,-.J..---:::_...-;--.J.--r---J.-.-'l. 
38 
Scheme 33 
The tri-coordinate phosphorus reagent enhances the attachment of lipophilic 
groups to the dinucleotide synthesis and improves the efficiency of uptake into 
the cell. Phosphitylating agents generally attack the amino as well as the 
hydroxyl groups of nucleosides. In conventional procedures for synthesizing 
oligonucleotides, selective reaction at the oxygen is achieved by using 
protective amino groups. For that reason, deoxynucleosides with their amino 
function protected, were used. 
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1 H tetrazole can be used as a promoter in both solution-phase and solid-
phase syntheses of dinucleotides via the phosphoramidite method. lt is fairly 
reactive towards phosphoramidites, such as N,N-diisopropyl-
phosphoramidites. lt allows rapid and highly chemoselective condensation of 
the phosphoramidite and the nucleoside and it leads to a high phosphitylation 
yield. Excess equivalents of the phosphoramidite, the promoter and the 
nucleoside will be utilized in solid-phase synthesis, which can be achieved 
with good chemoselectivity. 
lnternucleotide coupling procedure is performed with the 5'-hydroxyl group 
being capped with the di-lipophilic phosphate group to provide lipophilicity. In 
solid phase synthesis, a reaction sequence is followed, for the preparation of 
the 5'-dicetyl and 5'-dicholesterol and 5-ditocopherol phosphates of CpG 
dinucleotides, via the phosphitylation of the 5'0H group 
The N-protected-5'-free guanosine nucleoside 40 (after deprotection of the 5'-
0H group) anchored to a solid support (CPG) by the 3'-position, is coupled to 
the 3'-end of the N-protected-5'-protected-3'-cyanoethyl-phosphoramidite of 
cytidine 41, by utilizing the promoter. The product formed, will then be subject 
to oxidation to give the 5'-DMTr-3'-cyanoethyl-phosphate solid supported 
dinucleotide 42. 
Deprotection is repeated in order for the 5'-0H group to become available for 
the leading phosphitylation reaction with the novel synthesized N' ,N' 
diisopropyl-phosphoramidites of lipophilic compounds. The formed 5'-
phosphite of the 3'-cyanoethyl-phosphate solid supported dinucleotide 43, 
was again oxidized followed by global deprotection. Removal of all remaining 
protective groups and cleavage of the solid support, gave the dinucleotide 44, 
is in the form of its ammonium salt. 
A schematic diagram of this synthesis is shown in the Scheme 34 below. 
Scheme 34 
69 
DMTrOt--o-JP_G_____ HQ~.-o-JPG 
r Deprotection r-' 40 
Q-L" Q-t! 
+ 
DMTrO~PG 
~ 41 
DMTr~PG 
NC~o, p 
r=o 
O~PG 0 
Repeat 
Deprotection ~. 42 j Q-t:'o 
/R, 
NC~O N(i-Pr)2 
Oxidation 
Oxidation 
Global Deprotection 
Support Cleavage 
70 
___ _j 
DISCUSSION 
1. SYNTHESIS OF LINKERS 
(A). Acetal Linkers 
One of the main aims of this project was to synthesize new linker groups for 
the attachment of lipophilic molecules, which are designed to be easily 
cleaved off once the DNA construct has entered the cell. Acetal linkers were 
investigated firstly as they are stable enough to stand up the conditions of 
DNA synthesis but should also be easily hydrolyzed in the cell. 
Two approaches were investigated, where bis-benzotriaziol-1-yl methane and 
1-chloromethyl benzotriazole were employed as the acetal-forming reagents. 
The non-commercially available bis- benzotriaziol-1-yl methane 6 was 
prepared in two steps2D8 as shown in Scheme 35. 
((\ soe12 ((\ I I N N 79%yield 
4 lOH reflux, 60-80 De 5 LCI 
+ 
q q DMF ((\ 
heat N' 
N~ /N'-..../N, 'iN 60-80 De e Nac±l 6 N N 
Bis-benzotriazol-1-yl methane 
69%yield 
Scheme 35 
In the first step, 1-chloromethyl benzotriazole (5) was formed as white crystals 
in 79% yield, by refluxing 1-hydroxymethyl benzotriazole (4) with thionyl 
chloride. 
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In the second step, benzotriazole was treated with sodium hydride in DMF 
generating the benzotriazole anion, followed by addition to the already formed 
1-chloromethyl benzotriazole. Displacement of the chlorine atom from 5, gave 
the bis- benzotriaziol-1-yl methane 6, as a white solid in 69% yield. 
Compounds 5 and 6 were identical in melting point, 1H and 13C-NMR and 
analytical analysis with those reported in the literature.208 
(I) Linkers from cholesterol and tocopherol 
1 By using bis-benzotriazole methane 
For the formation of the acetal linkers, the benzotriazole methyl ethers of 
lipophilic alcohols, cholesterol1 and tocopherol (vitamin E) 2, were required. 
+ 
1 THF 
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THF 
r.t overnight 
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Scheme 36 
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Their synthesis involved treatment of the corresponding alcohols (1 and 2) 
with bis-benzotriazole methane {6) in the presence of trifluoroacetic acid, as 
shown in Scheme 36, above. The novel benzotriazole methyl ether of 
cholesterol was obtained in a 46% yield as crude product. This was purified 
further through recrystallization, wh"1ch was carried out from dichloromethane 
and petroleum ether and resulted in the recrystallized compound 8, furnished 
as white solid in a 35% yield. 
On the other hand, an attempt to synthesize the tocopherol derivative resulted 
in the precipitation and recovery of bis-benzotriazolyl methane as suggested 
by the spectroscopic and elemental analysis obtained. 1H and 13C-NMR data 
gave the corresponding signals for bis-benzotriazolyl methane while there 
were no aliphatic protons or carbons. 
2 By using 1-chforomethyf benzotriazole 
An alternative route for the synthesis of benzotriazole methyl ethers of the 
lipophilic alcohols was also followed. The anion of the corresponding 
lipophilic alcohol was generated with sodium hydride in THF and then treated 
with 1-chloromethyl benzotriazole 5. Displacement of chloride in 5 by the 
anion of cholesterol or tocopherol, gave the formed acetal linkers 7 and 8 as 
shown in Scheme 37 below. 
Tetrahydrofuran {THF) was the choice of solvent for cholesterol since it is the 
only solvent in which cholesterol is fully soluble, even at room temperature. 
On the other hand, tocopherol proved to be soluble in a wide variety of 
solvents. As 1-chloromethyl benzotriazole was more soluble in THF compared 
with a less polar solvent like for e.g. acetonitrile (CH3CN), this solvent was 
also employed in the case of tocopherol. 
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The compounds obtained using the procedure shown in Scheme 37, were 
furnished as crude products in an 87 and 75% yield. Then recrystallization 
was carried out frorn ethanol and water. The novel benzotriazole methyl 
ethers of tocopherol 7 and cholesterol 8 were afforded as white solids in both 
cases, in a 72 and 69% yield, respectively. 
1 13 1 
The structures were confirmed by H and C-NMR spectroscopy. H-NMR 
spectrum of the cholesterol derivative 8 showed a signal at 7.36 pp m 
corresponding to the 2 hydrogens of the CH2 of the benzotriazole ring which 
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appears more down field than the CH2 of the 1-chloromethyl benzotriazole 
(-6.42 ppm). 
lt also gave two doublets at 5.34 and 5.30 ppm and two multiplets at -3.55 
and 3.45 ppm with a ratio of 1 :8 for starting material cholesterol: synthesized 
product, that correspond to the Hb and H8 olefinic protons of cholesterol, 
respectively. 
13 C-NMR spectrum also showed all the signals for the aliphatic and aromatic 
carbon atoms. This evidence suggests the conversion of cholesterol to the 
desired benzotriazole methyl ether of cholesterol. The benzotriazole methyl 
ether of cholesterol formed using 1-chloromethyl benzotriazole 5 was 
compared with the previously synthesized novel compound (shown in 
Scheme 36), by I.R, 1H, 13C-NMR and melting point and was found to be 
identical, while the yield obtained was improved (69% yield). 
As for the tocopherol derivative 7, the spectral and elemental analysis 
suggests its formation. 1H and 13C-NMR spectroscopic analysis showed all 
the signals for the aliphatic and aromatic protons, while the OH broad band of 
the tocopherol was absent in the I.R spectrum. 
1 
In the H-NMR spectrum the signals of the aromatic protons have moved up-
field while in both 1H and 13C spectrum the signals, which correspond to the 
carbon and the 2 hydrogens of the CH2 of the benzotriazole ring, appear more 
downfield than the CH2 of the 1-chloromethyl benzotriazole. These evidence 
support the formation of the tocopherol ether. 
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(Ill Linkers from thioctic acid 
Thioctic acid 3, as it is known to have a biological importance, was employed 
in order to examine how it can be used for the formation of a sulfur linkage, 
wh'1ch can then be introduced into the synthes'1zed ol'lgonucleotide constructs. 
For the synthesis of this linker the known route, used before in the synthesis 
of the benzotriazole methyl ethers of cholesterol and tocopherol performed 
under basic conditions, was followed. 
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As shown in Scheme 38, the chlorine substituent of the synthesized 1-
chloromethyl benzotriazole (5), undergoes nucleophilic substitution by the 
nucleophilic anion of thioctic acid, which is generated by treatment with 
sodium hydride in DMF. This reaction furnished the crude product as dark 
yellow solid in a 77% yield. 
DMF was a more effective solvent for this reaction as it dissolves thioctic acid, 
better than THF. Further purification of the crude was performed through 
recrystallization from ethyl acetate and petroleum ether. The pure 
benzotriazole methyl ester of thioctic acid 9 was obtained as a pale yellow 
solid, in a 62% yield. 
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The spectral and elemental analysis obtained for compound 9, supported the 
proposed structure with 
1
H-NMR 
13
C-NMR spectroscopic analysis showed a 
singlet at 6.03 ppm and a peak at 67.2 ppm, respectively. These signals 
correspond to the 2H and the aliphatic carbon of the methylene group, 
respectively, that connects the benzotriazole ring to the anion of the thioctic 
acid (0-CHz-N). 
The 
1
H-NMR spectrum also gave all the signals for the aromatic protons and 
carbons, as well as, for the protons and carbons corresponding to the thioctic 
ester. 
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(8). Carbonate Linkers 
Carbonate linkages have shown to be resistant to enzymatic degradation and 
possess linkages, which are achiral. 
By using 4-Nitrophenyl Chloroformate 
Commercially available 4-nitrophenyl chloroformate 12 was investigated as 
the linker-forming reagent. The p-nitrophenoxy group exhibits a high 
propensity to act as a leaving group in nucleophilic displacement reactions, 
and can be introduced as a better leaving group for the future formation of 
nucleotide conjugates. 
Cholesterol 1 and tocopherol 2, were reacted with 4-nitrophenyl chloroformate 
(12), using triethylamine as the base as shown in Scheme 39 below. While N-
methylimidazole and 4-(dimethylamino)pyridine can also serve as efficient 
catalysts, triethylamine was employed due to its ease of removal by 
evaporation. 
The acid chloride 12 was used as the precursor and in the presence of 
triethylamine the a proton adjacent to the hydroxyl group of tocopherol is 
removed, thus forming the nucleophile that will attack and displace the 
electrophile (chloride). The pKa of tocopherol is approximately 10 making 
triethylamine strong enough to deprotonate the phenolic hydroxyl of 
tocopherol whereas the pKa of cholesterol will be about 16 and cannot be 
deprotonated by triethylamine. In that case the nucleophilic hydroxyl group of 
cholesterol will attack the electrophile and the base will remove the proton to 
generate the carbonate group. 
1 Equivalent of the electrophilic reagent and 1.1 equivalent of the base were 
used, whilst release of the chlorine atom in acid chloride furnished the desired 
carbonate linkers. Again THF and CH 3CN were found to be effective solvents 
for the cholesterol and tocopherol reaction, respectively. 
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The novel 4-nitrophenyl carbonate derivatives of cholesterol and tocopherol 
were obtained in 87 and 92% yield, respectively, as crude products. 
The cholesterol carbonate linker was recrystallized from dichloromethane and 
petrol to furnish the title compound 10, as yellow solid in 72% yield. Trituration 
of the tocopherol derivative from petroleum ether, afforded the desired 
compound 11 as yellow oil in 83% yield. As these carbonate linkers are 
moderately stable, care was taken in storage and they were kept under 
anhydrous conditions. 
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(C) Carbamate Linkers 
The carbamate linkage is attractive due to its stability over a wide pH range 
and its stability under hydrolysis by base. 
By using N,N'-Carbonyl-Diimidazole (COl) 
The use of CDI as a carbonyl synthon can afford clean, high yielding reactions 
in the synthesis of oligonucleotide analogues. 
Initially, the formation of the carbamate linker of cholesterol was investigated, 
in order to establish the reaction conditions and the number of equivalents of 
the reagents needed for the reaction to reach completion. lt was thought that 
the desired linkage could be formed by suitable basic activation of the 
hydroxyl function of cholesterol. 
Various experiments were performed using different bases and different 
equivalents of N', N'-carbonyl-diimidazole as shown in Table 1 below. 
(1.1 eq) 1.1 eq cholesterol 
Lithium bis silyl) amide 42% + 36% 
(1.2 eq) 1.1 eq cholesterol 
43% + 38% 
NaH (1.5 eq) 1.1 eq cholesterol 
42% + 28% 
NaH (1.5 eq) 1.5 eq cholesterol+ 12% 
recovered imidazole 
48% + 30% unreacted 
NaH (2 eq) 1.1eq cholesterol 
All reactions were performed at room temperature using THF as solvent as 
shown in Scheme 40, below. 
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Firstly the organolithium compound lithium bis (trimethyl-silyl) amide 45, which 
is known to have strong basicity, was employed. 
The use of 1.1 equivalent of 45 and carbonyl reagent, in THF at -78 °C, gave 
the required product only in 34% yield and 45% of the starting material was 
recovered. Increase of the base equivalent's to 1.2 led to a slight increase of 
the yield, along with recovery of the starting material. This suggests that the 
metal alkoxide formed may be too stabilized for the reaction to reach 
completion. 
Another method using sodium hydride in THF was also investigated. When 
1.5 equivalent of base and 1.1 equivalent of CDI were employed, 43% of the 
product was afforded along with 38% of unreacted cholesterol. Increase of 
COl's equivalent to 1.5 only led to an additional recovery of imidazole. A final 
attempt was made, using 2 equivalent of NaH but again reaction did not reach 
completion. 
Since the above reactions did not afford a higher yield of the desired product, 
an alternative procedure was followed based on a reported procedure293 for 
the conversion of the hydroxyl function of cholesterol to its 
carbonylimidazolide derivative. This was based on using toluene, both as the 
solvent and activator. Reaction of cholesterol with 1.1 equivalents of CDI 15, 
in refluxing toluene for 12h followed by aqueous extraction, furnished the 
cholesterol imidazole carbamate linker in a 78% yield as the crude product. 
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Recrystallization was carried out from dichloromethane and petrol, which gave 
the novel carbamate linker of cholesterol 13 as white solid in 71% yield. 
(Shown in Scheme 41). 
The successful development of the above procedure prompted an 
investigation into extending the reaction to tocopherol. The same method was 
followed with a decrease of the reaction time to 1 Oh. An attempt was made to 
purify the crude product by chromatography but it was unsuccessful due to 
the instability of the active carbamate. Trituration from hot hexane afforded 
the carbamate linker 14 as pale-yellow oil in an increased 76% yield. This 
linker was used without further purification. 
2 OH 
1 
15 
Toluene 
refiux 12h 
F\ NyN¥ 
0 13 0 
71% yield 
14 
76% yield 
Scheme 41 
The products are stable and can be stored indefinitely. The absolute structure 
of compound 13 was determined by X-ray crystallography. The structure is 
shown in the Appendices. 
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(D) Ester linkers 
Ester functions are known to have reactivity towards nucleophiles. Attachment 
of a lipophilic moiety through an ester bond is an attractive approach to 
obtaining oligonucleotide conjugates. However under conditions of 
oligonucleotide deprotection, esters are usually cleaved more rapidly than 
base protecting groups. 
For this reason, ester lipophilic conjugates of nucleotides can be prepared by 
performing the conjugation step post synthetically in solution or when the 
base residue requires no protection the ester conjugates can be assembled 
successfully using solid phase chemistry. 
Using 2,3,4,5,6-Pentafluorophenol 
As part of the investigation into preparing linkers as useful intermediates for 
further formation of nucleotide constructs containing lipophilic groups, the 
formation of ester linkers was proposed. 
The esters linkers proposed contain an extra CH2 group which improves 
stability needed for further conjugate-forming reactions. 2,3,4,5,6-
pentaflurorophenol18, was employed to form the active ester which is a good 
electrophile and can undergo nucleophilic displacement. 
In order to synthesize the pentaflurorophenyl ester linker of cholesterol or 
tocopherol, a sequential procedure that consisted of three steps (starting from 
the lipophilic compound) was followed as shown in Scheme 42. 
Formation of the ethyl ester of the lipophilic compound by alkylation with 
bromoacetate, followed by hydrolysis to the carboxylic acid and subsequent 
reaction with 2,3,4,5,6-pentaflurorophenol 18 and either EDCI or DCC as 
coupling agent, leads to the desired pentaflurorophenyl ester linkers 16 and 
17. 
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i) EtO~ 
R-OH _ _:___ 11 OR 
0 
ii) 
0 
11 OR + HO~ 
F*F F 
F """- I OH 
F 
iii) 18 
F*F F 
"""- I ~OR 
F 0 
RO = 
0 
F 
Reagents: i) NaH, Ethyl bromoacetate, ii) Aq NaOH, EtOH iii) EDCI or DCC, DMF 
Scheme 42 
This stepwise synthesis was firstly tested on cholesterol. Cholesterol was 
treated with ethyl bromoacetate in toluene under reflux but this reaction failed 
to give the product and led to the recovery of starting material. 
it was then decided to investigate the displacement of bromo substituent by a 
nucleophile, formed by generating the anion of cholesterol, using a suitable 
base. The reaction involved deprotonation of the hydroxyl group to generate 
the nucleophile that displaces the alkyl bromide to give an 0-alkylated 
product. The use of sodium hydride in THF was found to be an effective base 
in the preparation of the benzotriazole methyl ether linker of cholesterol (see 
Scheme 37). 
When 1.5 equivalent of base and 1.1 equivalent of ethyl bromoacetate were 
employed, 61% of the product was afforded along 18% of unreacted 
cholesterol. Increase of the equivalent of the coupling reagent to 1.5 gave the 
ethyl ester of cholesterol 47 as off-white solid in 78% yield, after 
recrystallization from dichloromethane and petroleum ether. 
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The same conditions were applied for tocopherol and crude ethyl ester of 
tocopherol was furnished in 91% yield, as shown in Scheme 43 below. The 
crude acetate derivative of tocopherol was triturated using 
afford the desired product 48 as pale yellow oil in 82% yield. 
2 l NaH HO 
1 j NaH + 0 
~Br 
EtO 
46 
stiratr.t, 12h stir at r.t, 12h 
THF THF 
0 
48 
82%yield 
47 78%yield 
Scheme43 
hot hexane to 
0 
OH 
Displacement of the bromo substituent by the anion of the lipophilic alcohol 
formed by sodium hydride in tetrahydrofuran, gave the ethyl ester derivatives 
of cholesterol 47 and tocopherol 48 in very good yields. 
Hydrolysis of the cholesterol and tocopherol esters with aqueous sodium 
hydroxide in ethanol afforded the corresponding carboxylic acids 49 and 50 in 
a 72 and 77% yield, respectively (Shown in Scheme 44). 
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The purified form of 49 was furnished as an off-white solid after 
recrystallization from ethyl acetate and dichloromethane, while trituration with 
hot hexane gave 50 as an off yellow solid. 
EIO~ O, ,c:::::-----T-....._,C-r-.__,(__-2\ 
0 
47 NaOH (aq) 
Et OH 
50 
49 72%yield 
Scheme44 
0 
48 
77%yield 
For the third and final step of the synthesis, the previously synthesized 
carboxylic acids 49 and 50 were reacted with 2,3,4,5,6-pentafluorophenol 12 
in the presence of a coupling reagent. The coupling reagents used were the 1, 
3-dicyclohexylcarbodiimide (DCC)294 51 and the water-soluble 1-ethyl-3- (-3'-
dimethylaminopropyl) carbodiimide hydrochloride (EDCif95 52, as shown in 
Scheme 45. 
DCC EDCI 
(CH3)zN~N=C=N-D 
52 
Scheme 45 
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As THF is reported296 to reduce reaction rates and encourage the formation of 
the N-acylurea side product and in this case, DMF was used as a more polar 
solvent. The coupling was carried out using the carboxylic acid of the 
corresponding lipophilic alcohol (1eq), 2,3,4,5,6-pentaflurorophenol (1eq) and 
coupling reagent (1.1eq), which was added portion wise to the solution of acid 
and alcohol in anhydrous DMF, cooled to 0 °C (Scheme 46). 
The reactions were performed in DMF over 4h at room temperature to afford 
the desired pentaflurorophenyl ester linkers of cholesterol 16 and tocopherol 
17 after recrystallization from diethyl ether and hexane, as white solid and off-
yellow solid respectively. 
Table 2 below shows that EDCI proved to be more effective over DCC as the 
yields obtained when the first was used were improved over the latter, even 
though the same conditions were used. 
Table 2 
Cholesterol DCC 62 
" EDCI 
Tocopherol 67 
EDCI 73 
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HOY"o 
0 
49 + 
F*F F 
""I 
F 0 
F ITO 
0 
DCCorEDCI 
DMF, 0 De, 4h 
16 62-68% yield 
17 
F*F F 
""I F OH 
F 
18 
67-73% yield 
Scheme 46 
0 
50 
DCeorEDCI, 
DMF, 0 De, 4h 
OF*F F o0 ,_I 
0 F 
F 
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(E) Linker for linking antibody to DNA 
Another proposal was made for the synthesis of a linker in order to connect 
the gastrin antisense DNA to GRE1 antibody. The linker 19 (shown in 
Scheme 48) was synthesized in two steps. The first step involved the reaction 
of 1-chloromethyl benzotriazole (5) with 1 ,8-octanedithiol (53) in the presence 
of triethylamine as shown in the Scheme 47 below. 
NaH, OMF 
2h, 60-80° c 
(X~\ ~ .. /'--... ;N + Hs· Ms ·sH 
N 
l 53 5 Cl 
1,8-octanedilhiol Et3N, CH3CN 
2h, reflux 
Scheme 47 
recovery of 
1-chloromethyl benzotriazole 
yield 70% 
Several attempts were made to synthesize the thioaminal compound (54). 
Originally sodium hydride was employed as the base, DMF as the solvent and 
a 1:1 ratio of 5 and 53 was used but unreacted starting material (1-
chloromethyl benzotriazole) was recovered (15%) after 2h of reaction time. An 
increase of the reaction time did not change the rate of reaction and 
unreacted 5 was again recovered. 
lt was then decided to use triethylamine as a base and acetonitrile as a 
solvent while the above ratio was changed to 1:1.25. After refluxing for 2h the 
reaction mixture was left to stand for 30 min, which forced the unreacted 1-
chloromethyl benzotriazole to precipitate. The white crystals were removed 
and the work up proceeded in the usual manner to afford 54 as yellow oil in a 
70% yield. This compound was in pure form and was used without further 
purification. 
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The 1H, 13C-NMR and elemental analysis data obtained supported the 
proposed structure where the 1H-NMR spectrum showed a singlet at o 5.69 
ppm which corresponds to the 2H of the CH2 bonded both to the nitrogen of 
the benzotriazole ring and the sulfur of the octanedithiol. This signal suggests 
the formation of compound 54 since the CH2 of 1-chroromethyl benzotriazole 
appears at 6.40 ppm. 
The second step of the proposed strategy was carried out, by stirring 
overnight in dichloromethane a mixture of the synthesized 54 and pyridyl 
disulfide 55, as shown in Scheme 48. The crude product was purified on silica 
eluting with petroleum ether and ethyl acetate (3: 1) to afford the desired linker 
19 as yellow oil in a 55% yield. 
The spectral and elemental analysis data was consistent with the proposed 
structure of the linker. The 
1
H-NMR spectrum gave all the signals of the 
aromatic protons (of the benzotriazole and the mercaptopyridine ring) 
whereas the 
13C-NMR showed all the signals for the eleven aromatic and the 
9 aliphatic carbons. 
((~'N / 
N 
54 ~S~SH + 
pyridyl disulfide 
DCM, r.t. 
stir, overnight 
sj) 
"---s N 
19 yield 55% 
Scheme 48 
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The synthesized linker 19 was used to link tumour targeting GRE1, GRE4 and 
G34 rabbit antibodies (NRbt lgG), to different DNA constructs containing an 
anti sense insert. Four different types of DNA anticancer agents were used: 
(a) Linearised Antisense DNA 
(b) G1rcular Plasmid DNA 
(c) Apoptotic Synthetic Peptides AK79 (sequence of 9 amino acids long) 
(d) Bisindolylmaleimide Ill HCI (selective inhibitor of protein kinase C) 
lmmunoglobin G (lgG) is the major class of antibody molecules in blood 
plasma. NRbt lgG stands for Rabbit lmmunoglobin G (antibody}. 
GRE1 and GRE4 rabbit antibodies (NRbt lgG) were in a solution form 
immobilized in Protein A columns, where G34 was in the solid state with a 
molecular weight of 2676. All of the antibodies were supplied by the labs in 
Queen's Medical Centre in Nottingham. 
The synthetic peptides used were each consisted of 9 amino acids. First 
consisted of LRQAGDDFC with a molecular weight of 986.97 and the second 
of LRRMSDEFC with a molecular weight of 1135.11 
A stands for Alanine (Ala), C for Cysteine (Cys), D for Aspartic acid (Asp), E 
for Glutamic acid (Giu), F for Phenylalanine (Phe), G for Glycine (Giy), L for 
Leucine (Leu), M for Methionine (Met), Q for Glutamine (Gin), R for Arginine 
(Arg), S for Serine (Ser). 
The Circular Plasmid DNA used had a molecular weight of 4352640, while 
Bisindolylmaleimide Ill HCI had a molecular weight of 420.9. The linearised 
antisense DNA provided was in 1 1-1mol solution. 
lminothiolane with a molecular weight of 137.6, was used to form available 
thiol groups, which can then be coupled to the disulfide linker 19 (MW 418.72) 
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(I) For G34 antibody (solid state) 
lminothiolane was attached to the free lysine residues of the affinity-purified 
antibody G34, by mixing a solution of G34 in MeOH with a solution of 
iminothiolane also in MeOH (Scheme 49). The resulting reaction mixtures 
were shaken gently at room temperature for 30min. 
Solutions of the synthesized linker 19 in CH3CN were respectively added to 
solutions of peptide A and B in H20 and MeOH (3:1), Bisindolylmaleimide Ill 
HCI in H20 and plasmid in MeOH. After the resulting reaction mixtures were 
shaken gently at room temperature for 30min, they were added to the 
previous bound G34 reaction mixtures as shown in Scheme 49 below. The 
reaction mixtures obtained were shaken gently at room temperature for 40 
min and then stored at 4 °C. 
y 
G34 antibody 
sol in MeOH 
iminothiolane 
sol in MeOH 
shaken gently 
at r.t for 30min 
~I m 
mixture of linker sol 
with peptide A and B sol, 
bisindolylmaleimide sol 
and plasmid sol 
Lk--o V 
------ 1-lm-Lk--o 
shaken gently 
at r.t for 40min 
Bisidolylmaleimide Ill = 
Scheme 49 
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(11) For GRE1 and GRE4 antibodies (solution state) 
lminothiolane was attached to the free lysine residues of GRE1 and GRE4 
antibodies, which were immobilized on affinity columns, by adding a solution 
of iminothiolane in MeOH onto the Protein A columns (Scheme 50). The 
bound antibody columns were shaken gently at room temperature for 30min. 
Excess of iminothiolane was removed by washing with methanol as shown in 
Scheme 43. 
Peptides A and 8, and the Linearised Antisense DNA (oligo) were coupled 
with the existing linker, by mixing a solution of linker 19 in CH3CN with a 
solution of peptide A and B in H20 and MeOH (3:1) and oligo in MeOH, 
respectively. 
After that, peptides A and B and oligo mixtures were added to the antibody 
columns. The aim was to use 10 fold of oligo and linker reaction mixture for 
the GRE1 column and 100 fold of the same reaction mixture for the GRE4 
column. 10 fold of peptide A and Band linker reaction mixtures were used for 
the remaining two GRE1 and GRE4 columns. 
Peptides A and B and the oligo were successively bound to the antibodies 
GRE1 and GRE4, after gently shaking the columns at room temperature for 
40min as shown in Scheme 50 below. Excess of reagents was removed by 
washing with methanol and the columns were then stored at 4 °C. 
The above experiment using the protein A columns with immobilized lgG was 
repeated. In this case though after the reaction to attach Peptides A, B and 
oligo to the antibodies, the washing of the excess of reagents did not take 
place. This was done in order to evaluate whether the bound materials were 
removed previously with washing since the detection system showed no 
biologically active antibody constructs (see results below) 
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Lk 
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The resulting solutions of bound G34 antibody and bound GRE1 and GRE4 
Protein A columns were sent out for purification of the biologically active 
antibody constructs. The antibodies retained at the binding sites were eluted 
using 0.1 M glycine buffer. The elutions, which were assayed, using ELISA as 
detection system, were performed in the labs in the Queen Medical Center. 
The steps taken in ELISA (Enzyme-Linked lmmunoSorbent Assay), shown in 
Scheme 51 below, are as follows: 
(i) Attachment of the specific antibody to a polymer support 
(ii) Addition of the sample (containing the protein of interest) 
(iii) Washing to remove the unbound material 
(iv) Addition of the second antibody attached to an enzyme. This 
antibody is specific for a different site on the protein being detected. 
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(v) Measurement of the fluorescent compound that is being formed by 
the catalytic action of this enzyme. 
yyy 
Polymer support 
Addition of sample (containing protein) 
+ y y y-. __ P_ro_te_in of interest being measured 
Polymer support 
Washing to remove the unbound molecules 
Addition of antibody 2 
Nonfluorescent 
substrate ~ 
Fluorescen~ 
product 
Enzyme 
t-. --Antibody 2 
y 
Polymer support 
Scheme 51 
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In the experiment to validate ELISA, avidin was used to coat the plate of the 
polymer support. lt appeared that the directly bound Rbt lgG (the ones 
retained on the binding sites) induced a specific signal, which was dependant 
on the concentration of avidin used. The NRbt control produced a much lower 
signal. An avidin coating concentration of 1: 500 was used for all the following 
assays and the results are shown below 
Assay 1 
The GRE1 and GRE4 Protein A columns were eluted with 0.1 M glycine buffer 
initially (pH 2.8) and no protein was detectable. The pH was increased to 
alkaline but again no protein was detectable in the elution. 
Assay 2 
Four samples were assayed. The samples consisted of the elutions from the 
columns assessed in assay 1 and the reaction mixtures in which the G34 
NRbt lgG was linked to peptides A and B, bisindolylmaleimide Ill HCI and 
plasmid. The reaction mixtures were in the form of a suspension that may 
have non-specifically affected the absorbance and so they were assessed 
with and without centrifugation. 
The results shown in Figure 5 below show very low levels of specific immuno-
reactivity (relating to the conjugate of NRbt lgG and biotin) in the reaction mix 
suspension and the supernatant following centrifugation. 
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Assay 2: Column elutions from immobilized reaction mix and 
suspension reaction mix 
Assay 3 
1.0,---------------------, 
0.8 
0.6 
0.4 
0.2 
-- Positive control (Rbt-lgG-biotin) 
· · ·'!' · · Negative control (Rbt lgG) 
-1!1- Elutions (Suspension) 
Elutions (following centrifugation) 
-4---- Reaction mix (Suspension) 
__. · · Reaction mix (following centrifugation) 
0.0 -1---------r-------,-----.---------l 
1e-1 1e-2 1e-3 1e-4 1e-5 
Antiserum protein cone. (mg/ml) 
Figure 5 
Four samples were assayed. The samples consisted of four consecutive 
elutions from the protein A columns with immobilized lgG which had not been 
washed after the reaction to attach the oligo, protein A and B to the Rbt lgG. 
The antibodies were eluted with 0.1 M glycine buffer (pH 2.8) and the results 
are shown in Figure 6 below. The second elution showed an increased 
signal. 
The protein concentration of the elutions (1 mg of NRbt protein was coupled to 
the Protein A column) was also determined by the use of absorbance at 
280nm and they are shown in Table 3 below. 
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Assay 3: Immunoreactivity of elutions from assay of 
immobilized NRbt 
m 
r (.i;i 
)> 
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1e-2 1e-3 
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Figure 6 
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Employment of the synthesized Jinker 19 is still under investigation to 
establish whether the tumour targeting rabbit antibodies (NRbt JgG) can be 
linked to a biotinylated oligonucleotide through 19 in a manner that appears to 
maintain increased biological activity. Plans were made to repeat experiments 
with GRE1 and GRE4 specific antibodies. This would be done to determine 
whether specific ELISA immuno-reactivity could be gained with further 
purification of the eluted antibodies retained at the binding sites. A study will 
also be done to assess the background signal gained with the biotinylated 
oligo. 
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2. GLOBAL AND 
NUCLEOSIDES 
PARTIAL PROTECTION OF 
(A). Protection of the 5'-position of nucleosides 
Nucleosides are conventionally attached to a solid support by the 3'-hydroxyl 
position, thus the 5'-position needs to be protected. The protection reaction is 
regioselective for the primary 5'-hydroxyl compared to the 3'-hydroxyl partly 
because of the bulk of the protective groups. 
Thymidine was used firstly as the sample nucleoside, as its nucleoside base 
does not need protection, in order to investigate hydroxyl protection using 
different protecting groups. Following adenosine and guanosine nucleosides 
were also protected. The protective groups triphenylmethyl chloride (TrCI), 4, 
4'-dimethoxytrityl chloride (DMTr) and terl-butyldimethylchlorosilane 
(TBDMSCI) were introduced at the 5'-position using different sets of 
conditions 
(I) Trityl Protection 
Trityl (triphenylmethyl) chloride 56 (Scheme 52) is conventionally a protecting 
group for primary hydroxyl functions but it has also been used to protect the 3' 
and 5' positions of 2'-deoxythymidine. The 5'-0-tritylthymidine is a key 
intermediate in the synthesis of thymidine derivatives and favours the 
introduction of 3'-substituents, which are susceptible to mild reducing or basic 
conditions. 
Tritylation of 2'-deoxythymidine and adenosine in pyridine with the presence 
of a catalytic amount of 4,4'-dimethylaminopyridine afforded 57 and 58 after 
recrystallization from ethanol and petrol in a high 71% yield and 64% yield as 
white crystalline solids, respectively.297-300 (Shown in Scheme 52). 
lOO 
1 . The H-NMR spectrum of compound 57 showed a multiple! at o 6.94-7.22 
ppm and another multiple! at o 7.30-7.55 which correspond to the 9 ortho and 
para hydrogens and the 6 meta hydrogens respectively, of the trityl groups of 
the protective group. 
1
H-NMR spectroscopic analysis of compound 58 showed 
the same multiplets at o 6.76-7.05 ppm and o 7.12-7.44 ppm. 
Trityl chloride (TrCI) 
+ HOR _P_Y_rid_in_e_(_d_ry) __ 
HO X DMAP (cat), r.t., 2h 
X=H, OH 0 
Me~ /H 
57 2'-deoxythymidine : X= H, B = t.} yield: 71% 
N/""'n 
' I 
58 adenosine :X= OH, B = 
NH2 
<tx) yield: 64% 
1';1 N 
I 
Scheme 52 
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(11) Dimethoxytrityl Protection 
The most useful protective group for the 5'-position is the 4',4'-
dimethoxytriphenyl-methyl group 59 (Scheme 53), which is the most easily 
cleaved of a family of acid- labile protective groups, the !abilities of which 
increase as the number of methoxy groups increases. 
Among the N-free 5'-0-dimethoxytritylated nucleosides, the adenosine and 
thymidine derivatives were prepared from the parent nucleosides in one step 
synthesis. The 5'-0-selective dimethoxytritylation of adenosine and 2'-
deoxythymidine was conducted in pyridine, using 4, 4'-dimethoxytrityl chloride 
in the presence of a catalytic amount of 4-dimethylaminopyridine. 
4,4'-dimethoxytrityl chloride (DMTrCI) 
M eO 
pyridine (dry) DMTrO~ 
HO X DMAP (cat). r.t., 4h 
M eO x~ H. OH 
60 2'-deoxythymidine : X= H, B = yield 71% 
61 adenosine : X= OH, B = yield 70% 
Scheme 53 
In the case of 2'-deoxythymidine the crude product was recrystallized from 
ethanol and petrol to give the 5'-0-protected derivative 60 as a white 
microcrystalline solid in 71% yield. 
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For adenosine dichloromethane and petrol were used to afford 61 in 70% 
yield again as a white microcrystalline solid (Scheme 53). Both of the 
compounds showed spectral data consistent with the reported data for 60 and 
61.301.302 
The selective incorporation of the protecting groups 56 and 59 at primary 
hydroxyl is undoubtedly one of the features accounting for the usage of these 
groups in the protection of the 5'-hydroxyl function of nucleosides. The 
sensitivity of a specific trityl ether linkage to acidic conditions is dependant on 
the electron-donating properties of the substituents carried by the trityl group. 
Each p-methoxy substituent enhances the rate of acid cleavage, consequently 
the di-p-methoxytrityl group is most commonly used. In the synthesis of 
oligonucleotides on polymer support, the removal of the 5'-0-DMTr group 
under acidic conditions can be particularly useful in evaluating the efficiency 
of the chain elongation step. The release of the di-p-methoxytrityl carbocation 
gives a bright orange colour, which confirms the deprotection of the 5'-
hydroxyl group. 
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(Ill) tert-Butyldimethylsilyl Protection 
tert-Butyldimethylsilyl chloride (TBDMSCI) 62 shown in Scheme 54, reacts 
selectively with hydroxyl groups in nucleosides and even in the presence of 
excess TBDMSCI the reaction occurs preferentially with the 5'-hydroxyl and 
not with amino groups. 
The TBDMS group is especially advantageous as it does not possess a chiral 
center and its derivatives are frequently nicely crystalline and suitable for 
analysis. it is stable to phosphorylation conditions and can be removed under 
conditions that do not affect other acid (e.g. trityl) or base labile protecting 
groups.230 
The ratio of nucleoside: TBDMSCI: imidazole is important in terms of yield and 
rate of reaction. Two solvents systems have been employed for the silylation 
of the four nucleosides: (i) the DMF-imidazole and (ii) pyridine. The presence 
of imidazole as catalyst is essential to the reaction with DMF since its 
absence gives around 5% yield. However if pyridine is used as solvent in 
place of DMF, it effectively replaces imidazole as catalyst. 
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1. Protection ofthe 5'-hydroxyl 
The DMF-imidazole system usually led to faster rates of reaction while 
pyridine, which works as both solvent and base, provided higher yields of the 
desired products. Many different approaches were attempted using different 
equivalents and reactions times but the reaction conditions shown in the 
Table 4 below list the conditions that led to optimum yields of 63, 64, 65 and 
66 (Shown in Scheme 54). 
3 F 8 
0 Pyridine 8 77 
1.1 2.2 DMF 3 
.3 2 77 
1.2 0 Pyridine 8 86 
1.2 2.4 DMF 3 
1.5 2 75 
1.2 0 Pyridine 6 81 
1.2 2.4 DMF 4 
1.3 2 78 
0 Pyridine 6 88 
a Conditions were 4ml of DMF per 1 mmol of nucleoside and 2ml of pyridine 
per 1 mmol of nucleoside 
Originally the reactions were tried, as a suspension of the nucleosides in 
DMF, pyridine and THF. tert-Butyldimethylsilyl chloride was found to react 
very slowly with the hydroxyl groups and in unsatisfactorily yields even when 
excess of silylating agent in excess solvent was left to react for many hours. 
The lengthy reactions times and the poor yields obtained was due to the poor 
solubility of the nucleosides in the variety of solvents utilized, even though 
these are the most polar solvents available. 
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tert-Butyl dimethyl silyl chloride 
(TBDMSCI) 
Me 
I 
Bu1-Si-CI 
I 
Me 
-
------------- TBDMSO~OO~ B DMF or pyridine )--{ 
imidazole HO X 
62 
63 2'-deoxythymidine : X= H, B = yield 67-77% 
64 adenosine :X= OH, B = yield 74-86% 
65 guanosine :X= OH, B = yield 72·81% 
66 cytidine :X= OH, B = yield 73-88% 
Scheme 54 
lt was observed that a simple change in the procedure led to a much cleaner 
reaction mixture. The suspension of the nucleoside in either concentrated 
DMF or pyridine was first heated up at around 70-90 °C for approximately 
20min till complete dissolution of the nucleoside. Then the silylating reagent 
was added neat followed by imidazole in the case of DMF. 
The major advantage of the method developed is that the reactions were 
performed in a concentrated solution instead of suspension as previously 
used, which accelerated the rate of reaction. This method is based on direct 
addition of the silylating agent to the dissolved nucleoside. Many ways of 
mixing the reagents were tried but the procedure developed (see 
Experimental) gave maximum results. 
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Good yields of the 5'-protected nucleosides were obtained in all four cases. 
The 5'-TBDMS-2'-deoxythymidine 63 was furnished in 66% yield after 1h 
reaction in DMF-imidazole or 77% yield after 8h reaction in pyridine. Again in 
DMF but increasing the ratio to 1: 1.5: 3 and the reaction time to 8h had a 
negligible increase in the yield. 
W1th adenos'ine the OMF-im'Jdazole system gave 5'-TBDMS-adenos'Jne 64 in 
74% yield after 3h and 77% after 2h but by increasing the ratio to 1:1.3:2.6. 
Pyridine again gave the best result with 86% yield after 8h of reaction. 
Similar yields were obtained for 5'-TBDMS-cytidine 65 (78% in DMF-imidazole 
and 88% in pyridine ). In this case the 1:1.1:2.2 ratio gave poor results and for 
that reason was increased to 1:1.2:2.4 and the reaction time to 4h. 
With guanosine yields of the 5'-TBDMS-guanosine 66, were generally lower 
compared to the previous nucleosides (75% in DMF-imidazole and 81% in 
pyridine). Even when the ratio was increased to 1:1.5:3 66 was furnished in 
1 
72% yield after 2h of reaction. The melting point, I.R, and H NMR spectra of 
all four 5'-0-protected derivatives product were identical with those prepared 
according to the literature.303 
Using the conditions described in Table 4 averted any silylation of the amino 
bases of the nucleosides, while the method developed allowed for reactions to 
be performed in homogeneous solutions, increased the rate of reactions. 
Using larger excesses of the silylating agent in some cases led to silylation of 
the base especially in the case of guanosine. lt was also noted that TBDMSCI 
deteriorates with time and repeated exposure to air such that higher ratios of 
the respected nucleosides must be used to obtain the maximum yields. 
The preference of TBDMSCI for reaction with hydroxyl groups adds 
cons'iderable versatility to nucleoside protecting groups The major advantage 
of the TBDMSCI reagent is that it rapidly converts the nucleosides into 
silylated derivatives and is stable to acidic and basic conditions, dry solvents 
and nonpotic bases such as pyridine. When pyridine was used as the solvent 
in place of DMF for adenosine, the pyridine effectively replaces imidazole. 
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2. Protection of the 2' and 3' -hydroxyls and Global Protection 
Adenosine, guanosine and cytidine were used for protection in this case as 
shown in Scheme 55 
Hp DMF-Imidazole ROP ROP 
+ 
Pyridine-lmidazole 
HO OH or Pyridine HO OR RO OH 
67 or 70 or 73 68 or 71 or74 
+ ROP 
RO OR 
69 or 72 or 75 
0 
67, 68, 69 where e = <t£r Guanosine 
t;i N NH2 
73, 7 4, 75 where B = 
NH2 c~ Cytidine 
t;l 0 
-, I 
NH2 
B= t:C; 
~N 
Adenosine 62 R=TBDMS• 
r· 
Bu1-Si-
~e 
' 
Scheme 55 
Again the two known systems (DMF-imidazole and pyridine) were used along 
with the new pyridine-imidazole conditions. Various reaction conditions were 
applied using different equivalents of TBDMSCI and imidazole and different 
reaction t';mes in order to access the reaction rate and selectivity. The method 
developed for the 5'-0H protection (heating of the nucleoside suspension till 
dissolution before addition of the silylating reagent) was also used in this 
case. 
I! was found that DMF-Imidazole system worked exceptionally well in the case 
of the global protection of guanosine and adenosine with 100% selectivity in 
derivatization of the 2',3',5'-hydroxy\ versus the 2',5' and 3',5'-hydroxyls. it 
gave the most rapid rates with completion of the reactions within 30min of 
stirring at room temperature and excellent yields. 
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Pyridine reactions were slower but gave more selectivity in favour of the 
formation of the 2'-hydroxyl and higher yields, especially when imidazole was 
also added as in the case of guanosine and adenosine. These results are 
summarized in Table 5 below. 
ne 
Cytidine 
Guanosine 
Guanosine 
uanosine 
Adenosine 
3.6 
3 
7 
2.2 
3.3 
5 
7 
4 
2.2 
3 
5 
3.3 
4 
4.4 
14 
7 
0 
14 
10 
0 
0 
7 
0 
8.8 
Pyridine 
D 
Pyridine 
Pyridine 
Pyridine 
DMF 
Pyridine 
Pyridine 
Pyridine 
DMF 
DMF 
60 
90 
90 
30 
60 
60 
60 
90 
90 
30 
41 
51 
67 
4 
45 
50 
62 
52 
4 
32 
19 
16 
8 
32 
26 
19 
16 
4 
a Conditions were 4ml of DMF per 1mmol of nucleoside and 2ml of pyridine 
per 1 m mol of nucleoside 
Good yields of the desired 2',5'-protected nucleosides were obtained when 
pyridine was employed in all three cases. For example the 2',5'-
disilylguanosine 67 was obtained after 90 min reaction in 67% and 51% yield 
when pyridine and pyridine-imidazole systems were used respectively. 2',5'-
Disilyladenosine 70 was formed after 60 min in pyridine in 62% and 50% yield 
when 3 and 5 equivalents of silylating reagent were used respectively. 
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89 
10 
8 
4 
85 
8 
4 
2 
9 
84 
92 
Addition of imidazole and increase of the time to 90 min only resulted to a 
52% yield. 2',5'-disilylcytidine 73 was obtained in 64% yield after a 60 min 
reaction in pyridine while addition of imidazole only gave 16% yield of the 
desired derivative. 
On the other hand employment of the DMF-imidazole system led to the 
decrease of selectivity in favour of the 2' ,5'-protected nucleosides. With 
guanosine the 2',5' and 3',5'-disylated 67 and 68 derivatives were furnished in 
41% and 32% yield respectively, while the 2',5' and 3',5'-disylated adenosine 
70 and 71 were obtained in 45 and 32% yield respectively. 
With cytidine the yield of the 2',5'-disilylcytidine 73 was slightly higher (50%) 
but again the selectivity suffered with the 3',5'-derivative 74 obtained in 34% 
yield. 
On the contrary in the case of the 2',3',5' TBDMS protection employment of 
the DMF-imidazole system led to excellent selectivity in derivatization of the 
global protected derivatives of adenosine and guanosine. They were 
furnished in satisfactory yields within 30 min of reaction, 92% for 2',3',5'-silyl 
adenosine 72 and 85% for 2',3',5'-silyl guanosine 69. 
With cytidine though, the pyridine-imidazole system proved to be more 
effective than DMF-imidazole, resulting in the selective production of the 
2',3',5'-silyl cytidine 75 in 89% yield after a 60 min reaction time. 
One excellent synthetic feature of the silylated nucleosides is that isomeric 
compounds separate very cleanly on silica gel chromatography and can be 
obtained by short column chromatography often in solvents such as ether and 
hexane. Products containing silyl groups on the exocyclic amino groups were 
not obtained in any quantity during these reactions. it appears that N-silylated 
nucleosides may be intermediates in the reactions but they either act as 
silylated agents themselves (i.e., transferring the N-silyl to a hydroxyl) or are 
hydrolyzed during work-up. 
The usage of TBDMSCI protecting group leads to the conclusion that for the 
nucleosides possessing a free amino group, the above ratio of the reagents 
used increases for optimum yields of adenosine cytidine and guanosine 
derivatives. 
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3. Selective 5'-desilylation of 2',5'-and 2',3',5'-silylated nucleosides 
The 2',3',5'-0-TBDMS and the 2'-5'-0-TBDMS nucleosides are useful building 
blocks for investigation of the coupling chemistry of the existing linkers. One 
of the main aims of this project was the employment of the linked nucleoside 
conjugates for the formation of CpG dinucleotides. In order to utilize them the 
5'-end needs to be free for coupling and subsequently removal of the 5'-
TBDMS groups is essential. it was proposed to investigate the 5'-selective 
desilylation method first on the non-coupled nucleosides in order to study the 
effects and then apply the optimized conditions on the linked nucleosides. 
One of the greatest challenges in the field of the TBDMS protection is the 
selective deprotection of the primary TBDMS groups in the presence of their 
secondary counterparts, a procedure with considerable utility in nucleotide 
synthesis.304 In the past, removal of silyl groups was done either by acid 
hydrolysis, base, Lewis acids or in the presence of tetrabutylammonium 
fluoride (TBAF). 
When base was used as the deprotecting reagent305 (9 M NH40H in ethanol 
at 70 °C), it was found that 2'-and 3'-silyl groups are more sensitive to base 
hydrolysis than the 5'-position. This resulted in the removal of the primary 
TBDMS group being more difficult when both of the 2'-and 3'-positions are 
protected. 
Cleavage of the primary TBDMS group using Lewis acids such as zinc 
bromide suffered from long reaction times, higher temperatures, low yields 
and complicated procedures.306•308 In the case of TBAF, the 2' and 3'-silyl 
groups were cleaved more rapidly than 5'-silyl, which demonstrated that the 
fluoride ion based reagent, possesses a lack of primary preference. This can 
be due to the strong affinity of fluoride ions for silicon. 
A useful feature of the silylated nucleosides is the fact that the 5'-silyl group is 
much more labile towards acid than either the 2'- or 3'-silyl. Therefore the 
primary silyloxy groups are cleaved under acidic conditions more easily than 
secondary ones.304 
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it was decided that acetic acid with a pka value of 4.76 seemed the 
appropriate candidate for selective deprotection, as is a moderate acid that 
can offer good selectivity. Consequently the 2',5'-derivatives of the 
nucleosides were treated with 80% aqueous acetic acid (HOAc) either at 
room temperature or on heating in order to remove the 5'-0H protection. Also 
the 2',3'-silylated nucleosides needed to be synthesized and they were 
prepared via the selective 5'-desilylation of the corresponding 2',3',5'-
trisylilated derivatives. 
The 5'-desilylation of 2',5'-and 2',3',5'-silylated guanosine, adenosine and 
cytidine using HOAc, is shown in Scheme 56 and the optimized results are 
summarized in Table 6 below. 
RO"Q 80% aq HOAc HO"Q 
(100 °c or 20 °C) HO OR HO OR 
67 or70 or 73 76 or 77 or 78 
RO"Q 80% aq HOAc HO:R 
(100 °C or 20 °c) RO OR RO OR 
69 or72 or 75 79 or 80 or 81 
0 
67, 69, 76, 79 where 8 = f£:e Guanosine 
t;J N NH2 NH2 
T 
73, 75,78,81 
AN Cytidine 
where B = l .. ,1 
70, 72, 77, 80 where Adenosine 
Scheme 56 
R=TBDMS= 
t;J~ 
I 
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100 
70 20 
70 100 
20 
73 
69 20 
69 100 
72 
75 
75 100 
When the 2',5'-derivatives of guanosine, adenosine and cytidine 67, 70 and 
73, were treated with HOAc at room temperature the reactions were longer 
but the yields obtained were better (up to 80%), compared to heating where 
the reactions were complete within 30min with yields up to 68-74%. 
The crude 5'-desilylated derivatives of guanosine and cytidine were re-
crystallized from ethyl acetate and hexane, to give the pure form of 76 and 78 
as white solids. In the case of adenosine re-crystallization from 
dichloromethane and petrol provided the purified 77 as white solid. 
In both cases though, along with the 5'-desilylated derivatives 76, 77 and 78 
guanosine, adenosine and cytidine were also furnished and especially when 
the reactions were heated, the yields of the fully deprotected nucleosides as 
by-products, were increased. 
The 2',3',5'-tri-0-TBDMS guanosine 69, adenosine 72 and cytidine 75 were 
also selectively deprotected to give very good yields of the corresponding 
2',3'-0-disilylated derivatives 79,80 and 81 (76-86%). 
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The crude 2',3' -0-disilylated derivatives of guanosine and cytidine were 
subjected to flash chromatography using chloroform and ethanol (4:1) and 
then to provide the pure forms of 79 and 81 as white solids. In the case of 
guanosine diethyl ether and hexane (2:1) and then diethyl ether was used as 
the eluent to afford the purified 80 as white solid. Again reactions at room 
temperature afforded higher yields with longer reaction times. 
Treatment of the globally protected nucleosides with the deprotecting reagent 
also resulted in the removal of the 3'-0-TBDMS group to produce the 2'-0-
derivatives 76, 77 and 78 as by-products. The 5'-silyl group in adenosine 
appears to be slightly more resistant to acid than in guanosine and cytidine. 
Steric effects can dominate the selectivity of desilylation. Although it was 
found by calculation of the Geistiger-Huckel charges309 that the 2', 3' and 5'-
0-TBDMS groups have almost the same charge on their oxygen atoms, their 
steric environments are different. 
The 5'-0-TBDMS groups of trisilylated nucleosides are obviously much less 
hindered than the 2' -group, leading to excellent selectivity in favor of the 
removal of the 5'-0-TBDMS group. These steric effects are somewhat 
reduced for the disilylated nucleosides in which the 3'-positions have smaller 
OH moieties leading to slightly poorer desilylation selectivity and yields. 
Our experiments revealed that although selective 5' -desilylation can be 
accomplished using 80% aqueous acetic acid with high yields up to 86%, it 
also resulted in side reactions and the production of by-products. Ideally this 
has to be avoided. 
Around the time that attempts were made to optimize the selective 
deprotection conditions in order to avoid by-product formation, A. lan Scott 
and his co-workers309 published a paper about the 5' -desilylation of 
multisilylated nucleosides. They discovered that a TFA-H20-THF (1 :1 : 4) 
system selectively deprotected the 5'-0-TBDMS group with very satisfactory 
results at 0 °C. 
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Employment of this system for our deprotection purposes, resulted in the 
2',3',5' and 2',5'-0-TBDMS nucleosides being quantitatively transformed into 
the expected 2',3' and 2'-0-TBDMS derivatives, as shown in Scheme 57. The 
results obtained from our experiments are shown in Table 7 below 
The use of the THF as the solvent afforded the following benefits: 
(i) Increase of solubility of nucleoside substrates and hence 
acceleration of the reaction time. 
(ii) Significantly improved selectivity of 5'-desilylation even when the 
reaction was carried out at room temperature. 
(iii) Complete absence of depyrimidination and depurination, which are 
common side reactions of the acidic hydrolysis of nucleosides. 
73 
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The corresponding 2' ,3'-0-disilyfated derivatives of guanosine 85 and 
cytidine 87 were afforded after purification on column chromatography 
using chloroform and ethanol (4:1) while the adenosine derivative 86 was 
provided using diethyl ether (2:1) as the eluent. 
The 2'-0-silylated derivatives of guanosine and cytidine 82 and 84 were 
recrystallized from ethyl acetate and hexane while 83 was recrystallized 
from dichloromethane and petrol. The yields obtained for the guanosine 85 
and cytidine 87 derivatives were slightly improved compared to Scott's 
while the yields for 82, 83, 84, and 86 were similar. 
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RO'q TFA-H20-THF (1:1:4) 
0 °C, 2-6h HO OR 
67 or70 or73 
Rq 
TFA-H20-THF (1:1:4) 
o "c. 2-6h RO OR 
69 or72 or 75 
0 
NJNH Guanosine 
67, 69, 82, 85 where B = ~ Jl. A 
1_ N NH2 
' 
HO'q 
HO OR 
82 or 83 or 84 
HO'q 
RO OR 
85 or86 or87 
NH2 C Cytidine N 73, 75, 84, 87 where B = [ ~~'-o 
~,~ 
Adenosine 
70, 72, 83, 86 where 
R=TBDMS= 
Scheme 57 
In comparison with the results obtained from the selective 5'-desilylation using 
80% aqueous acetic acid, Scott's system seemed to be more effective as the 
2',3',5' and 2',5'-0-TBDMS nucleosides were quantitatively transformed into 
their 2',3' and 2'-0-TBDMS derivatives. Along with yield improvement another 
advantage of this system was that deprotection of the 5'-0H group was 
performed without any side reactions or production of by-products. 
The synthesized 5' -desilylated derivatives of the nucleosides will be employed 
in the future formation of lipophilic nucleoside conjugates and subsequent 
synthesis of CpG dinucleotides. 
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3. SYNTHESIS OF LIPOPHILIC-NUCLEOTIDE 
CONJUGATES 
Modification of oligonucleotides with lipophilic groups to provide more potent 
antisense agents, has been considered as one possible method to improve 
their pharmacokinetics. lt has been shown that such modifications of 
oligonucleotides can enhance the uptake and cellular efficacy. 172 They have 
increased nuclease resistance,158•160 are more active in blocking the viral 
replication in cell cultures and more efficacious in antisense experiments, 
compared to non-derivatized oligonucleotides. 178•188 
For modified nucleotides to be suitable as diagnostic systems was postulated 
that certain structural criteria are required to effect efficient hybridization of the 
modified nucleoside with its targeted genetic sequence. These criteria include 
a stereoregular backbone (required for a homogeneous binding constant 
between the analogue and its complementary genetic sequence) and affinities 
of the oligonucleotide analogues for targeted genetic sequences that are 
sufficient to effect the desirable biological or physical action. 
Certain nucleoside linkages containing carbonyl moieties satisfy the above 
criteria and they can constitute a valuable class of nucleotide analogues. Our 
interest in this class was stimulated by the fact that their synthesis could be 
readily achieved while; these analogues can have important biochemical 
properties such as template activity and resistance to enzyme-catalysed 
degradation. Subsequently it was decided to synthesize lipophilic-nucleotide 
conjugates containing such linkages. 
The previously synthesized carbonate (10 and 11), carbamate (13 and 14), 
and ester (16 and 17) linkers were employed to link the lipophilic molecules to 
the 3'-terminus or the amino base of the nucleosides through internucleoside 
linkages. 
117 
(A) Lipophilic N-carbamate analogues of nucleosides 
Initially the modifications were performed at the exocyclic amino group of the 
nucleobases of adenosine and guanosine. This was done in order to form 
carbamate analogues of the nucleosides as they have shown to have 
excellent resistance to both chemical and enzymatic degradation and 
nuclease hydrolysis. 
The 2',3',5'-TBDMS-protected guanosine 69 and adenosine 72 were reacted 
with both the cholesterol 10 and tocopherol 11 carbonate linkers, as shown in 
Scheme 58 below. The reactions were first carried out using 1 equivalent of 
each of the reactants, 1.1 equivalents of triethylamine as the base, 
dichloromethane as the solvent and heating under reflux. This did not facilitate 
the formation of the amide bond and starting material was recovered 
unchanged. 
lt had been reported that 1 ,4-dioxane is an effective solvent for the formation 
of amide bonds in satisfactory yields. This solvent was used but the reaction 
was unsuccessful and no other identifiable product was isolated except for 
starting material. 
it was then decided to investigate other high boiling solvents such as DMF 
and THF to try and increase the solubility factor and force the reaction by 
heating at higher temperatures, However, disappointingly under the new 
conditions used, the yields afforded were low, between 26-35%. In most 
cases other unidentifiable products were recovered along with starting 
material while, only a small percentage of nucleobases underwent 
modification to form carbamate bond linkages. This may be due to 
triethylamine not being strong enough to deprotonate the amine to allow for 
the displacement of the 4-nitrophenyl group to occur. 
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Repetition of the reactions using pyridine in the place of triethylamine and 
refluxing in dichlromethane and 1 ,4-dioxane overnight, did not facilitate the 
synthesis of the desired lipophilic conjugates. When DMF and THF were 
employed as solvents in refluxing for 24h, the N-cholesteryl and tocopheryl 
carbamate derivatives of 2' ,3' ,5' -protected adenosine and guanosine 88-91 
were obtained in poor yields with the recovery of starting material. 
Table 8 below shows the outcome of the above conjugation reactions. This 
may infer that modification at the amino base of nucleosides does not work 
effectively under the conditions described, as the bases employed may not be 
strong enough to generate the amide bond. 
Table 8 
(1.1eq) react. react. react. react. 
1,4 dioxane reflux 6h No No No No 
react. react. react. react. 
DMF reflux 12h 31 35 29 33 
THF reflux 12h 31 36 30 35 
Pyridine DCM reflux no no no no 
(1.1eq) overnight react react react react 
1,4 dioxane reflux no no no no 
overnight react react react react 
DMF 31 38 32 35 
reflux 24h 
THF 33 37 32 35 
reflux 24h 
it was then decided to increase the equivalents of the protected nucleoside 
and base to 1.1 and 1.5, respectively in an effort to force the reaction to 
completion. 
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Anhydrous pyridine was employed as the base, THF and DMF as the solvents 
and the reactants were refluxed overnight, as these systems gave better 
results. The protected nucleosides 72 and 69 had under gone modification to 
give the N-carbarnate analogues 88-91 in improved yields, between 40-47%. 
However characterization showed that carbonate linker and was still present 
as starting material. Increase of the equivalents to 1.2 only led to undesirable 
reactions and other products were isolated that could be characterized. 
When pyridine was used both as solvent and base and heated under reflux 
conditions for 24h, the reaction led to the consumption of the starting material 
and formation of the desired products. In all cases the products were isolated 
after separation and purification by flash column chromatography using a 20:1 
mixture of chloroform and methanol. 1H-NMR spectroscopic analysis 
confirmed the formation of amide as evidence of a broad singlet at 7.68-7.73 
ppm for CONH while IR analysis showed two peaks at 1674-1697 cm·1 
indicating the presence of a secondary amide. 
The 2',3',5'-TBDMS-N-carbamate tocopheryl conjugates of adenosine 89 and 
guanosine 91 were afforded as off yellow products in 64 and 66% yield, 
respectively, while the 2',3',5'-TBDMS-N-carbamate cholesteryl of adenosine 
88 and guanosine 90 were furnished as off-white products in 60 and 61% 
yield, respectively. A summary of the results obtained is shown in Table 9 
below. 
(1.5eq) 
THF reflux overnight 45 43 47 40 
60 64 61 66 
a: were 4 ml per 1 m mol of reactant 
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The successful development of the procedure using pyridine as base and 
solvent prompted an investigation into extending the amino modification of 2'-
3',5'-TBDMS-protected guanosine 69 and adenosine 72 using the synthesized 
carbonylimidazolide linkers of cholesterol 13 and tocopherol 14. The reactions 
are shown in Scheme 59 below. However, disappointingly, this approach was 
not very successful and it led to undesirable reactions, as conjugates formed 
with the N-H bonds present in the protected nucleosides were isolated. The 
pyridine could be removing the electron density from the imidazole ring 
making it less susceptible to electrophilic attack. 
it was decided to repeat the reactions under acidic conditions so that the 
imidazole can be protonated and therefore converted into a better leaving 
group. Thus small amounts of concentrated hydrochloric acid were added and 
the reaction was promoted but it was found that the yields of the conjugates 
varied greatly with seemingly small changes in the amount of acid 
incorporated. The results are shown in Table 10 below. 
(2ml) 
(3ml) 
Acetic 
(5ml) 
reflux 47 
at r.t 68 
When acetic acid that has a lower pka value was used, instead hydrochloric 
acid, the protected nucleosides 72 and 69 under went modification to give the 
N-carbamate cholesteryl derivatives 92 and 94 as off-white products in 63 and 
66% yield respectively. The N-carbamate tocopheryl conjugates of the 
corresponding nucleosides were furnished as off-yellow products in 68 and 
70% yield as shown in Table 10 above. 
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The crude products were purified as in the case of the lipophilic analogues 
deriving form 4-nitrophenyl carbonate linkers. The structures of the purified 
compounds were confirmed by spectroscopic and elemental analysis and 
were found to identical to the previously synthesized conjugates 88-91. 
Carbonylimidazolide lipophilic derivatives in anhydrous pyridine have shown a 
high reactivity towards N-H bonds present in nucleoside building units. As a 
result several side reactions have been observed including degradation of 
guanosine and adenosine derivatives. In the presence of acid though 
carbonylimidazolide carbamate linkers managed to modify the exocyclic 
amino groups and form the desired carbamate conjugates in very good yields. 
A comparison of the results acquired using basic and acidic conditions 
showed that both of the methods were successful, as the yields obtained were 
similar. 
On the other hand, lipophilic derivatives containing 4-nitrophenyl-carbonate 
linkage are capable to transform, in aqueous pyridine, the free exo-NH2 
groups of adenosine and guanosine residues to the corresponding lipophilic 
carbamate nucleoside analogues, which were afforded in good yields. 
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(B) Lipophilic N-acetamide analogues of nucleosides 
Next in our investigation of the modification on the exocyclic amino group of 
the nucleosides was the formation of acetamide-linked analogues of the 
corresponding nucleotides. Acetamide-linked analogues are attractive due to 
their stability over a wide pH range and their enzymatic degradation. 
Furthermore, they possess linkages that are achiral, thus avoiding the difficult 
separation of diastereomers during their synthesis and purification. The 
purpose of this coupling is to form a different kind of amide linkage containing 
a more stable CH2 group that can stand up the conditions of DNA 
In this case, the pentaflurorophenyl ester linkers of cholesterol 16 and 
tocopherol17 were employed and reacted as previously with 2',3',5'-TBDMS-
protected guanosine 69 and adenosine 72. The reactions are shown in 
Scheme 60 below. 
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In order to deprotonate the amino group of the nucleobases stronger bases 
with high nucleophilicity, such as lithium bis (trimethyl silyl) amide and t-butyl 
lithium, were utilized. After treating 1.1 equivalent of the protected nucleosides 
with the same equivalent of bases at -78 °C in THF, the reactions were 
carried out at 0 °C for 1 h and then refluxing for 30 h. However, this approach 
was not successful as it gave very poor yields (15-23%) of the desired 
products. Various attempts were also made using an increased 1.2 equivalent 
of the bases. Disappointingly did not give the expected results, as the yields 
did not improve greatly (19-29%) even after refluxing for 30h. 
When pyridine was used as both solvent and activator after refluxing for 30h, 
the yields were improved {38-44%) but still they were not satisfactory. In some 
cases other unidentifiable products were recovered along with desired 
acetamide conjugates. The results obtained are summarized in Table 11 
below. 
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reflux 30h 
lithium (1.1 eq) THF 0° c 1h 23 22 
reflux 30h 
bis (trimethyl THF 0° c 1h 22 21 22 
silyl) amide (1.2eq) reflux 30h 
0° c 1h 29 25 
reflux 30h 
44 39 
a: reactant 
The next step in our investigation of the acetamide conjugate synthesis was 
the employment of acidic conditions. For that reason acetic acid was used as 
previously but reactions didn't proceed as expected as the yields only 
improved slightly (43-50%). However, when p-toluenesulfonic acid was used 
as the reagent of choice, it adequately protonated the amino group of the 
protected nucleosides in order for the conjugation to take place. 
The coupling of the pentafluorophenyl linkers with the tosylate of 69 and 72 
was effected after refluxing overnight in DMF in the presence of 
diisopropylamine. lt occurred selectively at the amine terminus giving the N-
acetamide-linked lipophilic analogues 96-99 in very good yields, between 68-
72%. Purification was accomplished by flash column chromatography eluting 
initially with 1% MeOH I 99% CHCI3 and then with 10% MeOH I 90% CHCb. 
to provide the N-acetamide cholesteryl and tocopheryl derivatives as off-white 
and off-yellow products, respectively. Table 12 shows the outcome of these 
reactions. 
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The synthesized compounds were assigned to be the desired N-acetamides 
by the presence in 1H-NMR spectrum of a broad singlet at 7.68-7.75 ppm for 
CONH and a singlet at 2.75-2.77 ppm corresponding to the two hydrogens of 
the CH2-CONH. Also evidence of two peaks at 1686-1695 cm·1 in lnfa Red 
spectral analysis indicated the formation of a secondary amide. 
p-toluenesulfonic 0° c 1h 68 70 69 72 
reflux 24h 
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(C) Lipophilic 0-carbonate analogues of nucleosides 
Modifications can also be carried out at the 3'-terminus of the nucleosides and 
it has been shown that incorporations at the 3'-end of a CpG dinucleotide 
potentiated the immunostimulatory activity and increases its stability against 
nucleases. 
Nucleotide analogues containing carboxymethyl linkages at the 3'-end have 
proved to have two disadvantages: the relative instability of the linkage under 
physiological conditions and the low solubility of the compounds that makes it 
difficult to test their biological activity. In view of that, our next step was the 
synthesis of analogues in which the 3'-0H of the nucleoside is joined to the 
lipophilic compounds by a carbonate linkage, as such compounds would not 
suffer from these disadvantages. In this case, the 2',5'-0-disilylated 
derivatives of guanosine 67 and adenosine 70 were reacted with the 
carbamate linkers of cholesterol 13 and tocopherol 14. The reactions are 
shown in Scheme 61 below. 
NH2 f+N 
TBDMSOYO--JJLj 
HnTBDMS 
70 
+ 
TBDMSO~d 
")::---j-...._'-f~::__::::J oyO OTBDMS 
0 100 
0 "" 
'"'" 
14 
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NJ f Jl"'NH 
TBDMso'\:-0--J N)__NH2 
HDTBDMS 
67 
+ 13 
TBDMSO~u 
\:--j-...._f--;-...._t--..:::::-; ~0 OTBDMS 
0 102 
Scheme 61 
+ 14 
TBDMSO~Gu 
0 """ I 
0 oyO OTBDMS 
0 103 
The formation of the lipophilic-carbonate analogues relies on the activation of 
the nucleoside hydroxyl functions using basic conditions. For this reason the 
strong bases, lithium bis (trimethyl silyl) amide and t-butyl lithium were 
utilized. 1 Equivalent of the 3'-0H-disilylated nucleosides 86 and 69 were 
treated with 1 equivalent of the bases at -78 De in THF. The formed alkoxide 
was subsequent exposed to 1 equivalent of the carbonylimidazolide linkers 
and the reactions were carried out at 0 De for 1h and then refluxing for 12 h. 
The free hydroxyls of the 2',3'-protected adenosine underwent smooth 
modification to provide the 0-lipophilic carbonates in very good yields as 
shown in Table 13 below. The 3'-0-cholesteryl carbonate derivatives of 
adenosine 100 and guanosine 102 were obtained in 59-64 and 59-65% yield 
respectively, while the 5'-0-tocopheryl analogues of the corresponding 
nucleosides were attained in 63-67 and 62-69% yield 
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t-butyl lithium gave better yields than lithium bis (trimethyl silyl) amide as it 
has with stronger nucleophilicity. The synthesized compounds were used 
without further purification as attempts to purify them, resulted in 
decomposition due to the instability of the active carbonates to 
chromatography 
bis (trimethyl 
silyl) amide (1eq) reflux 12h 
t-butyllithium (1 eq) THF 0° c 1h 64 67 65 69 
reflux 12h 
Pyridine" Pyridine reflux 30h 30 35 32 36 
65 
a: Conditions were 4 reactant 
b: Conditions were and 4.5 ml of dioxane:pydine (8: 1) per 1 m mol of reactant 
The next step in our investigation was employment of pyridine, as for the 
carbamate analogues. Various attempts to prepare the carbonate analogues 
in anhydrous pyridine resulted in slow reactions and poor yields (30-39%) 
owing to the decomposition of the carbonates in this solvent. it was found 
though that when a mixture of 8:1 of 1.4 dioxane: pyridine was used as the 
solvent and activator and 1.1 equivalents of 3'-0H-disilylated nucleosides 
were treated with 1 equivalent of carbonylimidazolide linkers, the reactions 
proceed at a much faster rate. The desired carbonate conjugates were 
obtained in 59-65% yield, without detectable decomposition. No effort was 
made to purify these compounds. 
The preparation of these conjugates demonstrates the utility of the synthetic 
sequences followed for the preparation of lipophilic carbamate and carbonate 
conjugates without the need for a protecting group on the base. 
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(D) Deprotection of the lipophilic-nucleosides conjugates 
The previously synthesized derivatives of guanosine containing the novel 
carbamate and acetamide lipophilic linkages can be used as useful building 
blocks for the formation of CpG dinucleotides. Future employment of those 
derivatives though, requires for the 5'-terminus to be accessible for coupling 
with the N-free-3'-phosphoramidites of cytidine. For that reason, the N-
carbamate 90-91 and the N-acetamide 98-99 lipophilic analogues of 
guanosine were engaged in selective cleavage of the 5'-0-TBDMS group. 
Previous efforts to selectively remove the 5'-protective group using 80% 
acetic acid either at 20 or 100 °C resulted in side reactions and the production 
of by-products. In turn the TFA-HzO-THF (1 :1: 4) system, which was used 
before to selectively deprotected the 5'-0-TBDMS group with satisfactory 
results, was employed as the desilylating agent. The compounds 90·91 and 
98·99 were treated with the above system for 3h at 0 °C, as shown in 
Scheme 62 below, to furnish the 2',3'-0-TBDMS carbamate and acetamide 
conjugates of guanosine in very good yields. The results are summarized in 
Table 14. 
Both the carbamate and acetamide linkages were proved to be stable to the 
acetic conditions employed and the desired 5'-0H free analogues of 
guanosine were furnished without detectable degradation of the linkages. 
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0 
<t£NH 0 
TBDMSO:hN N)-__A, or R2 
li 
TBDMS OTBDMS 
where 
90 or 91 
TFA-H20-THF (1:1:4) 
0 °C, 3h 
104 or 105 
0 
N._)lNH 0 (( jl_ A Jl /R, or R, TBDMSO~O~ N N('~ 
TBDMSnTBDMS H 
98 or 99 
TFA-H20-THF (1:1:4) 
0 °C, 3h 
0 
N.__,)lNH 0 (( jt_J__ U -R1 orR2 H0~0~ N ~('~ 
TBDMSnTBDMS H 
106 or 107 
= R2 91, 99, 105, 107 
0 
Scheme 62 
The lipophilic 0-carbonate conjugates of adenosine 100-101 and guanosine 
102-103 were also employed for selective desilylation. In a similar set of 
reactions various attempts were made to cleave the 5'-TBDMS group using 
the TFA-HzO-THF system as shown in Scheme 63 below. Disappointingly, 
these experiments were not successful and starting material was recovered. 
Removal of the protecting group utilizing hydrolytic conditions is a difficult 
reaction in the presence of a carbonate. The 0-carbonate analogues proved 
to be unstable and were hydrolysed to give 2',5'-0-disilylated nucleosides. 
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TBDMSO~u 
R R ---./0 OTBDMS 2 or 1 \I 
0 
where 
TFA-H20-THF (1:1:4) 
/ 
TFA-H20-THF (1:1:4) 
/ 
0 
Scheme 63 
HO~u 
R R ---./0 OTBDMS 2 or 1 n 
0 
H0\-1d 
R R ---./0 OTBDMS 2 or 1 ll 
=Rz 
0 
0 
Part of our investigation was also to test the synthesized modified lipophilic 
nucleotides to perceive whether they are taken up into the cell membrane 
more efficiently. In order for that to take place the compounds need to be 
released of their protecting groups. 
The results obtained in our desilylation experiments showed that although 
treatment with 80% aqueous acetic acid at 100 °C after 30-70 min or room 
temperature after 24-28h resulted in the selective 5'-desilylation, it also 
produced as a side reaction the fully deprotected nucleosides (see Table 6). 
lt was anticipated that by prolonging the reaction time complete deprotection 
would be achieved. In the case of conjugates aqueous conditions were best 
be avoided so acetic acid was employed in methanol. 
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The N-carbamate lipophilic analogues 90-91 were subjected to 80% acetic 
acid in methanol and after 3-4h at 100 °C or 30-32h at room temperature, 
complete removal of the tert-butyldimethyl silyl groups protective groups was 
effected. The reactions are shown in Scheme 64 below. The products were 
isolated in over 68% yield as shown in Table 15 below. Elemental and 
spectroscopic analysis confirmed the structure of the products. 
The use of tetrabutylammonium fluoride (TBAF) as a desilylating agent was 
also explored. The carbamate conjugates 90-91 were treated with 5 
equivalents of TBAF in THF, as shown in Scheme 64. The cleavage of the 
protecting groups was rapid and proceeded smoothly, giving the fully 
deprotected conjugates after 3h at room temperature in very good yields, as 
shown in Table 15 below. 
90 
91 "'' 22 
"'' 
90 1 M TBAF R.T 
91 "" R.T 3 
As it can be seen from the tables the yields furnished when TBAF was 
employed (76-80%.) were improved in comparison to the ones obtained with 
80% acetic acid. This can only be explained in terms of TBAF being a 
stronger acid resulting in successfully removing the silyl groups. In agreement 
with expectations, the nucleoside carbamate linkages were very stable to 
hydrolytic conditions and they appeared to have great pH stability. 
Desilylation employing 80% acetic acid or tetrabutylammonium fluoride 
occurred without detectable degradation of the carbamate linkage. 
!35 
0 
<N:CNH 0 TBDMSO~N N~1 orR2 
0 ~ 
TBDMS OTBDMS 
90 or 91 
80 % AcOH in MeOH 
100 °C, 3h orr.t 30h 
0 
<N:Cx 0 
HOhN N N~1 orR2 ~ 
H OH 
108 or 109 
90, 108, 110 
where 
0 
<N:CNH 0 
TBDMSvo'-) N'~1 orR2 
TBDMn.BDMS 
90 or 91 
1 M TBAF in THF 
r.t, 3h 
<NJ:NH 0 HO~N NAN~1 or R2 ~ 
H OH 
110 or 111 
=R2 91,109,111 
Scheme 64 
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(D) Alternative methods for the synthesis of lipophilic-
nucleoside conjugates 
Due to the harsh conditions used for the formation of the lipophilic conjugates 
of nucleosides, an interest was drawn towards developing a fast and efficient 
method for the lipophilic modification of the nucleosides. lt was decided to 
study different routes to try and improve the convenience of the procedures 
and explore if these syntheses could be effected under milder conditions. 
(I) Through the formation of an isocyanate 
Originally efforts were put into trying to alter the reactivity of the free amine of 
the nucleobases. The transformation of the amino group to the isocyanate 
was proposed, as it would formulate it a more reactive group that might allow 
easier generation of the lipophilic analogues. 
Triphosgene [bis(trichloromethyl carbonate]310 is known as an effective 
reagent for the preparation of isocyanates when reacted with amines in the 
presence of base. As a stable crystalline solid it has been used as a safe 
replacement to phosgene which a highly toxic gaseous chemical that form 
drastic conditions. Thus it was thought to investigate its use for the 
modification of the amino groups of the nucleobases. 
Various attempts were made to prepare the isocyanate by reacting 3 
equivalents of the 2,3,5'-0-TBDMS protected adenosine with 1 equivalent of 
triphosgene in the presence of a tertiary base diisopropylethylamine, in 
dichloromethane (Scheme 65). At the end of the reaction a compound was 
isolated along with starting material. lnfa red analysis of this compound didn't 
show a peak at 2250 cm·1 indicating that isocyanate was not formed. Several 
attempts were made varying the bases (triethylamine or diisopropylamine) in 
DCM or THF. However, disappointingly under the new conditions used the 
experiments were unsuccessful, as starting material was recovered and none 
of the desired isocyanate was formed. 
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a) DCM, OlEA or b) DCM, Et3N 
...... 
... 
0 
Cl A Cl 
Cl+-0 O~CI 
Cl Cl 
c) THF, Et3N or d) THF, DiPEA 
N=C=O 
'Scheme 65 
(Ill Through an acid chloride 
lt was also proposed to investigate different methods for the modification of 
the amino nucleobases using the lipophilic compounds. Carbamate formation 
can be attained through the reaction of an acid chloride with the free amino 
group. The acid chloride can then be directly reacted with the amine of 
adenosine and displacement of chlorine atom will provide the corresponding 
amide. Thus, it was decided to investigate the synthesis of the cholesteryl-
carbamate of globally protected adenosine through the commercially available 
chloroformate of cholesterol. 
In order to test this type of reaction, ethylenediamine 112 {shown in Scheme 
66) was used as the model compound of an amino group. The acid chloride 
was used as the precursor and the nucleophilic free amine attacks and 
displaces the electrophile {chloride) whilst pyridine removes one of the 
protons to generate the amide bond. 
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Cholesteryl chloroformate 113 was added dropwise to a 1:1 solution of 
ethylenediamine in dichloromethane: pyridine and after 2h at room 
temperature the cholesteryl carbamate of ethylenediamine was isolated. 
Recrystallization from hexane afforded the 2-(chlolesteryloxycarbonyl) 
ethylamine 114 as crystals in 72%yield. The reaction is shown in Scheme 65 
below. 
+ 
112 
1:1 DCM:pyridine 
2h, r.t 
114 
Scheme 66 
113 
72%yield 
The success of this reaction prompted us into applying the method for the 
modification of the amino base of 2',3',5,-0-TBDMS protected adenosine 72. 
In a similar reaction as above 72 was treated with cholesteryl chloroformate 
113 (as shown in Scheme 67 below) and after 5h at room temperature a 
crude product was isolated. Separation and purification by flash column 
chromatography using a 1:20 mixture of chloroform: methanol as the eluent 
afforded an off-white solid in 42% yield. 
The product was assigned to be the cholesteryl N-carbamate of globally 
protected adenosine 115 by evidence of the carbonyl peaks at 1684-1697 cm· 
1 in infa red spectra indicating the presence of a secondary amide. 1H-NMR 
spectroscopic analysis confirmed the formation of amide as evidence of a 
broad singlet at 7.64-7.76 ppm for CONH. 
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This infers that the desired amide is formed under the conditions described 
but the yield obtained was low in comparison to the ones furnished using 
pyridine as both the solvent and base (60%) and acetic acid (63%) (see 
Tables 9 and 10). Another drawback of this approach was the employment of 
cholesteryl chloroformate, which is an expensive starting material in contrast 
with the already synthesized carbonate and carbamate linkers used in the 
conventional methods above. 
NH2 (:CN 
TBOMSOyo'} NJ + 
TBOMSnTBDMS 
72 
1:1 DCM:pyridine 
5h, r.t 
0 
HN)l_O 
~N+N '-L-----..' 
TBDMSO~N~NJ 
42%yield 
TBDMS OTBDMS 
115 
Scheme 67 
113 
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(Ill) Through the formation of the acid chloride of thioctic acid 
Part of our investigation was also the synthesis of nucleoside conjugates 
employing thioctic acid 3 as the lipophilic compound. As thioctic acid holds a 
carboxylic acid moiety the reasonable method would be through the formation 
of an acid chloride. Amide bond formation can be achieved through the 
synthesis of an acid chloride that can be readily converted to substituted 
am ides. 
The preparation of the acid chloride was performed by reaction with thionyl 
chloride as shown in Scheme 68, but the gradual formation of a black solution 
(within 10 min of stirring at room temperature) drew doubts concerning the 
formation of the acid chloride. For this reason, an IR spectrum was run 
showing a peak at 1796 cm·1 while the 13C- spectrum showed a signal at 173 
ppm. Both of the values are evidence of formation of an acid chloride. The 
black colour could be due to the fact that the thionyl chloride is attacking the 
sulfur atoms of thioctic acid leading to formation of decomposition products. 
The acid chloride 116 was afforded after 2h at room temperature, in 72% yield 
as a black oil that and was used without further purification. 
~OH SOCI2 
s-s r.t., 2h 
~Cl 
s-s 
3 116 72%yield 
Scheme 68 
In the next step the reaction of the synthesized acid chloride 116 with the 
2',3',5'-0-TBDMS-protected adenosine 72 (shown in Scheme 70 below) was 
performed in DMF using a 1:1 ratio of the reactants. Disappointingly the 
reaction failed to give the desired product. A mixture containing starting 
material and an unidentifiable product was formed and an attempt to separate 
it was unsuccessful. 
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The failure of this reaction can be addressed to the poor nucleophilicity of this 
aromatic amine and the poor quality of the acid chloride employed. 
Due to the fact that there was no evidence that the amide had formed in the 
above reaction, a sample coupling reaction was performed using a simpler 
amine, aniline. A reaction of the acid chloride 116 with aniline 117 was carried 
out in pyridine at 0 °C and then warmed up to ambient temperature as shown 
in Scheme 69. The crude amide of aniline 118 was afforded as black oil in 
48% yield. 
0 
s-s 
116 + 
0 
pyridine ~NH 
s-s 0 
11s V 
yield 48% 
Cl 
o 0c to r.t. , 4h 
117 
Scheme 69 
The 
1
H-NMR spectrum of 118 showed that the crude product also contained 
some unreacted aniline and since the reaction was performed using 1 
equivalent of each of the reactants an excess of the acid chloride should be 
used to drive the reaction to completion. The unreacted aniline was separated 
from the crude product by flash column chromatography using a 1:1 mixture 
of petroleum ether and ethyl acetate and 118 was isolated in 48% yield. This 
experiment confirmed that the failed attempt of coupling the thioctic chloride 
116 with the NH2 of the TBDMS-protected adenosine 72 is basically due to 
the poor nucleophilicity of the aromatic amine of the adenine base. 
Nevertheless, a further attempt to form the thioctic-amide conjugate of the 
protected adenosine was carried out in the same successful conditions used 
above with aniline. 
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Pyridine was used as solvent but in this case the ratio of adenosine: chloride 
of thioctic acid was increased to 1:2 as shown in Scheme 70 below. However, 
the desired thioctic-adenosine analogue did not form and starting material 
was recovered. NH2 
~NylN TBDMSOYO-J--l~ + 
TBDMSnTBDMS 
72 
~Cl 
s-s 
116 
a) 1 eq of72 and 116, '.., b) 1 eq of72 and 2 eq of 116, 
DMF, r.t overnight pyridine, 0 °c to r. t. , 4h 
0 
HN~····(/ 
Ni:N s-s 
' I TBDMSOYO~ N~ 
TBDMSnTBDMS 
Scheme 70 
Since the above reactions did not afford the desired conjugate an alternative 
procedure was followed based on a reported procedure311 for the conversion 
of carboxylic acid to an amide, in a one-pot reaction using oxalyl chloride 
(shown in Scheme 71 below). Oxalyl chloride 119 was employed instead of 
thionyl chloride along with a catalytic amount of DMF to generate the acid 
chloride. Thioctic acid 3 was treated with oxalyl chloride in the presence of 
0 pyridine. In the reaction mixture that was cooled at 0 C, 72 was added and 
the reaction was stirred at room temperature for 2h. 
143 
During the reaction a black solid was formed, assumed to be pyridinium salts, 
which were then extracted into the aqueous layer on work-up by washing with 
saturated sodium bicarbonate and brine. A black oil was furnished after work 
up with ethyl acetate but the 1H-NMR spectrum showed no sugar protons of 
the ribose while there was no evidence given to support the formation of the 
desired amide. 
~OH 1 /Cl 
er'' I( s-s + 
3 
s-s 
116 
0 
119 
DMF (cat), pyridine 
DCM 
Cl 
N--X: •'""'~~,) 
TBDMSO OTBDMS 
72 
', pyridine, r.t. 2h 
0 
~······~ HN \ I N~N s-s 
TBDMSOyo~NJlj 
TBDMSnTBDMS 
Scheme 71 
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(IV) By employing coupling reagents 
Since the previous reactions performed failed to furnish the desired amide, an 
alternative route was proposed based on the employment of coupling 
reagents, typically used in peptide synthesis. 
One of the most common coupling reagents in the amide bond forming 
reactions of amines with carboxylic acids is 1,3-dicyclohexylcarbodiimide 
(DCC)294 51, which is shown in Scheme 45. 
The reactivity of amines depends on their order and basicity and can affect 
the reaction with acids in a different manner while the acid strength also has 
an effect on the reactivity. The choice of the solvent for the coupling reactions 
performed was done on the base of the reported results,296 as it has a distinct 
effect on the ratio of the reaction products. When acetonitrile is used as the 
solvent, the hydrated adduct dicyclohexylurea is formed and precipitating 
while THF is reported to reduce reaction rates and encourage the formation of 
the N-acylurea side product. 
Dichloromethane and DMF were used as the solvents. The amine in this case 
is weakly nucleophilic as well as sterically hindered. The coupling was carried 
out using 1eq of each of the thioctic acid and 2',3',5'-0-TBDMS adenosine 
and 1.1 eq of DCC. The coupling reagent was added proportionally to a 
solution of acid and amine in anhydrous DMF, cooled at 0 °C, as shown in 
Scheme 72. The desired amide 120 was afforded as yellow oil in a 51% yield 
after 4h of reaction. 
Another coupling reaction was carried out using the water soluble 1-ethyl-3-(-
3'-dimethylaminopropyl) carbodiimide hydrochloride) (EDC1)295 52, as the 
coupling reagent (shown in Scheme 45). The same ratio of reagents and 
reaction conditions were used as for DCC and the side products were 
removed by simple aqueous extraction with sodium bicarbonate and water. 
Again the amide 120 was obtained in a 55% yield as yellow oil as shown in 
Scheme 72 below. 
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~OH 
s-s 
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DCC EDCI 
4h 4h 
0 °c to r.t. 0 °C to r.t. 
51% yield 55% yield 
0 
PyBOP 
DIP EA 
r.t., 2h 
62%yield 
HN~'\1 N~N s-s 
TBDMSOyo~JLN_,) 
TBDMSnTBDMS 
120 
Scheme 72 
In an effort to improve the yields obtained and force the reaction to completion 
the employment of Benzotriazolyloxy-tris(pyrrolidino )-phosphonium 
hexafluorophosphate (PyBOP)312 121, shown in Scheme 73, was proposed. 
This is a recent coupling reagent being used in amide formation, an analog of 
BOP (benzotriazol-1-yl-oxy-tris( dimethylamino )-phosphonium 
hexafluorophosphate) where the dimethylamino groups are replaced by 
pyrrolidino. 
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PyBOP is the only analog whose utilization does not involve the use or 
formation of cytotoxic and carcinogenic compounds like BOP does (HMPA) 
and also exhibits equivalent properties to it. For that reason it was decided to 
use PyBOP instead. 
In the case of PyBOP, the same ratio of reagents and coupling reagent was 
used as before, but in addition the coupling reaction was performed with the 
assistance of diisopropylethyl amine (DIPEA) at room temperature. The crude 
product furnished was purified by flash column chromatography eluting with a 
95: 5 mixture of DCM and methanol to afford the formed amide 120 as a 
yellow oil in a 62% yield (as shown in Scheme 72) while elemental and 
spectroscopic analysis confirmed its formation. The broad singlet at i5 7.90 in 
the 
1
H-NMR spectrum which corresponds to the H next to amide bond (H-N-
C=O} and the signal at 177.0 ppm in the 13C-NMR spectrum, which 
corresponds, to the carbon of the carbonyl bond (C=O) indicated the presence 
of the amide. Also the broad signal of the NH2 of the TBDMS-protected 
adenosine that appears at i5 6.46 has disappeared. 
As it can be seen from the results, PyBOP proved to be most effective 
coupling reagent as the yield of 120 was improved over the ones obtained 
with EDCI and DCC, even after 2h at room temperature. 
147 
(E) Modification at the base of the nucleosides 
Apart from the natural bases adenine, guanine, cytosine and thymine also 
incorporated in oligodeoxynucleotides have been other, less common, 
synthetic bases. These efforts were usually aimed at testing the effect of other 
modifications, such as methylation of the bases, on the action of DNA-
modifying enzymes, examining alterations in hybridization characteristics. 
Changes at the bases are generally the most difficult chemically and require 
the greatest number of synthetic steps. 
As part of the investigation into new types of protecting groups the 
displacement of the amine group with other nucleophiles was studied. We 
were also interested in attaching phospholipid compounds to the nucleotides 
in order to form their derivatives, as they are more active in blocking the viral 
replication in cell cultures compared to the non-derivatized nucleotides. These 
derivatives have found to accumulate on the cell membrane and penetrate 
into the cells via endosomal vesicles. The investigation first started with the 
reaction of 6-chloropurine with sodium azide to give the synthetically useful 
azide of the purine base, which can used as the precursor for the coupling 
with the phospholipid compounds. 
6-Chloropurine 122 was treated with sodium azide (NaN3) in DMF and 
through an aromatic nucleophilic displacement reaction, the azide of the 
purine base 123 was readily prepared as an off-white solid in 85% yield (as 
shown in Scheme 74 below) 
([s > N,N, DMF 
~ N r.t overnight <x'S ~ N yield 85% 
122 123 
Scheme 74 
The structure of 123 was confirmed by evidence of a peak at 2154 cm·1 in the 
IR spectral analysis, indicating the formation of the azide. 
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The formed azide 123 was then reacted with triethyl phosphite which is a 
phosphine derivative. Dropwise treatment of 123 with triethyl phosphite under 
nitrogen, gave successfully the phosphorimidic acid triethyl ester derivative 
124, as shown in Scheme 75. 
In order to avoid hydrolysis of the phosphoramidate the reaction was carried 
out under anhydrous conditions. The reaction proceeded smoothly in 
anhydrous DMF at room temperature to form the triethyl ester 
phosphoramidate of purine 124 as an off-white solid. Recrystallization from a 
mixture of dichloromethane and petroleum ether (4: 1) afforded the desired 
compound 124 in 82% yield. 
N__J: 
< Jl) N N 
H 
123 
+ P(OEt)s 
DMF 
r.t 18h 
Scheme 75 
/OE! 
N=P\-OE! 
NJ(: OEt < I N 
N ) 
H N 
yield 82% 
124 
The 1H-NMR spectrum of the phosphoramidite 124 showed signals for the 
three ethyl groups attached to oxygen while the 31P NMR spectrum showed a 
singlet at o 1.93, constitent with a trialkyl N-aryl phosphoramidate. The 
phosphoramidate was stable and showed no tendency to undergo 
dealkylation to the corresponding diethyl phosphoramidate 125, as shown 
below. 
lEt 
N=~-OEt 
NJ(: OE! < I N 
N ) 
H N 
124 
--------~------- .. 
;? 
HN-R-OEt 
NJ(: bEt < I N 
N ) 
H N 
125 
This reaction was then extended to show that other nucleophiles containing a 
phospholipid compound could react in a similar fashion to triethyl phosphite. 
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For this reason the tricetyl phosphite of the known phospholipid compound 1-
hexadecanol (cetyl alcohol) 126, was synthesized. 
3 equivalents of cetyl alcohol in dichloromethane were treated with 
phosphorous trichloride n the presence of triethylamine, as shown in Scheme 
76 below. The reaction proceeded at ambient temperature to afford the tricetyl 
phosphite 127 as white solid in 63% yield, after recrystallization from ethanol 
and water. 
o °C then r.t 
overnight 
1oc15H33 
P\OC15H33 
oc15H33 
127 yield 63% 
Scheme 76 
OH 
126 
The synthesized azide of purine base 122 was in turn treated with the tricetyl 
phosphite 127 using anhydrous conditions to give the phosphorimidic acid 
tricetyl ester derivative, as shown in Scheme 77. The reaction proceeded 
successfully in anhydrous DMF at ambient temperature to afford the tricetyl 
ester phosphoramidate of purine as an off-yellow viscous liquid. 
Recrystallization from a mixture of ethyl acetate and hexane (3: 1) afforded the 
desired compound 128 in 71% yield. 
!50 
N_J: 
< Jl.) N N H 
123 
1oc16H33 
+ P\OC16H33 
oc16H33 
127 
DMF 
r.t 15 h 
128 yield 71% 
Scheme 77 
Due to time constraints though the chemistry of this compound could not be 
investigated further, although it represents a useful intermediate, which could 
be elaborated further into biologically active materials. 
151 
4. FORMATION OF THE CpG DINUCLEOTIDES 
Bacterial DNA and synthetic oligodeoxynucleotides containing CpG 
dinucleotides (CpG-DNAs) have been shown as potential adjuvants of the 
innate immune system. The goal of using of oligodeoxyribonucleotides 
containing CpG dinucleotides (CpG DNA) as immunomodulatory agents has 
been realized in recent years. Therapeutic applications of CpG DNA as 
antitumor, antiviral, antibacterial and anti-inflammatory agents and as 
adjuvants in combination with vaccines for a number of disease indications 
are rapidly expanding.250-252 The safety and efficacy of several first-generation 
CpG DNA agents are being evaluated in human clinical trials.254•256 
In order to improve the immunostimulatory activity of CpG phosphodiesters it 
was proposed to study chemical modifications in the backbone and the bases 
by attaching lipophilic molecules in the CpG motifs. One very important step in 
CpG dinucleotide formation using both solution and solid phase synthesis is 
the employment of 3'-phosphoramidites of cytidine. Described below is their 
synthesis so that they can be used as building blocks 
(A) Synthesis of N-free-3'-phosphoramidites of cytidine 
The N,N-diisopropylaminophosphoramidites313·314 of cytidine are extremely 
useful reagents for dinucleotide synthesis using phosphoramidite approach. In 
CpG polymer supported synthesis the key intermediate is the condensation of 
2'-deoxyguanosine covalently joined to a glass support with the 3'-
phosphoramidite of 2'-deoxycytidine. 
An essential process in phosphoramidite synthesis is the phosphorylation of 
the hydroxyl function of the nucleoside. Phosphorylation of nucleosides such 
as adenosine and cytidine that have the hydroxyl and amino group in the 
same molecule, takes place competitively at both the functions and hence the 
amino groups have to be protected in order to achieve selective a-
phosphorylation. However, deprotection often brings about undesired side 
reactions, particularly cleavage of the phosphate linkage resulting in serious 
loss of product. For that reason, 0-phosphorylation of nucleosides without the 
N-protection is obviously ideal. 
!52 
The N,N-diisopropylamino-phosphoramidites have been introduced as 
phosphitylating agents as they are significantly stable to moisture, can be 
stored for months and are easily activated using tetrazole. The removal of the 
protecting groups from the phosphate moiety plays an important role in the 
efficiency and success of dinucleotide synthesis. The protecting group should 
be such that it can be removed in short time under mild conditions without 
causing the formation of large amounts of salts and other side reactions. 
A group that fulfills these criteria is the 13-cyanoethyl group and for that reason 
the (2-cyanoethyl) (N,N-diisopropylamino) chlorophosphine was employed in 
this case as the phosphitylating agent. I! has been reported that the use of 
cyanoethyl phosphoramidites gave rise to increased coupling efficiencies and 
better product yields upon de protection. 
The N-free-3'-phosphoramidites of cytidine required for dinucleotide synthesis 
using both solid and solution phase synthesis were prepared as monomer 
units. 5'-0-(Dimethoxytrityl)-2-deoxycytidine and the synthesized 2',5'-0-
TBDMS cytidine both without the protection of the amino functions were 
employed as key intermediates and treated with the phosphitylating agent to 
furnish the desired phosphoramidites. 
Firstly in order to synthesize 5'-0-(Dimethoxytrityl)-2-deoxycytidine, 2'-
deoxycytidine was treated with 4,4'-dimethoxytrityl chloride (DMTrCI) in the 
presence of dichloroacetic acid and triethylamine in pyridine as shown in 
Scheme 78 below. The 5'-0-protected 2'-deoxycytidine 26 was furnished as 
white solid in a 72% yield, after recrystallization from a mixture of toluene and 
acetone (5: 1 ). 
5'-0-(Dimethoxytrityl)-2-deoxycytidine 26 and 2',5'-0-TBDMS cytidine 73 
were then condensed with (2-cyanoethyl) (N,N-diisopropylamino) 
chlorophosphine in THF, by the aid of ethyldiisopropylamine to afford the N-
free-3'-phosphoramidites of cytidine 27 and 129 as colourless solids after 
trituration from petroleum ether (shown in Scheme 78 below). The amidites 
27 and 129 were obtained in 85 and 83% yield, respectively, and were used 
for subsequent reactions without further purification. 
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The structures of the N-free-5'-dimethoxytritylated-3' -phosphoramidites of 
cytidine 27 and 129 were confirmed by the 31 P NMR signals appearing at o 
148.07, 148.3 and 150.5 ppm, respectively (signals due to the N-
phosphoramidityl products appear at o 124-127 ppm). 31P NMR also provided 
a diagnostic proof of the isomeric purity of 129 as it was found to be 
isomerically pure demonstrating the stability of silyl groups to the conditions of 
phosphorylation. 
The stability of the N-free amidites is similar to that of the N-protected 
derivatives and they can be stored for several months under nitrogen at -20 
°C with no apparent degradation. These phosphoramidites were obtained via 
a shorter pathway and in higher yields than their N-protected corresponding 
analogues and were utilized to enable us to synthesize dinucleotides without 
resort to N-protecting groups. 
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(B) Solution Phase synthesis of CpG dinucleotides 
(I) Without the attachment of lipophilic groups 
For the solution phase synthesis of CpG dinucleotides the formed N-free 
cytosyl phosphoramidite of cytidine 27 was reacted with the synthesized 2',3'-
0-TBDMS protected guanosine 79. Excess equivalents of the 
phosphoramidite and tetrazole, as the promoter, were employed which is a 
reaction generally used in solid-phase synthesis. Disappointingly, 
phosphitylation of 79 with a 1:1 mixture of tetrazole and 27 (25 equiv each to 
79) gave not only the desired phosphite 131 in a 62% yield {shown in 
Scheme 79 below) but also a 25% yield of its N-phosphitylated derivatives. 
~~ '"~'. 
? 
R 
c( "'N(i·Pr)z 
NC~ 
27 
79 
i)1eqof 79+25eqof 27 ii) 1:1 mixture of 27,79, 
tetrazole (25eq), CH3CN tetrazole (1 eq), CH3CN 
~~ '"'~ : N-phosphitylated products 
) fi:x ~0 'o:h.N N NH2 NC 
TBDMS OTBDMS 
55-62% yield 131 
Scheme 79 
18-25% yield 
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The presence of phosphite is supported by a signal at o 140 ppm in 13P NMR 
spectrum while, signals at o 123-127 ppm suggested the formation of the N-
phosphitylated products but their exact structures was not determined. 
An attempt to utilize equimolar amounts 79 and 27 and condense them using 
1 equivalent of tetrazole resulted again in the formation of N-phosphitylated 
products in 18% yield along with the production of phosphite 131 (shown in 
Scheme 79 above). These experiments suggest that tetrazole is not an 
effective promoter for the formation of CpG dinucleotide using solution phase 
synthesis, thus the utilization of a new promoter was evident. 
In previous research, Letsinger reported a pioneering DNA synthesis with N-
unprotected building blocks that employs a mixture a pyridinium hydrochloride 
and aniline226 as the activator of the phosphoramidites. However this method 
proved to have drawbacks and limitations as the pyridinium salt is very 
hygroscopic and thus not suitable for synthesis requiring anhydrous 
conditions. 
The employment of imidazolium triflate was reported315 as an activator, which 
proved to be a very effective promoter for solution-phase synthesis of 
dinucleotides using the phosphoramidite method without nucleoside base 
protection and an excellent activator towards 2-cyanoethyl N,N-
diisopropylphosphoramidites. 
This reagent was quantitatively prepared by mixing imidazole and 
trifluoromethanesulfonic acid in equimolar amounts in dichloromethane at 
ambient temperature, as shown in Scheme 80 below. 132 was used without 
further purification, had good solubility in acetonitrile and high stability when 
stored at ambient temperature under atmospheric conditions. 
H 0 H N DCM, r.t [) 11 N + CF-S-OH (~ TfO N 3 11 
H 0 Diethyl ether N+ H 
132 97%yield 
Scheme 80 
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lmidazolium triflate 132 was used for the chemoselective condensation of N-
free-3'-phosphoramidite of cytidine 27 and 2',3'-0-TBDMS protected 
guanosine 79, when equimolar amounts of these substrates were employed in 
acetonitrile. The reaction (shown in Scheme 81 below) proceed at room 
temperature within 20 min to give after oxidation with 1.0 M toluene solution of 
tert-butyl hydroperoxide (1.5 eq), 133 in 89% yield as a mixture of two 
diastereomers. 
The formation of 133 as crude material was confirmed by 31P NMR spectrum, 
which shows two signals at 8 -1.1 and -1.0 ppm, supporting the presence of 
diastereomeric phosphotriester functions but no detectable signal due to N-
phosphoryl products (the 31P NMR signals due to N-phosphoryl products 
appear at 80-2 ppm). 
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The crude product was purified on a silica gel pad eluting with a 10:1 mixture 
of dichloromethane and methanol to afford the pure form of 133 as a colorless 
amorphous solid in 76% yield. 31P NMR spectrum showed two signals at 8 -
1.95 and -2.01 arising from purified 133. 
The removal of the cyanoethyl protection was accomplished by employing 
anhydrous !-butylamine (5ml) and stirring for 2 days at room temperature 
(shown in Scheme 82 below). The product was isolated on a silica gel pad 
eluting with a 10:1 mixture of dichloromethane and methanol containing a 
trace amount of triethylamine to give 134 as off white foam in 73% yield. After 
generation of the internucleoside phosphate linkage, the dimethoxytrityl 
protection was removed by employing 5% dichloroacetic acid in 
dichloromethane (3.2eq) as shown in Scheme 82. 
Stirring at ambient temperature for 20 min furnished 135, after separation and 
purification using a 5:1 mixture of dichloromethane and methanol, in 68% 
yield. Silyl protection was cleaved using 2.4. equivalent of TBAF in THF 
(Scheme 82} and stirring at ambient temperature for 2h afforded the 
deprotected CpG 136 as colorless foam in 61% yield. The reaction sequence 
of the solution phase synthesis of the CpG dinucleotide is shown in Table 16 
below 
Cyanoethyl 
Deprotection 
Table 16 
of cytidine 27, 2',3'-0-TBDMS 
protected guanosine 79 and 
imidazolium triflate 132 
Detritylation 3% dichloroacetic acid in DCM 
(3.2eq} 
r.t for 20 min 
to next 
step 
68 
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(11) With the attachment of lipophilic groups 
Dinucleotides are very small synthetic molecules resembling single stranded 
DNA. The presence of chemically modified nucleosides or unusual structural 
determinants that are rare in mammalian cells may induce immunostimulatory 
effect.272·273 A number of studies have shown that modifications on the 
pentose sugar, phosphate backbone and nucleobases of the nucleosides has 
an effect on immunostimulatory activity.269"271 In order to enhance the ability of 
CpG dinucleotide to penetrate into intact cells and increase their stability 
towards nucleases, it was suggested to investigate the synthesis of 
dinucleotides modified with lipophilic groups. 
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In the present work we will study CpG dinucleotide formation containing 
lipophilic analogues of cytidine and guanosine. The successful approach 
employed above for the solution phase synthesis of CpG was extended into 
utilizing the synthesized lipophilic carbamate analogues of guanosine. N-free-
3'-phosphoramidite of cytidine 27 was coupled with the 2',3'-0-TBDMS-N-
carbamate cholesteryl 104 and tocopheryl 105 conjugates of guanosine using 
a 1:1 ratio of the reactants in the presence of imidazolium triflate. The reaction 
(shown in Scheme 83 below) took place in acetonitrile and the resulting 
phosphite intermediates were oxidized with tert-butyl hydroperoxide to give 
139 and 140 in 87 and 84% yield respectively as a mixture two diastereomers, 
each. 
31 P NMR spectrum showed two signals at o-1.24 and -1.33 ppm and o-1.28 
and -1.36 ppm arising from the diastereomeric phosphotriester functions for 
139 and 140 respectively but no detectable signal due to N-phosphoryl 
products. The crude products were purified on a silica gel pad eluting with a 
10:1 mixture of dichloromethane and methanol to afford the pure form of 139 
and 140 in 72 and 75% yield, respectively. The presence of purified 139 and 
140 was evident by signals at o -2.16 and 2.24 and o -2.19 and 2.3, 
respectively. 
The 2-cyanoethyl protecting group was cleaved with tart-butylamine (Scheme 
83) to give, after purification on a silica gel pad using a 10:1 mixture of 
dichloromethane and methanol containing a trace amount of triethylamine, 
141 and 142 in 70 and 72% yield, respectively. The stepwise removal of 
protecting groups-detritylation and desilylation-was carried out as before to 
afford dinucleotides 145 and 146 as shown in Scheme 83. The reaction 
sequence of the solution phase synthesis of CpG dinucleotide modified with 
cholesterol and tocopherol is represented in Table 17 below. 
lmidazolium triflate 132 proved to be an excellent promoter that allows rapid 
and highly chemoselective condensation of the N-free-3' -phosphoramidites of 
cytidine and N-free lipophilic conjugates of guanosine when equimolar 
amounts of these substrates were utilized. There was no evidence of N-
phosphorylation of the cytosyl base. 
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Table 17 
Coupling 1: 1:1 ratio of N-free-3'- r.t for 10 min Straight 
phosphoramidite of cytidine 27, to next 
2' ,3' -0-TBDMS-N-carbamate step 
cholesteryl 104 or tocopheryl 105 
conjugates of guanosine and 
imidazolium triflate 132 
r.t for 139 (72) 
140 (75) 
tert-butylami r.t for 141 (70) 
De protection 142 (72) 
r.t for 30 min 143 (63) 
(3.2eq) 144 (66) 
De si 1 M (2.4eq) r.t for 2h 145 (57) 
146 (60) 
0 
t!'NH 0 ~ H~O~JL~rJlR, or R2 (j+ TIO 
TBDMSH,.BDMS l'l ----H----, 
1 :1 mixture of 
104 or 105 27 and 104 or 105, 
CH3CN, rt 
oxidation 
;:~ 
0~-~0 0 
r (:c:J: Jl 
if b:R.N N NI R1 or R2 N~ l'l 
TBDMS OTBDMS 
1M TBHP (1.5 eq) 
137-138 
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105, 138, 140, 142, 144, 146 
f-BuNH2 (5ml), CH3CN 
r.t for 2 days 
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8 0/P'-:hN ~N~ orR 
o I ' ' R 
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The overall yields of CpG dinucleotide synthesis using N-unprotected building 
blocks with or without the attachment of lipophilic groups were found to be 
satisfactorily (57 -61%) and the results confirmed the success of solution 
phase synthesis of the CpG dinucleotides using N-free nucleosides. 
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(C) Formation of novel phosphoramidites of lipophilic 
compounds 
Phosphodiester synthetic oligonucleotides are increasingly used because of 
their potential activity as regulators of gene expression. One of their major 
drawbacks is that they are inherently prone to rapid degradation by nucleases 
and generally have half-lives of less than two minutes in vivo292·316 in 
particular exonucleases. Recent studies suggested that an accessible 5' -end 
of the CpG dinucleotide is critical for the immunostimulatory activity and 
blocking the 5'-end of CpG by conjugation of certain ligands increases 
immunostimulatory activity.253 
Based on this observation and to examine if cellular uptake is effected by 5'-
conjugation phosphodiester, it was proposed to investigate terminal 
modifications that can enhance exonuclease resistance, such as end capping 
with alkylic or lipophilic chains. Similar groups have also been attached to the 
3'-end of oligonucleotides by means of functionalised CPG. For that reason, 
CpG dinucleotides were synthesized with lipophilic moieties attached at their 
5'-end. 
Interest was drawn towards preparing phosphoramidites of lipophilic 
compounds, which can subsequently be coupled to CpG through their 5'-
terminus, in order to form the lipophilic phosphodiester dinucleotides. 
Phosphoramidites have very promising and attractive properties as reactive 
nucleoside intermediates for polymer support dinucleotide synthesis while; the 
tricoordinate phosphorus reagent enhances the attachment of lipophilic 
groups to the dinucleotide synthesis and improves the efficiency of uptake into 
the cell. 
For that reason, the novel N,N-diisopropyl-phosphoramidites of cetyl alcohol 
126 (cetyl = straight chain C1a group), cholesterol and tocopherol were 
synthesized by one-flask procedure. The diisopropylamino group was chosen 
because being attached to the tetra coordinate phosphorus center exhibits a 
high propensity to act as a good leaving group in nucleophilic displacement 
reaction when activated by the promoter in oligonucleotide formation. it has 
also been shown to furnish phosphoramidites in stable and pure form while 
producing higher stepwise coupling yields. 
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Other phosphoramidites like the N,N-dimethylamine and N-morpholine require 
stringent anhydrous and inert conditions to endure good condensation and 
storage while good purity can not be ensured. 
N,N diisopropylamine (2eq) in dry diethyl ether, was added dropwise to 
phosphorous trichloride (1eq) in dry ether which was cooled at -10 °C, over 
the period of 30 min to 1h. After stirring at -10 °C for 30 min, the lipophilic 
compound in THF was added dropwise along with triethylamine while the 
temperature was kept constant. 2 equivalents of each of the reactants were 
employed in each case assuming a 70% yield of the formed diichloro-
diisopropylamino phosphine intermediate. After 3 hours at room temperature 
amine hydrochloride was removed and the solution was concentrated under 
exclusion of moisture. The preparation of the N,N-diisopropyl-
phosphoramidites is represented in Schemes 84 and 85. 
The crude phosphoramidites of cholesterol and cetyl alcohol were purified by 
recrystallization from dichloromethane and petrol to furnish the purified 37 and 
38 as white powdery solids in 72 and 66% yield respectively. The purified 
N,N-diisopropyl-phosphoramidite of tocopherol 39 was obtained as yellow oil 
in a 69% yield, after trituration with hexane. These phosphoramidites, which 
were sufficiently pure for our synthetic purposes, where found to be stable 
under dry conditions and were kept under nitrogen at -20 °C with no apparent 
degradation. 
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The structures of the N,N-diisopropyl-phosphoramidites 37, 38 and 39 were 
confirmed by the 31 P NMR signals appearing at 8 178.82, 182.54 and 184.67 
ppm, respectively. These phosphoramidites will be utilized as useful building 
blocks for the formation of CpG dinucleotide phosphates using polymer 
support synthesis. 
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(D) Solid Phase synthesis of CpG dinucleotides 
The phosphoramidite monomers 37, 38 and 39 were employed in the 
preparation of antisense phosphorodiester dinucleotides, bearing 5'- polyalkyl 
cholesterol and tocopherol moieties, using the solid phase synthesis. 
lnternucleotide coupling procedure is performed with the 5'-hydroxyl group 
being capped with the dicetyl or dicholesterol phosphate group to provide 
lipophilicity. The compatibility of these phosphoramidites with the established 
dinucleotide synthesis was studied. Commercially available 5'-DMTr 2'-
deoxyguanosine 40 bearing benzoyl protection at the exocyclic amino group 
and derivatized at the 3'-end with Controlled Pore Glass (CPG) solid support 
with was used. The loading of this solid support utilized was 22 f.lmol/g. 
The synthesis of dinucleotides was performed in a stepwise procedure 
according to Table 18 using 1g of the CPG bound 2'-deoxyguanosine. In a 
column type reactor fitted with a sintered glass fritt, which could be maintained 
airtight with a serum cap. The 5'-0-DMTr group was removed using 3% 
trichloroacetic acid in dichloromethane and the column was shaken for 2 min. 
The deprotection was apparent by the appearance of a bright orange calor 
arising from the release of the dimethoxytrityl cation. 
After thorough washing with acetonitrile and drying of the glass beads in 
vacuo, phosphitylation of the free hydroxyl of guanosine attached to CPG was 
performed using a 1 :1 mixture of the promoter and the cyanoethyl-
phosphoramidite. 0.1 M of the 5' -dimethoxytritylated-3' -cyanoethyl 
phosphoramidite of cytidine 27 in CH3CN (25eq) was added to the column 
followed by the addition of 0.1 M of imidazolium triflate 132 in CH 3CN (25eq), 
with a syringe under nitrogen atmosphere. After condensation (shaking for 25 
min) the excess reagents were removed by washing with CH3CN. 
Standard iodine oxidation was followed using 0.1 M of iodine in 80:40:20 
solution of THF: pyridine: H20. After shaking and thorough washing, removal 
of the dimethoxytrityl protector of the 5' -hydroxyl group was repeated as 
above. 
166 
Finally phosphitylation and subsequent capping of the free 5'-0H group was 
attained using a 1:1 mixture of the promoter and the synthesized dicetyl 37, 
dicholesterol 38 and ditocopherol 39 phosphoramidites. 
0.1 M of N,N-diisopropylamino-phosphoramidite (25eq) in THF was added to 
the column followed by 0.1 M of imidazolium triflate (25eq) in CH3CN. After 
the final condensation, the excess reagents were removed by washing with 
CH3CN and the iodine oxidation step was repeated as before. Deprotection of 
the cyanoethyl group, removal of the exocyclic amino protection and 
subsequent cleavage of the product form the polymer support was 
accomplished by treatment with a solution of concentrated aqueous ammonia 
in ethanol (3:1) at ambient temperature for 30min and then at 55 °C for 16h. 
After completion and cooling down at room temperature, the supernatant 
liquid was removed and the glass beads were washed with distilled water. 
The combined supernatant and washings were concentrated to a small 
volume and the insoluble material resulting from the ~-elimination and 
polymerization of CH2=CH-CN was removed by filtering through a Millipore TM 
filter. The filtrate was applied to small column packed with celite and eluted 
firstly with 0.05 M of NH40Ac for desalting and removal of all the organic 
impurities and finally with acetonitrile. This afforded the crude CpG 
dinucleotides 147, 148 and 149 possessing a 5'-dicetyl, dicholesterol and 
ditocopherol phosphate, respectively. The solid phase synthesis of the 5' -di-
lipophilic phosphate of CpG dinucleotide is shown in the Scheme 86 below. 
Washing 
Coupling 
Table 18 
0.1 M cyanoethyl-phosphoramidite of 
cytidine (25eq) in CH3CN + 0.1 M 
imidazolium triflate (25eq) in CH3CN 
2min 
3 x 5ml for 2min 
Shake for 25m 
2min 
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Oxidation 0.1 M Jz in 80:40:20 solution of 2 x 2ml, shake for 
THF:pyridine:HzO 5min 
Washing CH3CN 10 x 3ml for 2min 
De protection As Above As Above 
Washing CH3CN 3 x 5ml for 2min 
Coupling 0.1 M dicetyl,or dicholesterol or Shake for 25min 
ditocopherol diisopropylphosphoramidite 
(25eq) in THF + 0.1 M imidazolium triflate 
(25eq) in CH3CN 
Washing CH3CN 10 x 3ml for 2min 
Oxidation As Above As Above 
Washing CH3CN 1 0 x 3ml for 2min 
Cleaving Off Treatment with a 3:1 solution of cone. Heat at 55 "C for 
NH40H:EtOH 16h 
Washing Distilled water 3x 1ml 
Filtering off Filter off controlled pore glass beads 
through Millipore ™ filter 
Desalting 0.05 M of NH40Ac 3x5ml 
CpG dinucleotide synthesis was repeated without capping of the free 5'-
hydroxyl group using the coupling protocol as before, except for the final 
condensation step with the lipophilic N,N-diisopropylamino phosphoramidites. 
The solid anchored 2'-deoxyguanosine 40 was again utilized but in this case 
the synthesized N-free-3'-cyanoethyl phosphoramidite of 2',5'-0-TBDMS 
cytidine 129 was employed as the coupling amidite. After condensation and 
oxidation, simultaneous deblocking of the cyanoethyl protector of the 
internucleoside linkage and detachment of the dinucleotide from the solid 
support occurred, by treatment with concentrated ammonia leaving only the 
silyl protecting groups intact. 
The TBDMS groups were removed by treating the supernatant liquid 
produced with 1 M TBAF in THF (5eq) for 2h. The reaction was then 
concentrated to a small volume and the insoluble material was removed as 
before by filtering. 
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The filtrate was applied to small column packed with celite and eluted firstly 
with 0.05 M of NH40Ac for desalting and removal of all the organic impurities 
and finally with acetonitrile. This afforded the crude CpG dinucleotides 150 in 
57% yield as shown in Scheme 87 below. 
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Support Cleavage 
where R1' = 147, R2' = 148, Ra' = 149 
Scheme 86 
The isolated yields of the crude CpG 5'-phosphates were 50% for 147, 52% 
for 148 and 55% for 149. The crude products were subjected to mass 
spectroscopy to confirm their structure. 
A high-resolution fast atom bombardment mass spectrum (HRFAB) of 147 
provided a single peak at mlz 1083.59968 in the region where the molecular 
peak appears. The result supported the structure of 147 (Cs1HsgNs013P2) 
where the molecular weight is 1083.60244. The same mass spectroscopic 
analysis of 148 C73H113Ns013P2 with calculated molecular weight of 
1371.79024 gave an eminent peak at mlz 1371.78746 where the mass 
spectra of 149 (CnH121Na01sPz) with a molecular weight of 1459.84267 
showed a peak at 1459.83968. 
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The presence of other side products was also evident in the mass 
spectroscopy and elemental analysis of 148 and 149. Purification of these 
products could be achieved by reverse phase HPLC analysis 
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Nevertheless, the formed crude 5' -di-lipophilic phosphates of CpG 
dinucleotides 147-150 were sent to Apthon Corporation laboratories to 
investigate whether the conjugation of lipophilic compounds at the 5'-end of 
CpG affects their immunostimulatory activity. 
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We were advised that the immunostimulatory activity of these dinucleotides 
would be studied in vitro using BALB/c mice spleen Jympocytes, measured in 
a Jympocyte proliferation assay. 
Typically mice spleen Jympocytes would be cultured with the dinucleotides at 
different concentrations for 48h and the proliferation 3H-uridine incorporation 
would be determined. The secretion of cytokines IL-12, JL-6 and IL-10 known 
to be induced by the activation of immune cells by CpG would also be studied 
in vitro. Their secretion induced by the formed CpG dinucleotides would be 
measured at different concentrations in BALB/c mice spleen cell cultures. 
The previously synthesized N-carbamate cholesteryl and tocopheryl 
analogues of guanosine 108 and 109 were also sent to investigate whether 
the coupling of the lipophilic groups had any effect in the improvement of 
nucleotide uptake by the cells. Typically the interaction of 108-109 with Krebs-
2 ascite carcinoma cells and L-929 mice fibroblasts would be studied and their 
uptake would be measured at different concentrations. 
In summary, excess equivalents of the synthesized phosphoramidites and the 
promoter were used in the solid-phase synthesis, which can be achieved with 
good chemoselectivity. Phosphitylation was performed using a 1:1 mixture of 
the promoter and the cyanoethyl- phosphoramidite or the synthesized di-
lipophilic phosphoramidites utilized for the subsequent capping of the 5'0H 
group 
lmidazolium triflate proved to be an excellent promoter towards the reactive 
N,N-diisopropylphosphoramidites. it allows rapid and highly chemoselective 
condensation of the phosphoramidite and the corresponding nucleoside. The 
process was repeated using 1 H-tetrazole as the promoter. Disappointingly 
this approach was not so successful as it produced a considerable amount of 
N-phosphoryl products of cytosyl derivative. 
The results obtained confirmed the efficient synthesis of 5'-di-Jipophilic 
phosphates of CpG and CpG dinucleotide by the phosphoramidite approach 
without cytidine base protection. The products generally have very good purity 
in the crude form and were obtained in satisfactory yields. 
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In comparison with solution phase synthesis, solid support holds an 
advantage, as it is easier to perform, requires less time as removal of the 13-
cyanoethyl group, de-N-acylation and cleavage from the polymer support 
were performed in one step taking 16 hours. The reaction cycle for the chain 
elongation required overall 75 min in contrast with solution phase, where 13-
cyanoethyl deprotection required up to 2 days resulting in a lengthy overall 
synthesis. Although the yields of the monomer units synthesized after each 
step in solid phase synthesis could not be obtained, the overall yields 
furnished using both synthetic approaches were similar. 
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EXPERIMENTAL 
1. GENERAL EXPERIMENTAL PROCEDURES 
(A) Purification of reagents and solvents 
Commercially available reagents were used as supplied from Aldrich, 
Lancaster, Amersham Pharmacia, Calbiochem-Novabiochem, Fluka, and 
Fisher Scientific chemical companies without purification unless otherwise 
stated. Air and moisture sensitive compounds were stored in a dessicator 
over self-indicating silica gel, under a nitrogen atmosphere. Sodium hydride 
was 60% dispersion in mineral oil and was washed free from oil with 
petroleum ether, prior to use. 
Light petroleum ether refers to the fractions boiling between 40 °C and 60 °C. 
Ethyl acetate and light petroleum ether were distilled from calcium chloride. 
Dichloromethane and chloroform were distilled from phosphorus pentoxide or 
calcium hydride. Methanol was distilled from magnesium methoxide. 
Tetrahydrofuran was distilled from sodium/benzophenone ketyl radical before 
use. Triethylamine and diisopropylethylamine were stored over potassium 
hydroxide pellets. Other solvents such as dimethylformamide, acetonitrile and 
toluene were purchased as anhydrous or HPLC grade solvents from the 
chemical companies stated above. 
(B) Chromatography techniques 
Analytical thin layer chromatography was carried out using either aluminium, 
plastic or glass plated coated with silica Merck Kieselgel 60 GF2s4 or alumina 
Merck neutral type E Fzs4· They were visualised under UV light (at 254 and/or 
360 nm) or by staining with visualising agents such as potassium 
permanganate solution or an ethanolic solution of phoshomolybdic ;:)Cid, 
(acidified with concentrated sulphuric acid), followed by heating. Flash 
chromatography was carried out using Merck 9385 Kieselgel 60-45 (230-400 
mesh) silica. 
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(C) Preparation of Glassware 
Air and moisture sensitive reactions were carried out using glassware that had 
been dried overnight in an oven at 150 °C. These were allowed to cool in a 
dessicator over self-indicating silica gel. All moisture and air sensitive 
reactions were carried out under a positive pressure of nitrogen. Reagents 
and solvents were introduced using syringe or cannula techniques, through a 
septum cap. 
(D) Melting point and Elemental Analysis 
Elemental analysis was performed on a Perkin-Eimer 2400 CHN elemental 
analyser. Melting Points were carried out on a Leica Gallin hot plate melting 
apparatus or an Electrothermai-IA 9100 apparatus and are uncorrected. 
(E) Spectroscopic Techniques 
lnfa-Red (IR) spectra were recorded on a Perkin-Eimer Fourier transform 
paragon 1000 spectrophotometer. I.R. spectra were recorded in the range 
4000-600 cm-1. Samples were run as thin films or nujol mulls on sodium 
chloride discs. 
High and low resolution mass spectra (MS) were recorded on a Jeol 
(JMX)SX102 instrument using electron impact (El) or fast atom bombardment 
(FAB) ionisation. 
1 13 31 . 
H • C and P nuclear magnelic resonance spectra were recorded using a 
Bruker AC-250 instrument operating at 250.13, 62.85 and 100.20 MHz 
respectively, or using a Bruker DPX-400 instrument operating at 400.13, 
100.59 and 161.97 MHz respectively. Spectra were recorded in deuteriated 
solvents with reference to tetramethylsilane (TMS) as the internal standard. 
Chemical shifts are reported as o values in ppm (parts per million). The 
coupling constants J are recorded in Hz. Spectroscopic data is annotated with 
the following notations: s: singlet, br s: broad singlet, d: doublet, q: quartet, m: 
multiple!. DEPT experiments of 13C-NMR spectrums were also recorded on 
the same instruments. 
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2. SYNTHESIS OF LINKERS 
(A). Acetal linkers 
1-chloromethyl-1 H-benzotriazole (5) 
((} 
~Cl 
To 1-hydromethyl benzotriazole (40 mmol, 1eq) kept at ice bath temperature, 
thionyl chloride (240 mmol, 6eq) was added dropwise from a dropping funnel 
over a period of 1 h with stirring. Vigorous evolution of gas (HCI, 802) was 
manifested as the reaction proceeded. When the evolution of gas ceased, the 
reaction mixture was heated under reflux at 60-80 ° C for 2h. The resulting 
solution was rotary evaporated to remove the excess thionyl chloride and the 
solid obtained was recrystallised from hexane to afford the desired product in 
a pure form as white crystals. 
1-chloromethyl-benzotriazole (79% yield): m.p. 134-136 °C (lit2°8 136-138 °C); 
Vmax I cm·1 (nujol) 3030, 1613, 1493, 1454, 1071, 745, 692; 1H-NMR (250 
MHz, CDCI3) 6.41 (s, 2H, CH2-CI), 7.43-7.49 (m, 1H, Ar), 7.60-7.70 (m, 2H, 
13 
Ar), 8.10-8.13 (m, 1H,Ar), C-NMR (100 MHz, CDCI3) 70.3 (N-CHz), 110.9, 
119.1, 124.1, 127.4, 132.3, 145.6; Anal. Calcd for C7H6CIN3: C, 50.17; H, 
3.61. Found: C, 50.35: H, 3.80; 
1-methylene bis-(1H benzotriazole) (6) QQ 
Ny /N"'-.../N'- 'lN 
N N 
To sodium hydride dispersion 60% in mineral oil (24 mmol, 1.5eq) washed 
with petrol, benzotriazole (16 mmol, 1eq) dissolved in 8ml of DMF was added 
dropwise and a vigorous reaction took place. To the stirred reaction mixture a 
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solution of 1-chloromethyl benzotriazole (16 mmol, 1eq) in 10ml of DMF was 
added and the reaction was heated under reflux for 2h. After cooling, the 
reaction was poured into ice-cold water (20 ml) and the precipitate was 
collected by suction filtration and washed with additional ice-cold water. The 
bulk of water was removed through filtration and the resulting product was 
dissolved in dichloromethane and dried over magnesium sulphate. The drying 
agent was filtered off and the solvent was evaporated to dryness to afford the 
title compound as a white solid. 
1,1-methylene bis-benzotriazole (69% yield): m.p. 189-190 QC (lit2Q8 191-192.5 
QC); Vmax I cm·1 (nujol) 3421' 3095, 1614, 1453, 1159, 763, 745; 1H-NMR (250 
MHz, CDCI3) 7.21 (s, 2H, CHz-CI), 7.32-7.38 (m, 2H, Ar), 7.45-7.55 (m, 2H, 
13 
Ar), 7.79-7.91 (m, 2H, Ar), 7.97-8.04 (m, 2H, Ar); C-NMR (100 MHz, CDCI3), 
. 58.05 (N-CH2), 109.8 (2C), 120.3 (2C), 124.9 (2C), 128.8 (2C), 135.5 (2C), 
144.7 (2C); Anal. Calcd for C13H1QN6: C, 62.39: H, 4.03. Found C, 62.20; H, 
4.02; 
(I) Linkers from cholesterol and tocopherol 
1 By using 1-chloromethyl benzotriazole 
To sodium hydride dispersion 60% in mineral oil (7.5 mmol, 1.5eq) washed 
with petrol, the lipophilic alcohol (2 mmol, 1eq) dissolved in 6ml of THF was 
added dropwise and a vigorous reaction took place. To the reaction mixture, 
1-chloromethyl benzotriazole (2 mmol, 1eq) dissolved in 8 ml of THF was 
added under nitrogen, and the reaction was heated under reflux for 4 and 5h 
for tocopherol and cholesterol, respectively. TLC showed the reaction to be 
complete. After cooling at room temperature, the reaction mixture was poured 
into ice water (20 ml) to remove sodium chloride and the solution slowly 
precipitated a solid. The crude products were isolated by suction filtration as 
white solid in both cases and were dried over high vacuum. The solid 
obtained was recrystallized from aqueous ethanol to afford the benzotriazole 
methyl ether of the lipophilic alcohols as white solids, in both cases. 
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1 H-1 ,2,3-benzotriazol-1-ylmethyl-[2,5, 7 ,8-tetramethyl-2-(4,8, 12-trimethyl-
tridecyl) chroman-6-yloxymethyl]-ether (7) 
0 
Benzotriazole methyl ether of tocopherol (7): crude product 87% yield, 
recrystallised product 72% yield; m.p. 193-195 °C; Vmax I cmJ (nujol) 3030, 
1 1614, 1577, 1460, 1209, 919, 850, 744; H NMR (250 MHz, CDC13), 0.75-0.95 
[m, 12H, (CH3-CH)4], 1.0-1.6 [m, 20H, (CH2)10], 1.6-1.8 [m, 3H, (CH-CH 3hJ, 
1.97 (s, 3H, CH3-Ar), 2.08 (s, 3H, CH3-Ar), 2.11 (s, 3H, CH3-Ar), 2.32 (s, 3H, 
CH3-C-O), 2.5-2.61 (m, 2H, CH2-Ar), 7.2-7.35 (m, 4H, 2H Ar+N-CH2-0), 7.55-
13 
7.6 (m, 1H, Ar), 7.8-8.1 (m, 1H, Ar), C-NMR (100 MHz, CDCI3), 11.7, 11.9, 
12.8, 19.5, 19.6, 19.6 (2C), 20.3, 20.4, 21.1, 21.2 (2C), 22.9, 23.3, 25.2, 26.4, 
31.1, 31.6, 35.8, 35.9, 35.9, 37.8, 73.5, 108.3 (O-CH2-N), 115.8, 118.7, 121.5, 
123.2, 125.1, 126.1, 126.9, 130.7, 139.0, 144.7, 147.9, 168.1; Anal. Calcd for 
C36H55Np2: C, 76.95; H, 9.87; N, 7.48; Found: C, 76.87; H, 9.58, N, 7.35; 
HRFABMS Calcd for C36H55N30 2: 561.42943 found 561.4277. 
1 H-1 ,2,3-benzotriazol-1-ylmethyl-[17 -(1 ,5-dimethylhexyl]-1 0, 13-dimethyl-
2,3,4,7,8,9, 10,11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl ether (8) 
acN~N 
N~O·~~-:~~~~L-~ 
Benzotriazole methyl ether of cholesterol (8): crude product 75% yield, 
recrystallised form 69% yield; m.p. 128-130 °C; Ymax I cmJ (nujol) 3092, 1613, 
1 1493, 1452, 1157, 763, 744; H-NMR (250 MHz, CDCI3), 0.83-2.53 (m, 45H, 
olefinic), 3.45-3.65 (m, 1H, 0-CH), 5.34 (d, 1H, J = 2.3 Hz, HC=C), 7.24 (s, 
2H N-CH2-0), 7.35-7.41 (m, 1H Ar), 7.48-7.55 (m, 1H, Ar), 7.84-7.90 (m, 1H, 
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13 
Ar), 7.98-8.05 (m, 1 H, Ar); C-NMR (100 MHz, CDCI 3), 11.8, 18.5, 19.5, 22.0 
(2C), 23.3, 23.5, 24.7, 24.8, 27.1, 27.8, 31.7, 32.0, 32.1, 36.1, 36.3, 36.5, 
37.4, 39.2, 39.6, 42.5, 50.1, 56.3, 56.9, 72.1, 75.0 (O-CH2-N), 109.8, 110.1, 
121.6, 124.9, 128.8, 145.8, 121.1 (C=CH), 140.9 (CH=C); Anal. Calcd for 
C34H51 N30: C, 78.80; H, 9.92; N, 8.11; Found: C, 78.92; H, 9.71, N, 7.95; 
HRFABMS Calcd for C34H51NP: 517.40312 found 517.4018. 
2 By using bis-benzotriazole methane 
To a stirred solution of bis-benzotriazole methane (2 mmol, 1eq) dissolved in 
5 ml of THF, 0.4ml trifluoroacetic acid were added dropwise and the resulting 
yellow solution were stirred at room temperature. After 15 min, a solution of 
cholesterol (2 mmol, 1eq) in 5 ml of THF was also added and the reaction 
mixture was heated slowly under reflux for 4h. The reaction was left to cool at 
room temperature and after leaving it to stir overnight, TLC showed that the 
reaction was completed. The solvent was removed under high vacuum to 
furnish an off-white solid, which was treated with water (10 ml) and 
neutralised to pH 7 by dropwise addition of saturated aqueous solution of 
sodium chloride. The mixture was then transferred into a separating funnel 
where it was extracted thoroughly with dichloromethane (4 x 40 ml). The 
organic fractions were washed with saturated sodium bicarbonate solution (2 
x 20 ml), then collected and dried over magnesium sulphate. The drying agent 
was filtered off and the solvent was evaporated to dryness, leaving the crude 
product as a white waxy solid. Recrystallization of the solid from 
dichloromethane and petroleum ether afforded the desired linker as white 
solid. 
Benzotriazole methyl ether of cholesterol (8): crude product 75% yield, 
recrystallised form 69% yield; m.p. 128-130 °C; Vmax I cm.1 (nujol) 3092, 1613, 
1 
1493, 1452, 1157, 763, 744; H-NMR (250 MHz, CDCI3), 0.83-2.53 (m, 45H, 
aliphatic), 3.45-3.65 (m, 1 H, 0-CH), 5.34 (d, 1 H, J = 2.3 Hz, HC=C), 7.24 (s, 
2H N-CHz-0), 7.35-7.41 (m, 1H Ar), 7.48-7.55 (m, 1H, Ar), 7.84-7.90 (m, 1H, 
13 Ar), 7.98-8.05 (m, 1H, Ar); C-NMR (100 MHz, CDC13), 11.8, 18.5, 19.5, 22.0 
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(2C), 23.3, 23.5, 24.7, 24.8, 27.1, 27.8, 31.7, 32.0, 32.1, 36.1, 36.3, 36.5, 
37.4, 39.2, 39.6, 42.5, 50.1, 56.3, 56.9, 72.1, 75.0 (O-CH2-N), 109.8, 110.1, 
121.6, 124.9, 128.8, 145.8, 121.1 (C=CH), 140.9 (CH=C); Anal. Calcd for 
C34H51 N30: C, 78.80; H, 9.92; N, 8.11; Found: C, 78.92; H, 9.71, N, 7.95; 
HRFABMS Calcd for C34H51 N30: 517.40312 found 517.4018. 
(11) Linkers from thioctic acid 
5-[(3R)-1 ,2-dithiolan-3-yl]-pentanoic acid 1 H-benzotriazol-1-ylmethyl 
ester (9) 
0 
s-s 
To sodium hydride (7.5 mmol, 1.5eq) washed free from oil with petroleum 
ether, a solution of thioctic acid (5 mmol, 1eq) in 20 ml of DMF was added 
dropwise and a vigorous reaction took place (colour of reaction changed to 
yellow). To the reaction mixture that was stirred under nitrogen, 1-
chloromethyl benzotriazole (5 mmol, 1eq) dissolved in 10 ml of THF was 
added and the reaction was heated slowly under reflux for 4h TLC showed 
that the reaction was completed. After cooling at room temperature, solvents 
were evaporated under high vacuum to give a yellow oily residue. The residue 
was treated with water (20 ml) and was neutralised to pH 7 by dropwise 
addition of 2M solution of aqueous hydrochloric acid. The mixture was 
extracted with ethyl acetate (4 x 50 ml) and the organic fractions were washed 
with sodium bicarbonate solution (2 x 20 ml) and brine (2 x 20 ml). The 
organic extracts were combined, dried over MgS04 , filtered and evaporated to 
dryness, to afford the crude product as dark yellow solid. Recrystallization 
from ethyl acetate and petroleum ether furnished the title compound as pale 
yellow solid. 
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Benzotriazole methyl ether of thioctic acid: crude product 77% yield, 
recrystallised form 62% yield; Vmax I cmJ (nujol) 3325, 2862 1732, 1434, 788, 
1 
734, 632; H-NMR (250 MHz, CDCI3) 1.25-2.0 (m, 6H, CH2 x 3 aliphatic), 
2.05-2.10 (m, 2H, CH2 cycle) 2.30-2.50 (m, 3H, O=C-CH2, CH-8 cycle), 3.05-
3.25 (m, 2H, CH2-S), 6.62 (s, 2H, N-CHrO), 7.30-7.45 (m, 1H,Ar), 7.56-7.68 
13 (m, 1H, Ar), 7.72-7.86 (m, 1H, Ar), 8.02-8.18 (m, 1H, Ar); C-NMR (100 MHz, 
CDCI3) 24.3, 28.6, 33.1, 33.7, 38.5, 40.1, 56.2, 67.2 (N-CH2-0), 110.8, 120.7, 
125.3, 126.7, 128.5, 133.2, 178.3 (O=C-CH2 quaternary); Anal. Calcd for 
C15H19Np282: C, 53.39; H, 5.67; N, 12.45; Found C, 53.51; H, 5.52; N, 12.25; 
HRFABMS Calcd for C15H19Np282: 337.09187 found 337.0888. 
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(B). Carbonate linkers 
4-Nitrophenyl chloroformate (5 mmol, 1eq), dissolved in 5 ml of CH3CN, was 
added dropwise to a stirred solution of tocopherol or cholesterol (5 m mol, 1eq) 
dissolved in 10ml of anhydrous CH3CN and 10 ml of anhydrous THF, 
respectively. The solution, which turned yellow immediately owing to the 
formation of the p-nitrophenoxy anion, was stirred at room temperature, under 
N2 . After stirring for 5 min triethylamine (5.5 mmol, 1.1 eq) was added 
dropwise and the colour of the reaction turned to dark yellow. The reaction 
was stirred overnight and then the solvent was removed in vacuo, to afford 
dark yellow oil in the case of tocopherol and dark yellow solid in the case of 
cholesterol. Both oil and solid were dissolved in 20 ml dichloromethane and 
10ml of water. The residual aqueous phase was extracted with 
dichloromethane (3 x 20 ml) and the organic fractions were washed with 
saturated sodium bicarbonate solution (2 x 10 ml) and brine (2 x 10 ml). The 
organic extracts were combined, dried over MgS04, filtered and evaporated to 
dryness, to give a dark yellow oil and solid for tocopherol and cholesterol, 
respectively. Recrystallization of the cholesterol derivative from 
dichloromethane and petrol furnished the title compound as yellow solid. The 
tocopherol derivative was triturated from petroleum ether and the desired 
linker, was afforded as yellow oil. 
Carbonic acid 17 -(1 ,5-dimethyl-hexyl)-1 0, 13-dimethyl-
2,3,4,7,8,9, 10, 11,12, 13, 14, 15, 16, 17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl-4-nitrophenyl ester (10) 
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4-Nitrophenyl-carbonate linker of cholesterol (10) crude product 87% yield, 
recrystallised form 72% yield; m.p. 112-115 °C; Vmax I cm.1 (nujol) 1742, 1591, 
1 1458, 1335, 850, 754; H-NMR (400 MHz, CDCI3), 0.67-2.34 (m, 45H, 
aliphatic), 4.51-4.71 (m, 1H, 0-CH), 5.35 (d, 1H, J = 2.6 Hz, HC=C), 6.80 (d, 
13 
2H, J = 8.85 Hz), 8.10 (d, 2H, J = 7.65 Hz), C-NMR (100 MHz, CDCI3), 16.7, 
17.3, 19.1, 20.6, 21.9, 22.3 (2C), 23.9, 26.5, 28.5, 29.9, 33.8, 34.2, 34.4, 34.5, 
37.5, 37.8, 41.3, 48.3, 54.7, 58.2 70.2, 72.4, 74.8, 75.5, 122.3 (2C), 124.2 
(2C), 123.2 (C=CH), 144.6, 149.5 (CH=C), 159.2, 168.1 (C=O); Anal. Calcd 
for C34H49N05: C, 74.04; H, 8.95; N, 2.53 Found: C, 74.19; H, 9.34, N, 2.45; 
HRFABMS Calcd for C34H49N05: 551.36107 found 551.3589. 
Carbonic acid 2,5,7 ,8-tetramethyl-2-(4,8, 12-trimethyl-tridecyl) chroman-6-
yl-4-nitrophenyl ester (11) 
4-Nitrophenyl-carbonate linker of tocopherol (11) crude product 92% yield, 
pure form 83% yield Vmax I cm·1 (neat) 1746, 1558, 1461, 1204, 1085, 858; 1H 
NMR (400 MHz, CDCI3), 0.75-0.95 [m, 12H, (CH3-CH)4], 1.0-1.6 [m, 20H, 
(CHz)10], 1.6-1.8 [m, 3H, (CH-CH3lo], 1.97 (s, 3H, CH3-Ar), 2.08 (s, 3H, CH3-
Ar), 2.11 (s, 3H, CH3-Ar), 2.32 (s, 3H, CH3-C-O), 2.5-2.61 (m, 2H, CH2-Ar), 
13 
7.48 (d, 2H, J = 8.65 Hz), 8.31 (d, 2H, J = 7.42 Hz), C-NMR (100 MHz, 
CDC13), 16.9, 19.5, 20.1 (2C), 20.9, 22.4 (2C), 21.1, 21.2, 22.9, 23.3, 25.3, 
28.5, 31.2, 32.1, 32.4, 34.7, 35.6, 35.9, 37.5, 37.8, 39.6, 41.2, 46.2, 74.7, 
121.5, 123.1, 124.2 (2C), 129.8, 130.5 (2C), 142.8, 148.5, 155.2, 168.5 
(C=O); Anal. Calcd for C36H53N06: C, 72.60; H, 8.97; N, 2.35; Found C, 72.74; 
H, 9.14; N, 2.43; HRFABMS Calcd for C36H53N06: 595.38729 found 595.3848. 
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(C) Carbamate linkers 
A solution of cholesterol or tocopherol ( 5 mmol, 1 eq) in dry toluene (30 ml) 
was treated with N',N'-Carbonyl-diimidazole (5.5 mmol, 1.1eq). The reaction 
mixture was heated under reflux for 12h for cholesterol and 1 Oh for 
tocopherol. After the reaction was left to cool down at room temperature, the 
solvent was evaporated to dryness to reveal off-brown oil and white solid for 
tocopherol and cholesterol, respectively. Both residues were dissolved with in 
ethyl acetate (40 ml) and water (10 ml). The organic layer was separated. The 
aqueous phase was neutralised by dropwise addition of 0.5 N HCI (5 ml) and 
then extracted further with ethyl acetate (4 x 40 ml). After washing the 
combined organic fractions with saturated sodium bicarbonate solution (2 x 10 
ml) and brine (2 x 10 ml), they were dried over magnesium sulphate, filtered 
and evaporated to dryness. The novel carbamate linkers of tocopherol and 
cholesterol were furnished, as pale-yellow oil after trituration from hot hexane 
and white solid after recrystallization from dichloromethane and petrol, 
respectively. 
lmidazole-1-Carboxylic acid 17 -(1 ,5-dimethyl-hexyl)-10, 13-dimethyl-
2,3,4, 7,8,9, 10,11, 12, 13, 14, 15, 16,17 -tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl ester (13) 
I \ N.::yNf 
0 
Carbonylimidazolide carbamate linker of cholesterol (13) crude product 78% 
yield, recrystallised form 71% yield; m.p. 108-110 °C; Vmax I cm·1 (nujol) 1748, 
1 1591, 1484, 1407, 1301, 1011.8, 765, 650; H-NMR (400 MHz, CDC13 ), 0.66-
2.45 (m, 45H, aliphatic), 4.80-4.86 (m, 1 H, 0-CH), 5.44 (d, 1 H, J = 2.4 Hz, 
HC=C), 7.05 (s, 1H, CH imid), 7.41 (s, 1H, CH imid), 8.13 (s, 1H, CH=N), 13C-
NMR (100 MHz, CDCI3), 17.2, 18.3, 18.5, 19.1, 20.6, 21.2, 22.5 (2C), 23.9, 
25.3, 28.5, 29.4, 30.6, 33.5, 34.4, 35.8, 35.9, 39.7, 45.7, 48.4, 51.2, 54.2, 
57.8, 71.4, 113.7, 121.2, 122.3 (C=CH), 123.2 (2C), 136.8, 149.5 (CH=C), 
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168.5 (C=O); Anal. Calcd for C31 H48N202 : C, 77.45; H, 10.06; N, 5.83; Found 
C, 77.78; H, 9.95; N, 5.94; HRFABMS Calcd for C31H48N202: 480.37157 found 
480.3698. 
lmidazole-1-Carboxylic acid 2,5, 7 ,8-tetramethyl-2-(4,8, 12-trimethyl-
tridecyl) chroman-6-yl ester (14) 
0 
A 
OYN0N 
0 
Carbonylimidazolide carbamate tinker of tocopherol (14) crude product 84% 
1 
yield, pure form 76% yield; Vmax I cm· (neat) 1754, 1464, 1384, 1232, 1160, 
1 
993, 763, 658; H NMR (400 MHz, CDCI3), 0.75-0.99 [m, 12H, (CH3-CH)4]. 
1.0-1.4 [m, 20H, (CH2)10], 1.6-1.8 [m, 3H, (CH-CH3h]. 1.96 (s, 3H, CH3-Ar), 
2.04 (s, 3H, CH3-Ar), 2.12 (s, 3H, CH3-Ar), 2.25 (s, 3H, CH3-C-O), 2.51-2.64 
(m, 2H, CH2-Ar), 7.08 (s, 1H, CH imid), 7.52 (s, 1H, CH imid), 8.25 (s, 1H, 
13 CH=N), C-NMR (100 MHz, CDCI3), 13.3, 20.1, 20.2 (2C), 22.9 (2C), 23.2, 
24.8, 25.2, 28.3, 33.2, 37.7, 37.8, 39.7, 40.3, 53.8, 74.6, 75.8, 77.1, 77.4, 
77.6, 77.7, 121.5, 122.4 (2C), 123.1, 126.9, 130.6, 135.3, 137.8, 147.6, 156.2, 
168.4 (C=O); Anal. Calcd for C33H52N203: C, 75.53; H, 9.99; N, 5.34; Found 
C, 75.64; H, 9.83; N, 5.25; HRFABMS Calcd for C33H52N203: 524.39779 found 
524.3953. 
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(D) Ester linkers 
To sodium hydride (7.5 mmol, 1.5eq) washed free from oil with petroleum 
ether, lipophilic alcohol (5mmol, 1eq) dissolved in 20 ml of THF was added 
dropwise and a vigorous reaction took place. To the reaction mixture that was 
stirred under nitrogen, ethyl bromoacetate (5.5 m mol, 1.1 eq) was added 
dropwise. The reaction was stirred overnight for 12h and then allowed to cool 
down at room temperature. TLC showed the reaction to be complete. The 
solvent was removed under high vacuum, to give an off-yellow residue in both 
cases. The residues were treated with water (10 ml) and were neutralised to 
pH 7 by dropwise addition of 2M solution of aqueous hydrochloric acid. The 
aqueous phase was extracted with dichloromethane (5 x 30 ml) and the 
combined organic fractions were washed with saturated sodium bicarbonate 
solution (2 x 20 ml) and brine (2 x 20 ml). The organic extracts were dried 
over magnesium sulphate, filtered and evaporated to dryness, to afford the 
crude derivatives of tocopherol and cholesterol. Recrystallization of the crude 
ethyl ester of cholesterol from dichloromethane and petroleum ether furnished 
the title compound as off-white solid. The crude ethyl ester of tocopherol was 
triturated from hot hexane to afford the desired product as pale yellow oil. 
[17 -(1 ,5-dimethyl-hexyl)-1 0, 13-dimethyl-
2,3,4,7,8,9, 10,11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yloxy]-acetic acid ethyl ester (47) 
Ethyl ester of cholesterol (47) crude product 88% yield, recrystallized form 
78% yield; m.p. 108-110 ° C; Vmax I cmJ (nujol) 1739, 1463, 1376, 1175, 1028, 
762, 683; 
1
H-NMR (400 MHz, CDCI3), 0.67-2.35 (m, 45H, aliphatic), 1.41 (t, 
3H, J = 7.13, CH2-CH3,), 2.92 (s, 2H, CH2-CO), 4.31 (q, 2H, CH2-CH3), 4.61-
13 4.70 (m, 1 H, 0-CH), 5.36 (d, 1 H, J = 2.2 Hz, HC=C), C-NMR (100 MHz, 
CDC13 ), 17.3, 18.5, 21.2, 22.6 (2C), 23.1, 23.9, 26.4, 28.5, 29.4, 30.6, 34.2, 
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35.6, 35.8, 36.8, 39.6, 42.5, 43.8, 46.7' 48.8, 51.2, 59.5, 62.5, 72.2, 75.2, 
113.7, 121.2, 122.8 (C=CH), 128.5, 148.4 (CH=C), 165.4 (C=O); Anal. Calcd 
for C31 H5z03: C, 78.76; H, 11.10 Found C, 78.84; H, 11.02; HRFABMS Calcd 
for C31 H520 3: 472.39164 found 472.3897. 
[2,5, 7 ,8-tetramethyl-2-( 4,8, 12-trimethyl-tridecyl) chroman-6-yloxy]-actic 
acid ethyl ester (48) 
Ethyl ester of tocopherol (48) crude product 91% yield, purified form 82% 
yield; Vmax I cm·1 (neat) 1751, 1459, 1392, 1245, 1182,993,774, 665; 1H NMR 
(400 MHz, CDCI3), 0.73-0.97 [m, 12H, (CH3-CH)4]. 1.0-1.5 [m, 20H, (CH2)10], 
1.58 (t, 3H, J = 7.22, CH2-CH3,), 1.64-1.82 [m, 3H, (CH-CH3hJ, 1.97 (s, 3H, 
CH3-Ar), 2.08 (s, 3H, CH3-Ar), 2.15 (s, 3H, CH3-Ar), 2.31 (s, 3H, CH3-C-O), 
13 2.52-2.64 (m, 2H, CH2-Ar), 2.98 (s, 2H, CH2-CO), 4.42 (q, 2H, CH2-CH3), C-
NMR (100 MHz, CDCI3), 13.6, 17.1, 19.4 (2C), 20.0, 21.2, 22.3 (2C), 24.9, 
26.3, 28.52 32.2, 37.8, 39.7, 41.3, 46.3, 61.5, 74.7, 75.6, 76.1, 76.6, 77.6, 
120.6, 121.7, 122.9, 123.7, 128.7, 131.7, 132.5, 134.5, 151.4, 154.0, 164.0 
(C=O); Anal. Calcd for C33H560 4 : C, 76.69; H, 10.92 0 12,38 Found C, 76.81; 
H, 10.78; HRFABMS Calcd for C33H560 4 : 516.41786 found 516.4158. 
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To a solution of ethyl acetate of cholesterol 47 or tocopherol48 (5 m mol, 1eq) 
in 20 ml of ethanol, 10 ml of 2M solution of aqueous potassium hydroxide 
were added. The reaction mixture was heated under reflux for 5h and then 
allowed to stir overnight while attaining ambient temperature. The solvent was 
removed under high vacuum and the aqueous residue was acidified to pH 1 
by dropwise addition of 2M solution of aqueous hydrochloric acid and then 
extracted thoroughly with dichloromethane (5 x 30ml). The organic extracts 
were combined, dried over MgS04, filtered and evaporated to dryness, to give 
the crude carboxylic acids of cholesterol and tocopherol. Recrystallization of 
the crude derivative of cholesterol from ethyl acetate and dichloromethane 
furnished the title compound as an off-white solid. The crude carboxylic acid 
of tocopherol was triturated with hot hexane to afford the desired product as 
an off-yellow oil. 
[17 -(1 ,5-dimethyl-hexyl)-1 0, 13-dimethyl-
2,3,4,7,8,9, 10, 11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H-
cyclopenta[a)phenanthren-3-yloxy) acetic acid (49) 
HOY"' 0-..._ t.~'.::::_......-J'-.....L:...-,-.......__f._......__' 
0 
Carboxylic acid of cholesterol (49) crude product 83% yield, recrystallized 
1 
form 72% yield; Vmaxl cm· (nujol) 2857,1732,1469,1373,1129,1051, 958; 
1
H-NMR (400 MHz, CDC13), 0.69-2.45 (m, 45H, aliphatic), 2.78 (s, 2H, CH2-
CO), 4.63-4.71 (m, 1H, 0-CH), 5.37 (d, 1H, J = 2.4 Hz, HC=C), 8.03 (br s, 1H, 
13 
OH), C-NMR (100 MHz, CDCI3), 18.9, 21.9, 22.5 (2C), 23.4, 24.4, 27.8, 
29.4, 32.7, 33.2, 34.1, 34.8, 35.8, 36.8, 39.6, 41.3, 43.5, 47.4, 48.2, 52.2, 
63.6, 73.6, 76.4, 115.7, 122.8, 123.1 (C=CH), 129.2, 149.5 (CH=C), 176.1 
(C=O), Anal. Calcd for C29H480 3: C, 78.33; H, 10.88 0 10,79 Found C, 78.45; 
H, 10.71; HRFABMS Calcd for C29H480 3: 444.36035 found 444.3593. 
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[2,5, 7,8-tetramethyl-2-(4,8, 12-trimethyl-tridecyl) chroman-6-yloxy] acetic 
acid (50) 
0 
Carboxylic acid of tocopherol (50) crude product 89% yield, purified form 77% 
. J 1 yteld; Vmax I cm (neat) 2875, 1752, 1463, 1385, 1252, 838, 757; H NMR (400 
MHz, CDCI3), 0.75-0.98 [m, 12H, (CH3-CH)4], 1.02-1.8 [m, 20H, (CH2)10], 
1.66-1.84 [m, 3H, (CH-CH3h]. 1.99 (s, 3H, CH3-Ar), 2.11 (s, 3H, CH3-Ar), 2.19 
(s, 3H, CH3-Ar), 2.34 (s, 3H, CH3-C-O), 2.55-2.67 (m, 2H, CH2-Ar), 2.74 (s, 
13 
2H, CH2-CO), 8.06 (br s, 1H, OH); C-NMR (100 MHz, CDCI3), 17.5, 19.8 
(2C), 21.7, 22.8 (2C), 23.4, 25.3, 28.5, 30.8, 35.2, 38.7, 40.25, 41.8, 46.4, 
74.9, 75.9, 76.8, 77.4, 77.9, 78.4, 120.8, 121.9, 123.7, 124.8, 129.5, 132.6, 
135.7, 152.8, 155.2, 177.0 (C=O); Anal. Calcd for C31 H520 4: C, 76.18; H, 
10.72, 0 13,09 Found C, 76.25; H, 10.61; HRFABMS Calcd for C31 H520 4: 
488.38656 found 488.3846. 
189 
To a stirred solution of 2,3,4,5,6-pentaflurorophenol (5 mmol, 1eq) dissolved 
in 1 Oml of anhydrous DMF, a solution of the carboxylic acid of cholesterol 49 
or tocopherol 50 (5 mmol, 1eq) in DMF (10ml) was added. In the resulting 
reaction mixture which was cooled in an ice bath to 0-5 °C and put under 
nitrogen, 1-ethyl-3-( -3'-dimethylaminopropyl)carbodiimide hydrochloride) 
(EDCI) (5.5 m mol, 1.1 eq), was added neat, while 1,3-
dicyclohexylcarboddimide (DCC) (5.5 mmol, 1.1 eq), was dissolved in 5 ml of 
DMF. The addition of the coupling reagent was made in both cases 
proportionally every 10 min. Within 30 m in the addition had concluded and the 
solution was left to stir at room temperature for 4h. The solvent was 
evaporated to dryness under high vacuum and the residue that resulted was 
dissolved in 40ml of ethyl acetate and 2 ml of 2M aqueous hydrochloric acid. 
The aqueous layer was extracted with further with ethyl acetate (4 x 20 ml) 
and the combined organic fractions were washed sequentially with saturated 
sodium bicarbonate solution (2 x 20 ml) and brine (2 x 20 ml). The organic 
extracts were dried over magnesium sulphate, filtered and evaporated to 
dryness to furnish the pentafluorophenyl ester derivatives of cholesterol and 
tocopherol as waxy solid and thick oil, respectively. Recrystallization from 
diethyl ether and hexane gave the desired purified linkers of cholesterol and 
tocopherol as white solid and off yellow solid, respectively. 
[17 -(1 ,5-dimethyl-hexyl)-1 0, 13-dimethyl-
2,3,4, 7,8,9, 10,11, 12, 13, 14, 15, 16,17 -tetradecahydro-1 H-
cyclopenta[a]phenanthren-3-yloxy] acetic acid pentaflurorophenyl ester 
(16) 
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Pentafluorophenyl ester linker of cholesterol (16): crude product 74-78% yield, 
1 
recrystallized form 62-68% yield; Vmax I cm· (nujol) 1745, 1473, 1354, 1258, 
1 
1172, 1048, 945, 755; H-NMR (400 MHz, CDCI3), 0.70-2.47 (m, 45H, 
aliphatic), 2.80 (s, 2H, CH2-CO), 4.64-4.73 (m, 1 H, 0-CH), 5.38 (d, 1 H, J = 2.5 
13 
Hz, HC=C); C-NMR (1 00 MHz, CDCI3), 17.9, 18.5, 21.2, 22.6 (2C), 23.1, 
23.9, 27.5, 28.2, 30.6, 32.1, 33.5, 34.2, 34.9, 35.8, 38.5, 41.1, 42.8, 47.4, 
48.4, 51.4, 62.6, 71.2, 75.1, 114.5, 122.8 (C=CH), 129.2, 125.9, 133.7 (2C), 
136.1, 140.8 (2C), 149.2 (CH=C), 170.2 (C=O), Anal. Calcd C35H47Fs03: C, 
68.83; H, 7.76, 0 7,86 Found C, 68.98; H, 7.61; HRFABMS Calcd for 
C35H47Fs03: 610.34454 found 610.3419. 
[2,5, 7,8-tetramethyl-2-(4,8, 12-trimethyl-tridecyl) chroman-6-yloxy] acetic 
acid pentaflurorophenyl ester (17) 
0 0F*Ii' F 0~ ~' 0 F 
F 
Pentafluorophenyl ester linker of tocopherol (17): crude product 80-86% yield, 
recrystallized form 67-73% yield; Vmax I cm·1 (nujol) 1742, 1482, 1375, 1332, 
1 
1264, 977, 832, 695; H NMR (400 MHz, CDCI3), 0.75-0.98 [m, 12H, (CH3-
CH)4], 1.06-1.85 [m, 20H, (CH2)10], 1.69-1.86 [m, 3H, (CH-CH3M 2.04 (s, 3H, 
CH3-Ar), 2.15 (s, 3H, CH3-Ar), 2.23 (s, 3H, CH3-Ar), 2.38 (s, 3H, CH3-C-O), 
13 2.59-2.71 (m, 2H, CH2-Ar), 2.82 (s, 2H, CH2-CO), C-NMR (100 MHz, 
CDCI3), 17.2, 19.4, 20.2 (2C), 20.7, 22.3 (2C), 24.1, 25.4, 28.5, 32.5, 34.3, 
35.5, 37.8, 39.7, 41.2, 46.1, 74.7, 75.8, 76.4, 77.1, 77.6, 120.6, 121.2, 121.9, 
123.7, 125.8, 129.5, 132.6, 134.7 (2C), 136.5, 141.2 (2C), 151.8, 154.7, 174.0 
(C=O); Anal. Calcd for C37H51 Fs04 : C, 67.87; H, 7.85, 0 9,77 Found C, 67.95; 
H, 7.92; HRFABMS Calcd for C37H51 Fs04 : 654.37075 found 654.3692. 
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(E) Linker for linking the antibody to DNA 
8-[(1 H-1 ,2,3-benzotriazol-1-ylmethyl)thio ]octyl hydrosulfide (54) 
((} 
~S~SH 
In a solution of 1 ,8-octanedithiol (5 mmol, 1.25eq) in 8 ml of CH3CN, 1-
chloromethyl benzotriazole (4 mmol, 1eq) dissolved in 5 ml of CH3CN was 
added and the solution was stirred at room temperature. After 5min 
triethylamine (5 mmol, 1.25eq) was added (a change in the colour was noted) 
and the reaction mixture was heated under reflux for 3h. The solution was left 
to stand at room temperature for 30 min and white crystals started 
precipitating. The crystals were collected by suction filtration and the filtrate 
was rotary evaporated to furnish off-yellow oil. The oil was dissolved in 
dichloromethane (40 ml) and water (20 ml) and the aqueous layer was 
extracted further with dichloromethane (4 x 30ml). The combined organic 
fractions were washed with saturated sodium bicarbonate solution (2 x 20 ml) 
and brine (2 x 20 ml) and then dried over magnesium sulphate. After filtration 
of the drying agent and evaporation of the solvent, the title compound was 
furnished as a yellow oil. 
Thioaminal compound (54): 70% yield; Vmax I cm.1 (neat) 3063, 2558, 1226, 
1 
1150, 778, 716, 661; H-NMR (250 MHz, CDCI3) 1.15-163 [m, 12H, (CH2)6], 
2.47-2.55 (m, 4H, CH2-S, CH2·SH), 2.65 (t, 1 H, J =4.2.1 Hz, CH2-SH), 5.69 (s, 
2H, N-CH2-S), 7.40 (t, 1H, J = 8.1Hz, Ar), 7.51 (t, 1H, J = 8.1Hz, Ar), 7.68 (d, 
13 1H, J = 8.2Hz, Ar), 8.06 (d, 1H, J = 8.0 Hz, Ar); C-NMR (100 MHz, CDCI3) 
[24.9, 28.6, 28.7, 29.4, 29.5, 31.7, 34.3, 39.4] (8 x CH aliphatic), 49.5 (N-CH2-
S), 110.2, 120.4, 124.6, 128.4, 132.3 (C quaternary, Ar), 146.8 (C quaternary, 
Ar); Anal. Calcd for C15H23N3S2: C, 58.21; H, 7.49; N, 13.58; Found C, 57.31; 
H, 7.74; N, 13.87; HRFABMS Calcd for C15H23N3S2: 309.13334 found 
309.1306. 
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8-[(1H-1 ,2,3-benzotriazol-1-ylmethyl)thio]octyl pyridin-2-yl disulfide (19) 
(XNJ 
N 
l_s s(J ""'~~ 
In a solution of the thioaminal compound 54 (2 mmol, 1eq) in 5 ml of 
dichloromethane, pyridyl disulfide (4 mmol, 2eq) also dissolved in 4 ml of 
dichloromethane, was added. A change in colour was observed and the 
reaction mixture was left to stir to room temperature overnight. After allowing 
the mixture to cool down at room temperature, the solvent was evaporated to 
dryness to afford a yellow residue that was partitioned between 30 ml of ethyl 
acetate and 10 ml of water. The aqueous layer was extracted further with 
ethyl acetate (4 x 40ml) and the combined organic fractions were washed 
sequentially with saturated sodium bicarbonate solution (2 x 10ml) and brine 
(2 x 10ml). The organic extracts were dried over magnesium sulphate, filtered 
and evaporated to dryness, to furnish a yellow solid. The crude product was 
purified by flash column chromatography over silica eluting with a 3:1 mixture 
of petroleum ether and ethyl acetate to afford the desired product as yellow 
oil. 
8-[(1 H-1 ,2,3-benzotriazol-1-ylmethyl)thio)octyl pyridin-2-yl disulfide (19): 55% 
yield; Vmax I cm·1 (neat) 3043, 2552, 1571, 1225, 1139, 1116, 758, 718, 665; 
1 
H-NMR (250 MHz, CDCI3) 1.15-1.30 (m, 8H, (CH2)4], 1.56-1.68 (m, 4H, 
(CHz)2], 2.44-2.68 (m, 2H, CHz-S-CHz-N), 2.72-2.79 (m, 2H, CH2-S-S), 5.67 
(s, 2H, N-CHz-S), 7.03-7.10 (m, 1H,Ar), 7.44-7.54 (m, 2H, Ar), 7.62-7.73 (m, 
13 2H, Ar), 8.12-8.23 (m, 2H, Ar), 8.42-8.47 (m, 1H, Ar); C-NMR (100 MHz, 
CDCI3) [28.2, 28.6, 29.1, 29.4, 29.6, 29.7, 31.7, 39.1] (8 x CH aliphatic), 49.3 
(N-CHz-S), [110.8, 119.7, 120.2, 120.7, 121.1, 124.7, 128.5, 132.1] (8 x CH 
aromatic), 137.4 (C quart, Ar), 137.6 (C quart, Ar), 149.5 (C quart, Ar); Anal. 
Calcd for C20H26N4S3: C, 57.38; H, 6.26; N, 13.38; Found C, 56.86; H, 6.13; N, 
13.12 HRFABMS Calcd for C20H26N4S3: 418.13196 found 418.1288. 
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BINDING OF THE SYNTHETIC PEPTIDES AK79, THE PLASMID AND THE 
BISINDOL YLMALEIMIDE Ill HCI WITH GRE34 ANTIBODY 
Stock solutions were made for each of the peptides, the plasmid, the 
bisindolylmaleimide Ill HCI, the linker, iminothiolane and the G34 antibody. 
Synthetic Peptide A (LRQAGDDFC) stock solution: 9.85 mg in 10 ml of 3:1 
mixture HzO:MeOH 
Synthetic Peptide B (LRRMSDEFC) stock solution: 11.35 mg in 10 ml of 3:1 
mixture HzO: MeOH 
Plasmid (pSV-beta-Galactosidase Control Vector) stock solution: 40 
J.tg=9.2 pmol in 23 J.!l of MeOH 
Bisindolylmaleimide Ill HCI stock solution: 1 mg=2.4 f.lmol in 500 f.ll of H20 
Linker 19 stock solution: 2000 nmol=2 f.lmoi=0.8 mg of linker in 2000 f.ll of 
CHaCN 
lminothiolane stock solution: 1 llmoi=0.138 mg in 1000 J.!l of MeOH 
CGGS-G34(16-34): Cys-23-Phe-NHz stock solution: 42 mg=1.57 1-1mol in 
1000 f.ll of MeOH 
Peptides A and B, the plasmid and the bisindolylmaleimide Ill HCI coupled 
with the existing linker, were bound to G34, which was already coupled with 
iminothiolane. 4 reaction mixtures were made. In the 1•t mixture: 400 J.tl (0.4 
J.tmol) of linker stock solution was added to 400 1-11 (0.4 Jlmol) of peptide A 
stock solution while, in the 2"d mixture: 4001-11 (0.4 1-1mol) of linker stock 
solution was added to 400 J.!l (0.4 J.lmol) of peptide B stock solution. In the 3'd 
mixture: 400 Jll (0.4 1-1mol) of linker stock solution was added to 83 1-11 (0.4 
J.tmol) of bisindolylmaleimide Ill stock solution while in the 4th mixture: 23 Jll 
(9.2 pmol) of linker stock was added to 9.2 pmol of plasmid stock solution. 
The 4 mixtures were shaken gently at room temperature for 30 min. 
In the meanwhile another 3 mixtures were made and in each one, 400 J.tl (0.4 
Jlmol) of iminothiolane stock solution was added to 250 Jll (0.4 Jlmol) of G34 
stock solution. A 4th mixture was made specially in order to bound the G34 to 
the plasmid (already coupled to the linker) as only a pmol quantity of plasmid 
was available. 
194 
--------------------------- - - - -
In this mixture 23 f!l (9.2 pmol) of iminothiolane stock solution was added to 
23 f!l (9.2 pmol) of G34 stock solution The 4 mixtures were shaken gently at 
room temperature for 30 min. These were then added successively to the 4 
mixtures of Peptides A and B, bisindolylmaleimide Ill HCI and plasmid 
(already coupled to the linker). The 4 reaction mixtures obtained were again 
shaken gently at room temperature for 40 min and kept at fridge temperature 
(4-6 °C). 
BINDING OF THE SYNTHETIC PEPTIDES AK79 AND THE LINEARISED 
ANTISENSE DNA (OLIGO) TO THE GRE1 AND GRE4 ANTIBODY 
COLUMNS 
Stock solutions were made for each of the peptides, the Linearised Antisense 
DNA, the linker and iminothiolane. 
Linearised Antisense DNA (Oiigo) stock solution: 1 f!mol=1000 nmol in 400 
f!l ofMeOH 
Synthetic Peptide A (LRQAGDDFC) stock solution: 9.85 mg in 10 ml of 3:1 
mixture H20: MeOH 
Synthetic Peptide 8 (LRRMSDEFC) stock solution: 11.35 mg in 10 ml of 3:1 
mixture H20: MeOH 
linker 19 stock solution: 2000 nmof=2 f..!mol=O.B mg of Jinker in 2000 f!l of 
CH3CN 
lminothiolane stock solution: 1 f!moi=0.138 mg in 1000 f!l of Me OH 
Peptides A and B, and the Linearised Antisense DNA (Oiigo) coupled with the 
existing linker, were bound to GRE1 and GRE4 antibody columns, which were 
already coupled with lminothiolane. 3 mixtures were made. 
In the 1st mixture: 60 f!l (60 f!mol) of linker stock solution was added to 60 f!l 
of peptide A stock solution, in the 2"d mixture: 60 f!l (60 f!mol) of linker stock 
solution was added to 60 f!l of peptide B stock solution while in the 3'd 
mixture: 400 f!l (400 f!mol) of linker stock solution was added to 400 f!l of 
oligo stock solution. The 3 mixtures were shaken gently at room temperature 
for 30 min. 
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In the meanwhile 60 fll of the iminothiolane stock solution was added to each 
of the 4 columns, which were then shaken gently at room temperature for 30 
min. Excess of iminothiolane was removed by washing with methanol. After 
that, peptides A and B and the oligo were bound to the antibody columns. The 
aim was to use 10 fold of oligo and linker reaction mixture for the GRE1 
column and 100 fold of the same reaction mixture for the GRE4 column. 10 
fold of peptide A and B and linker reaction mixtures were used for the other 
two GRE1 and GRE4 columns. 
60 fll (10x fold) of the 1st mixture was added to the 1st GRE1 column while; 
60 fll (10x fold) of the 2"d mixture was added to the 1st GRE4 column. 60 fll 
(10x fold) of the 3'd mixture was added to the 2"d GRE1 column while; 600 fll 
(100x fold) of the 3'd mixture was added to the 2"d GRE4 column. The 
columns were shaken gently at room temperature for 40 min. After washing 
out excess of the reagents with methanol, the columns were kept at fridge 
temperature (4-6 °C). 
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2. GLOBAL AND PARTIAL PROTECTION OF 
NUCLEOSIDES 
(A). Protection of the 5'-position of nucleosides 
(I) Using Triphenylmethyl chloride (56) 
5'-0-trityl-2'-deoxythymidine (57) and 5'-0-trityl-adenosine (58) 
To a magnetically stirred solution of 2'-deoxythymidine (suspension for 
adenosine) (5 mmol, 1eq) in dry pyridine {10 ml), triphenylmethyl chloride (7.5 
mmol, 1.5eq) was added along with a catalytic amount of 4-
. dimethylaminopyridine {0.125 mmol). The reaction mixture was left to stir at 
room temperature for 2h. The solution was evaporated to dryness under high 
vacuum and the residue furnished was dissolved in ethyl acetate {20 ml) and 
water {10 ml). The aqueous layer was extracted with ethyl acetate (3 x 25 ml) 
and the combined organic layers were washed with saturated sodium 
bicarbonate solution (2 x 10 ml). The organic fractions were dried over 
MgS04, the drying agent was filtered off and the solvent was rotary 
evaporated. A glossy residue was afforded which was recrystallized from 
ethanol and petrol to afford the 5'-0-trityl nucleosides as white crystalline 
solids. 
NHz t~N ·~~ 
HO OH 
58 
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5'-0-trityl-2'-deoxythymidine 57, 71% yield, m.p. 126-128 °C (iif97-300 128-130 
0 1 C); H-NMR (250 MHz, CDCI3,) 1.48 (s, 3H, CH3), 2.30 (d, J = 4.2Hz, 1 H, 
OH), 2.32-2.44 (m, 2H, Hz·2""), 3.38 (dd, J = 3.1, 10.5 Hz, 1H, Hs·), 3.48 (dd, J == 
3.1, 10.5 Hz, 1H, Hs·), 4.06 (m, 1H, H3-), 4.58 (m, 1H, H4·) 6.41 (dd, J = 6.0, 
7.8 Hz, 1H, H1'), 6.94-7.22 (m, 9H trityl), 7.30-7.55 (m, 6H, trityl), 7.56 (s, 1H, 
He), 8.61 (s, 1H, NH); Anal. Calcd for C29H28N20 5: C, 65.89; H, 5.42; N, 5.23; 
Found: C, 65.91; H, 5.30; N, 5.25. 
5'-0-trityl-adenosine 58, 64% yield, m.p. 100-102 °C (lit297-300 104-107 °C); 1H-
NMR (250 MHz, CDCI3, 0 20) 2.70-2.95 (m, 1H, Hz-), 3.05-3.22 (m, 2H, Hs·s"), 
4.05-4.28 (m, 1H, H4-), 4.44-4.65 (m, 1H, H3•), 6.14 (t, Japparent =7Hz, 1H, H1), 
6.30-6.76 (m, 6H, trityl), 7.05-7.44 (m, 9H, trityl), 7.88 (s, 1H, H2), 8.14 (s, 1H, 
Hs): Anal. Calcd for C29H27N50 6: C, 68.09; H, 5.71; N, 13.69; Found: C, 68.21; 
H, 5.50; N, 13.85. 
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(11) Using 4,4'-dimethoxytrityl chloride {59) 
5'-0-(Dimethoxytrityl)-2'-deoxythymidine (60) and 5'-0-(Dimethoxytrityl)· 
adenosine (61) 
To a suspension for adenosine (solution for 2'-deoxythymidine) (5 mmol 1eq) 
in dry pyridine (10 ml), 4,4'-dimethoxytrityl chloride (7.5 mmol, 1.5eq) was 
added along with a catalytic amount of 4-dimethylaminopyridine (0.125 mmol). 
The reaction mixture was left to stir at room temperature for 4h. The solvent 
was evaporated under high vacuum to give a residue that was dissolved in 
ethyl acetate (20 ml) water (10 ml). The aqueous layer was then extracted 
with ethyl acetate (3 x 30ml) and the combined organic fractions were washed 
with saturated sodium bicarbonate solution (2 x 10 ml). The organic fractions 
were dried over magnesium sulphate; the drying agent was filtered off and 
evaporation of the solvent afforded a glossy residue in both cases. The crude 
products obtained were recrystallized from ethanol-petrol and 
dichloromethane-petrol for 2'-deoxythymidine and adenosine respectively, to 
give the 5'-0-dimethoxytrityl nucleosides as white microcrystalline solids. 
0 Me{XH DMTrO? 0 
OH 
NH2 Nt:N (( I OMT<O~ N) 
HO OH 
60 61 
0 5'-0-(Dimethoxytrityl)-2'-deoxythymidine (60), 71% yield, m.p. 118-120 C 
(lit301 ·302 123-124 °C); 1H-NMR (250 MHz, CDC13) 1.66 (s, 3H, CH3), 2.48 (d, J 
= 5.1 Hz, 1H, OH), 2.54-2.65 (m, 2H, Hz·2"), 3.56 (dd, J = 4.3, 8.5 Hz, 1H, H5-), 
3.66 (dd, J = 4.3, 8.5 Hz, 1H, H5·), 3.96 [s, 6H, 0-(CJ::L)zl, 4.22-4.42 (m, 1H, 
H3-), 4.76 (m, 1H, H3-), 6.59 (dd, J = 6.0, 7.2 Hz, 1H, H1-), 6.75-7.10 (m, 9H 
trityl), 7.26-7.55 (m, 4H, trityl), 7.38 (s, 1H, Hs), 8.45 (s, 1H, NH); Anal. Calcd 
for C31 H32N20 7: C, 68.12; H, 6.27; N, 5.12; Found: C, 68.24; H, 6.15; N, 5.25. 
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5'-0-(Dimethoxytrityl)-adenosine (61), 70% yield, 1H-NMR (250 MHz, CDCI3, 
Dp) 2.94-3.15 (m, 1H, H2), 3.28-3.44 (m, 2H, 1H, H5'), 3.65 [s, 6H, O-(CH3)2]. 
4.10-4.34 (m, 1 H, H4·), 4.60 ( m, 1 H, H3·), 6.37 (t, Japparent = 9Hz, 1 H, H1·), 
6.55-6.90 (m, 4H, trityl), 7.10-7.50 (m, 9H, trityl), 7.92 (s, 1H, H2), 8.22 (s, 1H, 
He) Anal. Calcd for C29H31Np6 : C, 65.14; H, 5.82; N, 12.79; Found: C, 65.31; 
H, 5.70; N, 12.95. 
5'·0·(p,p'·Dimethoxytrityl)·2'·deoxycytidine (26) 
In a stirred suspension of 2'-deoxycytidine in pyridine (5 mmol, 1eq), 
dichloroacetic acid (5 mmol, 1eq) was added dropwise followed by the 
addition of triethylamine (5 m mol, 1 eq). After stirring at ambient temperature 
for 10 min the suspension became a homogeneous solution. 4,4'-
Dimethoxytrityl chloride (5.55 mmol, 1. 11 eq) was finally added and the 
resulting solution was stirred at 25 °C for 2h. After TLC showed completion of 
the reaction, the mixture was quenched with methanol (1 ml) and the solvent 
was removed under high vacuum. The resulting gummy residue was 
dissolved in dichloromethane (15 ml) and saturated sodium bicarbonate 
solution ( 10 ml). The aqueous layer was further extracted with 
dichloromethane (2 x 25 ml) and the combined organic fractions were washed 
with brine (2 x 10 ml). The combined organic extracts were dried over MgS04, 
filtered and evaporated to dryness to give an orange gum, as crude, in both 
cases. The crude product of 5'-protected 2'-deoxycytidine was recrystallized 
from a mixture of toluene and acetone (5:1) to afford the 5'-0-
Dimethoxytritylated derivative as white solid in 72% yield. 
;c2 
t.1 DMTrO~o;J 0 
Hr;6 
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5'-0-(Dimethoxytrityl)-2'-deoxycytidine (26), 72% yield; 1H-NMR (250 MHz, 
CDCI3, 020) 1.94-2.85 (m, 2H, H2'2'·), 3.24-3.37 (m, 2H, Hs·s"), 3.80 [s, 6H, O-
(CH3)2], 4.12-4.23 (m, 1H, H4'), 4.42-4.54 (m, 1H, H3·), 5.52 (d, Js.B= 8Hz, 1H, 
Hs), 6.17 (t, Japparent = 7Hz, 1H, H1·), 6.65-6.71 (m, 4H, trityl), 7.05·7.24 (m, 
9H, trityl), 7.82 (d, Js.6 = 8 Hz, 1H, H6); Anal. Calcd for C30H31 Np6: C, 68. 10; 
H, 5.90; N, 7.94; Found: C, 68.19; H, 5.76, N, 7.86. 
(Ill) Using tert-Butyldimethylsilyl chloride (62) 
5'·0-(tert-butyldimethylsilyl)-2'-deoxythymidine (63), 5'-0-(tert-
Butyldimethylsilyl) derivatives of adenosine (64), guanosine (65) and 
cytidine (66) 
A suspension of nucleoside (5 mmol, 1eq) in dry DMF (20 ml) or anhydrous 
pyridine (10 ml) was heated gently with stirring at 70-90 °C for 20 min (or until 
the nucleoside is completely dissolved}. After cooling the solution, tert-
butyldimethylsilyl chloride (variable equivalents see Table 4 in discussion) 
was added neat followed by imidazole (variable equivalents see Table 4 in 
discussion) and the reaction mixture was left to stir at room temperature 
(various times see Table 4 in discussion}. The solvent was then removed 
under high vacuum to give in all cases a viscous residue that was dissolved in 
ethyl acetate (40 ml). In the solution saturated sodium bicarbonate solution 
(20 ml) was added to extract the imidazolium salt and the layers were 
separated. The aqueous layer was then extracted with more ethyl acetate (3 x 
40 ml) and the organic layer was washed further with aqueous ammonium 
chloride solution (2 x 20 ml} and brine (3 x 20 ml). The organic fractions were 
combined dried over sodium sulphate, filtered and evaporated. Evaporation of 
the solvent afforded the 5'-0 protected-2'-deoxythymidine as a white powdery 
solid and the 5'-0 protected derivatives of adenosine, guanosine and cytidine 
as white foam. The crude products were recrystallized from aqueous ethanol 
to give the 5'-0 protected-nucleosides as white solids, which were dried under 
high vacuum. 
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5'-0-(tert-Butyldimethylsilyl)-2'-deoxythymidine (63), 67-77% yield, mp. 186-
188 °C (lit303 189-190 °C); 1H-NMR (250 MHz, COCI3, 0 20) 0.08 (s, 6H, Si-
CH3), 0.65 (s, 9H, C-CH3), 1.69 (s, 3H, CH3), 2.18-2.30 (m, 2H, H2'2'), 3.26 
(dd, J = 5.4, 8.7 Hz, 1H, Hs-), 3.38 (dd, J = 5.4, 8.7 Hz, 1H, H5·), 4.25-4.31 (m, 
1H, H3·), 4.58 (m, 1H, H3'), 6.14 (dd, Japparent = 6.3Hz, 6.8Hz, 1H), 7.15 (s, 1H, 
Hs). 
5'-0-(tert-Butyldimethylsilyl)-adenosine (64), 72-81%yield, mp. 162-164 °C 
(lie03 165-166 °C); 1H-NMR (250 MHz, CDCI3, 0 20) 0.11 (s, 6H, Si-CH3), 0.62 
(s, 9H, Si-CH3), 4.01-4.10 (m, 1H, H2o). 4.20-4.32 (m, 2H, 1H, Hs·), 4.48-4.55 
(m, 1 H, H4·), 4.95-5.05 (m, 1 H, H3), 5.92 (t, Japparent = 7Hz, 1 H, H1·), 7.65 (s, 
1 H, H2), 8.64 (s, 1 H, H8). 
5'-0-(tert-Butyldimethylsilyl)-guanosine (65), 74-86% yield, mp. 172-175 °C 
(lit303 175-177 °C); 1H-NMR (250 MHz, CDC13, 0 20) 0.08 (s, 6H, Si-CH3), 0.65 
(s, 9H, C-CH3), 2.96-3.08 (m, 2H), 3.65-3.77 (m, 1 H), 4.25 (t, Japparent = 10.2 
Hz, 1 H), 4.36 (t, Japparent = 10.2 Hz, 1H), 5.50 (d, Japparent = 7.5 Hz, 1H), 7.38 
(s, 1H), 7.64 (s, 1H, NH). 
5'-0-(tert-Butyldimethylsilyl)-cytidine (66), 73-88% yield, mp. 192-195 °C (lie03 
195-197 °C); 1H-NMR (250 MHz, COCI3 , Op) 0.65 (s, 6H, Si-CH3), 0.81 (s, 
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9H, C-CH3), 2.11-2.23 (m, 1H, H2·), 3.02-3.13 {m, 2H, Hs·s··) 3.64-3.77 (m, 1H, 
H4·), 4.15-4.20 {m, 1H, H3·), 5.22 {d, Js.6 = 6.6 Hz, 1H, Hs), 6.03 {t, Japparent = 
6.3Hz, 1H, H1'), 7.63 {d, Js.6= 7.5 Hz, 1H, Ha). 
Procedure for the global TBDMS protection of adenosine, guanosine 
and cytidine. 
2',3',5'-tri-0-(tert-Butyldimethylsilyf) derivatives of guanosine (69), 
adenosine (72) and cytidine (75) 
A suspension of nucleoside (5 mmol, 1 eq) in dry DMF (20 ml) or anhydrous 
pyridine (10 ml) was heated gently with stirring at 70-90 °C for 20min (or until 
the nucleoside is completely dissolved). After cooling the solution, terl-
butyldimethylsilyl chloride (variable equivalents see Table 5 in discussion) 
was added neat followed by imidazole (variable equivalents see Table 5 in 
discussion) and the reaction mixture was left to stir at room temperature 
(various times see Table 5 in discussion). The solvent was removed under 
reduced pressure and the residue was dissolved in ethyl acetate (80 ml). In 
the solution saturated aqueous ammonium chloride solution (40 ml) and water 
(40 ml) was added, and the layers were separated. The aqueous layer was 
then extracted with more ethyl acetate (4 x 50ml) and the organic layer was 
washed further with saturated aqueous sodium bicarbonate (3 x 5 Oml) and 
brine (3 x 50 ml). The organic fractions were combined dried over sodium 
sulphate, filtered and evaporated. Evaporation of the solvent afforded the 
2',3',5'-0-protected-nucleosides as white foam, in all cases. The white foam 
was further evacuated overnight under high vacuum and then was 
recrystallized from ethanol/water to give the 5'-0 protected-nucleosides as 
white solids. 
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2' ,3',5'-tri-0-(tert-Butyldimethylsilyl) guanosine (69) 72-81% yield, mp. 108-
110 °C (lie03 105-107 °C); 1H-NMR (250 MHz, CDCI3) 0.08 (s, 6H, Si-CH3), 
0.12 (s, 6H, Si-CH3), 0.18 (s, 6H, Si-CH3), 0.65 (s, 9H, C-CH3), 0.79 (s, 9H, C-
CH3), 0.92 (s, 9H, C-CH3), 3.58-3.75 (m, 2H) 4.01-3.14 (m, 1 H), 4.35 (t, 
Japparent = 9.4 Hz, 1 H), 4.46 (!, Japparent = 9.6 Hz, 1 H), 5.82 (d, Japparent = 8.3 Hz, 
1H), 6.52 (br s, 2H, NH2), 7.68 (s, 1H), 7.92 (s, 1H, NH); Anal. Calcd for 
C28H55N50sSb: C, 53.72; H, 8.86; N, 11.19; Found: C, 53.96; H, 8.62, N, 
10.95, HRFABMS Calcd for C28H55N50sSb: 625.35110 found 625.3487. 
2',3',5'-tri-0-(tert-Butyldimethylsilyl) adenosine (72) 74-86%yield, mp. 125-127 
°C (lit303 122-124 °C); 1H-NMR (250 MHz, CDC13) 0.11 (s, 6H, Si-CH3), 0.16 (s, 
6H, Si-CH3), 0.22 (s, 6H, Si-CH3), 0.62 (s, 9H, C-CH3), 0.82 (s, 9H, C-CH3), 
0.96 (s, 9H, C-CH3), 4.13-4.19 (m, 1H, H2-), 4.31-4.43 (m, 2H, 1H, H5·), 4.59-
4.64 (m, 1H, H4·), 5.02-5.12 (m, 1H, H3·), 6.03 (t, Japparent = 7.4 Hz, 1H, H1'), 
6.26 (br s, 2H, NH2), 7.71 (s, 1 H, H2), 8.75 (s, 1 H, H8); Anal. Calcd for 
C28H55N504Sb: C, 55.13; H, 9.09; N, 11.48; Found: C, 55.34; H, 8.87, N, 
11.24, HRFABMS Calcd for C28H55N504Sb: 609.35619 found 609.3531. 
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2',3',5'-tri-0-(tett-Butyldimethylsilyl) cytidine (75) 73-88% yield, mp. 144-147 
°C (1it3°3 146-148 °C); 1H-NMR (250 MHz, CDC13) 0.15 (s, 6H, Si-CH3), 0.19 (s, 
6H, Si-CH3), 0.27 (s, 6H, Si-CH3), 0.66 (s, 9H, C-CH3), 0.85 (s, 9H, C-CH3), 
0.92 (s, 9H, C-CH3), 2.07-2.18 (m, 1H, H2-), 3.02-3.11 (m, 2H, Hs·s"), 3.52-3.63 
(m, 1H, H4·), 4.08-4.14 (m, 1H, H3-), 5.12 (d, Js-6 = 6.3 Hz, 1H, Hs), 5.95 (t, 
Japparent = 6.0 Hz, 1H, Hr), 6.33 (br S, 1H, NH2), 7.51 (d, Js-6= 7.1 Hz, 1H, H6); 
Anal. Calcd for C27H55N30sSb: C, 55.34; H, 9.46; N, 7.17; Found: C, 55.22; H, 
9.85, N, 7.34, HRFABMS Calcd for C27H55NpsSi3: 585.34495 found 
585.3426. 
Procedure for the selective 5'-desilylation of 2',3',5'-tri-0-TBDMS and 
2',5'-0-TBDMS nucleosides using 80% aqueous acetic acid (HOAc) 
2',3',5'-tri-0-TBDMS or 2',5'-0-TBDMS nucleoside (2 mmol, 1eq) was 
dissolved in 20 ml of 80% aqueous acetic acid. The reaction mixture was left 
to either stir at room temperature or heated under reflux at 100 °C (Various 
times see Table 6 in discussion). After stirring the reaction mixture was 
neutralised (pH 8-9) with the addition of saturated aqueous sodium 
bicarbonate solution and then diluted with ethyl acetate (120 ml). After 
separation, the aqueous phase was further extracted with ethyl acetate (5 x 
40 ml) and the combined organic layers were washed with water (4 x 30 ml) 
and brine (4 x 30 ml). The organic fractions were dried over sodium sulphate, 
filtered and evaporated to afford a crude products which was subjected to 
flash chromatography and recrystallization to provide the 2',3'-0-protected 
and 2' -0-protected nucleosides respectively, as while solids. 
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Procedure for the selective 5'-desilylation of 2',3',5'-tri-0-TBDMS and 
2',5'-0-TBDMS nucleosides using TFA-H20-THF (1 : 1 : 4) 
To a magnetically stirred solution of 2',3',5'-tri-0-TBDMS or 2',5'-0-TBDMS 
nucleoside (2 m mol, 1eq) in 40 ml of THF, kept at 0 De, 20 ml of aqueous TFA 
solution (TFA:H20 = 1:1) was added. The reaction mixture was left to stir at 
room temperature (Various times see Table 7 in discussion). After stirring the 
reaction mixture was neutralised (pH 8-9) with the addition of saturated 
aqueous sodium bicarbonate and then diluted with ethyl acetate (100 ml). 
After separation, the aqueous phase was further extracted with ethyl acetate 
(5 x 40 ml) and the combined organic layers were washed with water (3 x 30 
ml) and brine (3 x 30 ml). The organic fractions were dried over sodium 
sulphate, filtered and evaporated to afford the crude products which were 
subjected to flash chromatography and recrystallization to provide the 2' ,3'-0-
protected and 2' -0-protected nucleosides as white solids. 
N£0 (( I NH H~ .~NH, 
NH2 
th HO~ N 
TBDMSO OTBDMS TBDMSO OTBDMS 
79 or 85 80 or 86 
c~ H00~0 
TBDMSO OTBDMS 
81 or 87 
2',3'-0-(lerl-Butyldimethylsilyl) guanosine (79 or 85), 71-95% yield, mp. 149-
152 DC (lit3D3 144-149 DC); 1H-NMR (250 MHz, 20% DMSO-d6 in CDCI3) 0.14 
(s, 6H, Si-CH3), 0.19 (s, 6H, Si-CH3), 0.81 (s, 9H, C-CH3), 0.92 (s, 9H, C-
CH3), 3.09-3.21 (m, 2H), 3.79-3.88 (m, 1H), 4.88 (t, Japparent = 11.2 Hz, 1H), 
5.08 (br S, 1 H, OH), 5.31 (I, Japparent = 11.6 Hz, 1 H), 5.92 (d, Japparent = 6.3 Hz, 
1H), 6.87 (br s, 2H, NH2), 7.67 (s, 1H), 7.89 (s, 1H, NH). Anal. Calcd for 
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C22H41 N50sSi2: C, 51.63; H, 8.08; N, 13.68; Found: C, 51.87; H, 7.88, N, 
13.93, HRFABMS Calcd for C22H41 N50sSi2: 511.26462 found 625.2615. 
2',3'-0-(tert-Butyldimethylsilyl) adenosine (80 or 86) 70-92%yield, mp. 186-
188 °C (lieDa 185-188 DC); 1H-NMR (250 MHz, 20% DMSO-da in CDCia) 0.18 
(s, 6H, Si-CHa). 0.25 (s, 6H, Si-CHa), 0.86 (s, 9H, C-CHa), 0.98 (s, 9H, C-
CHa), 4.17-4.22 (m, 1H, H2"). 4.34-4.47 (m, 2H, H5·5·-), 4.62-4.67 (m, 1H, H4-), 
5.08-5.20 (s, 1H, Ha·), 5.28 (br s, 1H, OH), 6.10 {!, Japparent = 6.6 Hz, 1H, H1-), 
6.29 (br s, 2H, NH2), 7.76 (s, 1H, H2), 8.79 (s, 1H, Ha): Anal. Calcd for 
C22H41 N504Siz: C, 53.30; H, 8.34; N, 14.13; Found: C, 53.54; H, 8.67, N, 
14.28, HRFABMS Calcd for C22H41 N504Sb: 495.26971 found 495.2676. 
2',3'-0-(tert-Butyldimethylsilyl) cytidine (81 or 87) 76-97% yield, mp. 190-192 
DC (litaDa 188-191 DC); 1H-NMR (250 MHz, 20% DMSO-da in CDCia} 0.19 (s, 
6H, Si-CHa), 0.27 (s, 6H, Si-CHa). 0.89 (s, 9H, C-CHa). 0.98 (s, 9H, C-CHa), 
2.10-2.21 (m, 1H, H2-). 3.05-3.14 (m, 2H, Hs·s··), 3.56-3.68 (m, 1H, H4-), 4.14-
4.19 (m, 1H, Ha·), 4.86 {br s, 1H, OH), 5.20 {d, Js-a= 6.8 Hz, 1H, H5), 5.98 (t, 
Japparent = 6.4 Hz, 1H, H1'), 6.38 (br s, 1H, NH2), 7.60 (d, Js.a= 7.4 Hz, 1H, HB); 
Anal. Calcd for C21 H41 NaOsSb: C, 53.47; H, 8.76; N, 8.91; Found: C, 53.22; H, 
8.95, N, 8.58, HRFABMS Calcd for C21 H41 N30sSi2: 471.25848 found 
471.2553. 
N£0 ~ I NH 
"R ,A,", 
HO OTBDMS 
NH2 
ti:J HO~ N 
HO OTBDMS 
76 or 82 77 or 83 
2'-0-(tert-Butyldimethylsilyl) guanosine (76 or 82) 70-88% yield, mp. 135-138 
DC (litaDa 134-136 DC); 1H-NMR (250 MHz, DMSO-d6) 0.14 (s, 6H, Si-CHa), 
0.81 (s, 9H, C-CHa), 3.11-3.24 {m, 2H) 3.85-3.94 {m, 1H), 4.50 {t, Japparent = 
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12.1 Hz, 1H), 4.64 (t, Japparent = 12.2 Hz, 1H), 5.12 (br s, 1H, OH), 5.24 (br s, 
1H, OH), 5.92 (d, Japparent = 7.5 Hz, 1H), 6.84 (br s, 1H, NH2), 7.79 (s, 1H), 
8.02 (s, 1H, NH); Anal. Calcd for C16H27N50sSi: C, 48.34; H, 6.85; N, 17.62; 
Found: C, 48.11; H, 6.98, N, 17.40, HRFABMS Calcd for C16H27N50sSi: 
397.17815 found 397.1754. 
2'-0-(tett-Butyldimethylsilyl) adenosine (77 or 83) 68-91%yield, mp. 174-176 
°C (lit303 175-178 QC); 1H-NMR (250 MHz, DMSO-de) 0.18 (s, 6H, Si-CH3), 
0.98 (s, 9H, C-CH3), 4.21-4.27 (m, 1 H, Hz-), 4.38-4.52 (m, 2H, Hs·s··), 4.68-4.72 
(m, 1H, H4), 5.10 (br s, 1H, OH), 5.16-5.27 (s, 1H, H3·), 5.32 (br s, 1H, OH), 
6.22 (t, Japparent = 7.4 Hz, 1H, H,·), 6.41 (br S, 2H, NH2), 7.89 (s, 1H, Hz), 8.92 
(s, 1H, Ha); Anal. Calcd for C16H27N504Si: C, 50.37; H, 7.13; N, 18.36; Found: 
C, 50.08; H, 6.89, N, 18.22, HRFABMS Calcd for C16H27N504Si: 381.18323 
found 381.1806. 
):2 
l.1 HO~ 0 
HO OTBDMS 
78 or 84 
2'-0-(tert-Butyldimethylsilyl) cytidine (78 or 84) 72-93% yield, mp. 170-173 QC 
(lit303 168-171 °C); 1H-NMR (250 MHz, DMSO-de) 0.19 (s, 6H, Si-CH3), 0.98 
(s, 9H, C-CH3), 2.15-2.27 (m, 1H, Hz·), 3.10-3.19 (m, 2H, Hs·s"), 3.61-3.73 (m, 
1H, H4·), 4.20-4.28 (m, 1H, H3·), 4.88 (br s, 1H, OH), 5.01 (br s, 1H, OH), 5.31 
(d, Js.e = 6.2 Hz, 1 H, Hs), 6.05 (t, Japparent = 6.4 Hz, 1 H, H1'), 6.44 (br s, 1 H, 
NH2), 7.66 (d, Js.e= 7.5 Hz, 1H, He); Anal. Calcd for C15H27NpsSi: C, 50.40; 
H, 7.61; N, 11.75; Found: C, 50.21; H, 7.85, N, 11.57, HRFABMS Calcd for 
C15H27NPsSi: 357.17200 found 357.1696. 
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3. SYNTHESIS OF LIPOPHILIC-NUCLEOTIDE 
CONJUGATES 
(A) Lipophilic N-carbamate analogues of nucleosides 
Reaction conditions that afforded poor yields 
A solution of 4-nitrophenyl carbonate linker of cholesterol 10 or tocopherol 11 
(3 mmol, 1eq) in 10ml of dichloromethane or 1,4-dioxane was added dropwise 
to a stirred solution of 2',3',5'-0-TBDMS protected guanosine 69 and 
adenosine 72 (3 mmol, 1eq) in dichloromethane or 1,4 dioxane (10 ml). After 
the addition was completed, triethylamine (3.3 mmol, 1.1 eq) was added and 
the reaction mixture was heated under reflux for 6h. This did not facilitate the 
formation of the amide bond and starting material was recovered unchanged. 
DMF and THF were also employed as solvents and the reaction mixtures 
were heated for 12h. After work-up, in most cases other unidentifiable 
products were recovered along with starting material and the yields afforded 
were low, between 26-35%. 
A second attempt was made using pyridine was used in the place of 
triethylamine and refluxing in dichlromethane or 1 ,4-dioxane overnight. These 
conditions did not facilitate the synthesis of the lipophilic N-carbamate 
conjugates. When DMF and THF were employed as solvents in refluxing for 
24h, the N-cholesteryl and tocopheryl carbamate derivatives of 2',3',5'-
protected adenosine and guanosine 88-91 were obtained in poor yields (31-
38%) along with starting material. 
A third attempt was made where anhydrous pyridine was employed as the 
base, THF or DMF as the solvents and increasing the equivalents of 69 or 72 
and base to 1.1 and 1.5, respectively. The N-carbamate analogues 88-91 
were afforded in improved yields, between 40-47% but starting material was 
still present. 
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Procedures for the synthesis of lipophilic N-carbamate conjugates 
Method A: A solution of 4-nitrophenyl carbonate linker of cholesterol 10 or 
tocopherol 11 (5 mmol, 1eq) in 20ml of anhydrous pyridine was added 
dropwise to a stirred solution of 2',3',5'-0-TBDMS protected guanosine 69 or 
adenosine 72 (5.5 mmol, 1eq) in 22ml of anhydrous pyridine. After the 
addition was completed, the reaction mixture was heated under reflux for 24h. 
The solvent was removed under high vacuum and the resulting residue was 
dissolved in 200ml of chloroform. In the solution saturated aqueous 
ammonium chloride solution (80 ml) and the layers were separated. The 
aqueous layer was then extracted with more chloroform (5 x 80 ml) and the 
organic fractions were washed further with saturated aqueous sodium 
bicarbonate (4 x 50ml) and brine (4 x 50 ml). The organic fractions were 
combined dried over sodium sulphate, filtered and evaporated. Separation 
and purification of the crude products by flash column chromatography using 
a 20:1 mixture of chloroform and methanol afforded the cholesteryl N-
carbamate analogues of adenosine 88 and guanosine 90 as off-white foam. 
The tocopheryl N-carbamate conjugates of adenosine 89 and guanosine 91 
were furnished as off-yellow oil. 
Method B: A solution of carbonylimidazolide finkers of cholesterol 13 or 
tocopherol 14 (3 mmol, 1eq) in 10ml of anhydrous THF was added dropwise 
to a stirred solution of 2',3',5'-0-TBDMS protected guanosine 69 or adenosine 
72 (5.5 mmol, 1eq) also in 20ml of anhydrous THF. To the stirred solution 
acetic acid (5 ml) was added and the reaction mixture was left to stir at room 
temperature for 15h. TLC showed completion of the reaction and the reaction 
mixture was neutralised (pH 8-9) with the addition of saturated aqueous 
sodium bicarbonate solution. Ethyl acetate (100 ml) was then added and the 
layers partitioned. The aqueous phase was further extracted with ethyl 
acetate (5 x 50 ml) and the combined organic layers were washed with 
saturated aqueous sodium bicarbonate solution (4 x 30 ml) and brine (4 x 30 
ml). The organic fractions were dried over sodium sulphate, filtered and 
evaporated to afford the crude products, which were subjected to flash 
column chromatography using a 20:1 mixture of chloroform and methanol. 
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The cholesteryl N-carbamate analogues of adenosine 92 and guanosine 94 
were afforded as off-white foam while, the tocopheryl N-carbamate conjugates 
of adenosine 93 and guanosines 95 were furnished as off-yellow oil. 
0 
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3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-2·(tert-butyl-dimethyl-silanyloxy)-
[9-( tetrahydro-furan-2-yi)-9H-purin-6yl)- carbamic acid 17 -(1 ,5-dimethyl-
hexyl)-1 0, 13-dimethyl-2,3,4, 7 ,8,9, 10,11, 12, 13, 14, 15, 16,17 -tetradecahydro-
1H cyclopenta[a]phenanthren-3-yl ester (88 and 92) 60 and 63% yield, Vmax 
I cm-
1 (nujol) 3256,3152, 1762,1674, 1410, 1364, 1268,1170,1066, 875; 1H-
NMR (400 MHz, CDCI3} 0.12 (s, 6H, Si-CH3), 0.18 (s, 6H, Si-CH3), 0.24 (s, 
6H, Si-CH3), 0.66 (s, 9H, C-CH3), 0.85 (s, 9H, C-CH3), 0.98 (s, 9H, C-CH3), 
0.63-2.52 (m, 45H, aliphatic), 3.48-3.66 (m, 1 H, 0-CH), 4.16-4.21 (m, 1 H, H2·), 
4.34-4.44 (m, 2H, Hs-), 4.62-4.66 (m, 1 H, H4·), 5.08-5.16 (m, 1 H, H3-), 5.35 (d, 
1H, J = 2.5 Hz, HC=C), 6.02 (t, Japparent = 6.7 Hz, 1H, Hr), 7.68 (br s, 1H, 
13 CONH), 7.84 (s, 1 H, H2), 8.25 (s, 1 H, Ha); C-NMR (1 00 MHz, CDC13), -6.5 
(6C), 14.7 (3C), 15.2, 17.3, 18.7, 20.7 (9C), 21.5, 22.2, 22.8 (2C), 23.9, 25.3, 
28.5, 29.4, 30.6, 33.2, 34.4, 35.8, 37.5, 39.6, 40.2, 42.5, 43.2, 45.8, 48.8, 
51.2, 64.7, 71.8, 73.3, 77.1, 77.7, 86.1, 123.5 (C=CH}, 128.4, 142.8 (CH=C), 
147.3, 144.4, 149.2, 152.0, 154.8, 171.1 (C=O); Anal. Calcd for 
C5eHggNsOeSi3: C 65.77, H 9.76, N 6.85, 0 9.39 Found C 65.62, H 9.88, N 
6.76; HRFABMS Calcd for CseHggNsOeSb: 1021.69032 found 1021.6887. 
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{9-[3,4-Bis-(tett-butyl-dimethyl-silanyloxy)-5-(terl-butyl-dimethyl-
silanyloxy)-tetrahydro-furan-2-yi)-9H-purin-6yl]-carbamic acid 2,5, 7,8-
tetramethyl-2-(4,8, 12-trimethyl-tridecyl)-chroman-6-yl ester (89 and 93) 
1 
64 and 68% yield, Vmax I cm- (nujol) 3295, 3176, 1750, 1685, 1336, 1264, 
1 . 
1110, 837, 778; H-NMR (400 MHz, CDCI3) 0.12 (s, 6H, S1-CH3), 0.18 (s, 6H, 
Si-CH3), 0.24 (s, 6H, Si-CH3), 0.66 (s, 9H, C-CH3), 0.85 (s, 9H, C-CH3), 0.96 
(s, 9H, C-CH3), 0.70-0.90 [m, 12H, (CH3-CH)4], 0.98-1.55 [m, 20H, (CHz)10], 
1.56-1.75 [m, 3H, (CH-CH3)3], 1.93 (s, 3H, CH3-Ar), 2.03 (s, 3H, CH3-Ar), 2.07 
(s, 3H, CH3-Ar), 2.27 (s, 3H, CH3-C-O), 2.45-2.57 (m, 2H, CHz-Ar), 4.16-4.21 
(m, 1H, Hz·), 4.34-4.44 (m, 2H, Hs·), 4.62-4.66 (m, 1H, H4·), 5.08-5.16 (m, 1H, 
H3-), 6.02 (t, Japparent = 6.7 Hz, 1 H, H1-). 7.70 (br s, 1 H, CONH), 7.84 (s, 1 H, 
Hz), 8.25 (s, 1 H, Ha): 13C-NMR (100 MHz, CDCI3), -6.5 (6C-silyl), 14.7 (3C), 
17.5, 19.8, 20.7 (9C), 21.3 (2C), 21.9, 22.9 (2C), 21.6, 21.7, 23.3, 23.9, 25.8, 
29.2, 31.6, 32.7, 32.9, 35.1, 36.0, 36.8, 38.0, 38.8, 40.2, 41.7, 46.6, 64.7, 
71.8, 75.2, 77.1, 77.7, 86.1, 122.0, 123.7, 128.4, 129.9, 144.4, 149.2, 152.0, 
154.8, 173.2 (C=O); Anal. Calcd for CsaH103Ns01Sb: C, 65.30, H, 9.73, N, 
6.57; Found C 65.65, H 9.94, N 6.85; HRFABMS Calcd for C58H1o3N501Sb: 
1065.71653 found 1065.7137. 
212 
90,94 
3,4-Bis-(terl-butyl-dimethyl-silanyloxy)-2·(terl-butyl-dimethyl-silanyloxy)-
[9-( tetrahydro-furan-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl]-carbamic acid 
17 -(1 ,5-dimethyl-hexyl)-1 0, 13-dimethyl-
2,3,4,7,8,9, 10, 11, 12, 13, 14, 15,16, 17-tetradecahydro-1H 
cyclopenta[a]phenanthren-3-yl ester (90 and 94) 61 and 66% yield, Vmax I 
cm·
1 (nujol) 3302, 3134, 1755, 1692, 1462, 1377, 1262, 1066, 836, 796; 1H-
NMR (400 MHz, CDCI3) 0.10 (s, 6H, Si-CH3), 0.14 (s, 6H, Si-CH3), 0.20 (s, 
6H, Si-CH3), 0.68 (s, 9H, C-CH3), 0.82 (s, 9H, C-CH3), 0.95 (s, 9H, C-CH3), 
0.63-2.52 (m, 45H, aliphatic), 3.42-3.62 (m, 1H, 0-CH), 3.65-3.82 (m, 2H), 
4.04-4.18 (m, 1H), 4.38 (t, Japparent = 9.1 Hz, 1H), 4.49 (t, Japparent = 9.4 Hz, 
1H), 5.35 (d, 1H, J = 2.5 Hz, HC=C), 5.85 (d, Japparent = 8.5 Hz, 1H), 7.70 (br S, 
13 
1H, CONH), 7.73 (s, 1H), 7.95 (s, 1H, NH); C-NMR (100 MHz, CDCI3), -6.2 
(6C), 14.4 (3C), 15.2, 17.3, 18.7, 20.2 (9C), 21.5, 22.2, 22.8 (2C), 23.9, 25.3, 
28.5, 29.4, 30.6, 33.2, 34.4, 35.8, 37.5, 39.6, 40.2, 42.5, 43.2, 45.8, 48.8, 
51.2, 65.5, 72.8, 75.6, 78.2, 79.4, 123.5 (C=CH), 138.2, 139.2, 142.8 (CH=C), 
148.4, 144.4, 163.6, 170.1, 172.5 (C=O); Anal. Calcd for CssH9eN50 7Sb: C, 
64.76, H, 9.61, N, 6.74; Found C 65.02, H, 9.91, N 6.92; HRFABMS Calcd for 
CssHeeNs07Sb: 1037.68523 found 1037.6832. 
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{9-[3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-
silanyloxymethyl)-tetrahydro-furan-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-
yl]-carbamic acid 2,5,7,8-tetramethyl-2-(4,8, 12-trimethyl-tridecyl)· 
chroman-6-yl ester (91 and 95) 66 and 70% yield, Vmax I cm-1 (nujol) 3264, 
3085, 1725, 1695, 1582, 1364, 1272, 1053, 848, 792; 1H-NMR (400 MHz, 
CDCI3) 0.10 (s, 6H, Si-CH3), 0.14 (s, 6H, Si-CH3), 0.20 (s, 6H, Si-CH3), 0.68 
(s, 9H, C-CH3), 0.82 (s, 9H, C-CH3), 0.95 (s, 9H, C-CH3), 0.72-0.92 [m, 12H, 
(CH3-CH)4], 1.01-1.57 [m, 20H, (CHz)10], 1.59-1.77 [m, 3H, (CH-CH3hJ, 1.95 
(s, 3H, CH3-Ar), 2.05 (s, 3H, CH3-Ar), 2.09 (s, 3H, CH3-Ar), 2.28 (s, 3H, CH3-
C-O), 2.46-2.57 (m, 2H, CHz-Ar), 3.65-3.82 (m, 2H), 4.04-4.18 (m, 1H), 4.38 
(t, Japparent = 9.2 Hz, 1 H), 4.49 {t, Japparent = 9.4 Hz, 1 H), 5.85 (d, Japparent = 8.3 
13 Hz, 1H), 7.72 {br s, 1H, CONH), 7.75 {s, 1H), 7.95 {s, 1H, NH); C-NMR (100 
MHz, CDCI3), -6.2 {6C-silyl), 14.4 {3C), 17.8, 20.1, 20.6 (9C), 21.6 (2C), 21.8, 
22.1, 22.9, 23.4 (2C), 23.7, 24.3, 25.9, 29.5, 31.9, 32.9, 33.3, 35.5, 36.4, 37.4, 
38.3, 38.9, 40.6, 42.5, 46.8, 65.0, 66.2, 73.2, 75.5, 76.3, 78.6, 79.8, 122.5, 
123.9, 130.3, 138.7, 139.4, 148.6, 163.9, 170.2, 173.0 {C=O),; Anal. Calcd for 
CssH1o3NsOsSb: C, 64.34, H, 9.59, N, 6.47; Found C, 65.02, H 9.91, N 6.18; 
HRFABMS Calcd for CssH1o3NsOsSb: 1081.71453 found 1081.7114. 
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(B) Lipophilic N-acetamide analogues of nucleosides 
Reaction conditions that afforded poor yields 
To a solution of 2',3',5'-0-TBDMS protected guanosine 69 or adenosine 72 
(3.3 mmol, 1.1eq) in 10ml of anhydrous THF, a 0.6 M solution of lithium bis 
(trimethyl silyl} amide or t-butyllithium in hexane (3.3 mmol, 1.1eq) was added 
dropwise at -78 °C. After the addition was completed the reaction mixture was 
stirred at 0 °C for h. A solution of pentaflurorophenyl ester linkers of 
cholesterol16 or tocopherol 17 (3 mmol, 1eq) in anhydrous THF (10 ml} was 
then added dropwise to the above stirred solution and the reaction mixture 
was heated under reflux for 30h. The solvent was removed under reduced 
pressure and the residues furnished were dissolved in ethyl acetate (80 ml) 
and saturated aqueous sodium bicarbonate solution (40 ml). The aqueous 
phase was further extracted with ethyl acetate (4 x 50 ml) and the combined 
organic layers were washed with saturated aqueous sodium bicarbonate 
solution (4 x 30 ml) and brine (4 x 30 ml). The organic fractions were dried 
over sodium sulphate, filtered and evaporated to afford the crude products in 
low yields (15-23%). Various attempts were also made using an increased 1.2 
equivalent of the bases, but the yields did not improve greatly (19-29%). 
Another attempt was made using pyridine as both solvent and base and after 
refluxing for 30h, the yields were improved (38-44%). In some cases other 
unidentifiable products were recovered along with the furnished conjugates. 
Procedure for the synthesis of lipophilic N-acetamide conjugates 
A solution of pentaflurorophenyl ester tinkers of cholesterol 16 or tocopherol 
17 (3 mmol, 1eq) in 10ml of anhydrous THF was added dropwise to a stirred 
solution of 2',3',5'-0-TBDMS protected guanosine 69 and adenosine 72 (3.3 
mmol, 1eq) also in 20ml of anhydrous THF. To the stirred solution kept at 0 
°C, p-Toluenesulfonic acid (3.3 mmol, 1eq) was added and the reaction 
mixture was left to stir at 0 °C for 1 h and then was heated under reflux for 
24h. TLC showed completion of the reaction and the reaction mixture was 
neutralised (pH 8-9) with the addition of saturated aqueous sodium 
bicarbonate solution. Ethyl acetate (100 ml) was then added and the layers 
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partitioned. The aqueous phase was further extracted with ethyl acetate (5 x 
50 ml) and the combined organic layers were washed with saturated aqueous 
sodium bicarbonate solution (4 x 30 ml) and brine (4 x 30 ml). The organic 
fractions were dried over sodium sulphate, filtered and evaporated to afford 
the crude products, which were subjected to flash column chromatography 
eluting initially with 1% MeOH 199% CHC!s and then with 10% MeOH I 90% 
CHCb. The cholesteryl N-acetamide analogues of adenosine 96 and 
guanosine 98 were afforded as off-white solids while, the tocopheryl N-
carbamate conjugates of adenosine 97 and guanosine 99 were furnished as 
off-yellow oil. 
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3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-2-(tert-butyl-dimethyl-silanyloxy)-
[9-( tetrahydro-furan-2-yl)-2·[17 ·(1 ,5-dimethyl-hexyl)-1 0, 13-dimethyl-
2,3,4,7 ,8,9, 10,11, 12, 13, 14, 15, 16,17 -tetradecahydro-1 H 
cyclopenta[a]phenanthren-3-yloxy-N-9H-purin-6-yl)-acetamide 96 60 and 
1 
63% yield, Vmax I cm· (nujol) 3236, 3104, 1742, 1690, 1575, 1416, 1272, 
1131, 1066, 852, 776; 
1
H-NMR (400 MHz, CDCI3} 0.14 (s, 6H, Si-CH3), 0.20 
(s, 6H, Si-CH3), 0.25 (s, 6H, Si-CH3), 0.66 (s, 9H, C-CH3), 0.87 (s, 9H, C-
CH3), 0.98 (s, 9H, C-CH3), 0.68-2.50 (m, 45H, aliphatic}, 2.77 (s, 2H, CH2-
CO}, 3.52-3.70 (m, 1H, 0-CH}, 4.18-4.23 (m, 1H, H2-), 4.36-4.46 (m, 2H, H5), 
4.65-4.71 (m, 1H, H4), 5.10-5.18 (m, 1 H, H3·), 5.38 (d, 1 H, J = 2.8 Hz, HC=C), 
6.11 (t, Japparent = 6.3 Hz, 1 H, Hr}, 7.68 (br s, 1 H, CONH}, 7.86 (s, 1 H, H2), 
13 
8.28 (s, 1H, Ha}; C-NMR (100 MHz, CDCI3), -6.2 (6C), 14.9 (3C), 15.7, 17.9, 
18.8, 21.1 (9C), 21.8, 22.7, 23.3 (2C), 24.4, 25.8, 29.0, 29.9, 30.8, 33.6, 34.9, 
36.2, 38.1, 40.1, 40.8, 42.7, 43.8, 46.1, 49.3, 51.7, 65.0, 71.7, 72.5, 73.7, 
216 
77.8, 78.2, 86.6, 123.8 (C=CH), 128.8, 143.2 (CH=C), 147.6, 144.8, 149.5, 
152.4, 155.2, 171.1 (C=O); Anal. Calcd for Cs7H1o1Ns06Sb: C 66.04, H 9.82, 
N 6.76; Found C 65.82, H 9.66, N 6.97; HRFABMS Calcd for Cs7H101Ns06Sb: 
1035.70597 found 1035.7028. 
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97 
N-{9-[3,4-Bis·(tert-butyl-dimethyl-silanyloxy)·5·(tert-butyl-dimethyl-
silanyloxymethyl)-tetrahydro-furan-2-yi)-9H-purin-6-yl]-2·[2,5, 7,8-
tetramethyl-2-(4,8, 12-trimethyl-tridecyl)-chroman-6-yloxyl]-acetamide 97 
70% yield, Ymax I cm·
1 (nujol) 3274, 3074, 1686, 1575, 1362, 1270, 1136, 864, 
782; 
1 
H-NMR (400 MHz, CDCI3} 0.14 (s, 6H, Si-CH3), 0.20 (s, 6H, Si-CH3), 
0.27 (s, 6H, Si-CH3), 0.68 (s, 9H, C-CH3), 0.88 (s, 9H, C-CH3), 0.98 (s, 9H, C-
CH3). 0.73-0.92 [m, 12H, (CH3-CH)4], 1.0-1.57 [m, 20H, (CH2)10], 1.59-1.78 
[m, 3H, (CH-CH3h]. 1.96 (s, 3H, CH3-Ar), 2.03 (s, 3H, CH3-Ar), 2.07 (s, 3H, 
CH3-Ar), 2.30 (s, 3H, CH3-C-O), 2.48-2.60 (m, 2H, CH2-Ar), 2.75 (s, 2H, CH2-
CO), 4.18-4.23 (m, 1H, H2·), 4.36-4.47 (m, 2H, Hs-), 4.65-4.69 (m, 1H, H4·), 
5.10-5.18 (m, 1H, Ha-), 6.12 (t, Japparent = 6.2 Hz, 1H, H1"), 7.75 (br S, 1H, 
13 
CONH), 7.89 (s, 1H, H2), 8.25 (s, 1H, Ha); C-NMR (100 MHz, CDCI3), -6.1 
(6C-silyl), 15.0 (3C), 17.9, 20.3, 21.0 (9C), 21.7 (2C), 22.2, 23.4 (2C), 21.8, 
22.2, 23.8, 24.3, 26.4, 29.7, 31.8, 33.0, 33.4, 35.6, 36.6, 37.2, 38.5, 39.1, 
40.7, 41.9, 46.9, 65.2, 71.6, 72.1, 75.6, 77.7, 78.5, 86.6, 122.4, 123.9, 128.7, 
130.2 144.7, 149.6, 152.5, 155.2, 173.5 (C=O); Anal. Calcd for 
Cs9H10sNs07Sb: C, 65.57, H, 9.79, N, 6.48; Found C 65.82, H 9.96, N 6.82; 
HRFABMS Calcd for CsaH1o3Ns0ySb: 1079.73218 found 1079.7193. 
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3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-2-(tert-butyl-dimethyl-silanyloxy)-
[9-( tetrahydro-furan-2-yl)-6-oxo-6,9-dihydro-1 H-purin-2-yl]-2-[17 -(1 ,5-
dimethyl-hexyl)-1 0, 13-dimethyl-2,3,4, 7,8,9, 10,11, 12, 13, 14, 15, 16,17-
tetradecahydro-1 H cyclopenta[a]phenanthren-3-yloxyl]-acetamide 98 
69% yield, Ymax I cm-1 (nujol) 3302, 3134, 1755, 1694, 1462, 1377, 1262, 
1001, 1066, 836; 
1
H-NMR (400 MHz, CDCI3) 0.13 (s, 6H, Si-CH3), 0.17 (s, 6H, 
Si-CH3), 0.22 (s, 6H, Si-CH3), 0.70 (s, 9H, C-CH3), 0.84 (s, 9H, C-CH3), 0.98 
(s, 9H, C-CH3), 0.66-2.55 (m, 45H, olefinic), 2.77 (s, 2H, OC-CH2 ), 3.45-3.64 
(m, 1 H, 0-CH), 3.67-3.85 (m, 2H), 4.06-4.20 (m, 1 H), 4.40 (!, Japparent = 8.8 
Hz, 1 H), 4.51 (t, Japparent = 9.1 Hz, 1 H), 5.37 (d, 1 H, J = 2.8 Hz, HC=C), 5.88 
(d, Japparent = 8.3 Hz, 1H), 7.73 (br s, 1H, CONH), 7.77 (s, 1H), 7.95 (s, 1H, 
NH);13C-NMR (1 00 MHz, CDCI3), -5.9 (6C-silyl), 14.8 (3C), 15.6, 17.8, 19.1, 
20.7 (9C), 21.8, 22.9, 23.2 (2C), 24.3, 25.7, 29.0, 29.8, 31.1, 33.7, 34.6, 36.2, 
37.9, 39.8, 40.6, 42.9, 43.7, 44.2, 49.4, 51.5, 65.9, 72.5, 73.3, 76.0, 78.6, 
79.7, 123.9 (C=CH), 139.1, 139.8, 143.2 (CH=C), 144.5, 148.7, 164.0, 170.5, 
172.7 (C=O); Anal. Calcd for CssH1o1Ns01Si3: C, 65.03, H, 9.67, N, 6.65; 
Found C 64.82, H, 9.93, N 6.95; HRFABMS Calcd for CssH1o1Ns01Si3: 
1051.70088 found 1051.6988. 
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N-{9·[3,4-Bis-(terl-butyl-dimethyl-silanyloxy)-5-(terl-butyl-dimethyl· 
silanyloxymethyl)-tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-1 H-purin-2-
yl]-2·[2 ,5, 7 ,8-tetramethyl-2·( 4,8, 12-tri methyl-tridecyl)-ch roman -6-yloxyl]· 
acetamide 99 72% yield, Vmax I cm·1 (nujol) 3242, 3042, 1744, 1695, 1586, 
1 -1337, 1270, 1086, 871, 768; H-NMR (400 MHz, CDCI3 ) 0.12 (s, 6H, S1-CH3), 
0.16 (s, 6H, Si-CH3), 0.22 (s, 6H, Si-CH3), 0.70 (s, 9H, C-CH3), 0.85 (s, 9H, C-
CH3), 0.98 (s, 9H, C-CH3), 0.75-0.95 [m, 12H, (CH3-CH)4], 1.04-1.60 [m, 20H, 
(CH2)10], 1.64-1.80 [m, 3H, (CH-CH3)3], 1.98 (s, 3H, CH3-Ar), 2.08 (s, 3H, CH3-
Ar), 2.13 (s, 3H, CH3-Ar), 2.31 (s, 3H, CH3-C-O), 2.48-2.60 (m, 2H, CH2-Ar), 
2.76 (s, 2H, OC-CH2 ), 3.68-3.85 (m, 2H), 4.07-4.21 (m, 1H), 4.41 (t, Japparent = 
8.7 Hz, 1H), 4.53 (!, Japparent = 9.0 Hz, 1H), 5.88 (d, Japparent = 7.9 Hz, 1H), 7.74 
13 (br s, 1H, CONH), 7.79 (s, 1H), 7.99 (s, 1 H, NH); C-NMR (100 MHz, CDCI3), 
-5.9 (6C-silyl), 14.8 (3C), 18.2, 20.5, 21.2 (9C), 21.9 (2C), 22.3, 22.7, 23.5, 
23.9 (2C), 24.4, 25.1, 26.4, 30.3, 32.3, 33.5, 34.0, 36.1, 36.9, 37.8, 38.7, 39.4, 
40.8, 42.9, 45.2, 65.5, 66.6, 71.9, 73.7, 75.8, 76.5, 78.4, 80.1, 122.9, 124.3, 
130.8, 139.1, 139.6, 148.8, 164.4, 170.5, 173.5 (C=O); Anal. Calcd for 
CsgH1osNsOsSb: C, 64.65, H, 9.66, N, 6.39; Found C, 64.91, H 9.90, N 6.16; 
HRFABMS Calcd for Cs9H10sNsOsSb: 1095.75040 found 1095.7486. 
219 
(C) Lipophilic 0-carbonate analogues of nucleosides 
Procedure for the synthesis of lipophilic 0-carbonate conjugates 
Method A: To a solution of 2',5'-0-TBDMS protected guanosine 67 or 
adenosine 70 (5 mmol, 1eq) in 12 ml of anhydrous THF, a 0.6 M solution of 
lithium bis (trimethyl silyl) amide or t-butyllithium in hexane (5 mmol, 1eq) was 
added dropwise at -78 °C. After the addition was completed the reaction 
mixture was stirred at 0 °C for 1 h. A solution of carbamate linker of cholesterol 
13 or tocopherol14 (5 mmol, 1eq) in anhydrous THF (12 ml) was then added 
dropwise to the above stirred solution and the reaction mixture was heated 
under reflux for 12 h. The solvent was removed under reduced pressure and 
the residues furnished were dissolved in ethyl acetate (1 00 ml) and saturated 
aqueous sodium bicarbonate solution (50 ml). The aqueous phase was further 
extracted with ethyl acetate (5 x 50 ml) and the combined organic layers were 
washed with saturated aqueous sodium bicarbonate solution (5 x 30 ml) and 
brine (5 x 30 ml). The organic fractions were dried over sodium sulphate, 
filtered and evaporated to afford the 3' -0-cholesteryl carbonate derivatives of 
adenosine 100 and guanosine 102 as off-white foam while, the 5'-0-
tocopheryl analogues of the corresponding nucleosides were attained as 
yellow oils. 
Method B: A solution of carbamate linker of cholesterol 13 or tocopherol 14 
(3 mmol, 1eq) in 13.5 ml of 8:1 mixture of anhydrous 1.4-dioxane: pyridine, 
was added dropwise to a stirred solution of 2',5'-0-TBDMS protected 
guanosine 67 or adenosine 70 (3.3 mmol, 1eq) in 15 ml of the same mixture. 
After the addition was completed, the reaction mixture was heated under 
reflux for 12 h. The solvent was removed under high vacuum and the resulting 
residue was dissolved in 240 ml of chloroform. In the solution saturated 
aqueous ammonium chloride solution (100 ml) and the layers were separated. 
The aqueous layer was then extracted with more chloroform (6 x 60 ml) and 
the organic fractions were washed further with saturated aqueous sodium 
bicarbonate (5 x 50ml) and brine (5 x 50 ml). The organic fractions were 
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combined dried over sodium sulphate, filtered and evaporated. The 3'-0-
cholesteryl carbonate derivatives of adenosine 100 and guanosine 102 were 
furnished as off-white foam while, the 5'-0-tocopheryl analogues of the 
corresponding nucleosides were attained as yellow oils. 
Various attempts to prepare the carbonate analogues in anhydrous pyridine 
resulted in poor yields (30-39% ). 
Carbonic acid 4-(terl-butyl-dimethyl-silanyloxy)-2-(terl-butyl-dimethyl-
silanyloxy)-tetrahydro-furan-3-yl ester 17 -(1 ,5-dimethyl-hexyl)-10, 13· 
dimethyl-2,3,4, 7,8,9, 10,11, 12, 13, 14, 15, 16,17 -tetradecahydro-1 H 
cyclopenta[a]phenanthren-3-yi-9H-purin-6-ylamine ester 100 59-64% 
yield, Vmax I cm·1 (nujol) 1736, 1647, 1382, 1268, 1170, 976, 845; 1H-NMR 
(400 MHz, CDCI3) 0.11 (s, 6H, Si-CH3), 0.18 (s, 6H, Si-CH3), 0.62 (s, 9H, C-
CH3), 0.98 (s, 9H, C-CH3), 0.65-2.54 (m, 45H, aliphatic), 3.49-3.67 (m, 1H, 0-
CH), 4.17-4.22 (m, 1H, Hz·), 4.35-4.45 (m, 2H, Hs·), 4.64-4.68 (m, 1H, H4·), 
5.10-5.18 (m, 1H, H3·), 5.37 (d, 1H, J = 2.9 Hz, HC=C), 6.05 (t, Japparent = 6.9 
13 Hz, 1H, H1·), 6.31 (br s, 2H, NH2), 7.86 (s, 1H, Hz), 8.27 (s, 1H, Ha); C-NMR 
(100 MHz, CDCI3), -6.1 (4C-silyl), 14.8 (2C), 15.5, 17.6, 19.0, 21.0 (6C), 21.8, 
22.5, 23.2 (2C), 24.4, 25.8, 28.9, 29.7, 30.9, 33.5, 34.8, 35.9, 37.9, 4.01, 40.8, 
42.7, 43.6, 46.1, 49.2, 51.6, 64.9, 72.2, 73.7, 77.6, 78.1, 86.6, 123.9 (C=CH), 
128.8, 143.3 (CH=C), 147.5, 144.7, 149.6, 152.4, 155.1, 166.8 (C=O); Anal. 
Calcd for CsoHssNsOsSiz: C 66.11, H 9.43, N 7.71, Found C 65.84, H 9.76, N 
7.98; HRFABMS Calcd for CsoHasNsOsSiz: 907.60384 found 907.6002. 
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Carbonic acid 5-(6-amino-purin-9-yl)-4-(tert-butyl-dimethyl-silanyloxy)-2-
( tert-butyl-d i methyl-si la nyloxymethyl)-tetra hydro-fu ra n-3-yl ester 2 ,5, 7,8-
tetramethyl-2-(4,8, 12-trimethyl-tridecyl)-chroman-6-yl ester 101 63-67% 
yield, Ymax I cmJ (nujol) 1734, 1676, 1582, 1269, 1157, 825, 793; 1H-NMR 
(400 MHz, CDC13) 0.13 (s, 6H, Si-CHJ), 0.16 (s, 6H, Si-CHs), 0.64 (s, 9H, C-
CH3), 0.95 (s, 9H, C-CH3), 0.68-0.87 [m, 12H, (CH3-CH)4], 0.95-1.52 [m, 20H, 
(CHz)10], 1.54-1.73 [m, 3H, (CH-CH3)3], 1.91 (s, 3H, CH3-Ar), 2.0 (s, 3H, CH3-
Ar), 2.05 (s, 3H, CH3-Ar), 2.24 (s, 3H, CH3-C-O), 2.42-2.54 (m, 2H, CHz-Ar), 
4.14-4.19 (m, 1H, H2·), 4.34-4.41 (m, 2H, H5·), 4.60-4.64 (m, 1H, H4·), 5.05-
5.13 {m, 1 H, H3•), 6.0 (I, Japparent = 6.2 Hz, 1 H, H1-), 6.34 (br S, 2H, NH2), 7.8 (s, 
13 
1H, Hz), 8.22 (s, 1H, Ha): C-NMR (100 MHz, CDCI3), -6.7 (4C-silyl), 14.5 
(2C), 17.1, 19.2, 20.3 (6C), 20.9 (2C), 21.5, 22.6 (2C), 21.2, 21.3, 22.8, 23.4, 
25.5, 28.7, 31.4, 32.3, 32.7, 34.8, 35.6, 36.5, 37.6, 38.4, 39.8, 41.3, 46.2, 
64.4, 71.5, 74.8, 76.6, 77.1, 85.9, 121.8, 123.4, 128.0, 129.5, 144.0, 148.9, 
151.7, 154.4, 167.2 {C=O); Anal. Calcd for CszHasNsO?Siz: C, 65.57, H, 9.42, 
N, 7.35; Found C 65.91, H 9.81, N 7.08; HRFABMS Calcd for CszHagN507Siz: 
951.63005 found 951.6275. 
222 
<"{N" '"DMSD~ ~"H, 
"'"'---7-----..L---.r---...... L~- oyO OTBDMS 
0 102 
Carbonic acid 2-amino-1 ,9-dihydro-purin-6-one 4-(tert-butyl-dimethyl-
silanyloxy)-2-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-3-yl ester 
17 -(1 ,5-dimethyl-hexyl)-10, 13-dimethyl-
2,3,4, 7 ,8,9, 1 0,11, 12, 13, 14, 15, 16,17 -tetradecahydro-1 H 
cyclopenta[a]phenanthren-3-yl ester 102 59-65% yield, Ymax I cm·1 (nujol) 
1757, 1686, 1433, 1358, 1267, 1084, 862, 785; 1H-NMR (400 MHz, CDCI3) 
. 0.09 (s, 6H; Si-CH3), 0.13 (s, 6H, Si-CH3), 0.66 (s, 9H, C-CH3), 0.81 (s, 9H, C-
CH3), 0.61-2.51 (m, 45H, aliphatic), 3.40-3.60 (m, 1 H, 0-CH), 3.64-3.80 (m, 
2H), 4.02-4.16 (m, 1 H), 4.36 (!, Japparent = 8.9 Hz, 1 H), 4.47 (!, Japparent = 9.1 
Hz, 1H), 5.32 (d, 1H, J = 2.4 Hz, HC=C), 5.83 (d, Japparent = 8.2 Hz, 1H), 6.71 
13 (br s, 2H, NH2), 7.70 (s, 1 H), 7.92 (s, 1 H, NH); C-NMR (100 MHz, CDCI3), -
6.4 (4C-silyl), 14.1 (2C), 15.0, 17.1, 18.4, 20.0 (6C), 21.2, 21.9, 22.5 (2C), 
23.7, 25.0, 28.2, 29.1, 30.3, 32.8, 34.1, 35.7, 37.4, 39.4, 39.9, 42.3, 42.9, 
45.7, 48.6, 51.0, 65.2, 72.4, 75.2, 78.0, 79.3, 123.1 (C=CH), 137.9, 138.8, 
142.4 (CH=C), 148.1, 144.2, 163.5, 167.7 (C=O), 169.7; Anal. Calcd for 
CsoHssNs01Si2: C, 64.96, H, 9.27, N, 7.58; Found C 65.29, H, 9.60, N 7.97; 
HRFABMS Calcd for CsoHssNs01Si2: 923.41010 found 923.4077. 
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Carbonic acid 2-amino-1 ,9-dihydro-purin-6-one 4-(tert-butyl-dimethyl-
silanyloxy)-2-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-3-yl 
ester 2,5, 7,8-tetramethyl-2-(4,8, 12-trimethyl-tridecyl)-chroman-6-yl ester 
103 62-69% yield, Vmax I cm_1 (nujol) 1744, 1682, 1585, 1372, 1270, 1076, 
845, 788; 
1
H-NMR (400 MHz, CDCI3). 0.10 (s, 6H, Si-CH3), 0.13 (s, 6H, Si-
CH3), 0.67 (s, 9H, C-CH3), 0.81 (s, 9H, C-CH3), 0.70-0.90 [m, 12H, (CH3-
CH)4], 1.0-1.54 [m, 20H, (CH2)10], 1.57-1.75 [m, 3H, (CH-CH3h], 1.92 (s, 3H, 
CH3-Ar), 2.01 (s, 3H, CH3-Ar), 2.06 (s, 3H, CH3-Ar), 2.26 (s, 3H, CH3-C-O), 
2.44-2.54 (m, 2H, CH2-Ar), 3.63-3.80 (m, 2H), 4.01-4.15 (m, 1H), 4.36 (t, 
Japparent = 9 Hz, 1 H), 4.45 (t, Japparent = 9.2 Hz, 1 H), 5.83 (d, Japparent = 8.2 Hz, 
13 1H), 6.72 (br s, 2H, NH2), 7.72 (s, 1H), 7.94 (s, 1H, NH); C-NMR (100 MHz, 
CDCI3), -6.5 (4C-silyl), 14.8 (2C), 18.1, 20.5, 21.0 (6C), 21.9 (2C), 22.1, 22.8, 
23.3, 23.7 (2C), 24.1, 24.6, 26.2, 29.8, 32.2, 33.4, 33.9, 35.8, 36.7, 37.9, 38.6, 
39.2, 40.8, 42.9, 45.1, 65.5, 66.6, 73.7, 75.9, 76.7, 78.9, 80.2, 122.8, 124.3, 
130.5, 139.0, 139.8, 148.9, 164.4, 168.4 (C=O), 173.0; Anal. Calcd for 
Cs2HsgNsOsSi2: C, 64.49, H, 9.26, N, 7.23; Found C, 64.84, H 9.61, N 6.94; 
HRFABMS Calcd for Cs2HsgNsOsSi2: 967.62497 found 967.6219. 
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(D) Alternative methods for the synthesis of lipophilic-
nucleoside conjugates 
(I) Through the formation of an isocyanate 
Triphosgene (2 mmol, 1 eq) was dissolved in dichloromethane. A mixture of 
2',3',5'-0-TBDMS protected adenosine (6 mmol, 3eq) and 
diisopropylethylamine or triethylamine or diisopropylamine (12 mmol, 6eq) in 
dichloromethane was slowly added to the stirred solution of triphosgene over 
a period of 30 min using a suringe pump. After the addition had finished the 
reaction mixture was left to stir at room temperature for 30 min. The solvent 
was rotary evaporated and the resulting residue was dissolved in 40 m/ of 
ethyl acetate and 30 ml of saturated sodium bicarbonate solution. The 
aqueous layer was further extracted with ethyl acetate (4 x 40ml} and the 
combined organic fractions were washed with saturated sodium bicarbonate 
solution (3 x 20 m/) and brine (2 x 20 ml). The organic extracts were dried 
over magnesium sulphate, filtered and evaporated to dryness. Disappointingly 
the experiments were unsuccessful, as starting material was recovered in all 
cases and none of the desired isocyanate was formed. 
(11) Through an acid chloride 
A solution of cholesteryl chloroformate (3 mmol, 1eq) in 10 ml of 
dichloromethane was added dropwise to a stirred 1:1 solution of 
ethylenediamine or 2',3',5'-0-TBDMS protected adenosine in 
dichloromethane (8 m/) and pyridine (8 m!). After the addition was completed, 
the reaction mixture was stirred at room temperature for 2 h. The solvent was 
removed under high vacuum and the resulting residue was dissolved in 100 
ml of dichloromethane and 80ml of water. The aqueous layer was extracted 
further with dichloromethane (4 x 30ml) and the combined organic fractions 
were washed with brine (4 x 20 ml). The organic extracts were dried over 
magnesium sulphate, filtered and evaporated to dryness, to give the title 
compounds. Recrystallization from hexane afforded 2-
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(chlolesteryloxycarbonyl)ethylamine as white crystals in 72% yield. The 
cholesteryl N-carbamate of globally protected adenosine was furnished as off-
white solid in 42% yield after separation and purification by flash column 
chromatography eluting with 1 :20 mixture of chloroform methanol. 
(2-amino-ethyl)-carbamic acid 17-(1 ,5-dimethyl-hexyl)-10, 13-dimethyl-
2,3,4,7,8,9, 10,11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H 
cyclopenta[a]phenanthren-3-yl ester 114 
0 
H2N~ )l f----1---t.--r-J.-.-.:::,. "-/'"-"' 
N 0'-'-"------.; 
H 
2-(chlolesteryloxycarbonyl)ethylamine (114) recrystallised form 72% yield; 
m.p. 152-155 °C; Vmax I cm·1 (nujol) 3355, 3252, 3148, 2456, 1755, 1306, 
1 
1461, 1170, 1047, 894; H-NMR (250 MHz, CDCI3), 0.63-2.52 (m, 45H, 
aliphatic), 3.04 (t, 2H, CH2NH2), 3.46-3.66 (m, 1H, 0-CH), 3.71-3.82 (m, 4H, 
NH2 and HNCH2), 5.36 (d, 1H, J = 2.3 Hz, HC=C), 7.62 (br s, 1H, CONH); 
13 
C-NMR (100 MHz, CDCI3), 17.3, 18.5, 20.5, 22.6 (2C), 23.9, 24.7, 25.3, 
28.5, 29.4, 30.7, 32.0, 33.2, 34.4, 35.8, 36.2, 37.5, 39.2, 40.6, 42.5, 43.6, 
48.7, 51.2, 56.4, 57.8, 73.3, 109.8, 122.8 (C=CH), 140.9 (CH=C), 159.5 
(C=O); Anal. Calcd for C3oHs2N202: C 76.22, H 11.09, N 5.93, 0 6.77 Found C 
75.96, H 11.10, N 5.86; HRFABMS Calcd for C3oHs2N202: 472.40288 found 
472.4011. 
3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-2-(tert-butyl-dimethyl-silanyloxy)-
[9·( tetrahydro-furan-2-yi)-9H-purin-6yl]· carbamic acid 17 ·(1 ,5-dimethyl-
hexyl)-1 0, 13-dimethyl-2,3,4, 7,8,9, 10,11, 12, 13, 14, 15, 16,17 -tetradecahydro-
1 H cyclopenta[a]phenanthren-3-yl ester 115 
0 
HN)____Q 
TBDMS OTBDMS 
226 
Cholesteryl N-carbamate of 2',3',5'-0-TBDMS-adenosine (115) purified form 
42% yield; m.p. 145-147 °C; Ymax I cm·1 (nujol) 3256, 3152, 1762, 1684, 1268, 
1 1410, 1364, 1255, 1170, 1066, 875; H-NMR (400 MHz, CDCI3} 0.12 (s, 6H, 
Si-CH3), 0.18 (s, 6H, Si-CH3), 0.24 (s, 6H, Si-CH3), 0.63-2.52 (m, 45H, 
aliphatic), 0.66 (s, 9H, C-CH3), 0.85 (s, 9H, C-CH3), 0.98 (s, 9H, C-CH3), 3.48-
3.66 (m, 1H, 0-CH), 4.16-4.21 (m, 1H, H2·), 4.34-4.44 (m, 2H, Hs·), 4.62-4.66 
(m, 1H, H4·), 5.08-5.16 (m, 1H, H3·), 5.35 {d, 1H, J = 2.5 Hz, HC=C), 6.02 (t, 
Japparent = 6.7 Hz, 1H, H,.), 7.65 (br s, 1H, CONH), 7.84 (s, 1H, H2), 8.25 (s, 
13 
1H, Ha); C-NMR (100 MHz, CDCI3), -6.5 (6C), 14.7 (3C), 15.2, 17.3, 18.7, 
20.7 (9C), 21.5, 22.2, 22.8 (2C), 23.9, 25.3, 28.5, 29.4, 30.6, 33.2, 34.4, 35.8, 
37.5, 39.6, 40.2, 42.5, 43.2, 45.8, 48.8, 51.2, 64.7, 71.8, 73.3, 77.1, 77.7, 
86.1, 123.5 (C=CH), 128.4, 142.8 (CH=C), 147.3, 144.4, 149.2, 152.0, 154.8, 
161.1 (C=O); Anal. Calcd for Cs5HggN50 6Si3: C 65.77, H 9.76, N 6.85, 0 9.39 
Found C 65.62, H 9.88, N 6.76; HRFABMS Calcd for Cs6H99N50 6Si3: 
1021.69032 found 1021.6887. 
(11) Through the formation of the acid chloride of thioctic acid 
5-[(3R)-1 ,2-dithiolan-3-yl] pentanoyl chloride (116) 
0 
Cl 
s-s 
To thioctic acid (5 mmol, 1eq) kept at ice bath temperature, thionyl chloride 
(30 mmol, 6eq) was added dropwise with stirring (no vigorous reaction was 
noted). After 10 min of stirring the dark orange solution turned into dark brown 
and gradually into black. The reaction mixture was stirred at room 
temperature for 2h and then the solvent was removed under reduced 
pressure to furnish the acid chloride as black oil. The compound was used 
without further purification 
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Acid chloride of thioctic acid (116) 72% yield Vmax I cm·1 (nujol) 2929, 2556 
1 
1812, 1461, 1323, 1284,932, 807, 735; H-NMR (250 MHz, CDCI3) 1.43-2.12 
(m, 6H, (CH2)3 aliphatic), 2.18-2.31 (m, 2H, CH2 cycle) 2.36-2.58 (m, 3H, 
13 O=C-CH2 + CH-S cycle), 3.12-3.32 (m, 2H, CH2-S), C-NMR (100 MHz, 
CDCI3) 25.2, 27.4, 35.3, 37.6, 38.5, 43.4, 52.8, 175.8 (O=C-CH2 quaternary); 
Anal. Calcd for C8H13CIOS2: C, 42.75, H, 5.83, 0, 7.12; Found C, 42.86, H, 
5.68; HRFABMS Calcd for CsH13CIOSz: 224.00963 found 224.0059. 
N1-phenyl-5-[(3R)-1,2-dithiolan-3-yl] pentanamide (118) 
0 
s-s 6 
To a solution of aniline (2 mmol, 1eq) in 1 ml of pyridine kept at ice bath 
temperature, the acid chloride of thioctic acid 116 (2 mmol, 1eq) dissolved in 5 
ml of pyridine, was added dropwise through a syringe. After the addition was 
completed, the reaction was allowed to warm at room temperature and then it 
was left to stir for 2 h. Pyridine was evaporated under high vacuum leaving a 
black oil which was dissolved in diethyl ether (20 ml) and water (10 ml). The 
aqueous layer was extracted further with diethyl ether ( 4 x 20 ml) while the 
combined organic fractions were washed sequentially with saturated sodium 
bicarbonate solution (2 x 10ml) and 20% aqueous hydrochloric acid (2 x 2ml) 
The combined organic extracts were dried over sodium sulphate, filtered and 
evaporated to dryness to furnish the crude amide of aniline as black oil. The 
crude product was purified by flash column chromatography using a 1:1 
mixture of petroleum ether and ethyl acetate as the eluent to afford the 
desired product as brown oil 
1 Thioctic amide of aniline (118) 48% yield; Ymax I cm· (nujol) 3354, 3072, 2935, 
2586 1675, 1510, 1442, 1257, 996, 881, 693; 1H-NMR (250 MHz, CDCI3) 
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1.52-2.16 (m, 6H, (CH2h aliphatic), 2.23-2.35 (m, 2H, CH2 cycle) 2.41-2.63 
(m, 3H, O=C-CH2 + CH-S cycle), 3.18-3.39 (m, 2H, CH2-S), 6.57-6.64 (m, 2H, 
13 Ar), 6.72-6.81 (m, 2H, Ar), 6.87-6.96 (m, 1 H, Ar), 7.62 (br s, 1 H, CONH); C-
NMR (100 MHz, CDCI3) 25.4, 27.8, 35.6, 37.8, 38.9, 43.6, 53.6, 118.4 (2C), 
124.2, 130.5 (2C), 142.5, 174.6 (O=C-CH2, quaternary); Anal. Calcd for 
C14H1gNOS2: C, 59.75, H, 6.80, N, 4.98, 0, 5.68; Found C, 59.60, H, 6.94, N, 
4.88; HRFABMS Calcd for C14H1gNOS2: 281.09080 found 281.0755. 
(Ill) By employing coupling reagents 
5-[ (3 R)-1 ,2-d ith iola n-3-yl) {9-[3,4-b is-( tert-butyl-d i methyl-si lanyloxy )-5-
(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yi-9H-purin-6-
yl}-pentanamide 120 
120 
DCC and EDCI 
To a stirred solution of thioctic acid (4 mmol, 1eq) in 5ml of dichloromethane, 
2',3',5'-0-(terl-butyldimethylsilyl) adenosine (4 mmol, 1 eq) was added 
dissolved in dichloromethane (5 ml). The resulting mixture was cooled in an 
ice bath at 0-5° C and the coupling reagent (2.2 mmol, 1.1eq) was added 
proportionally every 10 min. Within 30 min the addition had concluded and the 
yellow solution (pale yellow suspension in the case of DCC) was left to stir at 
room temperature for 4h. The reaction mixture was concentrated to dryness to 
give a yellow residue (pale yellow in the case of DCC), which was dissolved in 
ethyl acetate (15 ml) and 2M aqueous hydrochloric acid (2 ml) and the layers 
partitioned. The aqueous layer was extracted further with ethyl acetate (4 x 40 
ml) and the combined organic fractions were washed sequentially with 
saturated sodium bicarbonate solution (3 x 10 ml) and brine (3 x 10 ml). The 
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combined organic layers were dried over sodium sulphate, filtered and 
evaporated to dryness to furnish the formed amide as yellow oil in both cases. 
Thioctic carbamate analogue of 2',3',5'-0-(terl-Butyldimethylsilyl) adenosine 
(120) (51% yield from DCC), (55% yield from EDCI) Vmax I cm·1 (neat) 3382, 
2954, 1747, 1695, 1257, 1092, 838, 735, 667; 1H-NMR (400 MHz, CDC13) 
_ 0.10 (s, 6H, Si-CH3), 0.16 (s, 6H, Si-CH3), 0.22 (s, 6H, Si-CH3), 0.65 (s, 9H, 
C-CH3), 0.81 (s, 9H, C-CH3), 0.94 (s, 9H, C-CH3), 1.32-1.52 (m, 2H, CH2 
aliphatic), 1.54-1.62 (m, 4H, (CHz)2 aliphatic), 1.65-1.85 (m, 2H, CH2 cycle), 
2.23-2.45 (m, 2H, O=C-CHz), 3.0-3.22 (m, 2H, CH2-S), 3.35-3.52 (m, 1H, CH-
S), 3.78-3.95 (m, 1H, Hz·), 4.14-4.25 (m, 2H, Hs-). 4.51-4.72 (m, 1H, H4-), 4.78-
4.94 (m, 1H, H3-), 5.65 (t, Japparent =7Hz, 1H, Hr). 7.90 (br s, 1H, HNCO), 8.13 
13 . (s, 1H, Hz). 8.16 (s, 1H, Hs); C -NMR (100 MHz, CDCI3) -6.2 (6C-sllyl), 14.7 
(3C), 20.5 (9C), 26.5, 28.5, 34.4, 36.7, 39.8, 43.6, 54.0 (7C, thioctic), 62.3, 
72.4, 74.0, 87.0, 88.6, 128,5, 144.5, 148.5, 151.7, 155.1 177.0 (O=C-CH2 
quaternary). Anal. Calcd. for C36H67N50 5S2Sb: C, 54.16; H, 8.46; N, 8.77; 
Found C, 54.55; H, 8.18; N, 8.59; HRFABMS calcd for C36H67Np5S2Si3: 
797.38914 found 797.3869. 
230 
--·-------------------------------
--- -- ----------------------------------------------------------
PYBOP 
To a stirred solution of thioctic acid (2 mmol, 1eq) in 5ml of dichloromethane, 
2',3',5'-0-(tert-Butyldimethylsilyl) adenosine (2 mmol, 1eq) was added 
dissolved in dichloromethane (5 ml). After 5 min of stirring a solution of 
PyBOP coupling reagent (2.2 mmol, 1.1 eq) in 5ml of dichloromethane was 
added along with ethyldiisopropylamine (6 mmol, 3eq) and the reaction was 
stirred at room temperature for 2 h. The solvent was evaporated to dryness to 
give a yellow residue, which was dissolved in ethyl acetate (15 ml) and 2M 
solution aqueous hydrochloric acid (2 ml). The aqueous layer was extracted 
further with ethyl acetate (4 x 40 ml) and the combined organic fractions were 
washed sequentially with saturated sodium bicarbonate solution saturated 
sodium chloride (2 x 10 ml), and water (2 x 10 ml). The organic extracts were 
dried over sodium sulphate, filtered and evaporated to dryness to furnish the 
title compound. The crude product was purified by flash column 
chromatography using a 95: 5 mixture of DCM and methanol as the eluent to 
afford the formed amide as yellow oil. 
Thioctic carbamate analogue of 2',3',5'-0-(tert-Butyldimethylsilyl) adenosine 
1 (120) (62% yield); Vmax I cm· (neat) 3382, 2954, 1747, 1695, 1257, 1092, 838, 
735, 667; 
1
H-NMR (400 MHz, CDCI3), 0.10 (s, 6H, Si-CH3), 0.16 (s, 6H, Si-
CH3), 0.22 (s, 6H, Si-CH3), 0.65 (s, 9H, C-CH3), 0.81 (s, 9H, C-CH3), 0.94 (s, 
9H, C-CH3), 1.32-1.52 (m, 2H, CH2 aliphatic), 1.54-1.62 (m, 4H, (CH2)2 
aliphatic), 1.65-1.85 (m, 2H, CH2 cycle), 2.23-2.45 (m, 2H, O=C-CH2), 3.0-
3.22 (m, 2H, CH2-S). 3.35-3.52 (m, 1H, CH-S), 3.78-3.95 (m, 1H, H2·), 4.14-
4.25 (m, 2H, Hs·), 4.51-4.72 (m, 1H, H4·), 4.78-4.94 (m, 1H, H3·), 5.65 (t, 
Japparent = 7Hz, 1 H, Hr), 7.90 (br s, 1 H, HNCO), 8.13 (s, 1 H, H2), 8.16 (s, 1 H, 
H8); 
13
C -NMR (1 00 MHz, CDCI3) -6.2 (6C-silyl), 14.7 (3C), 20.5 (9C), 26.5, 
28.5, 34.4, 36.7, 39.8, 43.6, 54.0 (7C, thioctic), 62.3, 72.4, 74.0, 87.0, 88.6, 
128,5, 144.5, 148.5, 151.7, 155.1 177.0 (O=C-CH2 quart). Anal. Calcd. for 
C36H67N50 5S2Si3: C, 54.16; H, 8.46; N, 8.77; Found C, 54.55; H, 8.18; N, 
8.59; HRFABMS calcd for C36H67N50 5S2Si3: 797.38914 found 797.3869. 
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(E) Modification at the base of the nucleosides 
6-Azido-9H-purine 123 
txS ~ N 
6-chloropurine (3 mmol, 1eq), which slowly dissolved in anhydrous 
dimethylformamide (10 ml) with stirring, was treated with sodium azide (15 
mmol, 5eq) and the reaction mixture was stirred at room temperature 
overnight (15h). The solvent was evaporated under high vacuum and the 
residue was dissolved in water (10 ml). The off-white insoluble solid was 
collected by suction filtration, washed with water (2 x 10 ml) and dried in 
vacuo to give the title compound as an off white solid. 
1 Azide of purine base (123) 85% yield, Vmax I cm· (nujol) 2154, 1652, 1045, 
1 
845, 742; H-NMR (250 MHz, (DMSO-d6) 8.17 (m, 2H, HN-CH=N+N-CH=N), 
13 
9.54 (br s, 1H, NH); C -NMR (100 MHz, (DMSO-d6) 128.4, 144.8, 146.5, 
152.1, 154.9; Anal. Calcd. For CsH3N1: C, 37.27, H, 1.88, N, 60.85; Found C, 
37.08; H, 2.02; N, 60.63; HRFABMS calcd for C5H3N7: 161.04499 found 
161.0419. 
9H-Purin-6-yl-phosphorimidic acid triethyl ester 124. 
/OEt 
N=P\-OEt 
Ni: OEt < I N 
N ) 
H N 
In a solution of the azide 123 (2 mmol, 1eq) in anhydrous dimethylformamide 
(1 0 ml), triethyl phosphite (2 mmol, 1 eq) was added dropwise and the reaction 
mixture was stirred at room temperature under nitrogen, until TLC showed 
that consumption of the azide was complete (18h). The solvent was 
evaporated under high vacuum to give a light yellow solid. Recrystallization 
232 
from a mixture of dichloromethane and petroleum ether (4: 1) afforded the 
triethyl ester phosphoramidite as an off-yellow solid. 
Triethyl ester phosphoramidate of purine base (124) 82% yield, Vmax I cm.1 
• 1 (nujol) 1599, 1685, 1031, 857, 763; H-NMR (250 MHz, CDC13,) 1.28-1.35 (m, 
9H, CH3CHz), 4.06-4.20 (m, 6H, CH3CHz), 7.98 (m, 2H, HN-CH'=N+N-CH=N), 
13 9.37 (br s, 1H, NH); C -NMR (100 MHz, CDC13) 16.4 [3C, (CH3hJ, 47.2 [3C, 
31 (CHz)3), 127.4, 143.7, 145.6, 151.1, 153.7; P-NMR (100 MHz, CDCI3,) 1.93; 
Anal. Calcd. For C11H1sN403P: C, 44.15, H, 6.06, N, 23.40, 0, 16.04; Found 
C, 43.92; H, 6.34; N, 23.72; HRFABMS calcd for C11H 1aNs03P: 299.11473 
found 299.1117. 
Phosphorous acid trihexadecyl ester 127 
Cetyl alcohol (30 mmol, 3eq) was dissolved in 50ml of dichloromethane and in 
the solution which was kept at 0 °C and under nitrogen, phosphorous 
trichloride (10 mmol, 1eq) was added dropwise followed by the addition of 
triethylamine (30 mmol, 3eq). The reaction mixture was stirred at ambient 
temperature for 12h. After removing the triethyl-ammonium salts through 
suction filtration, the solution was transferred into an extraction funnel in which 
saturated hydrogen carbonate solution was added (30 ml). The aqueous layer 
was extracted further with dichloromethane (3 x 30 ml) and the combined 
organic fractions were washed with brine (2 x 20 ml). The organic extracts 
were dried over magnesium sulphate, filtered and evaporated to dryness, to 
give an off-white solid. Recrystallization from dichloromethane and petroleum 
ether furnished the tricetyl phosphite as white solid. 
Tricetyl phosphite (127) 63%yield, Vmax I cm-1 (nujol) 1463, 1474, 1040, 955, 
1 
730; H-NMR (250 MHz, CDCI3,) 0.88 (t, J"' 7.2, 9H, (CH3CH2)3], 1.52-1.75 
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13 (m, 84H, (CH2)42], 3.63 (t, J = 7.6, 6H, (OCH2)3]; C -NMR (100 MHz, CDCI3) 
14.2 [3C, (CH3)3], 23.4 [3C, (CHz)3CH3], 25.6 (3C), 29.5 (3C), 30.3 (27C), 32.4 
31 (3C), 32.8 (3C), 59.4 (3C); P-NMR (100 MHz, CDCI3,) 0.48; Anal. Calcd. For 
C48Hg903P: C, 76.33, H, 13.21, 0, 6.36; Found C, 76.59, H, 13.05; HRFABMS 
calcd for C4aH9903P: 754.73318 found 754.7299. 
9H-Purin-6-yl-phosphorimidic acid trihexadecyl ester 128 
pc1sH33 
N=P\OC1sH33 <::C; OC1sH33 
H N 
In a solution of the azide 123 (2 mmol, 1eq) in anhydrous DMF (10 ml), the 
formed tricetyl phosphite 127 (2 mmol, 1eq) dissolved in anhydrous 
dimethylformamide (10 ml), was added. The reaction mixture was stirred at 
room temperature under nitrogen, until TLC showed that consumption of the 
azide was complete (15h). The solvent was evaporated under high vacuum to 
give an off-yellow solid. Recrystallization from a mixture of ethyl acetate and 
hexane (3: 1) afforded the triethyl ester phosphoramidite as an off-yellow 
solid. 
Tricetyl ester phosphoramidite of purine base (128) 71 %yield, Vmax I cmJ 
(nujol) 1565, 1472, 1045, 932, 732; 1H-NMR (250 MHz, CDCI3,) 0.92 (t, J = 
7.4, 9H, (CH3CHzhJ. 1.56-1.79 (m, 84H, (CH2)42], 3.68 (!, J = 7.4, 6H, 
13 (OCH2)3]; 7.92 (m, 2H, HN-CH=N+N-CH=N), 9.27 (br s, 1 H, NH); C -NMR 
(100 MHz, CDCI3) 15.7 [3C, CH3h], 24.6 [3C, (CH2)3CH3], 26.5 (3C), 29.8 
(3C), 31.3 (27C), 33.1 (3C), 33.8 (3C), 60.1 (3C), 127.2, 143.7, 145.4, 151.3, 
31 
153.7; P-NMR (100 MHz, CDCI3,) 0.95; Anal. Calcd. For C53H1o2N503P: C, 
71.65, H, 11.57, N, 7.88, 0, 5.40; Found C, 71.91, H, 11.32, N, 7.53; 
HRFABMS calcd for C53H1o2N503P: 887.77203 found 887.7699. 
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4. FORMATION OF CPG DINUCLEOTIDES 
(A) Synthesis of N-free-3'-phosphoramidites of cytidine 
Procedure for the preparation of N-free 3'-cyanoethyl phosphoramidites 
of 2'-deoxycytidine 27 and 129 
A solution of 5'-0-(Dimethoxytrityl)-2-deoxycytidine 26 and 2',5'-0-TBDMS 
cytidine 73 (5 mmol, 1eq) in anhydrous THF (10 ml) was put under nitrogen 
and cooled at -78 °C. In the stirred solution ethyldiisopropylamine (7.5 mmol, 
1.5eq) was added, followed by dropwise addition of (2-cyanoethyi)(N,N-
diisopropylamino)chlorophosphine (5.5 mmol, 1.1eq). After the addition 
concluded, the reaction mixture was allowed to warm and after stirring at 
ambient temperature for 1h, TLC showed consumption of the starting 
material. The solvent was evaporated to dryness under high vacuum and the 
residue obtained was dissolved in dichloromethane (25 ml) and saturated 
sodium bicarbonate solution (25 ml). The aqueous layer fraction was 
extracted further with further dichloromethane (3 x 30ml) and the organic 
fractions were washed with saturated sodium bicarbonate solution (2 x 1 Oml) 
and brine (2 x 10ml). The combined organic extracts were dried over 
magnesium sulphate, filtered and evaporated to dryness, to give viscous oil. 
The oil was dissolved in dichloromethane (10 ml) and was poured into a 
vigorously stirred petroleum ether (100 ml) to give colourless precipitates in 
both cases. Suction filtration of the solid material afforded the 3'-
phosphoramidites of 2'-deoxycytidine as white solid in both cases. No further 
purification of the material was required. 
27 
NH2 Ct TeDM~ D 
0 OTBDMS 
I 
/p""' /'-. ___ o N(i-Pr)2 NC' '-/ 
129 
-- ·--·---------------------------------------------
235 
4,4'-Dimethoxy-biphenyl-diisopropyl-phosphoramidous acid-5-(4-amino-
2-oxo-2H-pyrimidin-1-yl)-2-(4methoxy-benzyloxymethyl)-tetrahydro-
furan-yl ester 2 isocyano-ethyl ester (27) 85% yield, Vmax I cm·1 (nujol) 
1 
1757, 1612, 1510,1362, 1179, 831; H-NMR (250 MHz, CDCI3) 1.02-1.15 (m, 
12H, CH3)4], 1.94-2.12 (m, 2H, H2T). 2.48-2.61 (m, 2H, (CH)2], 3.24-3.37 (m, 
2H, Hs·s··), 3.44-3.51 (m, 2H), 3.80 [s, 6H, O-(CH3)z], 3.88-3.94 (m, 2H), 4.12-
4.23 (m, 1 H, H4·), 4.42-4.54 (m, 1 H, H3·), 5.52 (d, J5•6 = 8 Hz, 1 H, H5), 6.17 (t, 
Japparent= 6.9 Hz, 1H, H1·), 6.34 (br s, 2H, NH2), 6.65-6.71 (m, 4H, trityl), 7.05-
7.24 (m, 9H, trityl), 7.82 (d, Js-6 = 8.1 Hz, 1H, H5);13P-NMR (250 MHz, CDC13) 
148.07, 148.3; Anal. Calcd for C39H48N501P: C, 64.01; H, 6.89; N, 9.57; 
Found: C, 63.58; H, 6.64, N, 9.72; HRFABMS Calcd for, C39H48N501P: 
729.32913 found 729.3266. 
Diisopropyl-phosphoramidous acid-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)· 
4-(terl-butyl-dimethyl-silanyloxy)-2-(terl-butyl-dimethyl-silanyloxy)-
tetrahydro-furan-3-yl ester 2 isocyano-ethyl ester (129) 83% yield, Vmax I 
1 1 
cm· (nujol) 1725, 1644, 1462, 1265, 1035, 842; H-NMR (250 MHz, CDCI3) 
0.20 (s, 6H, Si-CH3), 0.66 (s, 6H, Si-CH3), 0.82 (s, 9H, C-CH3), 1.0 (s, 9H, C-
CH3), 1.05-1.18 (m, 12H, (CH3)4], 1.98-2.16 (m, 1H, H2'), 2.53-2.65 (m, 2H, 
(CH)2], 3.28-3.41 (m, 1H, Hs·S"), 3.47-3.54 (m, 2H), 3.92-3.97 (m, 2H), 4.17-
4.28 (m, 1 H, H4-), 4.45-4.57 (m, 1 H, H3-), 5.56 (d, Js.a = 7.4 Hz, 1 H, H5), 6.21 
(t, Japparent = 6.5 Hz, 1 H, H1'), 6.39 (br S, 2H, NH2), 7.87 (d, Js-6 = 7.2 Hz, 1 H, 
H6);13P-NMR (250 MHz, CDCI3) 150.5; Anal. Calcd for C3oHsaNs05PSi2: C, 
53.62, H, 8.70, N, 10.42; Found: C, 53.24, H, 8.42, N, 10.84; HRFABMS 
Calcd for, C3oHs7NsOaPSb, 670.36633 found 670.3638. 
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(B) Solution Phase synthesis of CpG dinucleotides 
lmidazolium triflate 132 
H 
(~ TfO 
N+ 
H 
In a stirred solution of imidazole (20 mmol, 1eq) in dichloromethane (5 ml) 
trifluoromethanesulfonic acid (20 mmol, 1eq) was added dropwise. After the 
addition concluded the reaction mixture was stirred at ambient temperature for 
30 min. TLC showed the reaction to be complete. The reaction mixture was 
diluted with diethyl ether and the title compound was collected through suction 
filtration as crystals. The product did not require further purification 
lmidazolium Triflate 132, 97% yield, m.p. 194-196 °C (lit315 197-198 °C); Ymax I 
cm·
1 (nujol) 3148, 1594, 1452, 1259, 1H-NMR (250 MHz, CDpD) 8.12 (s, 
13 
2H), 9.42 (s, 1H), C-NMR (100 MHz, CD30D) 121, 125, 138, Anal. Calcd for 
C4H5F3N203S: C, 22.02; H, 2.31; N, 12.84; Found: C, 21.95; H, 2.34; N, 
12.77; 
Stepwise synthesis of dinucleotide CpG phosphates using 
stoichiometric amounts of imidazolium triflate 132, N-free-3'· 
phosphoramidite of cytidine 27 and 2',3'-0-TBDMS protected guanosine 
79 or 2',3'·0-TBDMS-N-carbamate cholesteryl 104 and tocopheryl 105 
conjugates of guanosine. 
Procedure for the synthesis of 2'-cyanoethyi-5'-DMTr·2'deoxycytidine-
2' ,3' • TBDMS guanosine or 2'-cyanoethyi-5'-DMTr·2'deoxycytidine-2' ,3'· 
0-TBDMS-N-carbamate cholesteryl and tocopheryl conjugates of 
guanosine 
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In a stirred solution of N-free-3'-phosphoramidite of cytidine 27 (4 mmol, 1eq) 
in 8 ml dry of acetonitrile, a solution of 2',3'-0-TBDMS protected guanosine 79 
or 2',3'-0-TBDMS-N-carbamate cholesteryl104 or tocopheryl 105 conjugates 
of guanosine (4 mmol, 1eq) was added along with a solution of imidazolium 
triflate 132 (4 mmol, 1eq) in 15 ml of dry acetonitrile. After the reaction mixture 
was stirred at room temperature for 10 min. 1.0 M of toluene solution of tert-
butyl hydroperoxide (TBHP) (1.5 mmol, 1.5eq) was added and the stirring 
continued for 10 min. Evaporation of the reaction mixture gave an oil which 
was dissolved in dichloromethane and subjected to chromatography on a 
silica gel pad eluting with a 10:1 mixture of dichloromethane and methanol. 
The organic filtrate was evaporated to dryness to afford purified 133 as a 
colorless amorphous solid in 76% yield, 139 as a off-white solid in 72% yield 
and 140 as an off-yellow solid in 75% yield 
NH2 
"N 
0 N:C 1.::;:-0 I! I ~H 
/H, \ A ~0 0~ N NH2 
N TBDMSO OTBDMS 
133 
4,4'-dimethoxy-biphenyl-phosphoric acid-5-(2-amino-6-oxo-1 ,6-dihydro-
purin-9-yl) 3,4-bis-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-
ylmethyl ester 5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-benzyloxymethyl)· 
tetrahydro-furan-3-ylmethyl ester 2 isocyano-ethyl ester (133) 76% yield, 
Vmax I cm.1 (nujol) 1727, 1695, 1548, 1477, 1265, 1045, 874; 1H-NMR (250 
MHz, CDCI3) 0.16 (s, 6H, Si-CH3), 0.20 (s, 6H, Si-CH3), 0.84 (s, 9H, C-CH3), 
0.96 (s, 9H, C-CH3), 1.97-2.19 (m, 2H, H2·2·-), 3.11-3.22 (m, 2H), 3.28-3.42 (m, 
2H, Hs·s"), 3.46-3.54 (m, 2H), 3.69-3.78 (m, 1 H), 3.84 [s, 6H, O-(CH3h]. 3.91-
238 
3.95 (m, 2H), 4.15-4.25 (m, 1 H, H4·), 4.45-4.58 (m, 1 H, H3-), 4.91 (t, Japparent = 
12.1 Hz, 1 H), 5.36 (t, Japparent = 11.5 Hz, 1 H), 5.56 (d, Js.s = 7.3 Hz, 1 H, Hs), 
5.98 (d, Japparent = 6.3Hz, 1H), 6.17 (t, Japparent = 7.1 Hz, 1 H, H1·), 6.34 (br S, 2H, 
NH2), 6.68-6.74 (m, 4H, trityl), 6.91 (br s, 2H, NH2), 7.07-7.27 (m, 9H, trityl), 
13 7.72 (s, 1 H), 7.84 (d, Js.s = 7.8 Hz, 1 H, Hs). 7.93 (s, 1 H, NH).; C-NMR (100 
MHz, CDCI3) -6.6 (4C-silyl), 15.5 (2C), 18.8, 21.3 (6C), 33.2, 56.9 (2C), 61.1, 
61.8, 65.1, 68.1, 68.9, 72.5, 74.6, 75.3, 76.9, 77.4, 77.9, 99.1, 114.9 (4C), 
117.2, 118.1, 127.8 (3C), 128.8 (6C), 130.1 (2C), 131.8, 137.6, 138.7, 140.6, 
148.8, 158.7 (C=O, cytidine), 160.7 (C=O, guanosine), 161.8 (2C), 163.7, 
13 
164.5; P-NMR (250 MHz, CDC13) 1.95, -2.01; Anal. Calcd for 
C55H7sNg013PSiz: C, 57.03, H, 6.61, N, 10.88, 0, 17.96; Found: C, 56.82, H, 
6.84, N, 1 0.53; HRFABMS Calcd for: CssH14N9013PSi2: 1155.48388 found 
1155.4809. 
;c~ 
'"'~ 0 
/~0 ~N:Cr Jt 
~0 Q:RN N NI 0,/_~ NC 1'1 
TBDMS OTBDMS 
139 
4,4'-dimethoxy-biphenyl-phosphoric acid-5-(4-amino-2-oxo-2H-
purimidin-1-yl) {9-[3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-
furan-2-yl]-6-oxo-6,9-dihydro-1 H -purin-2-yl}-carbamic acid 17 -(1 ,5-
dimethyl-hexyl)-10, 13-dimethyl-2,3,4, 7,8,9,10, 11, 12, 13, 14, 15, 16,17-
tetradecahydro-1 H cyclopenta[a]phenanthren-tetrahydro-furan-3-
ylmethyl ester 2 isocyano-ethyl ester (139) 72% yield, Ymax I cm.1 (nujol) 
3265, 3114, 1741, 1685, 1548, 1486, 1268, 1048, 855, 767; 1H-NMR (250 
MHz, CDCI3) 0.15 (s, 6H, Si-CH3), 0.18 (s, 6H, Si-CH3), 0.81 (s, 9H, C-CH3), 
0.92 (s, 9H, C-CH3), 0.69-2.38 (m, 45H, aliphatic),1.94-2.13 (m, 2H, H2·2"), 
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3.06-3.17 (m, 2H), 3.23-3.35 (m, 2H, H5·5"), 3.42-3.50 (m, 2H), 3.65-3.75 (m, 
1H), 3.81 [s, 6H, O-(CH3)zl, 3.86-3.90 (m, 2H), 4.11-4.21 (m, 1H, H4·), 4.41-
4.52 (m, 1H, H3·), 4.56-4.77 (m, 1H, 0-CH), 4.87 (!, Japparent = 11.6 Hz, 1H), 
5.32 (t, Japparent = 12.0 Hz, 1H), 5.38 (d, 1H, J = 2.6 Hz, HC=C), 5.52 (d, Js-6= 
8.2 Hz, 1H, Hs), 5.93 (d, Japparent = 6.7 Hz, 1H), 6.12 (!, Japparent =7Hz, 1H, 
H1-), 6.30 (br s, 2H, NH2), 6.64-6.70 (m, 4H, trityl), 7.02-7.23 (m, 9H, trityl), 
7.55 (br s, 1H, CONH), 7.67 (s, 1H), 7.80 (d, Js-6= 8Hz, 1H, H6), 7.89 (s, 1H, 
NH).; 13C-NMR (100 MHz, CDCI3) -5.6 (4C-silyl), 15.2 (2C), 17.3, 18.3, 18.8, 
19.4, 19.7, 21.3 (6C), 23.4 (2C), 26.5, 29.9, 31.5, 32.5, 33.2, 34.2, 35.4, 36.2, 
38.5, 39.6, 40.9, 42.5, 43.7, 48.3, 48.8, 51.2, 56.2 (2C), 61.2, 64.8, 67.8, 69.4, 
71.8, 72.8, 73.1, 7 4.5, 74.9, 76.3, 76.9, 77.4, 98.1, 115.1 (4C), 117.7, 122.8 
(CH=C), 126.4, 127.6 (3C), 128.2 (6C), 130.3 (2C), 131.5, 137.4, 138.5, 
139.6, 145.8, 148.2, 149.5 (CH=C), 155.9, 158.1, 159.2 (C=O, cytidine), 160.8 
(C=O, guanosine), 161.9 (2C), 163.2, 164.4, 170.0 (HN-C=O}; 13P-NMR (250 
MHz, CDCI3) -2.16, -2.24; Anal. Calcd for Cs3H11sNg01sPSh: C, 63.56, H, 
7.58, N, 8.04, 0, 15.28; Found: C, 63.21, H, 7.98, N, 7.86; HRFABMS Calcd 
for, Cs3H11sNg01sPSi2: 1567.80235 found 1567.7996. 
):2 
t1 
DMTrO? 0 O 
~0 <N:Cr JL N~o/ oyo'-] N 7 o ? 
TBDMSnTBDMS 1'1 "--
140 
4,4'-dimethoxy-biphenyl-phosphoric acid-5-(4-amino-2-oxo-2H 
purimidin-1-yl) {9·[3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-methyl-
tetra hyd ro-fu ra n-2 -yl]-6-oxo-6, 9-di hyd ro-1 H-pu ri n -2-yl}-ca rbam i c acid 
2, 7,8-trimethyl-2-(4,8, 12-trimethyl-tridecylhexyl)-chroman-tetrahydro-
furan-3-ylmethyl ester 2 isocyano-ethyl ester (140) 75% yield, Vmax I cm.1 
240 
(nujol) 3388, 3085, 1749, 1694, 1580, 1492, 1272, 1048, 874, 776; 1H-NMR 
(250 MHz, CDCI3) 0.16 (s, 6H, Si-CHa), 0.18 (s, 6H, Si-CH3), 0.83 (s, 9H, C-
CH3), 0.95 (s, 9H, C-CH3), 0.75-0.95 [m, 12H, (CH3-CH) 4], 1.12-1.73 [m, 20H, 
(CH2)10], 1.62-1.82 [m, 3H, (CH-CH3)a], 1.92 (s, 3H, CH3-Ar), 1.96-2.12 (m, 
2H, H2'2'-), 2.15 (s, 3H, CH3-Ar), 2.21 (s, 3H, CH3-Ar), 2.34 (s, 3H, CH3-C-O), 
2.55-2.68 (m, 2H, CH2-Ar), 3.10-3.21 (m, 2H), 3.23-3.34 (m, 2H, Hs·s"), 3.44-
3.51 (m, 2H), 3.65-3.75 (m, 1 H), 3.83 [s, 6H, O-(CH3h), 3.88-3.90 (m, 2H), 
4.12-4.22 (m, 1 H, H4•), 4.43-4.54 (m, 1 H, H3•), 4.89 (t, Japparent = 11.3 Hz, 1 H), 
5.35 (t, Japparent = 12.4 Hz, 1H), 5.56 (d, Js.s= 8.1 Hz, 1H, Hs), 5.97 (d, Japparent 
= 6.3 Hz, 1 H), 6.12 (t, Japparent = 7.5 Hz, 1 H, H1'), 6.30 (br s, 2H, NH2), 6.64-
6.70 (m, 4H, trityl), 7.02-7.23 (m, 9H, trityl), 7.58 (br s, 1H, CONH), 7.71 (s, 
13 1H), 7.82 (d, Js.s = 8 Hz, 1H, Hs), 7.91 (s, 1H, NH).; C-NMR (100 MHz, 
CDCI3) -5.6 (4C-silyl), 4.8, 5.0, 5.3, 15.2 (2C), 16.9, 18.6, 19.4, 20.1 (2C), 
21.3 (6C), 22.3 (2C), 25.5 (2C), 28.5, 31.7 (2C), 32.8, 34.2, 35.4, 37.4 (3C), 
38.8, 41.2, 45.6, 56.2 (2C), 61.2, 64.7, 67.7, 68.2, 71.8, 72.8, 73.7, 75.2, 75.8, 
76.3, 78.2, 98.8, 114.6 (4C), 117.7, 121.3, 123.1, 127.6 (3C), 127.8, 128.4 
(6C), 129.5 (2C), 131.3, 136.6, 138.3, 139.2, 144.5, 147.7, 155.3, 158.5, 
159.3 (C=O, cytidine), 160.5 (C=O, guanosine), 161.2 (2C), 162.7, 164.8, 
13 170.05 (HN-C=O); P-NMR (250 MHz, CDCI3) -2.19, -2.3; Anal. Calcd for 
Ca4H122Ns01sPSiz: C, 63.01, H, 7.68, N, 7.87, 0, 15.28; Found: C, 62.75, H, 
7.94, N, 7.57; HRFABMS Calcd for, Ca4H122N901sPSiz: 1599.82857 found 
1599.8253. 
Procedure for the removal of 2'-cyanoethyl protecting group. 
In a stirred solution of 133 or 139 or 140 (2 mmol, 1eq) in dry acetonitrile (4 
ml) anhydrous tert-butylamine (5 ml) was added and the reaction mixture was 
stirred at room temperature for 2 days. After completion of the reaction the 
solvent was evaporated to dryness and the residue was dissolved in 50 ml of 
dichloromethane and 50 ml of saturated sodium bicarbonate solution. After 
separation, the aqueous phase was further extracted with dichloromethane (5 
x 30 ml) and the combined organic layers were washed with brine (4 x 30 ml). 
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The organic fractions were dried over sodium sulphate, filtered and 
evaporated to dryness. The crude products were purified on a silica gel 
column eluting with a 10:1 mixture of dichloromethane and methanol 
containing a trace amount of triethylamine to afford 134 as a colorless foam in 
73% yield while 141 and 142 were furnished as an off-white foam and off-
yellow foam in 70 and 72% yield, respectively. 
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134 
4,4' -dimethoxy-biphenyl-phosphoric acid-5-(2-amino-6-oxo-1 ,6-dihydro-
purin-9-yl) 3,4-bis-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-
ylmethyl ester 5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-benzyloxymethyl-
tetrahydro-furan-3-yl ester (134) 73% yield, Vmax I cm.1 (nujol) 1735, 1686, 
1520, 1465, 1275, 1042, 797; 1H-NMR (250 MHz, CDCI3) 0.14 (s, 6H, Si-
CH3), 0.19 (s, 6H, Si-CH3), 0.82 (s, 9H, C-CH3), 0.94 (s, 9H, C-CH3), 1.94-
2.16 (m, 2H, Hzz-o), 3.25-3.38 (m, 2H, Hs·s), 3.44-3.51 (m, 2H), 3.67-3.76 (m, 
1H), 3.82 [s, 6H, O-(CH3)2], 4.13-4.22 (m, 1H, H4-), 4.42-4.55 (m, 1H, H3-), 
4.88 (t, Japparent = 11.5 Hz, 1H), 5.33 (t, Japparent = 12.2 Hz, 1H), 5.54 (d, Js.6= 
8.0 Hz, 1 H, Hs), 5.95 (d, Japparent = 6.3 Hz, 1 H), 6.14 (t, Japparenr = 7.2 Hz, 1 H, 
H1"), 6.33 (br s, 2H, NH2), 6.66-6.72 (m, 4H, trityl), 6.90 (br s, 2H, NH2), 7.05-
7.24 (m, 9H, trityl), 7.70 (s, 1H), 7.82 (d, Js.6 =8Hz, 1H, H5), 7.91 (s, 1H, 
NH).; 13C-NMR (100 MHz, CDCI3) -6.4 (4C-silyl), 15.2 (2C), 20.8 (6C), 32.8, 
56.2 (2C), 61.4, 64.8, 67.7, 68.2, 71.8, 74.4, 74.8, 76.3, 76.8, 77.4, 98.3, 
114.6 (4C), 127.5 (3C), 128.4 (6C), 129.8 (2C), 131.5, 137.3, 138.2, 139.5, 
148.5, 158.4 (C=O, cytidine), 160.3 (2C), 161.5 (C=O), 163.3, 164.5; Anal. 
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Calcd for Cs2H70Ns013PSiz: C, 56.56, H 6.57, N 10.15, 0 18.83; Found: C, 
56.24, H 6.96, N 9.84; HRFABMS Calcd for, Cs2H1oNs013PSi2: 1101.43385 
found 1101.4106. 
141 
4'-dimethoxy-biphenyl-phosphoric acid [5-(4-amino-2-oxo-2H-purimidin-
1-yl)] {9-[3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-yl)-6-
oxo-6,9-dihydro-1 H-purin-2-yl}-carbamic acid 17 -(1 ,5-dimethyl-hexyl)-
10, 13-dimethyl-2,3,4,7,8,9, 10, 11,12, 13, 14, 15, 16, 17-tetradecahydro-1H-
cyclopenta[a]phenanthren- tetrahydro-furan-3-ylmethyl ester (141) 70% 
1 
yield, Vmax I cm· (nujol) 3451, 3080, 1741, 1685, 1575, 1492, 1274, 1036, 855, 
792; 
1
H-NMR (250 MHz, CDCI3) 0.13 (s, 6H, Si-CH3), 0.17 (s, 6H, Si-CH3), 
0.80 (s, 9H, C-CH3), 0.94 (s, 9H, C-CH3), 0.67-2.36 (m, 45H, aliphatic),1.92-
2.11 (m, 2H, H2'2"'). 3.22-3.34 (m, 2H, Hs·s--J, 3.62-3.73 (m, 1 H), 3.79 [s, 6H, O-
(CH3h], 3.85-3.89 (m, 2H), 4.10-4.20 (m, 1H, H4·), 4.39-4.50 (m, 1H, H3·), 
4.53-4.74 (m, 1H, 0-CH), 4.85 (!, Japparenl = 11.3 Hz, 1H), 5.32 (!, Japparenl = 
12.4 Hz, 1H), 5.36 (d, 1H, J = 2.5 Hz, HC=C), 5.51 (d, Js.6 = 8.7 Hz, 1H, H5), 
5.91 (d, Japparent == 6.4 Hz, 1 H), 6.10 (t, Japparent == 7 Hz, 1 H, H1-), 6.32 (br S, 2H, 
NH2), 6.62-6.69 (m, 4H, trityl), 7.01-7.21 (m, 9H, trityl), 7.54 (br s, 1H, CONH), 
13 
7.65 (s, 1H), 7.79 (d, Js.s = 8.1 Hz, 1H, Hs), 7.87 (s, 1H, NH).; C-NMR (100 
MHz, CDCI3) -5.2 (4C-silyl), 15.0 (2C), 17.1, 18.2, 19.5, 19.9, 21.7 (6C), 23.8 
(2C), 26.9, 29.7, 31.8, 32.6, 33.5, 34.7, 35.6, 36.7, 38.6, 39.8, 41.3, 42.6, 
43.8, 48.5, 49.1, 51.5, 56.6 (2C), 64.9, 68.2, 69.5, 72.0, 72.7, 73.1, 74.6, 75.3, 
76.5, 77.0, 78.1, 99.3, 115.4 (4C), 123.1 (CH=C), 126.5 127.8 (3C), 128.4 
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(6C), 130.3 (2C), 131.5, 137.6, 138.7, 140.0, 146.3, 148.5, 149.5 (CH=C), 
156.2, 158.4 (C=O, cytidine), 159.6 (C=O, guanosine), 161.0 (2C), 163.2, 
164.5, 170.1 (HN-C=O); Anal. Calcd for CsoH114Ns01sPSi2: C, 63.45, H, 7.59, 
N, 7.40, 0, 15.82 Found: C, 63.12, H, 7.98, N, 7.07; HRFABMS Calcd for, 
CaoH114Ns01sPSi2: 1513.76798 found 1513.7651. 
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4,4'-dimethoxy-biphenyl-phosphoric acid 5-(4-amino-2-oxo-2H-
purimidin-1-yl) {9-[3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-methyl-
tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-1 H-purin-2-yl}-carbamic acid 
2, 7 ,8-tri methyl-2-( 4,8, 12-trimethyl-tridecyl hexyl )-chroman-tetrahydro-
1 furan-3-ylmethyl ester (142) 72% yield, Vmax I cm· (nujol) 3420, 3080, 1755, 
1 
1675, 1582, 1492, 1265, 1033, 882, 785; H-NMR (250 MHz, CDCI3) 0.15 (s, 
6H, Si-CH3), 0.17 (s, 6H, Si-CH3), 0.81 (s, 9H, C-CH3), 0.93 (s, 9H, C-CH3), 
0.73-0.94 [m, 12H, (CH3-CH) 4). 1.10-1.71 [m, 20H, (CH2)10], 1.60-1.80 [m, 3H, 
(CH-CH3h). 1.91 (s, 3H, CH3-Ar), 1.95-2.10 (m, 2H, H2'2'·), 2.14 (s, 3H, CH3-
Ar), 2.20 (s, 3H, CH3-Ar), 2.32 (s, 3H, CH3-C-O), 2.53-2.65 (m, 2H, CH2-Ar), 
3.21-3.32 (m, 2H, Hs·s"), 3.66-3.77 (m, 1 H), 3.82 [s, 6H, O-(CH3M 3.89-3.92 
(m, 2H), 4.11-4.20 (m, 1 H, H4·), 4.44-4.55 (m, 1 H, H3•), 4.91 (t, Japparent = 11.1 
Hz, 1 H), 5.34 (t, Japparent = 12.2 Hz, 1 H), 5.55 (d, Js-6 = 8.2 Hz, 1 H, Hs), 5.95 (d, 
Japparent = 6.3 Hz, 1H), 6.13 (t, Japparent= 7.5 Hz, 1H, H1), 6.31 (br S, 2H, NH2), 
6.66-6.72 (m, 4H, trityl), 7.05-7.24 (m, 9H, trityl), 7.60 (br s, 1H, CONH), 7.72 
13 (s, 1 H), 7.81 (d, Js-6 = 8.2 Hz, 1 H, H6). 7.92 (s, 1 H, NH); C-NMR (1 00 MHz, 
CDCI3 ) -5.8 (4C-silyl), 4.5, 5.0, 5.2, 15.0 (2C), 16.5, 19.1, 20.2 (2C), 21.6 (6C), 
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22.1 (2C), 22.7, 25.6 (2C), 29.2, 31.9 (2C), 33.1, 34.5, 35.7, 37.8 (3C), 39.3, 
41.6, 46.2, 56.7 (2C), 65.3, 67.9, 68.8, 72.1, 72.9, 74.1, 75.5, 75.9, 76.6, 79.1, 
100.2, 115.1 (4C), 121.5, 123.7, 127.8 (3C), 128.1, 128.8 (6C), 129.9 (2C), 
131.6, 137.2, 138.5, 139.6, 146.0, 147.4, 155.1, 158.7 (C=O, cytidine), 160.4 
(C=O, guanosine), 161.5 (2C), 163.2, 165.4, 170.5 (HN-C=O); Anal. Calcd for 
C81 H11sNs01ePSb: C, C, 62.89, H, 7.69, N, 7.24, 0, 16.55; Found: C, 62.66, 
H, 8.01, N, 7.12; HRFABMS Calcd for, Cs1H11sNs01ePSb: 1545.79420 found 
1545.7911. 
Detritylation of 134, 141 and 142. 
In a solution of 134 or 141 or 142 (1.5 mmol, 1eq) in 10 ml of 
dichloromethane, 3% dichloroacetic acid in dichloromethane (4.8 mmol, 
3.2eq) was added and the reaction mixture was stirred at room temperature 
for 20 min (30 min in the case of 139 or 140). After completion the reaction 
was quenched with by the addition 50 ml of saturated sodium bicarbonate 
solution and the solution was extracted with dichloromethane (2 x 50 ml). The 
organic extracts were washed with brine (4 x 30 ml) and saturated sodium 
bicarbonate solution (4 x 40 ml) and then dried over sodium sulphate, filtered 
and evaporated. Evaporation gave a residual oil in all cases, which was 
chromatographed using a 5:1 mixture of dichloromethane and methanol to 
afford 135, 143 and 144 in 68, 63 and 66% yield respectively. 
135 
245 
Phosphoric acid-5-(2-amino-6-oxo-1 ,6-dihydro-purin-9-yl) 3,4-bis-(tert-
butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-ylmethyl ester 5-(4-amino-
2-oxo-2H-pyrimidin-1-yl)-2-(4-methoxy-benzyloxymethyl)- tetrahydro-
furan-2-yl ester (135) 68% yield, Ymax I cm-1 (nujol) 3454, 1757, 1695, 1410, 
1265, 1135, 1048, 852, 694; 
1
H-NMR (250 MHz, 20% DMSO-d5 in CDCI3} 
0.17 (s, 6H, Si-CH3), 0.21 (s, 6H, Si-CH3), 0.85 (s, 9H, C-CH3), 0.97 (s, 9H, C-
CH3), 1.98-2.19 (m, 2H, H2"2"-). 3.29-3.42 (m, 2H, Hs·s·-}, 3.48-3.54 (m, 2H), 
3.70-3.79 (m, 1H), 4.16-4.25 (m, 1H, H4-), 4.45-4.57 (m, 1H, H3-), 4.91 (t, 
Japparent = 11.4 Hz, 1H), 4.99 (br S, 1H, OH), 5.36 (t, Japparent = 12.1 Hz, 1H), 
5.57 (d, Js.6= 8.2 Hz, 1H, Hs), 5.98 (d, Japparent = 6.5 Hz, 1H), 6.18 (t, Japparent= 
7Hz, 1H, H1"), 6.37 (br s, 2H, NH2), 6.93 (br s, 2H, NH2), 7.74 (s, 1H), 7.85 (d, 
Js.6 = 8.2 Hz, 1 H, H5), 7.94 (s, 1 H, NH).; 13C-NMR (100 MHz, 20% DMSO-d6 in 
CDCI3} -6.1 (4C-silyl), 15.8 (2C), 21.5 (6C), 33.4, 61.9, 65.2, 67.9, 68.8, 72.4, 
74.9, 75.6, 77.0, 77.6, 98.8, 132.1, 138.6, 140.2, 148.9, 158.8 (C=O, cytidine), 
161.8 (C=O, guanosine), 163.7, 165.1; Anal. Calcd for C31Hs2Na011PSb: C, 
46.55, H, 6.55, N, 14.01; Found: C, 46.24, H 6.84, N 13.72; HRFABMS Calcd 
for: C31Hs2Na011PSi2: 799.30317 found 799.3004. 
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Phosphoric acid mono-[5-(4-amino-2-oxo-2H-purimidin-1-yl)] {9-[3,4-Bis-
(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-
1H-purin-2-yl}-carbamic acid 17 -(1 ,5-dimethyl-hexyl)-1 0, 13-dimethyl-
2,3,4,7,8,9, 10,11, 12, 13, 14, 15,16, 17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl ester (143) 63% yield, vmax I cm-1 (nujol) 
3445, 3386, 3074, 1712, 1695, 1367, 1265, 1132, 1042, 874, 763; 1H-NMR 
(250 MHz, 20% DMSO-d6 in CDCI3) 0.16 (s, 6H, Si-CH3), 0.20 (s, 6H, Si-CH3), 
0.84 (s, 9H, C-CH3), 0.97 (s, 9H, C-CH3), 0.70-2.39 (m, 45H, aliphatic),1.95-
2.14 (m, 2H, H2'2"), 3.26-3.38 (m, 2H, Hs·s"), 3.66-3.77 (m, 1 H), 3.88-3.92 (m, 
2H), 4.12-4.22 (m, 1H, H4·), 4.43-4.53 (m, 1H, H3-), 4.57-4.76 (m, 1H, 0-CH), 
4.87 (t, Japparent = 11.2 Hz, 1 H), 4.98 (br S, 1 H, OH), 5.35 (t, Japparent = 12.2 Hz, 
1 H), 5.38 (d, 1 H, J = 2.4 Hz, HC=oC), 5.53 (d, Js-6 = 8.8 Hz, 1 H, Hs), 5.94 (d, 
Japparent = 6.3 Hz, 1H), 6.12 (t, Japparent= 7.1 Hz, 1H, H1·), 6.35 (br S, 2H, NH2), 
7.57 (br s, 1H, CONH), 7.68 (s, 1H), 7.82 (d, Js-6 = 8.2 Hz, 1H, H6), 8.0 (s, 1H, 
NH).; 13C-NMR (1 00 MHz, 20% DMSO-d6 in CDCI3) -4.9 (4C-silyl), 15.6 (2C), 
17.7, 19.9 20.2, 21.9 (6C), 24.3 (2C), 27.4, 29.9, 32.2, 32.8, 33.8, 35.1, 35.7, 
36.9, 39.3, 40.2, 41.8, 42.9, 44.3, 48.8, 49.5, 51.8, 65.32, 68.7, 69.8, 72.7, 
73.3, 73.9, 74.7, 75.6, 77.5, 78.6, 99.8, 123.7 (CH=C), 126.9, 130.8 (2C), 
132.2, 139.4, 140.5, 145.0, 149.1, 149.9 (CH=C), 159.5 (C=O, cytidine), 160.8 
(C=O, guanosine), 163.8, 164.6, 170.2 (HN-C=O); Anal. Calcd for 
CsgHg5Na013PSi2: C, 58.44, H, 7.98, N, 9.24, Found: C, 58.77, H, 8.24, N, 
8.96; HRFABMS Calcd for: CsgHg5Na01 3PSi2: 1211.63730 found 1211.6333. 
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Phosphoric acid mono-[5-( 4-amino-2-oxo-2H-purimidin-1-yl) {9-[3,4-Bis-( terl-
butyl-dimethyl-silanyloxy)-5-methyl-tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-
1 H-purin-2-yl}-carbamic acid 2, 7 ,8-trimethyl-2-( 4,8, 12-trimethyl-tridecyl)-
chroman-6-yl ester (144} 66% yield, Vmax I cm-1 (nujol) 3414, 3337, 3091, 
1736, 1692, 1352, 1269, 1114, 1044, 845, 773; 1H-NMR (250 MHz, 20% 
DMSO-de in CDCI3) 0.18 (s, 6H, Si-CH3), 0.21 (s, 6H, Si-CH3), 0.85 (s, 9H, C-
CH3), 0.97 (s, 9H, C-CH3), 0.78-0.98 [m, 12H, (CH3-CH) 4], 1.14-1.74 [m, 20H, 
(CH2)10], 1.64-1.84 [m, 3H, (CH-CH3)3], 1.94 (s, 3H, CH3-Ar), 1.98-2.12 (m, 
2H, H2'2"·), 2.17 (s, 3H, CH3-Ar), 2.25 (s, 3H, CH3-Ar), 2.36 (s, 3H, CH3-C-O), 
2.57-2.68 (m, 2H, CH2-Ar), 3.24-3.35 (m, 2H, Hs·s"), 3.69-3.80 (m, 1 H), 3.92-
3.96 (m, 2H), 4.14-4.23 (m, 1H, H4•), 4.47-4.57 (m, 1H, H3•), 4.92 (t, Japparent = 
11.3 Hz, 1 H), 4.99 (br S, 1 H, OH). 5.37 (t, Japparent = 12.2 Hz, 1 H), 5.58 (d, Js-6 
= 8.4 Hz, 1H, Hs), 5.97 (d, Japparent= 6.5 Hz, 1H), 6.15 (t, Japparent= 7.7 Hz, 1H, 
H1), 6.34 (br s, 2H, NH2), 7.62 (br s, 1H, CONH), 7.75 (s, 1 H), 7.83 (d, J5_e = 8 
Hz, 1H, Hs), 7.95 (s, 1H, NH); 13C-NMR (100 MHz, 20% DMSO-ds in CDC13)-
5.2 (4C-silyl), 4.9, 5.5, 5.8, 15.7 (2C), 16.9, 19.6, 20.7 (2C), 22.2 (6C), 22.8 
(2C), 23.1, 26.1 (2C), 29.8, 32.4 (2C), 33.6, 35.0, 36.3, 38.4 (3C), 39.6, 41.8, 
46.5, 65.8, 68.3, 69.5, 72.3, 73.2, 74.6, 75.8, 76.5, 79.6, 100.7, 122.1, 124.0, 
128.4, 131.9, 139.2, 139.9, 146.4, 147.8, 155.7, 159.2 (C=O, cytidine), 160.6 
(C=O, guanosine), 163.7, 165.9, 169.5 (HN-C=O); Anal. Calcd for 
CsoH1ooNs014PSh: C, 57.92, H, 8.10, N, 9.01; Found: C, 58.25, H, 8.38, N, 
8.76; HRFABMS Calcd for: CsoH10oNs014PSh: 1243.66354 found 1243.6603. 
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Desilylation of 135, 143 and 144. 
To a stirred solution of 135 or 143 or 144 (1 mmol, 1eq) in 15ml of THF a 1.0 
M THF solution of tetrabutylammonium fluoride (TBAF) (2.4 mmol, 2.4eq) was 
added and the reaction mixture was stirred at ambient temperature for 2h. 
After completion of the reaction, the solvent was evaporated under high 
vacuum to give a residue which was dissolved in 60 ml of ethyl acetate and 
50 ml of saturated ammonium chloride solution. The aqueous layer was 
extracted further with ethyl acetate (5 x 40 ml) and the combined organic 
fractions were washed with saturated sodium bicarbonate solution (3 x 30 ml) 
and brine (3 x 30 ml). The organic extracts were dried over sodium sulphate, 
filtered and evaporated to dryness to afford the deprotected CpG 136 as 
colorless foam in 61% yield, while 145 and 146 were furnished as an off-white 
foam in 57% yield and an off-yellow foam in 60% yield, respectively. 
136 
Phosphoric acid-5-(2-ami no-6-oxo-1 ,6-dihydro-purin-9-yl) 3,4-dihydroxy-
tetrahydro-furan-2-ylmethyl ester 5-(4-ami no-2-oxo-2H-pyrimidin-1-yl)-2-
hydroxymethyl-tetrahydro-furan-3-yl ester (136) 61% yield, Vmax I cm·1 
(nujol) 3352, 3274, 3155, 1683, 1345, 1286, 1146, 1050, 716; 1H-NMR (250 
MHz, DMSO-d6) 2.02-2.24 (m, 2H, H2'2'), 3.33-3.46 (m, 2H, H5·5 .. ), 3.53-3.59 
(m, 2H), 3.75-3.84 (m, 1 H), 4.20-4.29 (m, 1 H, H4·), 4.49-4.61 (m, 1 H, H3), 4.96 
(t, Japparent = 11.6 Hz, 1 H), 5.03 (br S, 1 H, OH), 5.13 (br s, 1 H, OH), 5.32 (br s, 
1 H, OH), 5.40 (t, Japparent = 12.4 Hz, 1 H), 5.61 (d, Js-6 = 8.2 Hz, 1 H, Hs), 6.03 
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(d, Japparent = 6.6 Hz, 1H), 6.22 (t, Japparent = 7.1 Hz, 1H, H1-), 6.43 (br S, 2H, 
NH2), 6.97 (br s, 2H, NH2), 7.78 (s, 1 H), 7.89 (d, Js.6 = 8.2 Hz, 1H, H5), 7.97 (s, 
13 
1 H, NH).; C-NMR (100 MHz, DMSO-d5) 33.9, 62.4, 65.7, 68.5, 69.3, 72.9, 
75.3, 75.9, 77.7, 78.2, 99.3, 132.6, 139.0, 140.8, 149.4, 159.3 (C=O, cytidine), 
162.4 (C=O, guanosine), 167.5, 165.7; Anal. Calcd for C19H24Ns011P: C, 
39.94, H, 4.23, N, 19.61; Found: C, 40.23, H 4.61, N 19.29; HRFABMS Calcd 
for: C19H24Ns011P: 571.13022 found 571.1275. 
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145 
Phosphoric acid mono-[5-(4-amino-2-oxo-2H-purimidin-1-yl)] [9-(3,4-
Dihydroxy-tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-1 H-purin-2-yl}-
carbamic acid 10, 13-dimethyl-17 -(1-methyl-hexyl)-
2,3,4,7,8,9, 10,11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl ester (145) 57% yield, Vmax I cm·1 (nujol) 
3458, 3386, 3244, 3085, 1734, 1684, 1385, 1268, 1124, 1080, 886; 1H-NMR 
(250 MHz, DMSO-d6 ) 0.75-2.42 (m, 45H, aliphatic), 2.0-2.19 (m, 2H, H2'2'), 
3.31-3.43 (m, 2H, Hs·s"), 3.71-3.82 (m, 1 H), 3.93-3.97 (m, 2H), 4.16-4.26 (m, 
1H, H4-), 4.47-4.58 (m, 1H, H3-), 4.62-4.81 (m, 1H, 0-CH), 4.92 (t, Japparent = 
11.4 Hz, 1 H), 5.01 (br s, 1 H, OH), 5.12 (br s, 1 H, OH), 5.30 (br s, 1 H, OH), 
5.37 (t, Japparent = 12.2 Hz, 1H), 5.40 (d, 1H, J = 2.3 Hz, HC=C), 5.57 (d, Js-s= 
9 Hz, 1 H, Hs), 5.98 (d, Japparent = 6.4 Hz, 1 H), 6.16 (t, Japparent = 7.4 Hz, 1 H, 
Hr), 6.39 (br s, 2H, NH2), 7.61 (br s, 1 H, CONH), 7.72 (s, 1 H), 7.86 (d, Js_6 = 
250 
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8.4 Hz, 1H, H5), 8.4 (s, 1H, NH).; C-NMR (100 MHz, DMSO-d5) 18.2, 20.4, 
20.9, 24.9 (2C), 27.9, 30.5, 32.8, 33.5, 34.2, 35.7, 36.4, 37.3, 39.8, 40.7, 42.4, 
43.3, 44.7, 49.2, 49.9, 52.1' 65.7, 68.9, 70.2, 73.4, 73.8, 74.3, 74.9, 75.8, 
77.9, 79.0, 100.1, 124.2 (CH=C), 127.4, 131.3 (2C), 132.8, 139.7, 140.9, 
145.6, 149.8, 150.2 (CH=C}, 159.8 (C=O, cytidine), 161.3 (C=O, guanosine), 
164.3, 164.9, 170.6 (HN-C=O); Anal. Calcd for C47H6sNs013P: C, 57.36, H, 
6.96, N, 11.39; Found: C, 57.72, H, 7.26, N, 11.07; HRFABMS Calcd for, 
C47HesNs013P: 983.46435 found 983.4612. 
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Phosphoric acid mono-[5-(4-amino-2-oxo-2H-purimidin-1-yl) [9-(3,4-
D i hyd roxy-5-methyl-tetra hyd ro-fu ra n-2-yl]-6-oxo-6,9-di hyd ro-1 H-puri n-2-
yl}-carbamic acid 2,7,8-trimethyl-2-(4,8, 12-trimethyl-tridecyl)-chroman-6-
yl ester (146) 60% yield, Vmax I cm·1 (nujol) 3427, 3356, 3392, 3234, 3096, 
1745, 1678, 1352, 1284, 1135, 867, 756; 1H-NMR (250 MHz, DMSO-d6) 0.82-
1.02 [m, 12H, (CH3-CH)4], 1.18-1.77 [m, 20H, (CH2)10], 1.69-1.88 [m, 3H, (CH-
CH3lJ], 1.98 (s, 3H, CH3-Ar}, 2.04-2.18 (m, 2H, H2·z"), 2.22 (s, 3H, CH3-Ar), 2.3 
(s, 3H, CH3-Ar), 2.41 (s, 3H, CH3-C-O), 2.62-2.73 (m, 2H, CH2·Ar), 3.29-3.40 
(m, 2H, Hs·s"), 3.74-3.85 (m, 1H), 3.96-4.01 (m, 2H), 4.18-4.27 (m, 1H, H4·), 
4.51-4.61 (m, 1 H, H3·), 4.97 (t, Japparent = 11.2 Hz, 1 H), 5.02 (br S, 1 H, OH), 
5.12 (br s, 1H, OH), 5.30 (br s, 1H, OH}, 5.40 (t, Japparent = 12.4 Hz, 1H}, 5.62 
(d, Js-6 = 8.4 Hz, 1 H, Hs), 6.02 (d, Japparent = 6.5 Hz, 1 H), 6.19 (t, Japparent = 7.7 
Hz, 1H, H1'), 6.38 (br s, 2H, NH2), 7.67 (br s, 1H, CONH), 7.79 (s, 1H), 7.83 
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13 (d, Js-s= 8Hz, 1H, Hs), 8.01 (s, 1H, NH); C-NMR (100 MHz, DMSO-d6) 5.4, 
5.9, 7.2, 17.3, 19.9, 21.3 (2C), 23.4 (2C), 23.7, 26.8 (2C), 30.4, 32.9 (2C), 
34.2, 35.8, 37.4, 38.9 (3C), 40.2, 42.3, 46.9, 66.4, 68.7, 69.9, 72.7, 73.6, 75.0, 
75.9, 77.1, 80.3, 101.4, 122.7, 124.6, 128.9, 132.5, 139.7, 140.4, 146.9, 
148.5, 156.2, 159.8 (C=O, cytidine), 161.2 (C=O, guanosine), 164.3, 166.4, 
170.2 (HN-C=O); Anal. Calcd for C4sH12Ns014P: C, 56.80, H, 7.15, N, 11.04; 
Found: C, 57.09, H, 7.41, N, 10.77; HRFABMS Calcd for: C4sH12Ns014P: 
1015.49056 found 1015.4873. 
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(C) Formation of novel phosphoramidites of lipophilic 
compounds 
Procedure for the preparation of the N.N-diisopropyl-phosphoramidites 
of cetyl alcohol cholesterol and tocopherol 
In a three necked flask fitted with addition funnel, mechanical stirrer and argon 
delivery system, phosphorous trichloride (0.01 mol, 1eq) was placed and 
dissolved in dry diethyl ether (10 ml). In the solution, which was cooled at-
10°C, N,N-diisopropylamine (0.02 mol, 2eq) dissolved in 20 ml of dry diethyl 
ether, was added dropwise by means of the dropwise funnel. When the 
addition concluded the solution was stirred at -10 °C for 30 min. While 
temperature was kept constant at -10 °C, tocopherol, cholesterol or cetyl 
alcohol (0.014 mol, 2eq, assuming 70% yield of the diichloro-diisopropylamino 
phosphine intermediate formed) was dissolved in dry THF, in which 
triethylamine (0.014 mol, 2eq) was added. The solution of the each of the 
alcohols was added dropwise to the above reaction mixture through the 
means of a dropwise funnel. After addition concluded, the mixture was stirred 
at room temperature for 3h. Diisopropyl-amine hydrochloride salts were 
removed by suction filtration while washed with diethyl ether. The filtrate and 
washings were evaporated to complete dryness to afford the 
phosphoramidites of cholesterol and cetyl alcohol as white solid while; the 
phosphoramidite of tocopherol was furnished as yellow oil. Any remaining 
unreacted cholesterol or cetyl alcohol was removed by recrystallization using 
dichloromethane and petrol to furnish the purified N,N-diisopropyl-
phosphoramidites of cetyl alcohol and cholesterol in a 72 and 66% yield 
respectively. The purified N,N-diisopropyl-phosphoramidite of tocopherol was 
obtained in a 69% yield, after trituration with hexane. 
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Diisopropyl-phosphoramidous acid dihexadecyl ester (37) 72% yield, Vmax 
I cmJ (nujol) 2354, 1466, 1378, 1242 1035, 985, 720; 1H-NMR (250 MHz, 
CDCI3,) 0.85 (t, J = 6.7, 6H, (CH3CH2)2], 1.19 (s, 12H, (CH3CH)4). 1.38-1.58 
(m, 56H, (CH2)2sl. 2.64-2.75 (m, 2H, (N-CH)2l 3.58 (t, J = 6.8, 4H, (OCH2)2]; 
13 
C-NMR (100 MHz, CDCI3) 14.6 [2C, CH2(CH3)2), 23.9 [2C, (CH2)2CH3], 24.2 
[4C, (HC-CH3)4), 26.4 (2C), 29.3 (2C), 30.7 (18C), 32.1 (2C), 32.5 (2C), 36.5 
31 [2C, HN(CH)2], 60.6 [2C, (OCH2)2]; P-NMR (100 MHz, CDCI3,) 178.82; Anal. 
Calcd. For C3sHsoN02P: C, 74.33, H, 13.13, N, 2.28; Found C, 74.02, H, 
12.84, N, 2.58; HRFABMS calcd C3sHsoN02P: 613.59267 found 613.5897. 
Diisopropyl-phosphoramidous acid bis-[17 ·(1 ,5-dimethyl-hexyl)-1 0,13-
dimethyl-2,3,4, 7,8,9, 10,11, 12, 13, 14, 15, 16,17 -tetradecahydro-1 H-
cyclopenta[a)phenanthren-3-yl] ester (38) 66% yield, Vmax I cm·1 (nujol) 
1 
2455, 1462, 1343, 1045, 1023, 958, 862; H-NMR (400 MHz, CDCI3), 0.79 (s, 
12H, (CH3CH)4), 0.85-2.23 (m, 90H, aliphatic), 2.42-2.51 (m, 2H, (N-CH)21 
13 5.39 (d, 1 H, J = 3.5 Hz, HC=C), 5.51 (d, 2H, J = 305 Hz, HC=C); C-NMR 
(100 MHz, CDCI3) 16.9 (2C), 17.5 (2C), 18.5 (2C), 19.4 (2C), 20.8 (2C), 21.9 
(2C), 22.7 (4C), 23.9 (2C), 25.1 [4C, 2 x CH(CH3)2], 26.1 (2C), 28.5 (2C), 29.8 
(2C), 30.5 (2C), 33.8 (2C), 34.5 (2C), 35.0 (2C), 35.8 (2C), 37.2 (2C), 38.8 
(2C, N(CH)2), 41.7 (2C), 42.5 (2C), 43.9 (2C), 47.4 (2C), 48.8 (2C), 52.7 (2C), 
70.2 (2C), 123.5 (2C, C=CH), 149.2 (2C, CH=C), 31 P-NMR (100 MHz, CDCI3,) 
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182.54; Anal. Calcd for C6oH104N02P: C, 79.85, H, 11.62, N, 1.55; Found: C, 
80.18; H, 11.91, N, 1.23; HRFABMS Calcd for C6oH104N02P: 901.78047 found 
901.7776. 
Diisopropyl-phosphoramidous acid bis-[2,5, 7,8-tetramethyl-2-{4,8, 12-
1 trimethyl-tridecyl)-choman-6-yl] ester (39) 69% yield Vmax I cm· (neat) 
2364, 1575, 1476, 1346, 1159, 1204, 1044, 918, 853; 1H NMR (400 MHz, 
CDCI3) 0.82 (s, 12H, (CH3CH)4], 0.85-1.05 [m, 24H, (CH3-CH)a], 1.21-1.83 [m, 
40H, (CH2hol. 1.91-2.12 [m, 6H, (CH-CH3)6], 2.24 (s, 6H, (CH3)2-Ar], 2.30 (s, 
6H, (CH3)2·Ar], 2.34 (s, 6H, (CH3)2-Ar], 2.55 (s, 6H, O-C-(CH3)2), 2.62-2.71 
13 (m, 2H, (N-CHhJ, 2.83-2.94 (m, 4H, (CH2)2-Ar]; C-NMR (100 MHz, CDCI3), 
16.8, 17.6, 19.7 (2C), 20.1 (2C), 20.9 (4C), 21.2 (2C), 22.5 (2C), 23.7 (4C), 
24.8 (4C), 25.6 [4C, HC-(CH3)4], 29.5 (2C), 32.8 (4C), 35.5 (2C), 36.2 (2C), 
37.0 (4C), 37.9 (2C), 39.5 (2C, N(CH)2], 41.7 (2C), 46.5 (2C), 73.9 (2C), 121.8 
(2C), 122.5 (2C), 123.3 (2C), 124.5 (2C), 125.7 (2C), 151.1 (2C), 152.7 (2C); 
31 
P-NMR (100 MHz, CDCI3,) 184.67; Anal. Calcd for C54H112N04P: C, 77.60, 
H, 11.40, N, 1.41; Found C, 7.94; H, 11.14; N, 1.72; HRFABMS Calcd for 
C54H112N04P: 989.83290 found 989.8298. 
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(D) Solid Phase synthesis of CpG dinucleotides 
Procedure for the preparation of the 5'-dicetyl, 5'-ditocopherol and 5'-
dicholesterol phospate of the CpG dinucleotide via the phosphitylation 
of the 5'0H group 
24 11mol (1g) of the controlled glass beads (CPG) containing 5'-0-
dimethoxytritylated-deoxyguanosine were placed in a column type reactor 
which was maintained airtight throughout the process with a septum cap. The 
5'-0-dimethoxytritylated-deoxyguanosine was detritylated using 3% 
CCI2COOH in dichloromethane (5 x 2 ml). The suspension was shaken for 2 
min and after washing with acetonitrile (3 x 5 ml for 2 min), the beads were 
dried in vacuo for 5 min. 0.1 M solution of the solid active 3'-cyanoethyl 
phosphoramidite of 2'-deoxycytidine (600 11mol, 25eq) in CH3CN and 0.1 M 
solution of imidazolium triflate (600 f.tmol, 25eq) also in CH3CN were added to 
the column. The column was capped with a septum cap and flushed with 
nitrogen. The suspension of the CPG beads was shaken gently for 25 min. 
The excess of the reagents were removed by washing with CH3CN (10 x 3 ml 
for 2 min). 
Oxidation was then performed using 4ml (2 x 2 ml) of 0.1 M iodine in 80:40:20 
solution of THF: pyridine: H20. After shaking gently for 5 min, the excess of 
oxidizing agent was removed by washing with acetonitrile (10 x 3 ml for 2 
min). Deprotection of cytidine 2-cyanoethyl phosphoramidite (removal of 
dimethoxytrityl group) and washing with acetonitrile was performed as above. 
After drying in vacuo for 5 min 0.1 M solution of the solid dicetyl, dicholesterol 
or ditocopherol phosphoramidite (600 flmol, 25eq) in THF and 0.1 M solution 
of imidazolium triflate (600 flmol, 25eq) also in CH3CN were added to the 
column. The suspension was again shaken gently for 25 min. The excess of 
the reagents were removed by washing with acetonitrile (10 x 3 ml for 2 min). 
The oxidation and washing of excess, steps, were repeated as above. 
After the final elongation step of the desired sequence, the CPG beads were 
thoroughly washed and dried. Then they were transferred to a flask and 
treated with a 3:1 solution of concentrated aqueous ammonia: ethanol for 30 
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min at room temperature and then heating at 55 °C for 16h to remove the 
protecting groups and detach the product from the solid support. 
After cooling the supernatant liquid was separated from the polymer by 
suction filtration and washed with methanol. The combined supernatant and 
washing were concentrated to a small volume and the insoluble material 
resulting from the 13-elimination and polymerisation of the CH2=CH-CN was 
removed by filtering through millipore filter. The filtrate was evaporated to 
dryness to give the ammonium salt of the desired 5'-dicetyl, 5'-dicholesterol 
and 5'-ditocopherol CpG dinucleotide as off-white solid in all three cases. 
Ammonium salt of phosphoric acid-5-(2-amino-6-oxo-1,6-dihydro-purin· 
9-yl) 3-hydroxy-tetrahydro-furan-2-ylmethyl ester 5·(4-amino-2-oxo-2H-
pyrimidin-1-yl)·2·(bis-hexadecyloxy-phosphoryloxymethyl-tetrahydro-
furan-3-yl ester (136) 50% yield, Anal. Calcd for C51H89N8013Pz: C, 56.50, H 
8.27, N 10.33; Found C, 56.96; H, 8.65; N, 10.72; HRFABMS Calcd for: 
Cs1 HegNe013Pz: 1083.60244 found 1083.5997. 
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Ammonium salt of phosphoric acid 5-{4-amino-2-oxo-2H-purimidin-1-yl)· 
4· hydroxy-tetrahydro-furan-2-yl-1 ,9-d ihydro-purin-6-one-2-(bis-[17 ·(1 ,5· 
dimethyl-hexyl]1 0, 13-dimethyl-17 -(1-methyl-hexyl)· 
2,3,4,7,8,9, 10,11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H· 
cyclopenta[a]phenanthren-3-yl methyl ester (148) 52% yield, Anal. Calcd 
for C73H113Ns013Pz: C, 63.87, H, 8.30, N, 8.16; Found C, 64.46; H, 8.76; N, 
8.68; HRFABMS Calcd for: C73H113Ns013Pz: 1371.79024 found 1371.7875. 
Ammonium salt of phosphoric acid 5·(4-amino-2-oxo-2H-purimidin-1-yl)· 
4· hydroxy-tetrahydro-furan-2-yl-1 ,9-dihydro-purin-6-one-2-(bis-[2,5, 7,8· 
tetramethyl-2-{4,8, 12-trimethyl-tridecyl)-chroman-6-yl ester (149) 
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55% yield, Anal. Calcd for CnH121Ns01sP2: C, 63.31, H 8.35, N 7.67; Found 
C, 63.87; H, 8.89; N, 8.12; HRFABMS Calcd for: CnH121Ns01sP2: 1459.84267 
found 1459.8397. 
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Phosphoric acid-5-(2-amino-6-oxo-1 ,6-dihydro-purin-9-yl)-3-methyl-
tetrahydro-furan-2-ylmethyl ester 5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-
hydroxymethyl-tetrahydro-furan-3-yl ester (150) 61% yield, Vmax I cm.1 
. 1 (nujol) 3364, 3263, 3157, 1689, 1348, 1291, 1165, 1054, 757; H-NMR (250 
MHz, DMSO-ds) 2.03-2.25 (m, 1 H, H2"2"-), 3.34-3.45 (m, 2H, Hs·s·-), 3.55-3.60 
(m, 2H), 3.77-3.85 (m, 1H), 4.21-4.30 (m, 1H, H4-), 4.50-4.62 (m, 1H, H3·), 4.98 
(t, Japparent = 10.5 Hz, 1 H), 5.04 (br s, 1 H, OH), 5.14 (br s, 1 H, OH), 5.40 (br s, 
1H, OH), 5.44 (t, Japparent = 12.2 Hz, 1H), 5.63 (d, Js.s= 8.1 Hz, 1H, Hs), 6.08 
(d, Japparent = 6.3 Hz, 1 H), 6.25 (t, Japparent = 7.7 Hz, 1 H, H1-), 6.45 (br S, 2H, 
NH2), 6.99 (br s, 2H, NH2), 7.80 (s, 1H), 7.92 (d, Js.6 = 8.4 Hz, 1H, H6), 7.98 (s, 
13 
1H, NH).; C-NMR (100 MHz, DMSO-d6) 33.9, 62.4, 65.7, 68.5, 69.3, 72.9, 
75.3, 75.9, 77.7, 78.2, 99.3, 132.6, 139.0, 140.8, 149.4, 159.3 (C=O, cytidine), 
162.4 (C=O, guanosine), 167.5, 165.7; Anal. Calcd for C19H24Ns01 1P: C, 
39.94, H, 4.23, N, 19.61; Found: C, 40.19, H 4.58, N 19.26; HRFABMS Calcd 
for, C19H24Ns011 P: 571.13022 found 571.1275. 
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CONCLUSIONS 
The recent widespread use of modified oligonucleotides as diagnostic 
biochemical probes and as tools for the control of gene expression by 
antisense and antigene strategies has fostered the development of synthetic 
methods for the preparation of nucleic acids containing a wide variety of 
modified bases and backbone structures. 
In order to block the synthesis of virus components in a cell it is reasonable to 
use the antisense inhibition of this process by short complementary 
oligonucleotides, which are regarded as one of the most promising tools for 
the treatment of a variety of diseases, including viral infections and cancer. 
However, their application is considerably limited by their inadequate stability 
in the presence of nu cl eases and their low efficiency of their penetration into 
intact cells. In recent years, chemical modifications of antisence 
oligonucleotides have resulted in improved solubility, stability towards 
nucleases, cellular uptake and appropriate hybridization to target genes. 
For this purpose in this research we aimed at synthesizing nucleotide 
constructs modified with lipophilic substituents as they can enhance their of 
the nucleotides to penetrate the cell membrane. Originally a series of novel 
acetal, carbonate, carbamate and ester linkers of tocopherol and cholesterol 
have been successfully prepared in high yield. They were used for the 
incorporation of the lipophilic compounds to the nucleotide derivatives. An X-
ray structure of the first example of a carbonylimidazolide derivative of 
cholesterol was determined. 
These linker groups were intended to be easily cleaved off once the DNA 
construct has entered the cell, stable enough to stand up the conditions of 
DNA synthesis but also be easily hydrolyzed in the cell. They also acted as 
good leaving groups for the subsequent coupling reactions. This reduced the 
potential for side reactions and simplified purification. The reagents were 
soluble in organic solvent suitable for the coupling procedure and could 
withstand the deblocking procedure. 
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Another linker was also synthesized to link tumour targeting GRE1, GRE4 and 
G34 rabbit antibodies to different DNA constructs containing antisense insert. 
The antibodies retained at the binding sites were eluted and showed biological 
activity, which unfortunately could not be maintained. Future plans involve 
establishing whether the tumour targeting rabbit antibodies can be linked to a 
biotinylated oligonucleotide through synthesized linker in a manner that 
appears to maintain increased biological activity. Also investigation into 
determining whether immuno-reactivity could be gained with further 
purification of the eluted antibodies retained at the binding sites is underway. 
New improved methods were developed for the global and partial protection 
of nucleosides employing terl-butyldimethylsilyl chloride (TBDMSCI). lt has 
proved to be an exceedingly useful group that provided a rapid and sufficient 
protection of the hydroxyl moieties of the nucleosides without the need for 
base protection. The method developed averted any silylation of the amino 
bases, and provided increased rate of reactions resulting in high yields of the 
protected nucleosides. Selective 5'-desilylation was also achieved and the 
silylated derivatives were employed in the formation of lipophilic nucleoside 
conjugates and subsequent synthesis of CpG dinucleotides. 
Nucleotides were covalently linked to the lipophilic molecules through sites 
present naturally in nucleic acids such as the exocyclic amino base or the 3'-
hydroxyl group. Lipophilic N-carbamate and N-acetamide conjugates of 
globally protected guanosine and adenosine were synthesized in very good 
yields, forming novel carbonyl-type links. Conjugation at the 3'-terminus of the 
nucleosides, which can potentiate their immunostimulatory activity, gave 
lipophilic a-carbonate analogues in good yields. 
These modifications can enhance the uptake and cellular efficacy of the 
nucleotides, increase their nuclease resistance, thus increasing their 
efficiency in antisense experiments, compared to non-derivatized 
oligonucleotides. Modifications at the 2'-position of the sugar or the 
nucleobases and lipophilic conjugation using other nucleosides can also be 
investigated. 
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In order to test whether the synthesized modified lipophilic nucleotides are 
taken up into the cell membrane more efficiently they were released of their 
protecting groups, to give the deprotected analogues for comparison. 
Deprotection was achieved in good yields and the lipophilic nucleotide 
conjugates were sent for testing. Results are not known as investigation is still 
underway. 
Thioctic acid was also employed as a lipophilic compound for the formation of 
N-carbamate analogues. Different attempts were made firstly through the 
formation of the acid chloride of thioctic acid and then by converting the 
thioctic acid to the amide of carboxylic acid to an amide in a one-pot reaction 
using oxalyl chloride. These methods failed but the formation of the thioctic N-
carbamate analogue of adenosine was finally achieved through employment 
of coupling reagents. 
CpG dinucleotides were successfully prepared in good yields with or without 
the attachment of lipophilic molecules using both solution and solid phase 
synthesis. Accessibility at the 5'-end of the CpG dinucleotide is critical for the 
immunostimulatory activity and in order to examine if terminal modifications 
with alkylic or lipophilic chains can enhance cellular uptake and increase 
immunostimulatory activity, the 5'-dicetyl, dicholesterol and ditocopherol 
phosphates of the CpG dinucleotides were synthesized. For that purpose the 
N,N-diisopropyl-phosphoramidites of cetyl alcohol, cholesterol and tocopherol 
were synthesized in very good yields and they were subsequently coupled to 
CpG through its 5'-end, in order to form the lipophilic phosphodiester CpG 
dinucleotides. 
Efficient synthesis of 5'-di-lipophilic phosphates of CpG dinucleotides was 
attained by the phosphoramidite approach without cytidine base protection. 
The crude products were generally of very good purity and were obtained in 
satisfactory yields. 
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Solid-phase synthesis was achieved with good chemoselectivity and 
phosphitylation was performed using a 1:1 mixture of the promoter and the 
cyanoethyl- phosphoramidite or the synthesized di-lipophilic 
phosphoramidites. lmidazolium triflate proved to be an excellent promoter 
allowing rapid and highly chemoselective condensation of the 
phosphoramidite and the corresponding nucleoside. 
The immunostimulatory activity of these dinucleotides is currently being 
studied in vitro using BALB/c mice spleen lympocytes, measured in a 
lympocyte proliferation assay. The secretion of cytokines IL-12, IL-6 and IL-10 
known to be induced by the activation of immune cells by CpG is also being 
studied in vitro. The formed N-carbamate lipophilic analogues of guanosine 
are also being investigated to determine whether the coupling of the lipophilic 
groups had any effect in the improvement of nucleotide uptake by the cells. 
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APPENDIX 
N1 C1 
C2 C3 N2 
C31 C30 
Data collected on a Bruker SMART 1000 diffractometer, conditions as shown in Table 1. 
The structure was solved by direct methods and refined by full-matrix least-squares on 
F2 using SHELXTL 1• All non-hydrogen atoms were refined with anisotropic atomic 
displacement parameters and hydrogen atoms were inserted at calculated. 
1. G.M. Sheldrick, SHELXTL version 5.1, Bruker-AXS, Madison Wl, 1998. 
Table I. Crystal data and structure refinement for gw3. 
Identification code 
Empirical fonnula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit ceJJ dimensions 
Volume 
z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta~ 25.00' 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data I restraints I parameters 
Goodness-of-fit on F2 
Final R indices [1>2sigma(l)] 
R indices (all data) 
Absolute structure parameter 
Largest diff. peak and hole 
gw3 
C, H" N, 0 2 
480.71 
150(2) K 
0.71073 A 
Monoclinic 
P2(1) 
a~ 5.7921(5) A 
b ~ 9.7965(9) A 
c ~ 24.932(2) A 
1410.1(2) A' 
2 
1.132 Mg/m3 
0.070mm·1 
528 
0.05 x 0.14 x 0.30 mm3 
1.64 to 25.00'. 
p~ 94.634(2)'. 
y~ 90'. 
-6<~h<~6, -11 <~k<~ 11' -29<~1<~29 
10189 
4767 [R(int) ~ 0.0359] 
99.9% 
Multiscan 
1.00000 and 0.622497 
Full-matrix least-squares on F2 
4767 I I I 316 
0.963 
RI ~ 0.0442, wR2 ~ 0.0992 
RI~ 0.0614, wR2 ~ 0.1075 
-0.5(15) 
0.187 and -0.234 e.A-3 
Table 2. Atomic coordinates ( x I 04) and equivalent isotropic displacement parameters (A'x I O') 
for gw3. U(eq) is defined as one third of the trace of the orthogonalized U;i tensor. 
X y z U(eq) 
C(l) 4597(4) 2560(3) 6817(1) 28(1) 
N(l) 5109(3) 2493(3) 7331(1) 33(1) 
C(2) 2989(4) 2371(3) 7554(1) 34(1) 
C(3) 1227(4) 2367(3) 7172(1) 30(1) 
N(2) 2242(3) 2483(2) 6687(1) 26(1) 
C(4) 1074(4) 2523(3) 6173(1) 24(1) 
0(1) -992(3) 2547(2) 6097(1) 31(1) 
0(2) 259I(2) 2549(2) 5802(1) 27(1) 
C(5) 1630(4) 2645(3) 5241(1) 25(I) 
C(6) 3611(4) 3101(3) 4924(1) 28(1) 
C(7) 2912(4) 3156(3) 4326(1) 26(1) 
C(8) 3420(5) 4241(3) 4040(1) 31 (1) 
C(9) 2903(5) 4377(3) 3446(1) 33(1) 
C(10) 2188(4) 3035(2) 3172(1) 25(1) 
C(ll) 1066(4) 3273(3) 2607(1) 27(I) 
C(l2) 2440(5) 4051(3) 2211(1) 35(1) 
C(13) 1144(5) 3720(3) 1660(1) 39(1) 
C(14) -630(4) 2580(3) 1748(I) 29(1) 
C(I5) 235(4) I962(2) 2303(1) 24(I) 
C(I6) -I569(4) 1319(3) 2638(1) 26(I) 
C(I7) -562(4) IOI6(3) 3213(1) 26(1) 
C(IS) 53 I(4) 2257(2) 3511(1) 24(I) 
C(I9) 1700(4) I900(2) 4080(1) 22(1) 
C(20) -189(4) I46I(3) 4445(1) 25(I) 
C(2I) 668(4) 130I(2) 5038(1) 27(1) 
C(22) -976(4) 1636(3) I 255(1) 31(1) 
C(23) -2697(5) 487(3) I 323(1) 39(1) 
C(24) -17I8(5) 2467(3) 750(I) 4I(I) 
C(25) -I99I(5) I652(3) 226(1) 43(1) 
C(26) -2238(5) 2552(4) -272(1) 45(1) 
C(27) -2645(5) I788(3) -799(I) 4I(l) 
C(28) 
C(29) 
C(30) 
C(31) 
-5032(6) 
-2229(5) 
2231 (5) 
3481(4) 
1152(4) 
2690(4) 
964(3) 
746(3) 
-873(1) 63(1) 
-1276(1) 50(1) 
2236(1) 30(1) 
4048(1) 28(1) 
Table 3. Bond lengths [A] and angles ['] for gw3. 
C(l)-N(l) 1.295(3) C(12)-C(I3) 1.545(3) 
C(l )-N(2) 1.378(3) C(13)-C(l4) 1.545(4) 
N(l)-C(2) 1.393(3) C(14)-C(22) 1.538(3) 
C(2)-C(3) 1.338(3) C(l4)-C(l5) 1.557(3) 
C(3)-N(2) 1.391(3) C(I5)-C(I6) 1.526(3) 
N(2)-C(4) 1.401(3) C(15)-C(30) 1.534(3) 
C(4)-0(l) 1.196(2) C(I6)-C(17) 1.533(3) 
C(4)-0(2) 1.326(2) C(17)-C(I8) 1.534(3) 
0(2)-C(5) 1.466(2) C(I8)-C(19) 1.561 (3) 
C(5)-C(21) 1.502(4) C(19)-C(31) 1.537(3) 
C(5)-C(6) 1.512(3) C(19)-C(20) 1.539(3) 
C(6)-C(7) 1.514(3) C(20)-C(21) 1.529(3) 
C(7)-C(8) 1.326(3) C(22)-C(23) 1.523(4) 
C(7)-C(I9) 1.521 (3) C(22)-C(24) 1.532(3) 
C(8)-C(9) 1.494(3) C(24)-C(25) 1.528(4) 
C(9)-C(IO) 1.524(3) C(25)-C(26) 1.519(4) 
C(IO)-C(ll) 1.520(3) C(26)-C(27) 1.514(4) 
C(IO)-C(18) 1.534(3) C(27)-C(28) 1.514(4) 
C(II)-C(I2) 1.521(3) C(27)-C(29) 1.516(4) 
C(ll)-C(l5) 1.548(3) 
N(I)-C(I)-N(2) 111.9(2) C(21)-C(5)-C(6) 111.0(2) 
C(l)-N(I)-C(2) 105.10(19) C( 5)-C( 6)-C(7) 111.79(19) 
C(3)-C(2)-N(l) 111.3(2) C(8)-C(7)-C(6) 120.3(2) 
C(2)-C(3)-N(2) I 05.5(2) C(8)-C(7)-C(19) 123.2(2) 
C(l)-N(Z)-C(3) 106.25(18) C( 6)-C(7)-C( 19) I 16.5(2) 
C(l)-N(2)-C(4) 127.50(18) C(7)-C(8)-C(9) 124.7(2) 
C(3)-N(2)-C(4) 126.25(18) C(8)-C(9)-C(IO) 113.2(2) 
0(1)-C(4)-0(2) 126.93(19) C(ll )-C(1 O)-C(9) 111.3(2) 
0(1)-C(4)-N(2) 123.2(2) C(ll )-C(I 0)-C(l8) 110.37(18) 
0(2)-C(4)-N(2) 109.91(18) C(9)-C(I 0)-C(18) 109.88(19) 
C(4)-0(2)-C(5) 116.38(16) C(IO)-C(II)-C(l2) 118.1(2) 
0(2)-C( 5)-C(21) 111.6(2) C(IO)-C(II)-C(I5) 114.7(2) 
0(2)-C(5)-C(6) 105.77(17) C(12)-C(I1)-C(15) 104.84(19) 
C(li)-C(I2)-C(13) 103.3(2) C(7)-C(19)-C(20) 108.34(19) 
C(I4)-C(I3)-C(l2) 107.9(2) C(31 )-C(I9)-C(20) 109.75(19) 
C(22)-C(I4)-C(I3) 111.6(2) C(7)-C(l9)-C(l8) 109.70(18) 
C(22)-C(l4)-C(l5) 119.2(2) C(31 )-C(I9)-C(I8) 111.17(19) 
C(!3)-C(I4)-C(I5) 103.68(19) C(20)-C(l9)-C(l8) 108. 78(18) 
C(l6)-C(1 5)-C(30) 1 10.6(2) C(21 )-C(20)-C(19) 114.11 (19) 
C(I6)-C(15)-C(II) 105.90(19) C(5)-C(21)-C(20) 108.64(19) 
C(30)-C(I5)-C(II) 112.02(19) C(23 )-C(22)-C(24) 110.1(2) 
C(I6)-C(I5)-C(I4) 117.56(19) C(23 )-C(22)-C(l4) 113.5(2) 
C(30)-C(15)-C(14) 110.0(2) C(24)-C(22)-C(14) 11 0.3(2) 
C(l1)-C(15)-C(I4) 100.25(19) C(25)-C(24)-C(22) 115.3(2) 
C( 15)-C(16)-C(J 7) 111.51(19) C(26)-C(25)-C(24) 113.0(2) 
C(16)-C(l7)-C(18) 114.2(2) C(27)-C(26)-C(25) 1 14.8(3) 
C( JO)-C(l8)-C(l7) 112.23(18) C(26)-C(27)-C(28) 112.8(2) 
C(1 0)-C(l8)-C(19) lll.61(17) C(26)-C(27)-C(29) 111.7(2) 
C(J 7)-C(l8)-C(19) 113.20(19) C(28)-C(27)-C(29) 11 0.2(2) 
C(7)-C(19)-C(31) 109.05(18) 
Table 4. Anisotropic displacement parameters (A2x 103) for gw3. The anisotropic 
displacement factor exponent takes the form: -2n2[ h' a*2Uil + ... + 2 h k a• b* Ui2] 
Ull U22 U'l U" Ul' u12 
C(1) 30(1) 30(1) 25(1) -1 (1) 4(1) I (I) 
N(l) 38(1) 39(1) 23(1) -2(1) 0(1) 5(1) 
C(2) 43(1) 38(2) 22(1) I (I) 6(1) 5(1) 
C(3) 33(1) 31(2) 27(1) I (1) 11(1) -3(1) 
N(2) 27(1) 27(1) 23(1) 0(1) 2(1) 0(1) 
C(4) 30(1) 19(1) 25(!) -I (I) 4(1) 3(1) 
0(1) 29(1) 39(1) 25(1) 1(1) 3(1) 2(1) 
0(2) 29(1) 37(1) 15(1) 2(1) 5(1) -2(1) 
C(S) 31 (I) 29(1) 16(1) 2(1) 1 (1) I (I) 
C(6) 35(1) 31 (I) 1 9(1) -4(1) 3(1) -9(1) 
C(7) 27(1) 29(1) 21(1) -1(1) 4(1) -2(1) 
C(8) 44(2) 25(2) 23(2) -4(1) 2(1) -8(1) 
C(9) 50(2) 25(1) 25(1) 1(1) 6(1) -9(1) 
C(IO) 29(1) 25(1) 22(1) -3(1) 5(1) -3(1) 
C(I1) 34(1) 27(2) 22(1) 0(1) 6(1) -!(I) 
C(l2) 53(2) 28(2) 24(2) -1(1) 6(1) -13(1) 
C(13) 63(2) 34(2) 22(1) 0(1) 7(1) -8(1) 
C(l4) 36(1) 30(1) 22(1) 1(1) 5(1) 2(1) 
C(15) 26(1) 24(1) 21(1) 1(1) 3(1) 0(1) 
C(16) 28(1) 30(2) 21(1) -3(1) 2(1) 0(1) 
C(l7) 25(1) 29(1) 23(1) 1 (1) 5(1) -5(1) 
C(18) 25(1) 27(2) 19(1) 0(1) 3(1) 3(1) 
C(19) 25(1) 24(1) 18(1) 0(1) 4(1) -1(1) 
C(20) 26(1) 24(1) 24(1) 2(1) 2(1) -2(1) 
C(21) 29(1) 30(2) 23(1) 4(1) 4(1) -1 (1) 
C(22) 36(1) 34(2) 22(1) -1 (1) 3(1) 1(1) 
C(23) 46(2) 43(2) 27(2) -3(1) 3(1) -6(1) 
C(24) 61(2) 37(2) 25(1) 0(2) 0(1) 2(2) 
C(25) 68(2) 40(2) 21 (1) 1 (I) -1(1) I (2) 
C(26) 68(2) 42(2) 26(1) 0(2) 2(1) -7(2) 
C(27) 58(2) 37(2) 27(2) -3(1) -2(1) 3(2) 
C(28) 
C(29) 
C(30) 
C(31) 
83(2) 
67(2) 
33(1) 
30(1) 
60(2) 
54(2) 
32(2) 
29(2) 
44(2) 
29(2) 
24(1) 
25(1) 
-2(2) 
0(2) 
-2(1) 
I (I) 
-4(2) 
2(1) 
4(1) 
0(1) 
-22(2) 
-3(2) 
-I (I) 
2(1) 
Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2x IO ') 
for gw3. 
X y z U(eq) 
H(l) 5711 2652 6560 34 
H(2) 2817 2300 7928 41 
H(3) -378 2299 7222 36 
H(5) 377 3351 5211 30 
H(6A) 4925 2461 4991 34 
H(6B) 4137 4017 5049 34 
H(8) 4167 4985 4227 37 
H(9A) 4295 4733 3287 40 
H(9B) 1643 5051 3374 40 
H(10) 3608 2466 3144 30 
H(11) -356 3828 2651 33 
H(12A) 4064 3729 2227 42 
H(12B) 2427 5044 2284 42 
H(13A) 339 4544 1511 47 
H(13B) 2254 3411 1404 47 
H(14) -2150 3033 1792 35 
H(16A) -2138 459 2465 32 
H(16B) -2904 1946 2650 32 
H(17A) 628 294 3200 31 
H(l7B) -1812 654 3422 31 
H(18) -769 2897 3571 28 
H(20A) -1448 2147 4415 30 
H(20B) -853 581 4312 30 
H(21A) -627 1019 5248 32 
H(21B) 1885 591 5077 32 
H(22) 554 1209 1199 37 
H(23A) -2820 -84 999 58 
H(23B) -4218 875 1380 58 
H(23C) -2162 -71 1635 58 
H(24A) -3213 2917 803 49 
H(24B) -559 3195 711 49 
H(25A) -623 1054 205 52 
H(25B) -3374 1060 230 52 
H(26A) -3546 3189 -238 54 
H(26B) -814 3107 -283 54 
H(27) -1492 1028 -792 49 
H(28A) -5182 639 -1212 94 
H(28B) -6209 1872 -883 94 
H(28C) -5249 533 -573 94 
H(29A) -661 3070 -1229 75 
H(29B) -3362 3435 -1300 75 
H(29C) -2394 2147 -1607 75 
H(30A) 1634 150 2043 45 
H(30B) 2937 699 2591 45 
H(30C) 3397 1405 2031 45 
H(31A) 2717 -61 3883 42 
H(31B) 4145 519 4411 42 
H(31C) 4717 1045 3829 42 
Table 6. Torsion angles['] for gw3. 
N(2)-C(l )-N(l )-C(2) -0.3(3) C(l2)-C(ll)-C(l5)-C(l6) 
-167.9(2) 
C(l )-N(l)-C(2)-C(3) 0.0(3) C(IO)-C(ll)-C(l5)-C(30) -59.8(3) 
N(l )-C(2)-C(3)-N(2) 0.3(3) C(12)-C(ll )-C(l5)-C(30) 71.4(2) 
N(l )-C(l)-N(2)-C(3) 0.5(3) C(IO)-C(Il)-C(l5)-C(l4) -176.42(19) 
N(l )-C( I)-N(2)-C( 4) 179.9(3) C(l2)-C(ll)-C(I5)-C(l4) -45.2(2) 
C(2)-C(3)-N(2)-C(l) -0.4(3) C(22)-C(l4)-C(l5)-C(l6) -83.5(3) 
C(2 )-C(3 )-N(2)-C( 4) -179.9(3) C(l3)-C(14)-C(l5)-C(l6) 151.8(2) 
C(l )-N(2)-C(4)-0(1) -174.5(3) C(22)-C(l4)-C(l5)-C(30) 44.3(3) 
C(3)-N(2)-C( 4)-0(1) 4.9(4) C(l3)-C(l4)-C(l5)-C(30) -80.5(2) 
C(l )-N(2)-C( 4)-0(2) 4.6(4) C(22)-C(l4)-C(l5)-C(ll) 162.4(2) 
C(3)-N(2)-C(4)-0(2) -176.0(2) C(13)-C(14)-C(l5)-C(11) 37.7(2) 
0( I )-C( 4)-0(2)-C( 5) 1.3(4) C(30)-C(l5)-C(l6)-C(l7) 63.9(3) 
N(2)-C( 4)-0(2)-C(5) -177.7(2) C(ll )-C(l5)-C(l6)-C(l7) -57.7(3) 
C( 4)-0(2)-C(5)-C(21) -76.6(3) C(l4)-C(l5)-C(l6)-C(l7) -168.7(2) 
C(4)-0(2)-C(5)-C(6) 162.6(2) C(15)-C(l6)-C(l7)-C(l8) 55.0(3) 
0(2)-C( 5)-C( 6)-C(7) 176.2(2) C(l1 )-C(IO)-C(I8)-C(l7) 47.4(3) 
C(21 )-C( 5)-C( 6)-C(7) 55.0(3) C(9)-C(IO)-C(l8)-C(l7) 170.6(2) 
C( 5)-C( 6)-C(7)-C(8) 132.4(3) C(11 )-C(l O)-C(I8)-C(19) 175.72(19) 
C( 5)-C( 6)-C(7)-C(19) -49.6(3) C(9)-C(l O)-C(l8)-C(l9) -6 1.2(3) 
C(6)-C(7)-C(8)-C(9) 177.3(2) C(16)-C(l7)-C(18)-C(1 0) -48.4(3) 
C(l9)-C(7)-C(8)-C(9) -0.5(4) C(I6)-C(l7)-C(18)-C(19) -175.84(19) 
C(7)-C(8)-C(9)-C(l 0) -12.3(4) C(8)-C(7)-C(l9)-C(31) 104.9(3) 
C(8)-C(9)-C(1 O)-C(l1) 164.6(2) C(6)-C(7)-C(l9)-C(31) -73 .0(3) 
C(8)-C(9)-C(IO)-C(l8) 42.0(3) C(8)-C(7)-C( 19)-C(20) -135.7(3) 
C(9)-C(IO)-C(II)-C(l2) 56.9(3) C( 6)-C(7)-C(19)-C(20) 46.4(3) 
C(l8)-C(IO)-C(l1)-C(l2) 179.2(2) C(8)-C(7)-C(l9)-C(l8) -17.1(3) 
C(9)-C(l O)-C(ll)-C(l5) -178.7(2) C( 6)-C(7)-C( 19)-C(l8) 165.0(2) 
C(I8)-C( 10)-C( 11 )-C(I5) -56.4(3) C(1 O)-C(I8)-C(I9)-C(7) 47.4(2) 
C(l 0)-C(Il )-C(l2)-C(J3) 163 .5(2) C(I7)-C(J 8)-C(l9)-C(7) 175.19(19) 
C(15)-C(I1)-C(l2)-C(I3) 34.3(3) C(1 O)-C(l8)-C(l9)-C(31) -73.3(2) 
C(11)-C(12)-C(J3)-C(14) -9.8(3) C(I7)-C(l8)-C(I9)-C(31) 54.5(2) 
C(l2)-C(13)-C( 14 )-C(22) -147.4(2) C(1 0)-C(l8)-C(l9)-C(20) 165.76(19) 
C(12)-C(13)-C(14)-C(15) -17.9(3) C(17)-C(J 8)-C(I9)-C(20) -66.5(2) 
C(1 O)-C(11 )-C(l5)-C(16) 60.9(2) C(7)-C(19)-C(20)-C(21) -51.5(3) 
C(3 I )-C(I9)-C(ZO)-C(ZI) 67.4(3) C(I 5)-C( I 4)-C(Z2)-C(24) -I 77.3(2) 
C(I 8)-C(I 9)-C(ZO)-C(Z I) -I70.74(I9) C(Z3)-C(ZZ)-C(Z4)-C(Z5) -57.2(3) 
0(2)-C(5)-C(2 I )-C(20) -I77.I9(17) C(I 4)-C(22)-C(24 )-C(25) I 76.8(2) 
C( 6)-C( 5)-C(2 I )-C(20) -59.5(2) C(ZZ)-C(24)-C(Z5)-C(Z6) -I68.2(2) 
C(I 9)-C(20)-C(2 I )-C(5) 59.6(3) C(24)-C(25)-C(26)-C(27) -I76.8(2) 
C( I 3)-C(I 4)-C(22)-C(23) I 79.5(2) C(25)-C(26)-C(Z7)-C(28) 70.7(3) 
C(I 5)-C(I 4)-C(22)-C(23) 58.7(3) C(25)-C(26)-C(27)-C(29) -I64.5(3) 
C(I 3)-C( I 4 )-C(22)-C(24) -56.5(3) 
Plan View of Carbonylimidazolide derivative of Cholesterol 13 
C31 
Side View of Carbonylimidazolide derivative of Cholesterol 13 
C31 C30 
C23 
Side View of Carbonylimidazolide derivative of Cholesterol 13 showing 
thermal ellipsoids 
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